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De todos los instrumentos del hombre, el más asombroso es, 
sin duda, el libro. Los demás son extensiones de su cuerpo. El 
microscopio, el telescopio, son extensiones de su vista; el 
teléfono es extensión de la voz; luego tenemos el arado y la 
espada, extensiones del brazo. Pero el libro es otra cosa: el 
libro es una extensión de la memoria y la imaginación.  
Jorge Luis Borges
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ABSTRACT 
Phenolic compounds are a group phytochemicals widely but not uniformly distributed in the 
plant kingdom. These compounds have generated great expectations in the scientific 
community as natural therapeutics due to their antioxidant, anti-inflammatory and 
anticarcinogenic properties. In an attempt to associate the intake of phenolic compounds 
with reduced risk of chronic diseases, much effort has been invested in the phenolic 
characterization of plant-based products. 
Phenolic compounds are usually taken orally through food or supplements intake. The 
gastrointestinal tract, therefore, is the main route of entrance to the body. Initial attention 
has been focused on studying the bioavailability of the native compounds present in food. 
Nevertheless, their apparent low bioavailability has awoken the possibility of contemplating 
other related metabolites rather than the original forms. The obstinacy to really cover the 
general metabolism of phenolic compounds in the human body provided their colonic fate 
with a central role. This is partly explained because phenolic compounds are modestly 
absorbed and, therefore, a considerable amount of unmetabolized products reaches the 
colon.  
The different works that make up the body of this Doctoral Thesis are focused on the study 
of the colonic metabolism of the more representative phenolic compounds present in three 
plant-based products. The products concerned were enriched olive oil in its own phenolic 
compounds and in combination with thyme phenolic compounds, pomegranate and Arbutus 
unedo (strawerry tree) fruit.  
In-vitro fermentation and human interventions were conducted for the purpose of exploring 
the fate of phenolic compounds in the gut. Different metabolic pathways have been 
proposed based on in-vitro fermentations and corroborated through the analysis of human 
faeces after dietary treatment. Because of the potential benefits that phenolic compounds 
can cause to the local ecosystem, it is vital to monitor the behaviour of these 
phytochemicals in the large intestine. For this reason, the impact of phenolic compounds in 
the activity and composition of gut microbiota was also evaluated. 
  
RESUMEN 
Los compuestos fenólicos son una clase de fitoquímicos que se encuentran amplia pero no 
uniformemente distribuidos en el reino vegetal. Dadas sus propiedades antioxidantes, anti-
inflamatorias y anticancerígenas, dichos compuestos han despertado gran interés en la 
comunidad científica como posibles sustancias terapéuticas de origen natural. Con el fin de 
encontrar asociaciones positivas entre la ingesta de compuestos fenólicos y mejora de 
marcadores de salud, muchos esfuerzos se han invertido para definir el perfil fenólico de 
muchos productos. 
Los compuestos fenólicos normalmente se consumen de forma oral a través de alimentos 
o suplementos, por lo tanto, el tracto gastrointestinal constituye la principal vía de entrada 
al organismo. En un principio, muchos trabajos de investigación se centraron en estudiar la 
biodisponibilidad de aquellos compuestos originalmente presentes en los alimentos. Sin 
embargo, su modesta biodisponibilidad ha despertado la posibilidad de contemplar otras 
rutas metabólicas mediante las cuales estos compuestos lleven a cabo su actividad 
biológica, ampliando la búsqueda de otros compuestos asociados a las formas originales. 
Con el objeto de considerar la distribución general de los compuestos fenólicos en el  
organismo humano, el metabolismo en el intestino grueso juega un papel central. Dicho 
interés se apoya en evidencias científicas que sostienen que los compuestos fenólicos se 
absorben de forma modesta y, por consiguiente, una porción considerable llega al colon 
sin metabolizar. 
Los diferentes trabajos que conforman el núcleo principal de esta Tesis Doctoral se han 
focalizado en el estudio del metabolismo en el colon de los compuestos fenólicos más 
representativos de tres productos de origen vegetal. Los productos en cuestión fueron 
aceite de oliva enriquecido en sus propios compuestos fenólicos y en combinación con 
compuestos fenólicos presentes en el tomillo, granada y Arbutus unedo (madroños).  
Diferentes ensayos incluyendo fermentaciones in vitro y tratamientos dietéticos con 
humanos se llevaron a cabo con el propósito de explorar qué ocurre con los compuestos 
fenólicos cuando llegan al colon. Como resultado de esto, se propusieron una serie de 
rutas metabólicas deducidas de las observaciones de los experimentos in vitro, que fueron 
posteriormente contrastadas con los datos obtenidos del análisis de heces humanas. 
Asimismo, el posible impacto que los compuestos fenólicos pueden tener sobre el 
  
 
ecosistema intestinal se evaluó mediante el análisis del perfil metabólico y microbiano de 
heces obtenidas antes y después de la ingesta fenólica. 
  
RESUM 
Els compostos fenòlics són una classe de fitoquímics que es troben àmplia però no 
uniformement distribuïts en el regne vegetal. Donades les seves propietats antioxidants, 
anti-inflamatories i anti-cancerígenes, aquests compostos han despertat gran interès en la 
comunitat científica com a possibles substàncies terapèutiques d'origen natural. Amb la 
finalitat de trobar associacions positives entre la ingesta de compostos fenòlics i la millora 
de marcadors de salut, molts esforços s'han invertit per definir el perfil fenòlic de molts 
productes. 
Els compostos fenòlics normalment es consumeixen de forma oral a través d'aliments o 
suplements, per tant, el tracte gastrointestinal constitueix la principal via d'entrada a 
l'organisme. Al principi, molts treballs de recerca es van centrar a estudiar la 
biodisponibilitat d'aquells compostos originalment presents en els aliments. No obstant 
això, la seva modesta biodisponibilitat ha despertat la possibilitat de contemplar altres rutes 
metabòliques mitjançant les quals aquests compostos puguin a terme la seva activitat 
biològica, ampliant la cerca d'altres compostos associats a les formes originals. Amb 
l'objecte de considerar la distribució general dels compostos fenòlics en l'organisme humà, 
el metabolisme en l'intestí gruixut juga un paper central. Aquest interès es recolza en 
evidències científiques que sostenen que els compostos fenòlics s'absorbeixen de forma 
modesta i, per tant, una porció considerable arriba al còlon sense metabolitzar. 
Els diferents treballs que conformen el nucli principal d'aquesta tesi doctoral s'han focalitzat 
en l'estudi del metabolisme en el còlon dels compostos fenòlics més representatius de tres 
productes d'origen vegetal. Els productes en qüestió van ser oli d'oliva enriquit en els seus 
propis compostos fenòlics i en combinació amb compostos fenòlics de la farigola, magrana 
i Arbutus unedo (arboç).  
Diferents assatjos incloent fermentacions in vitro i tractaments dietètics amb humans es 
van dur a terme amb el propòsit d'explorar què ocorre amb els compostos fenòlics quan 
arriben al còlon. Com a resultat d'això, es van proposar una sèrie de rutes metabòliques 
deduïdes de les observacions dels experiments in vitro, que van anar posteriorment 
contrastades amb les dades obtingudes de l'anàlisi de femta humana. Així mateix, el 
possible impacte que els compostos fenòlics poden tenir sobre l'ecosistema intestinal es va 
  
 
avaluar mitjançant l'anàlisi del perfil metabòlic i microbià de femta obtinguda abans i 
després de la ingesta fenòlica. 
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1. An approach to the concept of phenolic compounds based 
on their occurrence, classification, distribution and properties  
Dietary phenolic compounds are minority components of the plant kingdom. Approximately 
8000 different phenolic compounds have been described in fruit, vegetables, leaves, roots, 
flowers, seeds and the products obtained from them, such as chocolate, and alcoholic 
(wine and beer) and non-alcoholic beverages (tea, coffee and juices). There is a growing 
recognition that these natural phytochemicals play an important role in the prevention of 
chronic diseases, which are considered subjects of study in an important number of 
scientific reports 
 
1.1. Natural occurrence of phenolic compounds 
Phenolic compounds include a broad spectrum of natural phytochemicals widely distributed 
in the plant kingdom. They are secondary metabolites derived from the shikimate pathway 
of plants that possess, in their chemical structure, at least one benzene (phenol) ring with a 
varied number of adjacent hydroxyl substituents (Tsao et al., 2010; Weaver et al., 1997). 
There is not a definitive consensus that explains the reason why phenolic compounds are 
synthesized by plants. The activity of the shikimate pathway increases in the event of 
environmental stress such as nutrient deprivation, ultraviolet light exposure, wounding and 
biological threat (herbivores, microorganisms and fungus) (Weaver et al., 1997). In 
addition, it has been suggested that phenolic compounds are involved in the symbiotic 
relationship between microorganisms and plants, favouring the development of beneficial 
microbiota (Weaver et al., 1997). All this seems to indicate that phenolic compounds play a 
relevant role in the protection of plants during their growth and development, ensuring their 
survival in hostile environments.  
 
1.2. Classification of phenolic compounds 
Despite phenolic compounds sharing common features, each of these compounds 
maintains its own unique characteristics, allowing their classification in different groups. 
Taking into consideration the phenolic part of the molecule, called aglycone, phenolic 
compounds could be organized into two big groups: flavonoids and non-flavonoids. 
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Flavonoids 
This phenolic category includes those compounds containing aglycone skeleton, consisting 
of two phenolic rings (ring A and ring B) connected by a heterocyclic ring (ring C). The 
whole structure is commonly represented as C6-C3-C6. Flavonoids are sub-classified into 
six sub-groups: anthocyanidins, flavan-3-ols, isoflavones, flavanones, flavones and 
flavonols (Beecher et al., 2003; Manach et al., 2004; Tsao et al., 2010). This classification 
is based on the hydroxylation (position 3), double bound (2,3-dihydro) and the presence of 
carbonyl group (position 4) of the C ring, as well as the binding position of B ring to C ring 
(see Figure 1 and Figure 2). 
 
 
 
 
 
 
 
Figure 1. Schematic representation of the flavonoid aglycone 
 
In food, flavonoids are normally combined with aliphatic and aromatic acids, methyl groups 
and/or glycosides to form numerous types of conjugates. The glycosyl anthocyanidins are 
called anthocyanins. In the particular case of flavan-3-ols, they can occur as monomers 
(catechin and epicatechin), monomers associated with gallic acid (epigallocatechin gallate) 
or in a varied combination of interconnected monomer units to form proanthocyanins 
(polymeric forms). On occasions, proanthocyanins are considered as an individual group 
called condensed tannins (Beecher et al., 2003).  
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Figure 2. Description of flavonoid sub-groups including the most representative 
constituents as well as some examples of plant-products sources. 
 
Non-flavonoids 
This classification includes those compounds that possess a benzoic (phenol) ring but the 
phenolic skeleton does not respond to the C6-C3-C6 chemical pattern. Phenolic acids 
(hydroxybenzoic and hydroxycinamic acids), phenolic alcohols, phenolic monoterpenes, 
lignans and stilbenes are some of the sub-groups considered as non-flavonoids. Within the 
hydroxybenzoic acids, gallic and ellagic acids can be found in food, forming more complex 
structures. These are called gallotannins and ellagitannins, respectively, and they are 
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derived from the linkage between different monomer units, which are normally 
interconnected by sugars or aromatic acids. Polymeric forms of gallic and ellagic acids are 
also known as hydrolyzable tannins (Beecher et al., 2003). 
Hydroxycinamic acids include caffeic acid, ferulic acid, and coumaric acid, to mention some 
examples. Caffeic and ferulic acids are also found in vegetal sources as tartrate and quinic 
esters (e.g. chlorogenic acid is a quinic ester of caffeic acid). In addition, caffeic acid 
esterified with dihydroxyphenylactic acid forms rosmarinic acid. Figure 3 shows a summary 
of the latter mentioned non-flavonoids with a brief description of the foods that contain 
considerable amounts of these compounds. 
 
 
Figure 3. Classification of phenolic compounds belonging to the non-flavonoid group. Each 
sub-group includes an example of their most representative compounds as well as the 
plan-products sources. 
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1.3. Distribution of phenolic compounds in plant products 
As an integral part of the human diet, an estimated average of 1-3 g of phenolic 
compounds is consumed per day through plant-derived products (Saura-Calixto et al., 
2007; Scalbert et al., 2000). Of course, the amount and specific type of phenolic 
compounds ingested vary between populations and markedly depend on their dietary 
habits (Beecher et al., 2003; Brat et al., 2006; Manach et al., 2004; Scalbert et al., 2000). 
Phenolic compounds are widely but not uniformly distributed in the plant kingdom. Beyond 
the genetic predisposition, other factors, such as edaphoclimatic conditions and technical 
procedures during manufacturing and storage, determine the qualitative and quantitative 
profile of phytochemicals in plant-based foods (Brat et al., 2006; Manach et al., 2004; 
Mphahlele et al., 2014). 
Certain phenolic compounds are widely present in many products, whereas others are 
limited to specific families or species (Manach et al., 2004; Scalbert et al., 2000; Williamson 
et al., 2005). Under this assumption, scientific interest can be focused on the study of the 
predominant individual phenolic compounds in a food or else on its content in a specific 
one. Red wine is a good example for a better understanding. This alcoholic beverage 
obtained from the fermentation of grapes has been extensively studied. Its interest is 
focused on the content of anthocyanins, flavan-3-ols and/or phenolic acids as major 
phenolic constituents (Scalbert et al., 2000) (Table 1). In addition, the presence of 
resveratrol, although in modest quantities, has been the subject of numerous publications, 
since this stilbene is found in red grapes in greater amounts than in other products 
(Scalbert et al., 2000) (Table 1).  
Marked differences also exist among plant products in terms of total phenolic 
concentration. Based on this supposition, we could distinguish between low and high 
phenolic-content products. For example, a serving of melon provides less phenolic 
compounds than strawberries (Brat et al., 2006) (Table 1). However, more important than 
the total phenolic contribution is the frequency of dietary intake or the possibility of including 
the product as part of the regular diet.  
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Table 1. Phenolic concentration of fruit, vegetables and their derivatives products  
Product Phenolic compounds Concentration (mg/100 g) 
Fruits   
Blackberry Cyanidin-3-O-glucoside 
Ellagic acid 
Epicatechin 
3-caffeoyquinic acid 
138±37.1 
43.7±24.5 
11.5±10.9 
4.53±0.59 
Strawberry Pelargonidin-3-O-glucoside 
Catechin 
Ellagic acid glucoside 
Resveratrol 
47.1±14.6 
6.36±5.46 
2.85±1.12 
0.35±0.00 
Orange Hesperetin 
Naringenin 
33.6±7.35 
11.2±0.64 
Melon Lariciresinol 
Pinoresinol 
4.40±0.00 
2.20±0.00 
Apple 
(peeled) 
5-Caffeoyl quinic acid 
Procyanidin trimer C1 
Epicatechin 
18.2±10.6 
7.02±3.47 
6.72±4.50 
Apple 
(whole) 
Procyanidin dimer B2 
5-Caffeoyl quinic acid 
14.6±9.19 
13.4±11.3 
Vegetables   
Broccoli 
(raw) 
Kaempferol-3-O-sophoroside 
Quercetin-3-O-sophoroside 
16.6±0.00 
6.50±0.00 
Onion (raw) Quercetin-3,4’-O-diglucoside 
Quercetin-4’-O-glucoside 
3.12±2.50 
2.25±1.80 
Beverages  Concentration (mg/100 mL) 
Red wine Malvidin-3-O-glucoside 
Procyanidin dimer B3 
Catechin 
Gallic acid 
Caffeoyl tartaric acid 
Resveratrol-3-O-glucoside 
9.97±5.48 
9.47±4.29 
6.81±6.24 
3.59±2.71 
3.35±3.79 
0.62±0.65 
Coffee (filter) 5-Caffeoyl quinic acid 
4-Caffeoyl quinic acid 
4-feruloyl quinic acid 
43.1±0.00 
19.0±0.00 
13.3±0.00 
Pomegranate 
juice 
Punicalagin 
Ellagic acid glucoside 
Cyanidin-3-O-glucoside 
43.6±71.3 
3.97±3.77 
3.43±4.53 
Others  Concentration (mg/100 g) 
Black 
chocolate 
Epicatechin 
Proanthocyanins tetramer 
Procyanidin dimer B2 
Ferulic acid  
70.4±29.5 
53.8±20.1 
36.5±11.7 
24.0±0.00 
Cellery (fresh) Luteolin-7-O-(2-aplosyl-6-malonyl)-glu 
Apigenin-7-O-(6’’-aplosyl-6-malonyl)-glu 
35.8±0.00 
31.6±0.00 
Thyme (dried) Rosmarinic acid 829±260 
Extra virgin 
olive oil 
3,4-DHPEA-EDA 
4-HPEA-EDA 
Oleuropein aglycone 
Apigenin 
Pinoresinol 
25.2±26.3 
14.3±7.32 
3.66±2.43 
1.17±1.28 
0.42±0.28 
Sunflower oil  Total phenolic content 1.00±0.00 
3,4-DHPEA-EDA: dialdehydic form of decarboxymethylelenolic acid linked to hydroxytyrosol; 4-HPEA-EDA : dialdehydic 
form of decarboxymethylelenolic acid linked to tyrosol. Source: phenol-explorer.ue (access December 2015). 
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This aspect could be connected to many examples. Olive oil is consumed as the main 
source of fat in the Mediterranean area, replacing refined oils commonly used in other 
countries. The frequency of olive oil intake provides an important daily contribution of 
phenolic alcohols, lignans and flavones, which are not present in other culinary fats (García 
et al., 2003) (Table 1). The regular consumption of beverages such as wine, coffee, tea, 
and juices is also an important phenolic source (Brat et al., 2006; Manach et al., 2004). In 
addition, phenolics are not distributed evenly throughout the food product. For example, the 
qualitative and quantitative phenolic profile is not the same in the outer and inner parts of 
the product (Table 1). In the case of fruits and some vegetables, the peel and seeds 
normally concentrate major polymerized substances and a higher phenolic concentration 
than the flesh (Scalbert et al., 2000). 
In summary, the estimation of the average phenolic intake in a specific population requires 
the collection of detailed information, such as the variety of fruit or vegetable, frequency of 
intake, means of consumption (whole products, raw or cooked) and form and time of 
conservation. These aspects are not always included in food or dietary surveys. Deducing 
the correlation between biological effects and phenolic intake is quite difficult due to the 
variable aspects mentioned below. In addition, lack of solid conclusions regarding the 
amount and class of phenolic compounds necessary to intake to acquire beneficial effects 
hinders the elaboration of dietary recommendations. 
Moreover, when selecting products with the aim of increasing phytochemicals intake, it is 
important to consider the overall composition of the food in order to limit the incorporation 
of other components such as alcohol (in wine and beer), sugar (when added to fruit juices), 
fat (nuts and olive oil), high density calories (chocolate and nuts) or stimulants (caffeine in 
coffee). 
 
1.4. The properties of phenolic compounds 
Based on the specific area of study, phenolic compounds may have several functions with 
different end objectives. 
 
Technological properties 
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The incorporation of phenolic compounds into food products that have experienced 
important losses or else are naturally deprived of phenolic constituents improves their 
microbiological quality and minimizes their oxidation (Li et al., 2012; Murcia et al., 2004). 
For example, a rancidity delay of meat and meat products, fish and fish products, refined 
oils, butter or margarine is achieved thanks to the addition of phenolic compounds, 
especially those inhibitors of phospholipids peroxidation (Murcia et al., 2004).  
Phenolic-rich foodstuff has emerged as a therapeutic alternative in animal feeding. 
Supplementation with phenolic compounds improves animal systemic physiology and 
productivity (Liu et al., 2014; Starčević et al., 2015; Tedeschi et al., 2014). Moreover, other 
benefits, such as increase of shelf-life and antioxidant protection, are transferred to the end 
products, such as fresh meat or meat products, obtained from these animals (Di Trana et 
al., 2015; Liu et al., 2014; Ortuño et al., 2014; Starčević et al., 2015).  
In addition, an innovative approach is the inclusion of phenolic-rich oils or extracts for 
antimicrobial and antioxidant applications. This allows an expansion of the shelf-life, and 
maintains the nutritional value and safety of packaged foods (Espitia et al., 2014; Perazzo 
et al., 2014). The purpose of increasing the general quality of food products using naturally 
occurring compounds is an attractive alternative to limit the use of synthetic preservatives 
(Murcia et al., 2004). This latter point is of particular importance if we take into 
consideration the latest trends in consumer choice, based on the increasing popularity of 
foods formulated with natural additives. Phenolic extracts for animal feeding or food 
antioxidants are usually derived from by-products generated by the food industry. This 
motivation offers an extra incentive, since it collaborates with good environmental practices 
through the recovery of industrial waste (Li et al., 2012). The main limitation of the use of 
phenolic compounds in food conservation is alteration of sensory perception, due to flavour 
transference (Lesschaeve et al., 2005). 
 
Sensorial properties 
In the elaboration and commercialization of foods, one of the interests in the phenolic 
composition lies in the fact that phenols are responsible for the colour, bitterness, 
astringency and development of some flavours. These sensorial characteristics define the 
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general appearance and the texture in the mouth, two important factors that govern the 
choice of consumers (Lesschaeve et al., 2005).   
Astringency and bitterness should be properly balanced because their high intensity would 
promote consumer rejection (Lesschaeve et al., 2005). Therefore, in some products, such 
as wine, for example, a note of astringency seems to be well perceived (Lesschaeve et al., 
2005). Anthocyanins contribute with the red, blue and purple colour of fruits and 
vegetables. This attribute is really appreciable in berries, pomegranate, eggplant, red 
grapes, as well as their derived products (juices, jams and purees). Other particular colour 
shades are due to the transformation of phenolic compounds during technological 
processes, such as in the case of black tea and red wine (Cheynier et al., 2005; Wang et 
al., 2003).  
 
Biological properties 
During the last few decades, increasing attention has been focused on the association 
between diet and health. Based on the results reported by epidemiological studies, heath 
authorities have advocated the importance of the intake of fruit and vegetables as a policy 
to reduce the incidence of chronic disease (Boeing et al., 2012; Nishida et al., 2004). Fruit 
and vegetables provide a wide range of phytochemicals, such as phenolic compounds, 
fibre, minerals and vitamins. Strictly speaking, phenolic compounds are not considered to 
be nutrients, since they are not indispensable for essential growth or maintenance of life, 
and phenolic-deprived diets do not cause deficiency-related diseases. Nevertheless, they 
have been recognized as protective agents to combat chronic disease (Cardona et al., 
2013; Del Rio et al., 2013). 
Chronic diseases or non-communicable diseases (NCDs), adopting the definition proposed 
by the Word Health Organization (WHO), are characterized by a slow or silent 
development. The most frequent causes are associated with genetic factors and/or 
continuous exposure to an unhealthy lifestyle. Nowadays, chronic diseases are the primary 
cause of death in developed countries and already raise concern in emerging societies. An 
important number of diagnostic cases include chronic conditions associated with 
cardiovascular disease (CVD) (heart attacks and strokes), cancer (especially colon and 
breast cancer), diabetes type 2, respiratory diseases and neurodegenerative alterations 
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(Alzheimer and Parkinson) (Boeing et al., 2012; Nishida et al., 2004). A cure is generally 
not possible for most of these diseases. Therefore, primary prevention and the 
maintenance of conditions under control by patients, as soon as the disease is diagnosed, 
are of pivotal importance. 
Phenolic compounds exhibit a wide range of bioactive functions, among them antioxidant, 
anti-inflammatory and antiproliferative properties, which make them good weapons to fight 
against chronic diseases (Figure 4). 
 
 
Figure 4. Graphic representation of the main biological activities described for phenolic 
compounds in human beings 
 
Antioxidant properties 
Free radicals are normal products of cell metabolism and, in basal amounts, they 
participate as molecular mediators in several physiological events (Görlach et al., 2015). 
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On the other hand, free radicals are very reactive species capable of attacking cellular 
components, including lipids (disruption of cellular membrane), proteins (alteration of 
structural and regulatory proteins) and nucleic acids (DNA damage) (Coates et al., 2007; 
Rezaie et al., 2007). Therefore, sustained exposure to over-physiological concentrations of 
free radicals compromises the structure and function of organs and tissues, increasing the 
risk of developing metabolic complications (Görlach et al., 2015; Rezaie et al., 2007). 
Oxidative stress is the term essentially used to describe a situation of uncontrolled 
generation of free radicals and/or the reduced ability of the endogenous antioxidant 
machinery (superoxide dismutase (SOD), catalase, and glutathione peroxidase (GPO)) to 
neutralize them (Rezaie et al., 2007). The antioxidant status of the organism can be 
reinforced by the intake of phenolic-rich foods (Murcia et al., 2004; Rezaie et al., 2007; 
Tsao et al., 2010). Their antioxidant properties are supported by the capacity of phenolic 
compounds to act as metal chelators and free radical scavengers (Tsao et al., 2010). 
Reduction of aberrations caused to the organism by free radicals is linked to the protection 
against diseases associated with oxidative stress, such as cardiovascular disease (Siti et 
al., 2015) and cancer (Coates et al., 2007; Hietanen et al., 1994).  
 
Anti-inflammatory properties 
Inflammation is a physiological response to external or internal injuries that could 
compromise the body’s well-being. Inflammation is a very sophisticated biological process 
of signalization in which a series of mediators, transcription factors, protein kinases and 
enzymes take part. The inflammatory response may turn into a vicious circle of continued 
stimulation, resulting in its perpetuation. This phenomenon could bring structural and 
physiological changes to the affected tissue, resulting in the development of chronic 
diseases such as arteriosclerosis and inflammatory bowel disease (IBD) (Rezaie et al., 
2007). 
Free radicals are also involved, since they can activate several pathways involved in the 
stimulation and prolongation of the inflammatory response (Görlach et al., 2015; Rezaie et 
al., 2007). Nevertheless, phenolic compounds are not only considered as anti-inflammatory 
agents due to their ability to inhibit free radicals, but also to interfere with other specific 
biological events (Colombo et al., 2013). Most of these properties are still to be completely 
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elucidated. However, the capacity of phenolic compounds to modulate the activity of a wide 
range of enzymes and molecular pathways involved in inflammation has been proposed as 
the main mechanism of defence (Colombo et al., 2013). For example, the intake of 
phenolic-rich products has been associated with the improvement of markers associated 
with inflammation in cardiovascular disease, cancer, diabetes, intestinal environment and 
obesity (Cardona et al., 2013; Colombo et al., 2013; Del Rio et al., 2010; Martin et al., 
2015), to give some examples.  
 
Antiproliferative properties 
The efficacy of phenolic compounds to prevent or treat cancer has been studied in several 
types of malignancies both in-vivo and in-vitro (Coates et al., 2007; Cardona et al., 2013). 
Oxidative stress and inflammation seem to play a relevant role in the initiation of 
carcinogenesis (Coates et al., 2007; Colombo et al., 2013). The antioxidant and anti-
inflammatory properties of phenolic compounds might therefore reduce the risk of cancer 
development (Figure 4). Independent of the antioxidant and anti-inflammatory properties, 
evidence of chemopreventive and chemotherapeutic properties of diet phenolic compounds 
may also be achieved throughout cell cycle arrest, induction of cell death and inhibition of 
metastasis (Cardona et al., 2013; Coates et al., 2007). The anticarcinogenic effects of 
several phenolic compounds has been demonstrated in different cancer cells and animal 
models including prostate (Ma et al., 2015), breast (Kubatka et al., 2015) and colon (Coates 
et al., 2007). 
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2. Metabolism of phenolic compounds during gastrointestinal 
digestion 
Phenolic compounds are normally consumed through the daily intake of foods and 
beverages of plant origin, but can also be ingested via dietary supplements (Kubatka et al., 
2015). Whatever the vehicle, both forms include the gastrointestinal tract as the principal 
route of entry into the body. The human gastrointestinal tract includes a series of 
compartments with specific functions and physiological conditions to favour the digestion 
and absorption of food components, providing nutrients to the organism (Kararli et al., 
1995). Digestion starts in the mouth and is completed in the stomach, small intestine 
(subdivided into duodenum, jejunum and ileum) and colon (cecum, ascendant, transversal 
and descendent colon) (Figure 5). The study of the phenomena occurring during digestion 
promotes the understanding and contributes to explaining the general metabolism and fate 
of phenolic compounds in living beings. Gastrointestinal digestion is a very sophisticated 
process where internal (enzymatic and microbial activities, pH, transit time) and external 
(chemical and physical characteristics of the phenolic compounds, dose and food 
composition) factors govern the stability, bioaccessibility and bioavailability of the food 
components (Kararli et al., 1995). 
Bioaccessibility and bioavailability are different but closely related concepts. The former is 
understood as the liberation of phenolic compounds from the food matrix into the digestive 
juice (Saura-Calixto et al., 2007). The release and the subsequent solubilization in the 
intestinal lumen considerably increase the possibility of phenolic compounds being 
absorbed by the intestinal epithelium. On the other hand, bioavailability is referred to when 
phenolic compounds are absorbed by intestinal cells and pass into the bloodstream, 
becoming available for physiologic processes and/or storage in organs and/or tissues 
(Jackson et al., 1997). Certain phenolic compounds have been described as poorly 
absorbed molecules; thus, this non-absorbable fraction is a valuable nutritional resource for 
the gut microbiota (Kahle et al., 2005). 
In-vitro gastrointestinal digestion models are usually used to evaluate the bioaccessibility of 
phenolic compounds in mouth, stomach and small intestine. Furthermore, to predict what 
happens in the colon with non-absorbed compounds, in-vitro fermentations are the model 
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of choice. These models imitate the conditions of the different parts of the gastrointestinal 
tract to achieve a more accurate approximation to the in-vivo situation (Figure 5).  
 
 
Figure 5. Physical and chemical conditions used in in-vitro digestion to represent the main 
compartments of the gastrointestinal tract involved in food digestion 
 
2.1. Oral digestion 
Digestion starts in the oral cavity with the mechanical action of mastication together with 
the activity of the salivary enzymes (α-amylases) (Hoebler et al., 1998). The oral digestion 
of phenolic compounds is not always considered in in-vitro bioavailability studies. This 
would be partially justified because they are minimally affected during the short time of 
artificial saliva exposure (Correa-Betanzo et al., 2014; Tenore et al., 2015). Therefore, the 
physical (change in particle size and viscosity of the food) and chemical (modifications of 
food matrix structure) changes in food, promoted by saliva and trituration, make it available 
for enzymatic degradation in the stomach and small intestine (Hoebler et al., 1998; Tenore 
et al., 2015). The changes in the food matrix after the oral step probably increase the 
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possibility of phenolic compounds liberation and solubilization in the intestinal juice. 
However, the incubation with artificial saliva does not contemplate the action of oral 
microbiota on phenolic compounds, which possesses the capacity to release aglycones 
from glycosylated phenolic structures usually present in plant-based foods (Kahle et al., 
2011). 
 
2.2. Gastric digestion 
The digestion in the stomach is carried out at low pH in combination with mechanical action 
(peristaltic waves) and enzymatic activity (proteases), which increase the degree of food 
disintegration (Karali et al., 2005). During digestion, changes in the phenolic profile can 
occur in two ways: by modifications of the molecular structure (qualitative changes) or else 
by differences in the amount recovered with respect to the original product (quantitative 
changes). The impact of gastric digestion on the qualitative profile is more pronounced in 
certain polymeric forms, whereas simpler compounds have shown good stability 
(Bermudez-Soto et al., 2007; Borges et al., 2007; Colombo et al., 2013; Correa-Betanzo et 
al., 2015; Fernández et al., 2013; Kahle et al., 2005; Kahle et al., 2011; Lamothe et al., 
2014; Ríos et al., 2002; Serra et al., 2010; Tenore et al., 2015). Among the polymeric 
forms, whereas ellagitannins were not affected (Colombo et al., 2013; Borges et al., 2007), 
the hydrolysis resistance of proanthocyanidins under acidic conditions seems to be related 
to their molecular characteristics. The hydrolysis of proanthocyanidins of cloudy apple juice 
(Kahle et al., 2011) and grape skin extract (Fernández et al., 2013) was major compared to 
the proanthocyanins present in grape seed extract (Fernández et al., 2013; Serra et al., 
2010) and cocoa beverage (Ríos et al., 2002). Occasionally, disappearance of ellagitannins 
during gastric incubation was noticed; this was not attributable to their hydrolysis but to the 
complexation with the protein present in the food and, to a lesser extent, to digestive 
enzymes (Borges et al., 2007; Lamothe et al., 2014).  
From a quantitative point of view, the results obtained from different in-vitro studies have 
shown that, under gastric conditions, most of the phenolic compounds are recovered in 
similar amounts to those already present in the initial product (Bermúdez-Soto et al., 2005; 
Correa-Betanzo et al., 2014; Lamothe et al., 2014; Serra et al., 2010; Tenore et al., 2015). 
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Some losses were reported for flavan-3-ols (Bermúdez-Soto et al., 2007; Tenore et al., 
2015). 
Moreover, food matrix characteristics and other food that may be ingested simultaneously 
with the phenolic source also affect the stability and release of phenolic compounds in the 
stomach, since physical properties of the food could determine access by digestive 
enzymes (Lamothe et al., 2014).  
In synthesis, gastric digestion is important for two reasons. Firstly, it has been suggested 
that some phenolic compounds could be absorbed in the stomach (Borges et al., 2007; 
Kararli et al., 1995; Manach et al., 2004). Secondly, it determines the nature of food bolus 
that reaches the small intestine (duodenum), where the digestion process continues.  
 
2.3. Intestinal digestion 
The structural architecture and specific function convert the small intestine into the most 
suitable gastrointestinal segment to absorb a varied repertoire of food components. When 
the chyme (or digesta) passes from the stomach to the duodenum, the pH starts to 
increase gradually until reaching neutral to low alkaline values (Karali et al., 1995). The 
action of the secreted pool of digestive enzymes continues to promote the degradation of 
food, favouring the release of smaller components to the lumen (Karali et al., 1995).  
In-vitro studies have shown that the stability of phenolic compounds is closely linked to the 
pH of the media, while enzymatic degradation seems to play a secondary role (Bermúdez-
Soto et al., 2007; Correa-Betanzo et al., 2014; Kahle et al. 2011; Rubiò et al., 2014; Tenore 
et al., 2015). The amount of phenolic compounds recovered after simulated incubations 
reveals that their stability depends on their chemical resistance to the lumen environment 
(Correa-Betanzo et al., 2014; Bermúdez-Soto et al., 2007; Fernández et al., 2013; Kahle et 
al., 2011; Rubiò et al., 2014; Tenore et al., 2013; Tenore et al., 2015). On occasions, an 
increase in the concentration of phenolic compounds was observed due to reactions of 
hydrolysis of the more complex structures or to isomerization of monomers (Bermúdez-
Soto et al., 2007; Coates et al., 2007; Colombo et al., 2013; Khale et al., 2011; Rubiò et al., 
2014).  
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Different studies have shown that the nature of the food matrix influences the 
bioaccessibility of specific phenolic compounds. Thus, digestive enzymes have easier 
access to liquid and semi-liquid products (juices and smoothies), whereas solid matrices 
hampered the enzymes’ accessibility (Saura-Calixto et al., 2007). Consequently, a solid 
food matrix might protect phenolic compounds that are more sensitive to the intestinal 
conditions by gradual liberation to the media (Lamothe et al., 2014; Saura-Calixto et al., 
2007). In fact, the combination of a phenolic-rich source with other foods in the context of a 
complete diet favours the stability of phenolic compounds during digestion in comparison 
with when they are digested alone (in water) (Lamothe et al., 2014; Serra et al., 2010).  
Once phenolic compounds are released into the digestive juice after digestion, they are 
susceptible to being absorbed. The chemical structure, which in turn determines the 
solubility and stability, has a profound impact on the degree of absorption of phenolic 
compounds (Bergmann et al., 2010; Rubiò et al., 2014; Williamson et al., 2005). For 
example, the type and position of conjugate moieties are likely to affect the bioavailability 
(Kahle et al., 2005). The mechanism of absorption also differs according to the compound. 
Whereas, for some, transcellular transport predominates, others preferably cross the 
epithelium by mediated paracellular transport (restricted by tight junctions) (Konishi et al., 
2004) (Figure 6). For those compounds in which transcellular absorption takes place, the 
passage through the membrane can predominantly occur by passive diffusion or carried-
mediated transport (Konishi et al., 2004; Lançon et al., 2004) (Figure 6). 
Phenolic compounds are not always absorbed in the form in which they are present in the 
food. Previously, they can be deglucosylated in the lumen by lactase phlorizin hydrolase 
(LPH) or in the cytosol of intestinal cells by β-glucosidase (Bergmann et al., 2010, Kahle et 
al., 2005) (Figure 6). Once phenolic compounds have been absorbed, they undergo 
extensive intestinal, hepatic and renal phase I and II metabolism (glucuronidation, 
sulphatation, and methylation), these metabolites being the most abundant in biological 
fluids (Rubiò et al., 2014; Williamson et al., 2005). Nevertheless, it has been reported that 
some dimers and trimers (proanthocyanins), as well as anthocyanins, are absorbed and 
excreted intact (Serra et al., 2010). Additionally, some of these phenolic compounds that 
escape gastro-intestinal absorption reach the large intestine, becoming a potential source 
 Introduction 
20 
 
of microbial substrate (Cardona et al., 2013; Colombo et al., 2013; Kahle et al., 2005; Kahle 
et al., 2006; Saura Calixto et al., 2007). 
 
 
Figure 6. Graphic representation of the different mechanisms of intestinal trans-epithelial 
transport and deglucosylation of phenolic compounds 
 
 
2.4. The large intestine 
During the last few years, a huge body of information regarding the fate of phenolic 
compounds in the colon has been published. The main interest lies in the aspect that some 
phenolic compounds escape digestion and, consequently, reach the colon unmetabolized 
(Cardona et al., 2013; Colombo et al., 2013; Kahle et al., 2005; Kahle et al., 2006; Saura-
Calixto et al., 2007). The major proportion of this phenolic fraction consists of non-
absorbable compounds, completed by additional phenolic metabolites of phase II derived 
from the intestinal efflux and enterohepatic recirculation (Kahle et al., 2005; Kahle et al., 
2006; Saura-Calixto et al., 2007) (Figure 7).  
The microorganisms that colonize the large intestine are the main element responsible for 
phenolic metabolism. This complex and enormous population is commonly defined as gut 
microbiota. Its great variety confers a broad range of enzymes capable of transforming the 
native phenolic compounds into simpler metabolites (Cardona et al., 2013). This enzymatic 
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cocktail performs activity of phase I metabolism, such as depolymerization 
(proanthocyanins and ellagitannins), deconjugation (phase II metabolites), ring cleavage of 
flavonoids, deglycosylation, deserterification, deacetylation, dehydroxylation, 
demethylation, decarboxylation and oxidation, to mention some of the more commonly 
described degradation steps (Cardona et al., 2013; Williamson et al., 2010). These 
structural modifications produce changes in the physiological and physical properties of the 
native molecule. Thus, microbial metabolites do not necessarily share the same 
characteristics as their precursors (Colombo et al., 2013). 
 
Figure 7. Different routes by which phenolic compounds reach the colon 
 
The general bioaccessibility of phenolic species keeps increasing in the colon thanks to the 
microbial capacity to break down the linkage that maintains phenolic compounds 
associated with the food digesta in a way that the small intestine cannot (Saura-Calixto et 
al., 2007). The absorption efficiency of nutrients decreases in the colon compared with 
small intestine, but is partially promoted by its slower intestinal motility. It has been 
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demonstrated that microbial metabolites are absorbed and reach considerable systemic 
concentrations, in an even higher amount than their precursors (Cardona et al., 2013; 
Williamson et al., 2010). This prolonged time of residence is also responsible for the 
generation of a broad spectrum of phenolic metabolites. The composition of the lumen 
includes native compounds (present in the food), their products of early catabolism (initial 
metabolites) and a diverse mix of low molecular weight metabolites (Cardona et al., 2013; 
Cueva et al., 2015) generated from the subsequent microbial degradation of initial 
metabolites. 
To fully understand the role of phenolic compounds in the gut and their possible 
involvement in local and systemic physiology, certain specific issues should be addressed 
(Figure 8): 
 Deciphering the colonic metabolic pathways of phenolic compounds is a key to 
identifying the metabolites generated by microbial catabolism. After the identification, 
microbial metabolites should be studied to establish their potential bioactivity and 
hypothetical mechanisms of action.  
 The time-degradation rate of phenolic compounds when they are in contact with gut 
microorganisms could explain the appearance of microbial metabolites in biological 
fluids at different time points. Pre-identification may encourage the inclusion of 
phenolic metabolites in future bioavailability and clinical studies.  
 The identification of microbial metabolites as intermediates and end-products could 
be useful to establish biomarkers of consumption, treatment compliance and to 
correlate their presence with the improvement of health status. The selected 
biomarker (in faeces or in other fluids or tissue) should be sensitive to the variations 
in the intake of the dietary component of interest. 
 The analysis of faeces or other biological fluids (urine or plasma) after a phenolic-
rich dietary intervention helps to determine the average concentration that parent 
compounds and/or their microbial metabolites have in the intestine or at systemic 
level. This information is of vital importance to establish physiological concentration 
to be tested in future studies.  
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 The degree to which parent compounds and/or their metabolites could interfere with 
gut microbiota structure and activity. Moreover, the identification of specific bacteria 
involved in phenolic transformations could further provide valuable information about 
the potential role of phenolic compounds in the gut ecosystem.  
 Different patterns of bioconversion of phenolic compounds in the colon by humans 
may be useful to make a link between healthy or at-risk populations. Factors such as 
the individual variability, physiological state, dose, and presence of other meal 
components when a phenolic source is studied should be considered to ensure 
success of therapeutic treatment for the major proportion of the population.  
 
 
Figure 8. Information to be considered when colonic pathways of phenolic compounds are 
studied  
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3. Role of phenolic compounds in the large intestine 
In early times, the large intestine was considered to be a segment of the gastrointestinal 
tract involved in water absorption and excretion of digestive waste (Karali et al., 1995). Gut 
was an “ignored organ”, and nowadays it is the central topic of numerous scientific studies. 
Phenolic compounds and/or their microbial metabolites are accumulated in the intestinal 
lumen for long residence time; hence, they may exert local protection against pro-oxidant, 
pro-inflammation and pro-carcinogenic events as well as impact on gut microbiota 
configuration and/or activity.  
 
3.1. Possible implication of phenolic compounds in the large intestine 
health status 
Several deleterious substances with potential pro-oxidant, pro-inflammatory and/or pro-
carcinogenic effects enter or are generated daily in the alimentary canal, making the 
intestinal mucosa susceptible to functional and structural alterations (Coates et al., 2007; 
Rezaie et al., 2007). This hypothetical situation may be offset by the presence of luminal 
phenolic compounds, which could counteract the vulnerability to intestinal diseases. 
Phenolic compounds may act as antioxidants in the gut, providing local protection and 
preventing the racking of pro-oxidants from the intestine to the organism. Besides being 
pro-oxidant species, free radicals are also involved in the activation of pro-inflammatory 
mediators. When this occurs at intestinal level, it increases the risk of suffering the most 
common forms of inflammatory bowel disease (IBD), called ulcerative colitis and Crohn’s 
disease (Rezaie et al., 2007; Colombo et al., 2013). In turn, chronification of inflammation 
involves complex and interconnected mechanisms of molecular mediators, whose 
continued feedback increases the risk of colorectal cancers (Hagland et al., 2015; Martin et 
al., 2015; Seril et al., 2003). 
The protective effects of phenolic compounds against intestinal alterations (inflammation 
and cancer) have been demonstrated in different experimental studies using cell and 
animal models (Cardona et al., 2013; Coates et al., 2007; Colombo et al., 2013; Martin et 
al., 2015; Williamson et al., 2010). In any case, to what extent dietary phenols and their 
microbial metabolites contribute to reducing intestinal oxidative stress, inflammation and 
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cancer is unknown, and this fact is mainly due to the limited data available derived from 
human studies (Colombo et al., 2013; Martin et al., 2015).  
 
3.2. Phenolic-microbiota relationship 
The large intestine is the body cavity that concentrates the most abundant and varied 
microbiota, reaching approximately 1012 bacteria per gram of intestinal content (Williamson 
et al., 2015). All this makes the gut a complex and multifunctional ecosystem where host 
and microorganism live in symbiosis. Whereas humans confer a suitable niche, providing 
access to nutrients from non-absorbed food (especially non-digestible carbohydrates and 
proteins), microorganisms participate in protective, immunologic and metabolic activities 
(Conlon et al., 2015; Donaldson et al., 2015; Hagland et al., 2015) (Figure 9). The gut 
microbiota protect the host, strengthening the intestinal barrier architecture and, through 
competitive exclusion (competing for food and physical space), controlling the overgrowth 
of pathogenic bacteria (Round et al., 2009). Gut inhabitants are aligned to the gut 
immunological system, ensuring it proper functioning and maturation (Round et al., 2009). 
In terms of metabolism, gut bacteria participate in several pathways, such as vitamin 
synthesis, optimization in the utilization of nutrients by fermentation of non-digested dietary 
compounds, and degradation of xenobiotics and endogenous compounds (Donaldson et 
al., 2015; Hagland et al., 2015).  
Gut microorganism can negatively affect the host through either acute episodes (typical of 
foodborne illness) or chronic effects by the recurrent activation of pro-oxidant, pro-
inflammatory and pro-carcinogenic pathways (Donaldson et al., 2015). On the other hand, 
other bacteria groups are considered positive for the host (Donaldson et al., 2015; Hagland 
et al., 2015). According to this premise, bacteria could roughly be classified under two 
categories: “beneficial” and “harmful”. The proper balance of microbial composition 
reinforces health status of the host and is normally called microbial homeostasis. On the 
contrary, disruption of microbial composition is known as dysbiosis and is associated with 
metabolic disorders (Round et al., 2009). Although abundance of bacteria in the alimentary 
tract is important, some authors have highlighted the fact that diversity may be the most 
relevant consideration to be taken into account in terms of the impact on gut ecology 
(Donaldson et al., 2015). 
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Figure 9. Symbiosis between human host and gut microbiota 
 
It may be possible to promote the maintenance of microbial homeostasis with the 
intervention of phenolic-rich diets (Cardona et al., 2013; Colombo et al., 2013; Cueva et al., 
2015). Phenolic compounds-microbiota relationship could be described as a two-way 
interaction. On the one hand, microorganisms transform the original compounds present in 
the food into related metabolites which could be subsequently utilized by secondary 
degraders, hence stimulating cross-feeding. Food phenolic compounds, in turn, may 
influence the reshaping of the microbiota population by favouring or hampering the growth 
of certain groups of microorganisms (Cardona et al., 2013; Cueva et al., 2015). It has been 
proposed that phenolic compounds and their microbial metabolites possess selectively 
antimicrobial properties, where beneficial bacteria are less affected (Cardona et al., 2013; 
Colombo et al., 2013).  
The composition of the gut microbiota is a fundamental pillar of human health and its 
manipulation offers the possibility of maintaining general well-being, improving health and 
preventing disease (Colombo et al., 2013; Donaldson et al., 2015). Human studies in this 
area are scarce and the results obtained from different in-vitro and animal approaches are 
not conclusive (Cardona et al., 2013; Colombo et al., 2013; Cueva et al., 2015). Based on 
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this, it cannot be affirmed categorically that phenolic compounds are able to modulate gut 
microbiota toward a healthier composition. There is cumulative evidence that suggests that 
dysbiosis is involved in the development of several diseases, such as type 2 diabetes, 
obesity, intestinal diseases and hepatic and brain alterations (Donaldson et al., 2015). 
Therefore, there is a real need to establish the capacity of phenolic compounds to perform 
microbiota modulation, since they will be appropriate for therapeutic use. 
 
3.3. Metabolic profile of the large intestine: implication of non-absorbed 
phenolic compounds 
Colonic metabolism involves the interaction between available luminal substrates and gut 
microbiota. As a consequence of the colonic metabolism, a large number and type of 
compounds are formed, participating in the modulation of physiological, metabolic and 
immunologic pathways at gut level (Donaldson et al., 2015; Hagland et al., 2015; Krishnan 
et al., 2015; Nicholson et al., 2012; Tremaroli et al., 2012). Some of the colonic metabolites 
are beneficial for the host, but others may be conferring negative effects when they are 
present in high amounts (Donaldson et al., 2015; Nicholson et al., 2012; Tremaroli et al., 
2012). The way in which phenolic compounds modify microbiota activity has not been 
completely described. Recent publications have proposed that phenolic compounds 
probably interfere with the enzymatic activity, with the availability of colonic substrates and 
with the bacteria development at gut level (Cueva et al., 2015). In this respect, the 
comprehension of the faecal metabolic pathways could be important to explain changes 
coinciding with regulation of the activity or growth of gut microorganisms, as well as to 
associate these changes with host metabolic and physiological alterations (Nicholson et al., 
2012; Tremaroli et al., 2012). Among the bacteria fermentation products, those derived 
from carbohydrates, proteins, fats and sterols have probably been the most studied 
compounds (Cueva et al., 2015; Nicholson et al., 2012; Tremaroli et al., 2012).  
Short chain fatty acids (SCFAs) 
Short chain fatty acids (SCFAs) are the predominant end-products of bacterial fermentation 
of non-digested carbohydrates (poly and oligosaccharides and resistant starch) and 
proteins (Krishnan et al., 2015; Tremaroli et al., 2012). 90-95% of SCFAs is represented by 
acetic acid, propionic acid and butyric acid. Acetic acid is the predominant acid in the 
 Introduction 
28 
 
faeces of healthy humans, followed by propionic and butyric acids. The proportion 
commonly found in the distribution of acetic, propionic and butyric acids is 60:20:20. The 
remaining fraction (5-10%) corresponds to isobutyric acid, isovaleric acid and valeric acid, 
called branched chain fatty acids. SCFAs are rapidly absorbed and metabolized by 
colonocytes, liver and muscle (Tremaroli et al., 2012). From among the SCFAs 
compounds, butyric acid has received more attention since it is the main source of energy 
for colonocytes and possesses selective anticarcinogenic and anti-inflammatory effects 
(Alcock et al., 2015; Hagland et al., 2015; Nicholson et al., 2012; Tremaroli et al., 2012). On 
the contrary, branched chain fatty acids (BCFAs), products of protein fermentation, are 
considered toxic for colonic cells (Macfarlane et al., 1992), which explains their major 
abundance in the faeces of individuals who have higher susceptibility to suffering from gut 
pathologies (Ou et al., 2012)  
The production of SCFAs is an indicator of bacterial activity, and in some cases major 
production of acetic, propionic and/or butyric acids is accompanied by an increase in 
beneficial bacteria such as Bifidobacterium and Lactobacillus spp. (Blatchford et al., 2015; 
Cueva et al., 2015; Khodaei et al., 2016). Exploration of the effects that non-absorbed 
phenolic compounds may have on the bacterial production of SCFAs has also aroused the 
curiosity of several researchers, but a definitive argument has not been established in this 
aspect due to the differences observed between results. Phenolic compounds present in 
red wine (Cueva et al., 2015) and pomegranate extract (Bialonska et al., 2010) increase the 
in-vitro production of SCFA (especially butyrate), whereas those of aqueous passion fruit 
extract (da Silva et al., 2013) and isolated punicalagin (Bialonska et al., 2010) have shown 
the opposite effect. No modifications in SCFAs concentration was observed in rats after the 
administration of trans-resveratrol and quercetin (alone or in combination) (Etxeberria et al., 
2015). The effects regarding these interactions seem to be confused, since the fibre of 
many plants is closely bound to phenolic compounds (Saura-Calixto et al., 2007). It is 
therefore difficult to discriminate whether SCFAs production results from the presence of 
fibre or is caused by phenolic compounds linked to fibre or the combination of both. 
 
Sterols 
Bile salts are metabolized in the liver from cholesterol and secreted into the intestinal lumen 
to facilitate the digestion of lipophilic compounds (fat-soluble nutrients and xenobiotics), 
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whereas diet and intestinal cellular turnover contribute with luminal cholesterol. Enzymes 
produced by certain gut microbial products catalyze the conversion of primary bile acids, 
cholic and chenodeoxycholic acids, into their respective secondary bile acids, lithocholic 
and deoxycholic acids (Hill et al., 1975; Nicholson et al., 2012). Microbial conversion of 
cholesterol generates mainly coprostanol and, to a lesser extent, coprostanone and 
cholestanone (Hill et al., 1975). 
Whereas at physiological concentration the sterols and their microbial products are 
involved in the regulation of the pathways involved in the host metabolism, at higher 
amounts they are associated with anatomic and local function alterations related to the 
aetiology of colon cancer and other intestinal diseases (Nicholson et al., 2012; Tremaroli et 
al., 2012). High fat diets, especially those of animal origin, associated with metabolic 
alterations, increase the amount of bile acids and cholesterol in the colon lumen (Rafter et 
al. 1987).  
 
Proteins 
Every day, variable amounts of nitrogenous compounds of dietary and endogenous origins 
reach the colon. Protein-rich diets, particularly those containing red meat, increase gut 
toxicity as a consequence of an overproduction of microbial products derived from protein 
fermentation. These substances, also called putrefactive compounds, include ammonia, 
faecal phenolic (phenol and p-cresol) and indolic compounds (indol and skatole), sulphur 
compounds (hydrogen sulphide, methyl mercaptan, and dimethyl sulphide), branched chain 
fatty acids, and polyamides (putrescine, agmatine, cadaverine, tyramine, and histamine). 
Intestinal ammonia is generated through the microbial deamination of urea and amino acids 
(Smith et al., 1997, Vince et al., 1973). Phenolic and indolic compounds are mainly derived 
from the microbial catabolism of aromatic amino acids (phenylalanine, tyrosine, and 
tryptophan) (Smith et al., 1997). Sulphate-reducing bacteria produce sulphur metabolites as 
a product of anaerobic respiration during the catabolism of cysteine and methionine 
(Magee et al., 2000).  
Elevated undigested luminal proteins could alter the intestinal ecology, stimulating the 
activity of nitrogen-degrading bacteria, which are considered to have detrimental effects on 
gut homeostasis (Nicholson et al., 2012; Tremaroli et al., 2012). The metabolism of 
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proteins, monitored by microbial products of their fermentation, also seems to be modified 
by the inclusion of phenolic-rich sources in the diet, as reported by in-vitro (Cueva et al., 
2015) and in-vivo studies (Hara et al., 1995). The solution is not to eliminate the proteins 
from the diet, since they are essential nutrients for the human organism. However, a dietary 
recommendation based on control of the intake of proteins should be followed. 
 
Fat 
Unmetabolized saturated and unsaturated diet fats are partially transformed in the large 
intestine. The role of fats in the gut is still confusing, since there are no conclusive results. 
Reviews show that saturated and polyunsaturated fatty acids, especially omega-6, may 
cause dysbiosis and promote proinflammatory events, whereas omega-3 and 
monounsaturated fatty acids (present in olive oil) seem to protect against bacteria 
translocation and reduce the risk of inflammation (Alcock et al., 2015). 
Choline takes part in cell membranes and, thus, red meat and eggs are probably the main 
dietary choline source. Trimethylamine is the end-product of the choline bacteria 
metabolism that is produced by intestinal microbes. The presence of this metabolite and its 
hepatic derivative has been associated with cardiovascular disease (Tremaroli et al., 2012). 
 
Figure 10. Microbial metabolism of carbohydrates (including fibre), proteins and faecal 
sterols in the large intestine 
  Introduction 
31 
 
4. Metabolic fate of phenolic compounds in the large intestine. 
4.1. In vitro models to study the colonic fate of phenolic compounds  
In-vitro models, including both enzymatic incubations and cell or tissue-based models, have 
gained a respectable position in preliminary studies to predict and interpret the behaviour of 
phenolic compounds in living beings. The main advantages that justify the use of these 
models are linked to the possibility of monitoring, under constant surveillance of 
environmental conditions, a large amount of samples with a relatively low investment in 
time and money, and the total absence of ethical conflicts. The main downside of in-vitro 
studies is that they do not fully imitate in-vivo systems. Certain parameters, such as 
enterohepatic recirculation, the continuous absorption (or efflux) by intestinal epithelium 
and the inclusion of microbiota associated with intestinal mucosa, are probably the most 
difficult to achieve in digestion models (Williamson et al., 2010).  
The different options to study the microbial transformation of phenolic compounds in the gut 
are shown in Figure 11. In-vitro fermentations have been extensively used to obtain a 
closer insight into the colon metabolism where a phenolic source comes into contact with 
gut microorganisms (Williamson et al., 2010). The phenolic test includes pure or isolated 
compounds, phenolic-rich extracts, food or pre-digested material (Correa-Betanzo et al., 
2014; Cueva et al., 2015) (Table 2). The pre-digested material can be supplied by intestinal 
content obtained from humans (ileostomy) (Langkilde et al., 2002) or from in-vitro 
gastrointestinal digestions (oral, gastric and/or duodenal steps) (Correa-Betanzo et al., 
2014) (Table 2). In turn, in-vitro gastrointestinal digestions could be different depending on 
the incubation time, incubation temperature, pH, composition of buffers, and modality, 
which includes static or dynamic models. Static digestion is performed in closed containers 
(whether or not including agitation system) and the potential bioaccessibility of each 
phenolic compound is normally calculated after the centrifugation to separate the 
undigested fraction from the digested (soluble) fraction (Bermúdez-Soto et al., 2007; 
Correa-Betanzo et al., 2014; Kahle et al., 2011). The dynamic digestion mimics the transit 
time and introduces a mechanism that simulates the biodisponibility of compounds during 
intestinal passage (Coates et al., 2007; Rubiò et al., 2014).  
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To carry out colon-simulated fermentations, faeces from animals or humans are used as 
microbial inocula (Cueva et al., 2015). In addition, to avoid high variability and to identify 
the role of faecal microorganisms and/or their produced enzymes, phenolic subtracts have 
also been exposed to a defined community of faecal microbiota composed of individual 
bacteria or a bacteria-mix (Correa-Betanzo et al., 2014). 
 
Figure 11. Scheme of the different substrates and models used for in vitro colonic 
fermentation of phenolic compounds 
 
Except for the anaerobic conditions, the techniques of in-vitro incubations do not always 
respond to the same instrumental and methodological characteristics. Colonic fermentation 
can be performed using simple (reactors, vessels, tubes) or more complex multi-
compartmental continuous systems. These consist of interconnected reactors that 
represent the different segments of the large intestine and, sometimes, oral, gastric and 
intestinal digestion steps are also included (Cueva et al., 2015). Microbial incubations 
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including simpler procedures are usually sufficient to study the colonic metabolism of 
phenolic compounds and their time-based bioconversions (Table 2).  
 
 T
a
b
le
 2
. 
D
e
s
c
ri
p
ti
o
n
 o
f 
in
 v
it
ro
 f
e
rm
e
n
ta
ti
o
n
s
 u
s
in
g
 d
if
fe
re
n
t 
p
h
e
n
o
lic
 c
o
m
p
o
u
n
d
s
 a
n
d
 t
h
e
ir
 r
e
s
p
e
c
ti
v
e
 
m
ic
ro
b
ia
l 
m
e
ta
b
o
lit
e
s
. 
T
a
b
le
 4
. 
P
h
e
n
o
lic
 m
ic
ro
b
ia
l 
m
e
ta
b
o
lit
e
s
 d
e
te
c
te
d
 i
n
 a
n
im
a
l 
b
io
lo
g
ic
a
l 
fl
u
id
s
 a
ft
e
r 
th
e
 i
n
ta
k
e
 o
f 
p
h
e
n
o
lic
-
ri
c
h
 s
o
u
rc
e
s
. 
 
 Introduction 
34 
 
The most complex continuous models are probably best-adapted to observe the effects on 
the microbial population, including long-term studies that intend to imitate a continuous 
intake of phenolic compounds. Those dynamic models containing different vessels are also 
appropriate to predict the sites of the colon (ascendant, transversal or descendent)  where 
fermentation predominates and how the primary metabolites generated are transported and 
transformed during faecal stream (Cueva et al., 2015). Nevertheless, multicompartment 
reactors are expensive and require more labour, economic investment and time for the in-
vitro procedure than static models of in-vitro incubations.  
Complementary to microbial metabolism, the exposure of test substance to cell culture 
models is used to study cellular transport (apparent bioavailability), metabolism, 
permeability (integrity of intestinal barrier) and molecular mechanisms modulation. For the 
bioavailability studies, transport mechanisms and intracellular metabolism, differentiated 
Caco-2 cells are often chosen (Konishi et al., 2004; Rubiò et al., 2014), although other cell 
lines such as hepatocytes have also been used to study hepatic metabolism (Khale et al., 
2011; Rubiò et al., 2014) and cellular transport (Lançon et al., 2004).  
To elucidate the regulation of molecular mechanisms by means of which phenolic 
compounds may exert biological activity (antioxidant, anti-inflammatory and 
anticarcinogenic effects), tumour and activated cells have been used (Coates et al., 2007; 
Colombo et al., 2013). In a simplified way, cell culture models consist of the exposure of 
cells to a certain amount of phenolic-source under defined environmental conditions and 
time periods (Coates et al., 2007; Colombo et al., 2013). Imperfections in cell culture 
models may occur when high concentration or pure standards or extracts are used, since 
the use of crude fruit or vegetable extracts or preparations may overestimate the biological 
activity and is not comparable with what occurs in the human organism. A more realistic 
approach to reach the adaptation to in-vivo situations could be the use of phenolic fractions 
obtained after in-vitro digestion or else from intestinal aspirations collected from humans or 
animals (Coates et al., 2007; Rubiò et al., 2014).  
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Figure 12. Cellular in vitro experiments used to study phenolic metabolism and/or 
molecular mechanisms 
 
 
4.2. In vivo studies to monitor the metabolism of phenolic compounds  
Human studies 
The scientific community is clamouring for further human trials to explore the role of 
phenolic compounds in the organism and to correlate their presence in biological fluids, 
such as plasma and/or urine, with the modulation of biomarkers of disease. Probably, the 
most popular design adopted to investigate the human colonic metabolism of phenolic 
compounds is through the analysis of biological fluids after an acute or sustained intake of 
a phenolic-rich source (Kahle et al., 2005) (Table 3). The main limitations related to human 
clinical studies are usually marked by economic, instrumental and infrastructural 
availability. Additionally, there are key points which differ among studies, such as the 
characteristics of the volunteers (health status, age, sex, and lifestyle), the type of 
biospecimen collected (urine, blood, faeces, breath, tissues, gastrointestinal content), the 
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phenolic source (food, extract or pure compounds) and the biomarkers to monitor the 
efficacy of the phenolic compounds studied (Williamson et al., 2005).  
 
Table 3. Phenolic microbial metabolites detected in human biological fluids after the intake 
of different phenolic-rich sources. 
 
In the particular case of colonic metabolism studies, one of the aspects to be considered is 
to clarify how phenolic compounds reach the colon. For this, the analysis of ileum fluids, 
provided by ileostomy patients, offers valuable data regarding the qualitative and 
quantitative phenolic profile of the product leaving the small intestine (Kahle et al., 2005). 
Comparison of biological fluids (mainly urine and plasma) between ileostomy patients and 
volunteers with intact colon offers an overview of the potential prominence of colon 
metabolism in the human body. 
 Introduction 
37 
 
To understand more about phenolic bioavailability and to have partial results about the 
tissue and organ exposure, the analysis of plasmatic and urinary phenolic concentrations is 
probably the predominant approach in human studies (Williamson et al., 2005). To study 
absorption both in the small intestine and in the colon, the most extensive approach is the 
phenolic analysis of samples at different collection time-points after a single or continuous 
administration of a phenolic dose (Khale et al., 2011; Williamson et al., 2005). The time 
lapse required for phenolic compounds to pass into the bloodstream depends on the 
intestinal absorption site. For example, those compounds detected within 0.5 h post-
ingestion are considered to be absorbed into the stomach. Those compounds absorbed 
into the small intestine are normally detected within an hour, and the maximum 
concentration is usually less than 4 h. Phenolic compounds and/or phenolic metabolites 
that appear 4 h post-intake are generally considered to have been absorbed at colon level.  
In the context of human bioavailability studies on phenolic compounds, blood (or plasma) 
and urine are probably the biological fluids most suitable to determine the phenolic 
metabolites concentration (Khale et al., 2011; Williamson et al., 2005). Although faeces are 
more accessible and easy to collect than blood samples, they have not been extensively 
analyzed after phenolic interventions. Faecal samples obtained before and after a dietary 
intervention offer the possibility to study local microbial and metabolic reactions to the 
treatment as well as resistance of phenolic compounds to the digestion process.  
 
Animal studies 
Certain approaches regarding colon metabolism under in-vivo conditions are impracticable 
in humans or require strict measures for their approval by Ethics Committees. To overcome 
these limitations, animal models can be a good alternative (Borges et al., 2007; Martin et 
al., 2015). Rodents and, on occasions, pigs have been used to study colonic fate and/or 
general metabolism of phenolic compounds (Borges et al., 2007; Espín et al., 2007). 
Beyond the possibility of diet and environmental control, animal models should be suitable 
to imitate, as far as possible, the human metabolism.  
Studies with animals offer the alternative of understanding the colonic fate of phenolic 
compounds in a deeper manner, due to the possibility of studying phenolic deposition and 
distribution in organs and tissue (Borges et al., 2007). However, results derived from animal 
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studies are not always well-received by certain sectors of the scientific community. In terms 
of colonic studies, some researchers remain sceptical about the extrapolation of the effects 
observed on humans. The main argument put forward to explain this behaviour is the 
difference in microbiota composition between animals and humans (Lee et al., 2011).  
Germ-free rodents have opened up an exceptional area that allows an understanding of the 
metabolic role of the colon, thus limiting differences between species. Germ-free animals 
born and grown in sterile conditions are hence a model that lacks colonic microbial 
metabolism. This makes it possible to explore the role of gut microbiota in the metabolism 
and fate of phenolic compounds through comparison with their conventional counterparts or 
with germ-free animals inoculated with selected microbial species (Schneider et al., 2000) 
or whole communities from humans (Tamura et al., 2009). Transplantation of human 
faeces to sterilized rodents offers advantages such as reducing the differences observed 
between humans and animals in terms of gut metabolism. 
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Phenolic compounds are a small fraction of phytochemicals of plant-based products. 
Despite their low concentration, phenolic compounds have generated great expectations as 
natural therapeutics, due to their antioxidant, anti-inflammatory and anticarcinogenic 
biological properties.  
An important percentage of the phenolic compounds ingested through the diet survive 
gastrointestinal digestion and reach the large intestine unmetabolized. Once there, the local 
microbiota transforms the original compounds present in the food into simpler related 
metabolites that do not necessary share the same biological features as their precursors. 
As a result, a variable mixture of native phenolic compounds and their microbial products 
stay in the large intestinal lumen. The accumulation of this complex mixture of dietary 
phenols and their metabolites not only provides local antioxidant, anti-inflammatory and 
anticarcinogenic protection, but also could have indirect implications in host health through 
the modification of microbiota composition and/or its activity. In addition, the absorption of 
these compounds through the colon contributes to the bioavailability of food phenols and 
consequently to their potential systemic bioactivity. 
The present Doctoral Thesis is framed in the context of two different projects: (i) the 
MEFOP project: Metabolic Fate of Olive Oil Phenolic Compounds in Humans: Study of 
metabolic pathways and tissue distribution. The global aim of the project was to assess the 
metabolic fate of olive oil phenolic compounds by using a nutrigenomic approach, and (ii) 
the INCOMES project: Guide for the substantiation of health claims in foods: immune, 
cognitive functions and metabolic syndrome (Collaborative project between Food 
Companies & Research Centres). The main goal of the Consortium INCOMES, co-funded 
by the Spanish Government, was to give free access to the results, mainly conclusions and 
guidelines intended to clarify methodologies for scientific support of health claims in 
foods/ingredients. Prior to the efficacy studies of the food bioactive compounds, it is 
necessary to perform nutrikinetic studies: from the simplest in vitro assays, recommended 
in early stages of the development of a functional food, to human intervention studies, 
which have been carried out in the framework of this Doctoral Thesis. 
In an attempt to complete the information concerning the fate of phenolic compounds in the 
human body, the hypothesis of the Doctoral Thesis was based on the fact that the process 
that take place in the colon should not be ignored, since it is a site of relevant metabolic 
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activity. The phenolic-bacteria interaction could modify several aspects of the gut 
ecosystem that could affect the local and general health of the host. 
In the context of the interest in the colonic metabolism of food bioactive compounds, the 
main objective of the present Doctoral Thesis was to study the colonic metabolic 
pathways of different phenolic groups from in-vitro to in-vivo approach, and the possible 
implications that phenolic compounds (or their microbial derivatives) may have in the large 
intestine ecosystem. For this, three phenolic sources containing a wide and complete range 
of phenolic groups were selected: virgin olive oil, pomegranate, and Arbutus unedo fruit. 
Different specific objectives have been defined in order to achieve the general aim: 
 
I. Characterize and quantify the phenolic compounds of olive oil enriched with its own 
phenolic compounds and in combination with thyme phenolic compounds, 
pomegranate products (juice, pulp and peel extract) and Arbutus unedo fruit. 
II. Propose the colonic metabolic pathways of the most representative phenolic 
compounds present in phenol-enriched olive oils, pomegranate and Arbutus unedo 
through the application of in-vitro colonic fermentation. 
III. Compare and define the behaviour of the phenolic compounds in the large intestine 
according to their individual chemical structure and the nature of their microbial 
derivatives.  
IV. Study the in-vivo colonic metabolism in humans of the main phenolic compounds 
detected in phenol-enriched olive oils, pomegranate juice and Arbutus unedo fruit 
through the analysis of faeces after dietary interventions.  
V. Assess, through the analysis of human faecal samples, the changes in the gut 
ecosystem (microbial and metabolic modifications) as a consequence of the lumen 
accumulation of phenolic compounds and/or their microbial metabolites promoted 
by the sustained intake of phenol-enriched olive oils and pomegranate juice.  
VI. Compare the results obtained from in-vitro and in-vivo studies in order to establish 
whether the observations derived from in-vitro experiments are appropriate to 
predict the colonic metabolism of phenolic compounds in human beings 
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Figure 13. The proposed objectives achieved in each publication contained in this Doctoral 
Thesis 
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Scope: In the present study, the individual colonic metabolism of the main components of the virgin olive 
oil phenolic fraction was evaluated by an in vitro model using human faecal microbiota. To assess 
differences in metabolism related to the molecular structure, four phenolic standards were selected, 
tyrosol, hydroxytyrosol, hydroxytyrosol acetate and oleuropein. After studying the in vitro colonic 
metabolism pathways of the individual phenols, the presence of their colonic metabolites was investigated 
in human faecal samples obtained before and after the sustained intake (3 weeks) of a daily dose of 25 
mL of a phenol-enriched olive oil. 
Methods and results: The in vitro colon fermentation of the four individual phenolic compounds revealed 
(i) an increase in phenolic acids, (ii) the stability of hydroxytyrosol and tyrosol and (iii) the high 
degradation of hydroxytyrosol acetate and oleuropein. Additionally, a moderate intake of a phenol-rich 
olive oil raised the concentration in human faeces of free hydroxytyrosol and phenylacetic and 
phenylpropionic acids. 
Conclusion: The products of colonic catabolism of olive oil phenolic compounds could be good 
candidates for novel preventive strategies and open a promising line of research into the preventive 
action of olive oil phenols in colon and other bowel diseases. 
 
Keywords:  
Faecal microbial metabolism / Gut phenolic metabolites / Hydroxytyrosol / Metabolic pathways / Olive oil 
phenolic compounds 
 
1. INTRODUCTION 
Virgin olive oil is the most popular fat source in 
Mediterranean countries where it is consumed 
daily in moderate amounts [1]. Its production is 
based on mechanical procedures that imply the 
presence of minor bioactive substances in 
contrast with refined olive oil and other 
commercial oils [2]. Among these substances, the 
phenolic compounds have received much 
attention over recent years because they have 
properties related to a decreased risk and risk 
factors of chronic diseases such as cardiovascular 
disease [3] and certain cancers [4]. The phenolic 
fraction of virgin olive oil is made up of simple 
phenols, the most representative of which are the 
phenolic alcohols (tyrosol, hydroxytyrosol, 
hydroxytyrosol acetate) and complex phenols, 
such as oleuropein and ligstroside and their 
aglycone derivatives (secoiridoids) [5–7]. 
Several research groups have investigated the 
absorption, metabolism, distribution and excretion 
of olive oil phenols, especially tyrosol, 
hydroxytyrosol, secoiridoids (oleuropein and 
ligstroside) and their aglycones, under both in vitro 
and in vivo conditions [8–10]. These studies are 
useful for the knowledge they supply about the 
bioavailability and the mechanism of action of 
these compounds in the body and to understand 
how they could carry out their bioactive function. 
Results and Discussion 
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The digestion process of the aforementioned 
phenolics has been widely studied, especially the 
phenomena in the upper gastrointestinal tract: 
(stomach and small intestine). Over recent years, 
the behaviour of phenolic compounds in the colon 
has attracted much attention because they may 
act as prebiotics, since they are able to reach the 
colon and be used by bacteria such as 
bifidobacteria [11], which exert beneficial effects. 
Also, microbial fermentation of phenolic 
compounds in the colon results in the release of 
low molecular weight metabolites that could 
influence host health [12]. Virgin olive oil phenols 
could reach the colon by different ways: non-
absorbed food fraction, metabolites resulting from 
the enterohepatic recirculation or as a 
consequence of the basolateral-apical transport of 
intestinal cells [13]. For a first assessment of gut 
metabolism and to characterise microbial 
fermentation products of dietary polyphenols, 
many researchers opt for an in vitro fermentation 
model using faeces from human or animals as 
microbial inoculums. In vitro experiments have 
been extensively used to study colonic catabolism 
of polyphenols such as flavan-3-ols [14–16], 
estilbenes [12], lignans and isoflavones [17, 18].  
The main limitation of in vitro fermentation 
procedures is that they do not mimic the in vivo 
conditions but are useful for studying the 
metabolic fate of the compounds in the colon 
because it is possible to follow their performance 
over time and they are good models to 
complement with in vivo studies. 
Despite the relevant information in the literature 
related with the olive oil polyphenols, the study of 
their colon fate has yet to be considered. To the 
best of our knowledge, only two studies have 
been focused on the colon metabolism of 
oleuropein, one in vitro [9] and the other from a 
study in rats [19], but there is no information about 
the most characteristic olive oil phenols as 
hydroxytyrosol, tyrosol and hydroxytyrosol-acetate 
colonic pathways. In this context, the aim of this 
work is to study the individual colonic metabolism 
of the main components of the virgin olive oil 
phenolic fraction through an in vitro model using 
human faecal microbiota. To assess differences in 
metabolism related to the molecular structure, four 
phenolic standards were selected, these being 
tyrosol, hydroxytyrosol, hydroxytyrosol acetate 
and oleuropein. After studying the in vitro colonic 
metabolism pathways of the four individual 
phenolics, the presence of their colonic 
metabolites was investigated in human faecal 
samples obtained before and after the sustained 
intake of a daily dose of 25 mL of a phenol-
enriched olive oil during 3 weeks. 
 
2 MATERIALS AND METHODS 
2.1. In vitro colonic fermentation 
Faecal samples were collected from three healthy 
volunteers who followed normal dietary habits and 
declared they had not ingested antibiotics for at 
least 3 months prior to the sample collection. The 
fermentation medium was carbonate–phosphate 
buffer and this was prepared according to Durand 
et al. [20] by mixing (g/L): 9.240 NaHCO3, 3.542 
Na2HPO4·2H2O, 0.470 NaCl, 0.450 KCl, 0.227 
Na2SO4·10H2O, 0.055 CaCl2 (anhydrous), 0.100 
MgCl2·6 H2O, 0.400 urea with 10 mL of trace 
element solution containing (mg/L) 3680 
FeSO4·7H2O, 1159 MnSO4·H2O, 440 
ZnSO4·7H2O, 120 CoCl2·6H2O, 98 CuSO4·5H2O 
and 17.4 Mo7(NH4)6O24·4H2O. The medium was 
adjusted to pH 7.0 using hydrochloric acid. Before 
its use, the culture medium was maintained in 
anaerobic chamber for 48 h, using gas generator 
bags (CO2) to generate anaerobic atmosphere. 
The anaerobic environment was continuously 
monitored by anaerobic indicator strips (Becton 
Dickinson, MD, USA). Standards of tyrosol and 
oleuropein were purchased from Extrasynthese 
(Genay, France). Hydroxytyrosol and 
hydroxytyrosol acetate were purchased from 
Seprox Biotech (Madrid, Spain). 1,2-dihydroxy 
benzoic acid, phenylacetic acid, 4-hydroxybenzoic 
acid, 2-phenylpropionic acid, 2-(4’_hydroxyphenyl) 
acetic acid, 2-(3’-hydroxyphenyl)acetic acid, 3,4-
dihydroxybenzoic acid, 2-(3’,4’-dihydroxyphenyl) 
acetic acid, 3-(4’-hydroxyphenyl)propionic acid 
and caffeic acid were purchased from Sigma-
Aldrich (St. Louis, MO, USA). 
The in vitro colonic fermentation method used in 
this study was adapted from Serra et al. [21]. For 
each volunteer, 15 g of fresh faeces were 
homogenised 60 s in a stomacher bag with 300 
mL of culture medium to make 5% faecal slurry. 
Results and Discussion 
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After homogenization, the faecal slurry was 
filtered and left to stand for 30 min. After this time, 
10 mL were added to 15 mL disposable tubes. 
After the addition of 5 µmol of the standard 
aqueous solution (phenol standard final 
concentration 500 µM), the disposable tubes were 
incubated in anaerobic chambers at 37 ºC in an 
orbital shaker (60 strokes/min) in order to mimic 
colon conditions (anaerobic conditions were 
controlled by anaerobic indicator strips). The high 
initial concentration (500 µM) of the parent 
molecule was chosen in order to determine, at low 
concentration levels, the generated metabolites 
being possible to establish the colonic 
fermentation pathways for each molecule. 
Samples were collected at 0, 2, 6, 12, 24 and 48 h 
of incubation. Aliquots of the fermented faecal 
samples (500 µL) were collected from each 
time/tube and stored immediately at −80 ºC until 
the chromatographic analysis. All the fermentation 
samples were incubated in triplicate. Parallel to 
the fermentation samples, a control (faecal slurry 
without phenolic substrate) was prepared for each 
fermentation time point to identify the metabolite 
signals no generated by the phenolic standards 
added to the fermentation tubes. Also, incubations 
of the phenolic standards without faecal 
inoculation (blank 1) and with heat-inactivated 
faecal slurry (blank 2) were incubated at each time 
points (0, 2, 6, 12, 24 and 48 h) to take into 
account possible chemical degradation of the 
phenolic compounds. 
2.2. Human intervention study: In vivo model 
Faecal samples from ten subjects were used to 
determine olive oil phenolic metabolites identified 
in the in vitro colonic fermentation model. The 
faecal samples were obtained before and after the 
consumption (25 mL/day) of phenol-rich olive oil 
(Table 1) for a period of 3 weeks. Preceding the 
intervention there was a 2-week wash-out period 
where common olive oil (blend of refined and a 
small percentage of virgin olive oil) was the main 
fat consumed. To avoid an excessive intake of 
phenolic compounds during the intervention 
period, participants were advised to limit the 
consumption of phenol-rich foods. Faecal samples 
from each volunteer were collected after the 
wash-out period (pre-olive oil intake) and at the 
end of the 3 weeks of the intervention study (post-
olive oil intake).  
 
Table 1. Hydroxytyrosol derivatives composition of ingested phenol-enriched olive oil
Compound mg/kg oil 
Hydroxytyrosol 8.5 ±  0.6  
Hydroxytyrosol acetate 33.4 ±  2.2  
3,4-DHPEA-EDA 269.3 ±  14.8  
3,4-DHPEA-EA 28.5  ±  2.5  
Total hydroxytyrosol derivatives 339.8  
Tyrosol 4.4 ±  0.4  
p-DHPEA-EDA 11.4 ±  1.2  
p-DHPEA-EA 9.9 ±  0.7  
Total tyrosol derivates 25.7  
3,4-DHPEA-EDA: hydroxytyrosol linked to the dialdehydic form of elenolic acid 
3,4-DHPEA-EA: hydroxytyrosol linked to elenolic acid p-DHPEA-EDA: tyrosol linked to the dialdehydic form of elenolic acid 
p-DHPEA-EA: tyrosol linked to elenolic acid 
 
The subjects gave their written informed consent 
before participation (Ethics Committee for Human 
Research of the IMIM-Hospital del Mar, 
Barcelona, Spain, CEIC-PSMAR 2009/3347/I). 
Freshly voided faecal samples were collected by 
the volunteers into a sterile pot and brought to the 
laboratory under anaerobic conditions within 2 h 
after defecation, immediately mixed in a 
phosphate buffer (PBS; final concentration 10% of 
faecal sample) and centrifuged for 5 min at 13000 
rpm. The supernatant was divided into aliquots of 
500 µL and stored at −20ºC until chromatographic 
analysis. 
 
2.3 Metabolite analysis 
2.3.1 Sample pre-treatment 
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Samples of in vitro colonic fermentations and the 
supernatant, obtained from the faeces of the 
human intervention study (500 µL), were slowly 
thawed in ice, transferred into a disposable tube 
and acidified with 60 µL of hydrochloric acid (37%) 
to inactivate the microbiota. A liquid–liquid 
extraction was carried out twice by adding 5 mL of 
ethyl acetate and centrifuged (10 min, 9000 rpm, 
at room temperature). The supernatants of both 
centrifugations were combined and evaporated 
under nitrogen flow at 30ºC. The residue was 
reconstituted with 500 µL of 
water/acetonitrile/methanol (86:12:2, v/v/v), 
filtered with a 0.22 µm nylon syringe filter and 
transferred into chromatographic vials to be 
analysed. 
 
2.3.2. Chromatographic analysis 
The chromatographic analysis of tyrosol, hy-
droxytyrosol, hydroxytyrosol acetate and 
oleuropein was performed with a Waters Acquity 
Ultra-PerformanceTM LC coupled to MS/MS 
(UPLC-ESI-MS/MS) system (Waters, Milford, MA, 
USA), equipped with a binary pump system 
(Waters). The chromatographic column was an 
Acquity BEH C18 (100 × 2.1 mm i.d.) with a 1.7 
µm particle size (Waters). A binary mobile phase 
with a gradient elution was used. Eluent A was 
Milli-Q water/acetic acid (99.8:0.2, v/v) and eluent 
B was ACN. The gradient was performed as 
follows: 0–2.10 min, 3% B; 2.10–7 min, 3–7% B; 
7–25 min, 7–40% B; 25–25.10 min, 40–100% B; 
25.10–27.10 min, 100–3% B; 27.10–30 min, 3% B 
isocratic. The flow rate was 0.4 mL/min and the 
injection volume was 2.5 µL. The MS/MS analyses 
were carried out on a triple quadrupol detector 
mass spectrometer (Waters) equipped with a Z-
spray electrospray interface. The analyses were 
done in the negative ion mode and the data were 
acquired with the selected reaction monitoring 
mode. The MS/MS parameters were as follows: 
capillary voltage, 3 kV; source temperature, 150 
ºC; cone gas flow rate, 80 L/h and desolvation gas 
flow rate, 800 L/h; desolvation temperature, 400 
ºC. Nitrogen (>99% purity) and argon (99% purity) 
were used as the nebulising and collision gases, 
respectively. The cone voltages and collision 
energies were optimised for each analyte by 
injection of each standard compound in a mixture 
of acetonitrile/water (50/50, v/v) at a concentration 
of 10 mg/L. Two transitions were studied for each 
compound. The most abundant transition was 
used for quantification, while the second most 
abundant was used for confirmation purposes. 
The dwell time established for each transition was 
30 ms. Data acquisition was carried out with the 
MassLynx v 4.1 software. 
1,2-Dihydroxybenzene, phenylacetic acid, 4-
hydroxybenzoic acid, 2-phenylpropionic acid, 2-
(4’-hydroxyphenyl)acetic acid, 2-(3’-
hydroxyphenyl)acetic acid, 3,4-dihydroxybenzoic 
acid, hydroxytyrosol, tyrosol, hydroxy-tyrosol 
acetate, oleuropein, 2-(3’,4’ -dihydroxyphenyl) 
acetic acid, 3-(4’-hydroxyphenyl)propionic acid 
were quantified by using its own calibration curve. 
Elenolic acid was quantified using the caffeic acid 
calibration curve and oleuropein aglycone was 
quantified using the oleuropein calibration curve. 
 
2.4. Statistical analysis 
From in vitro study, each sample was analysed in 
triplicate (three replicates by three volunteers; n = 
9) and data are presented as mean values ± 
standard deviation (n = 9) minus the concentration 
of the compound in the control (faecal 
culturemedium without phenolic compound). From 
the in vivo study, the differences in the 
concentration of metabolites in human faecal 
samples between day 0 (before the intake of 
phenol-rich olive oil) and day 21 (after the intake 
of phenol-rich olive oil during 3 weeks) were 
analysed by ANOVA using STAT-GRAPHICS 
Plus 5.1. The level of significance was p 0.05. 
 
3 RESULTS AND DISCUSSION 
3.1 Kinetics of colonic metabolism in in vitro 
fermentation  
Changes in the precursor phenolic compounds 
tyrosol, hydroxytyrosol, hydroxytyrosol acetate 
and oleuropein as well the formation of the 
microbial metabolites, were monitored during the 
in vitro colon fermentation (from 0 to 48 h). Three 
independent fermentations were carried out using 
three human faecal samples provided by three 
healthy volunteers (H1, H2 and H3). The results 
correspond to the average concentration (three 
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replicates from three volunteers) at each 
fermentation time (0–48 h). The amounts of the 
phenolic compounds were corrected for the 
endogenous levels of the phenolic metabolites 
detected in the control fermentations of the 
respective donor faeces (faecal culture medium 
without phenolic compound; Sections 2 and 2.2). 
 
Figure 1. (A) Conversion of tyrosol (solid line) during in vitro colon fermentation and generation of 2-(4’’-
hydroxyphenyl)acetic acid (dotted line). (B) Conversion of hydroxytyrosol (solid line) during in vitro colon 
fermentation and generation of phenylacetic acid, 2-(4’-hydroxyphenyl)acetic acid and 2-(3’,4’’-
dihydroxyphenyl)acetic acid (dotted lines). (C) Conversion of hydroxytyrosol acetate (solid line) during in 
vitro colon fermentation and generation of hydroxytyrosol, phenylacetic acid, 2-(4’’-hydroxyphenyl)acetic 
acid, 2-(3’’,4’’-dihydroxyphenyl)acetic acid, 3(4’’-hydroxyphenyl)-propionic acid (dotted lines). (D) 
Conversion of oleuropein (solid line) during in vitro colon fermentation and generation of hydroxytyrosol, 
hydroxytyrosol acetate, elenolic acid and oleuropein aglycone (dotted lines). 
 
To monitor the possible non-microbial degradation 
of the phenolic compounds during incubation, two 
controls were included: culture medium with 
phenolic compound but without faecal inoculums 
(blank 1), and faecal culture medium with heat-
inactivated microbiota incubated with phenolic 
compound (blank 2). When these two controls 
were analysed, in blank 1 more degradation of 
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phenolic compounds was observed than in blank 
2. Tyrosol, hydroxytyrosol, hydroxytyrosol acetate 
and oleuropein showed an important degree of 
degradation when they were incubated in culture 
medium (pH 7.0) without faecal inoculums (blank 
1) with a practically absent generation of 
metabolites. This suggests that these phenolic 
compounds were chemically degraded as a 
consequence of incubation conditions. Chemical 
degradation of olive oil phenols was also observed 
in other studies in digestive mediums at pH 6.5 
[22]. However, when olive oil phenols were 
fermented in a faecal medium with heat-
inactivated microbiota (blank 2), the parent 
compound reached concentrations similar to those 
in samples at 0 h. These suggest that faecal 
matrix could protect olive oil phenols from 
chemical degradation and put in evidence that the 
metabolism of parent compound is also due to the 
action of colon microbiota. Kinetic studies of 
tyrosol, hydroxytyrosol, hydroxytyrosol acetate 
and oleuropein are presented in Fig. 1A–D, 
respectively (tables with complete data are 
presented in Supporting Information). The four 
phenolics studied showed modifications in their 
concentration during the first period of incubation 
(0–6 h) being the more unstable hydroxytyrosol 
acetate (Fig. 1C) and oleuropein (Fig. 1D). In 
contrast, tyrosol (Fig. 1A) and hydroxytyrosol 
(Fig. 1B) showed a partial degradation until 6 h to 
remain stables until 48 h of fermentation. Similar 
stability has also been observed with other low 
molecular weight phenols, such as gallic acid, 
after in vitro colonic fermentation by using rat [23] 
or human [24] faecal inoculums. 
Figure 2 shows the colonic pathways of tyrosol, 
hydroxytyrosol and hydroxytyrosol acetate. When 
tyrosol was fermented, 2-(4’-hydroxyphenyl)acetic 
acid was the only fermentation product detected 
and its concentration was greater than 10 µM after 
48 h of incubation (Fig. 1A). On the other hand, 
more effective catabolism was observed when 
hydroxytyrosol was incubated (Fig. 1B). Three 
metabolites, 2-(3’,4’-dihydroxyphenyl)acetic acid, 
2-(4’-hydroxyphenyl)acetic acid (common 
metabolite obtained from the metabolism of 
tyrosol) and phenylacetic acid (Fig. 2) were 
identified. Phenylacetic acid was the main end 
catabolite through the fermentation in all the 
samples, reaching a peak at 24 h. Low recovery of 
parent compounds through the initial time of 
fermentation may be related to their low solubility 
and/or bond to another compounds presented in 
the fermentation matrix. Moreover, low recovery of 
metabolites compared with the rate of degradation 
of parent compounds hydroxytyrosol and tyrosol 
could be a caused of chemical degradation, as we 
observed when we analysed blank 1.  
When hydroxytyrosol acetate was fermented, a 
rapid transformation into hydroxytyrosol was 
observed (Fig. 1C). The metabolism of 
hydroxytyrosol acetate resulted in a high number 
of catabolites (Fig. 2), with 2-(3’,4’-
dihydroxyphenyl)acetic acid, 2-(4’-hydroxyphenyl) 
acetic acid and phenylacetic acid, being common 
to hydroxytyrosol metabolism. Besides these 
common metabolites, some others, such as 3-(4’-
hydroxyphenyl) propionic acid was only detected 
in the hydroxytyrosol acetate fermentation 
medium and reached their maximum 
concentration at 48 h (Fig. 1C). As a general 
trend, tyrosol, hydroxytyrosol and hydroxytyrosol 
acetate showed a rise in the production of 
phenylacetic and phenylpropionic acids and their 
hydroxylated forms in faecal culture mediums over 
up to 48 h of fermentation, reaching their 
maximum concentration between 12 and 48 h. 
These phenolic acids were also reported after 
fermentation of other types of flavonoids [23–28]. 
Figure 2 shows the common metabolic pathways 
of the proposed routes for the colonic metabolism 
of tyrosol, hydroxytyrosol and hydroxytyrosol 
acetate. The first reaction of catabolism for the 
three phenolic compounds is probably due to a 
microbial oxidation of the primary alcohol that 
transforms the original molecule into hydroxylated 
phenylacetic acids. There are two microbial 
enzymes involved in the oxidation of alcohols in 
the colon, namely alcohol dehydrogenase and 
aldehyde dehydrogenase [29]. The first one 
transforms the phenol alcohol into phenylaldehyde 
while the second one, which has also been 
reported as a possible pathway of flavonols and 
flavones [30], transforms, in general terms, 
hydroxyphenylacetaldehyde and dihydroxyphenyl 
acetaldehyde into hydroxyphenylacetic acid and 
dihydroxyphenyl acetic acid, respectively.  
In this research, hydroxytyrosol was the main end 
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product of hydroxytyrosol acetate as a 
consequence of a first hydrolysis of the molecule 
(Fig. 2), probably due to the action of microbial 
esterases that cleave the ester bond from the 
molecule. Despite oscillations, a constant increase 
in the concentration of hydroxytyrosol over the 
fermentation time was observed (Fig. 1C). Non-
substract-specific demethylases have been 
described in human faeces [31]. These may be 
involved in the demethylation of hydroxytyrosol 
acetate to produce 2-(3’,4’-dihydroxyphenyl)acetic 
acid as an intermediate product or they may be 
produced in parallel by the oxidation of the 
molecules of hydroxytyrosol yielded by the 
hydrolysis of hydroxytyrosol acetate, as described 
above in the in vitro fermentation of 
hydroxytyrosol. Subsequent dehydroxylations of 
2-(3’,4’-dihydroxyphenyl)acetic acid caused the 
appearance of 2-(4’-hydroxyphenyl)acetic and 
phenylacetic acids (Fig. 2). Colon bacteria 
dihydroxylation is an extended activity in the colon 
where a wide range of substances undergo the 
loss of one or more hydroxyl groups [32]. In this 
research, 3-(3’-hydroxyphenyl)propionic acid and 
3-(4’-hydroxyphenyl)propionic acid (Fig. 2) were 
also detected as microbial metabolites of 
hydroxytyrosol acetate (in the figure is only shown 
3-(4’-hydroxyphenylpropionic) acid). However, we 
were unable to establish the reaction involved in 
this transformation (Fig. 2).  
 
 
 
 
 
Figure 2. Proposed colonic pathway of tyrosol, hydroxytyrosl and hydroxytyrosol acetate. Compounds 
marked in bold were detected in the fermentation medium between 0 and 48 h. Compounds marked in 
grey were not detected in the fermentation medium at any time. 
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The final metabolites, 4’-hydroxybenzoic acid and 
1,2-dihydroxybenzene (marked in grey), described 
in the metabolic fate of tyrosol, hydroxytyrosol and 
hydroxytyrosol acetate (Fig. 2) were not detected 
during 48 h of fermentation. This may indicate that 
dihydroxylation is the preferential catabolic route 
of microorganisms present in human faeces. 
However, 4-hydroxybenzoic acid appears in urine 
after flavan-3-ols intake but it was absent from the 
in vitro fermentation samples of these flavonoids 
suggesting that this compound is a product of the 
post absorption of faecal metabolites [27]. 2-(3’-
hydroxyphenyl)acetic acid was detected at very 
low quantities supporting the idea of the sensitivity 
of the hydroxyl group in third position to be 
degraded. Alternatively, it may have been rapidly 
transformed to release phenylacetic acid into the 
medium, a metabolite absent in tyrosol 
fermentation (Fig. 2). Oleuropein is an ester of 
hydroxytyrosol and elenolic acid linked to glucose 
present in the olive fruit. During the virgin olive oil 
extraction process, this glycoside phenolic is 
hydrolysed by endogenous glucosidases releasing 
the aglyconic forms (secoiridoids) and the simple 
phenols, such as hydroxytyrosol and tyrosol. 
Oleuropein was degraded significantly during the 
first period of incubation (Fig. 1D). This instability 
was also observed by Corona et al. when 
oleuropein was fermented in the presence of 
human faecal inoculums [9]. Figure 3 shows the 
colonic pathway of oleuropein. Fermentation of 
oleuropein yielded hydroxytyrosol as the main 
metabolite increasing its concentration 
progressively during the 48 h of incubation (Fig. 
1D). Hydroxytyrosol was also detected when 
oleuropein was fermented in the presence of 
human faeces together with two other metabolites 
that could not be identified [9]. In our study, 
besides hydroxytyrosol, we detected 
hydroxytyrosol acetate, elenolic acid and 
oleuropein aglycone (Fig. 3) probably formed as 
consequence of the hydrolytic transformation of 
oleuropein. Interestingly, hydroxytyrosol acetate 
that might be produced as a consequence of the 
oleuropein aglycone hydrolysis, contrary to when 
it was fermented alone, remained in the medium 
for the 48 h of incubation. A similar stability was 
observed when caffeic and chlorogenic acids 
(caffeic acid linked to quinic acid) were fermented 
[24]. 
As it is shown in Fig. 1D, oleuropein was rapidly 
deglycosylated to oleuropein aglycone. This 
compound was subsequently hydrolysed to 
elenolic acid and hydroxytyrosol, probably by 
microbial esterase activity. Previous studies have 
shown that oleuropein and its aglycone were 
degraded by the enzyme mentioned below [33]. 
In our study, elenolic acid and oleuropein 
aglycone were detected at initial times of 
incubation at low amounts, decreasing to trace 
levels at 12 h until there were no negligible 
amounts at 24 h of incubation (Fig. 1D). 
A recent study has been reported that bacterial 
strains of Lactobacillus, Bifidobacterium and 
Enterococcus, common inhabitant of the human 
colon, were capable of hydrolysing oleuropein, 
releasing hydroxytyrosol as the main product. 
However, only two strains were capable of 
producing oleuropein aglycone [34]. These results 
suggest that specific bacteria could be involved in 
the production of oleuropein aglycone and its 
rapid degradation by esterase enzymes could 
justify its low concentration in the oleuropein 
fermentation medium in our study. 
The microbial origin of the aforementioned 
metabolites was already demonstrated herein by 
in vitro fermentation. Interestingly, in the in vitro 
fermentation, 2-(3’-hydroxyphenyl)acetic acid, 
although it was proposed in the metabolic fate of 
tyrosol (Fig. 2) and hydroxytyrosol (Fig. 2), was 
detected at very low concentrations in the 
fermentation medium. 
Colonic microbial fermentation products from 
polyphenol-rich foods and other types of dietary 
ingredients, such as proteins [35], produce a wide 
range of phenolic acids, especially phenylacetic 
and phenylpropionic acids. However, specific 
metabolites may be characteristic of a specific 
food source or polyphenol class. For example, the 
production of phenyl-γ-valerolactones and phenyl-
valeric acid is typical when flavan-3-ols are 
fermented [27]. In our study, a highest production 
of phenylacetic and phenylpropionic acids was 
found when olive oil polyphenols were fermented. 
Nevertheless, the presence of hydroxytyrosol and 
other oleuropein metabolites could be the 
consumption marker of olive oil phenols in faeces.
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Figure 3. Proposed colonic pathway of oleuropein. Compounds marked in bold were detected in the 
fermentation medium between 0 and 48 h. Compounds marked in grey were not detected in the 
fermentation medium at any time. 
3.2 Human intervention study: In vivo model 
In this work, an in vitro colon fermentation and an 
in vivo intervention study were combined. We 
considered the in vitro experiment to elucidate the 
main colon metabolites of olive oil polyphenols to 
facilitate the exploratory analysis of human faecal 
samples in an in vivo study. The phenolic 
metabolites in faecal samples from the ten 
volunteers were determined after the wash-out 
period (prior to olive oil intake) and after 21 days 
of moderate intake of 25 mL/day of a phenol-rich 
olive oil (post-olive oil intake) and the results 
obtained are shown in Fig. 4. After 3 weeks, an 
increase in the concentration of phenylacetic acid, 
2-(4’-hydroxyphenyl)acetic acid, 2-(3’-
hydroxyphenyl)acetic acid, 3-(4’-hydroxyphenyl)-
propionic acid, and the total phenol content 
obtained by the sum of all the phenolic 
metabolites quantified was observed (Fig. 4A) but 
the differences in the samples between the pre- 
and post-olive oil intakes were not statistically 
significant. The microbial origin of the 
aforementioned metabolites was already 
demonstrated herein by in vitro fermentation. 
Interestingly, in the in vitro fermentation, 2-(3’- 
hydroxyphenyl)acetic acid, although it was 
proposed in the metabolic fate of tyrosol (Fig. 2) 
and hydroxytyrosol (Fig. 2), was detected at very 
low concentrations in the fermentation medium. 
However, an important increase in this metabolite 
in human faeces was observed after the intake of 
olive oil (Fig. 4A). 
To the best of our knowledge, there are no data 
regarding the effects of olive oil intake on the 
colonic phenol metabolites in human intervention 
studies; but the intake of other phenol-rich foods 
has showed changes in their concentration in 
faeces. For example, an increase of phenolic 
acids was observed after the intake of raspberries 
[36] and orange juice [37], similarly to the results 
observed in our study. This common catabolism of 
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different phenolic groups could explain the 
presence of these phenolic acids in human faeces 
obtained before the phenol-rich olive oil intake 
(Fig. 4A). It is not possible to ascertain whether or 
not a small portion of these metabolites were 
derived from the catabolism of olive oil phenolic 
compounds. However, the intervention period with 
the phenol-rich olive oil during 3 weeks resulted in 
an increase in the concentrations of these 
phenolic acids in human faeces.  
 
 
Figure 4. (A) Phenylacetic acid: PhelAA, 2-(4’-hydroxyphenyl)acetic acid: 2–4’-OH-PhelAA, 2-(3’-
hydroxyphenyl)acetic acid: 2–3’-OH-PhelAA, 3-(4’-hydroxyphenyl)propionic acid: 3–4’-OH-PhelPA and the 
total; and (B) hydroxytyrosol metabolites in human faecal samples before (pre-) and after (post-) intake of 
phenol-enriched olive oil. The asterisk (*) indicates the mean value is significantly different from the 
baseline concentration (p < 0.05).  
Of special interest is the significant increase in the 
concentration of free hydroxytyrosol after the 
intake of phenol-rich olive oil (p < 0.05; Fig. 4B). 
Besides low concentrations of free hydroxytyrosol 
being detected in the faeces of the all participants 
in the study, the increase in its concentration after 
3 weeks of phenol-rich olive oil intake could be 
used as a biomarker of virgin olive oil 
consumption (Fig. 4B). Therefore, while a rapid 
absorption occurred in the small intestine [8], and 
eventual losses could occur during intestinal 
transit [22], a small proportion of hydroxytyrosol 
and its derivatives still pass into the large intestine 
[38]. The presence of low but significant amounts 
of free hydroxytyrosol in faeces in the present 
work could be related with the high stability of 
hydroxytyrosol observed in the in vitro study. In 
relation to other olive oil phenols, tyrosol and 
hydroxytyrosol acetate were detected in higher 
amounts in two and three faecal samples, 
respectively, while oleuropein was negligible in all 
the faecal samples analysed (data not shown) 
after the 3 weeks intervention period. Detection of 
tyrosol in only two of ten faecal samples may be 
related with the low quantities of tyrosol and 
ligstroside aglycone compared with the 
concentration of hydroxytyrosol and oleuropein 
derivatives in the phenol-rich olive oil used in the 
intervention study (Table 1). 
Oleuropein was not detected in any of the faecal 
samples probably due to its low concentration in 
the olive oil and its instability during digestion. As 
we have observed in the in vitro experiment, 
oleuropein aglycone and elenolic acid were 
detected in the fermentation medium during the 
first 12 h of fermentation at low concentration (Fig. 
1D), despite the high amount of oleuropein 
submitted to fermentation. In a recent in vivo 
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study, the parent compound oleuropein and three 
metabolites, homovanillic acid, elenolic acid and 
oleuropein aglycone, were detected in rat faeces 
collected over 24 h after an acute oral dose of 
oleuropein [19]. However, in our study, 
homovanillic acid was not detected in human 
faeces. This discrepancy could be explained by 
differences in the gut metabolic responses 
between rat and human. For example, 
homovanillic acid has been detected when 
catechins were fermented with rat faeces as 
inoculums [21] but has not been found in catechin 
fermentation with human faeces [26]. The 
presence of methylated metabolites in plasma 
after olive oil intake has been noticed before [10], 
suggesting that homovanillic acid in rat faeces 
may be a product of the basolateral-apical efflux 
back into the intestinal lumen or by the 
enterohepatic recirculation of the absorbed 
phenolics. The differences in phenolic metabolite 
types or concentration can reflex inter-individual 
variation response to polyphenol consumption. 
Phenolic luminal compounds might provide 
additional benefits to the colonic epithelium. The 
aqueous phase of the colon content, namely 
faecal water, interacts directly with the colonic 
epithelium. Consequently, the type of substances 
solubilised could condition the development of 
colon diseases. In addition, faecal water has been 
reported to be a highly variable bioactive material, 
whose composition could be influenced by the 
diet, thus modifying its antioxidant power. Current 
epidemiological and experimental studies support 
the beneficial role of dietary polyphenols in 
several gastrointestinal diseases, including 
intestinal bowel disease (ulcerative colitis and 
Crohn’s disease) and colon cancer. For example, 
a dietary supplement with virgin olive oil enriched 
with phenol extract reduced the severity and 
extent of progressive chronic colonic damage in 
mice by reducing intestinal inflammatory 
mediators and cell proliferation [41]. Moreover, 
there is clear evidence that olive oil intake 
contributes to a fall in the incidence of colorectal 
cancer [4]. For example, faecal water activity has 
been proposed as a risk biomarker of colon 
cancer [39] because its genotoxicity could be 
responsible for the DNA cell damage that may 
contribute to an enhanced risk of colorectal cancer 
[42, 43]. Fatty acid synthetase expression appears 
to play an important role in the growth and 
pathogenesis of colon carcinoma [44]. Notarnicola 
et al. have reported that hydroxytyrosol 
suppresses the expression of fatty acid 
synthetase, as well as its activity, and significantly 
inhibits cell proliferation through a proapoptotic 
effect in colon adenocarcinoma HT29 cells in an in 
vitro assay [45]. Growth inhibition of colon cancer 
HT29 and SW480 due to the presence in the 
cytoplasm of oleuropein derivatives and its cell 
metabolites was noticed by Fernandez-Arroyo et 
al. when these cells were treated with olive oil 
polyphenol extracts [46]. These observations, 
together with our data on the increase of some 
phenolic metabolites in human faecal samples 
after the intake of a phenol-rich olive oil, support 
the view that the prevention of colon disease 
exerted by olive oil could be ascribed to its content 
of phenolic compounds. 
 
4. CONCLUDING REMARKS 
To sum up, the scientific data on beneficial effects 
of olive oil polyphenols, together with our findings, 
provide additional information regarding the gut 
metabolism of polyphenols. The in vitro colon 
fermentation of the four individual phenols 
revealed (i) an increase in phenolic acids, (ii) the 
stability of hydroxytyrosol and tyrosol and (iii) the 
high degradation of hydroxytyrosol acetate and 
oleuropein in a faecal culture medium. 
Additionally, a moderate intake of a phenol-rich 
olive oil raised the concentration in human faeces 
of phenylacetic and phenylpropionic acids; 
although their concentration increase was not 
statistically significant. Of special interest is the 
significant increase in the concentration of free 
hydroxytyrosol after the intake of phenol-rich olive 
oil (p < 0.05). These products of catabolism of 
olive oil phenolic compounds could be good 
candidates for novel preventive strategies and 
opening a promising line of research into the 
preventive action of olive oil phenols in colon and 
other bowel diseases. Nevertheless, more studies 
focused in the investigation of the roll of olive oil 
phenols in the large intestine are needed to 
strengthen the knowledge concerning the re-
lationship between these compounds and human 
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intestinal health. 
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ADDITIONAL INFORMATION 
 
Table 1. Metabolites detected during in vitro fermentation of hydroxytyrosol. Results are expressed as the 
mean of the three individual replicates SD for each of the incubation times studied. H1, H2 and H3 
correspond to the faeces of the three donors. 
Compound (M) 
Faecal 
sample 
Incubation time (h) 
0 2 6 12 24 48 
Hydroxytyrosol 
 
H1 32416.4 17311.9 14915.9 1359.67 16412.1 1444.17 
H2 24825.2 21462.2 15822.4 1667.37 1514.53 1630.94 
H3 32253.7 1777.91 1619.97 13521.42 1549.81 1164.94 
2-(3',4'-
dihydroxyphenyl) 
acetic acid  
H1 n.d. n.d. n.d. n.d. n.d. 0.600.27 
H2 0.050.07 n.d. n.d. 0.130.06 2.190.06 0.210.23 
H3 n.n n.d. n.d. n.d. 2.250.02 3.480.06 
2-(4’-
hydroxyphenyl) 
acetic acid 
H1 0.070.07 0.100.2 n.d. n.d. 2.814.77 6.164.13 
H2 n.d. 0.800.15 n.d. 0.06 2.481.32 3.802.57 
H3 0.020.16 n.d. 0.380.21 0.10 7.942.7 1.610.9 
2-(3’-
hydroxyphenyl) 
acetic acid 
H1 0.230.07 2.113.41 n.d n.d. 1.280.23 0.070.79 
H2 n.d 1.200.09 0.160.19 n.d. n.d 1.190.43 
H3 0.321.98 n.d n.d 0.47 0.911.13 n.d 
Phenylacetic 
acid 
 
H1 1.173.88 n.d. 3.298.49 n.d. 36.613.9 10.19.88 
H2 1.642.48 3.881.04 4.644.69 n.d. 11.21.71 12.912.0 
H3 0.102.18 5.9518.7 3.595.19 n.d. 9.8719.43 n.d 
4-
hydroxybenzoic 
acid 
 
H1 0.190.33 n.d. n.d. n.d. 0.840.39 0.130.03 
H2 n.d. n.d. n.d. n.d. n.d n.d 
H3 n.d. 2.394.13 n.d. n.d. n.d 0.070.23 
Protocatecuic 
acid 
 
H1 0.070.02 n.d n.d. n.d. 0.550.47 0.110.35 
H2 n.d 0.200.06 n.d. n.d. 0.050.06 n.d. 
H3 0.010.04 n.d n.d. 0.070.06 0.230.02 n.d. 
Catechol H1 0.010.02 n.d n.d. n.d. 0.240.09 n.d 
H2 n.d. 0.020.04 n.d. n.d. n.d 0.080.06 
H3 n.d. n.d n.d. n.d. 0.030.06 n.d 
3-(4'-
hydroxyphenyl) 
propionic acid 
H1 n.d. n.d n.d. n.d. 1.052.53 6.133.29 
H2 n.d. 53.317.6 n.d. n.d. n.d. 1296.86 
H3 n.d. 0.592.36 2.440.88 3.250.08 5.0010.8 n.d 
Phenylpropionic 
acid 
H1 n.d. 1.309.09 n.d. n.d. 4.0715.57 0.169.49 
 H2 n.d. n.d. n.d. n.d. 10.45.66 12.75.05 
H3 n.d. n.d. 2.014.35 5.743.21 5.4620.8 n.d 
Data are expressed as mean in µmol/L.  
Mean values were calculated subtracting to the average value of the three replicates the control content of the 
respective substance. 
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Table 2. Metabolites detected during in vitro fermentation of hydroxytyrosol acetate. Results are expressed 
as the mean of the three individual replicates SD for each of the incubation times studied. H1, H2 and H3 
correspond to the faeces of the three donors. 
Compound (M) 
Faecal 
sample 
Incubation time (h) 
0 2 6 12 24 48 
Hydroxytyrosol 
acetate 
H1 12784.7 35.23.71 3.332.00 2.362.72 2.564.43 n.d 
H2 22898.3 12242.0 9.402.45 6.281.08 2.532.42 n.d 
H3 23666.8 13.46.39 n.d 5.153.17 3.760.98 4.130.52 
Hydroxytyrosol H1 64.840.9 80.210.7 64.110.6 68.159.2 87.213.4 1522.12 
H2 61.828.1 12325.9 64.116.8 81.846.9 75.012.5 12327.9 
H3 20423.4 13531.9 78.66.94 19463.6 10614.4 15716.0 
2-(3',4'-
dihydroxyphenyl) 
acetic acid 
H1 n.d. n.d. n.d. n.d 1.980.01 0.600.16 
H2 n.d. n.d n.d 4.110.64 5.310.65 6.130.76 
H3 1.990.03 n.d n.d 1.980.04 2.010.04 0.580.08 
2-(4'-
hydroxyphenyl) 
acetic acid 
H1 n.d n.d. 0.080.05 n.d. 10.49.95 n.d 
H2 n.d. n.d n.d. 0.200.04 n.d 10.71.67 
H3 n.d n.d n.d 0.660.21 6.284.15 16.11.56 
2-(3'-
hydroxyphenyl) 
acetic acid 
H1 n.d 0.100.68 0.891.34 n.d 0.630.11 0.110.15 
H2 n.d. n.d. 0.210.33 0.080.16 n.d n.d 
H3 n.d 4.260.95 0.560.39 0.250.15 0.130.73 0.270.52 
Phenylacetic 
acid 
H1 n.d 10.16.99 5.2613.9 n.d 50.118.09 n.d 
H2 n.d n.d n.d n.d n.d n.d 
H3 n.d n.d n.d n.d n.d 45.3±3.47 
Protocatechuic 
acid 
H1 n.d n.d. 0.380.19 Tr 0.410.04 Tr 
H2 n.d 0.140.05 0.110.04 0.130.09 Tr 0.380.18 
H3 Tr n.d. Tr Tr Tr 0.180.15 
Catechol H1 n.d. n.d n.d n.d Tr n.d 
H2 n.d Tr n.d n.d n.d n.d 
H3 n.d n.d n.d n.d n.d n.d 
4-hdroxybenzoic 
acid 
H1 n.d. n.d. n.d. n.d. n.d. n.d. 
H2 n.d n.d n.d. n.d n.d n.d 
H3 n.d n.d n.d. n.d n.d n.d 
3-(4'-
hydroxyphenyl)  
propionic acid 
H1 n.d n.d n.d n.d 1.990.37 21.10.94 
H2 2.852.82 20.53.88 n.d. 0.851.38 n.d. 13.210.0 
H3 n.d n.d n.d n.d n.d 15.10.42 
Phenylpropionic 
acid 
H1 n.d 0.734.11 6.2714.3 n.d 60.312.3 6.2716.4 
H2 n.d 3.232.1 n.d n.d n.d 4.5110.7 
H3 n.d n.d 2.951.44 0.110.99 n.d 30.03.78 
Data are expressed as mean in µmol/L. 
Mean values were calculated subtracting to the average value of the three replicates the control content of the 
respective substance. 
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Table 3. Metabolites detected during in vitro fermentation of oleuropein. Results are expressed as the 
mean of the three individual replicates. SD for each of the incubation times studied. H1, H2 and H3 
correspond to the faeces of the three donors.  
Compound (M) 
Faecal 
Sample 
Incubation time (h) 
0 2 6 12 24 48 
Oleuropein H1 71.6±0.35 43.3±2.88 14.7±3.04 0.16±0.18 0.11±0.05 Tr 
H2 53.3±2.54 37.4±0.82 0.84±0.11 0.16±0.08 0.20±0.02 Tr 
H3 62.3±12.79 5.54±5.56 n.d. n.d. Tr Tr 
Hydroxytyrosol 
 
H1 3.32±0.83 11.3±2.78 14.6±0.80 20.1±1.4 33.2±3.21 36.7±9.09 
H2 36.8±6.88 15.8±1.95 19.8±2.05 25.4±4.98 30.5±3.09 29.1±6.20 
H3 23.65±9.43 10.1±0.39 15.5±1.47 12.6±5.03 20.6±1.27 21.8±7.95 
Hydroxytyrosol 
acetate 
H1 3.31±2.92 n.d 7.60±0.41 5.66±0.58 5.77±1.97 6.41±0.82 
H2 n.d. 6.28±0.52 7.60±2.22 7.47±1.6 6.04±0.67 3.56±0.52 
H3 n.d. 8.38±1.16 11.2±2.65 8.66±2.86 7.81±1.58 8.35±2.45 
Oleuropein 
aglycone 
H1 0.46±0.10 1.35±0.32 0.40±0.03 n.d 0.25±0.00 n.d 
H2 3.26±0.53 1.27±0.31 Tr n.d n.d n.d 
H3 2.73±0.64 n.d. n.d. n.d. n.d. n.d. 
Elenoic acid H1 1.08±0.02 1.20±1.35 1.04±0.03 n.d n.d 0.340.59 
H2 1.68±0.26 1.32±0.06 1.03±0.01 n.d n.d n.d. 
H3 1.61±0.10 1.24±0.02 1.01±0.01 n.d. n.d. n.d. 
3-(3’,4’-
dihydroxyphenyl) 
propionic acid 
H1 n.d. n.d. Tr 0.38±0.05 0.54±0.08 1.75±0.6 
H2 n.d. Tr n.d. 0.100.01 0.570.14 0.830.27 
H3 Tr Tr 0.79±0.09 0.10 Tr 0.16±0.15 
3-(4’-
hydroxyphenyl) 
propionic acid 
H1 n.d. 0.13±0.61 0.32±0.38 1.77±3.2 0.44±0.77 n.d. 
H2 n.d. n.d. n.d. 0.83±0.15 2.24±0.57 0.43±0.43 
H3 n.d. n.d n.d 1.492.26 0.250.39 0.770.9 
Coumaric acid H1 0.11±0.11 1.48±0.09 2.36±0.28 n.d n.d n.d 
H2 3.01±1.51 3.50±0.26 3.77±0.21 1.67±0.53 Tr n.d 
H3 1.54±1.02 1.26±0.08 n.d. n.d. n.d. n.d. 
Protocatechuic acid H1 0.18±0.02 0.40±0.08 0.44±0.04 0.16±0.18 0.20±0.02 1.17±0.45 
H2 0.41±0.23 0.33±0.05 0.38±0.06 0.28±0.11 0.26±0.12 Tr 
H3 16.8±27.7 0.35±0.02 0.47±0.05 0.27±0.10 0.31±0.15 0.36±0.19 
2-(3’-
hydroxyphenyl) 
acetic acid 
H1 n.d. n.d. 0.10±0.2 n.d. 0.73±0.08 1.37±0.33 
H2 0.340.50 n.d. 0.42±0.23 n.d. n.d. n.d. 
H3 n.d. n.d. n.d. 0.68±1.31 0.40±1.21 1.98±2.26 
4-hydroxybenzoic 
acid 
H1 n.d. n.d. n.d. n.d. n.d. Tr 
H2 n.d. n.d. n.d. n.d. n.d. n.d. 
H3 n.d. n.d. n.d. Tr n.d. Tr 
Data are expressed as mean in µmol/L. 
Mean values were calculated subtracting to the average value of the three replicates the control content of the 
respective substance 
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Table 4. Metabolites detected during in vitro fermentation of tyrosol. Results are expressed as the mean of 
the three individual replicates. SD for each of the incubation times studied. H1, H2 and H3 correspond to 
the faeces of the three donors. 
C’ompound (M) 
Fecal  
sample 
Incubation time (h) 
0 2 6 12 24 48 
Tyrosol 
 
H1 337±28.1 309±8.39 288±20.3 279±19.9 274±0.25 255±3.52 
H2 332±44.4 308±9.59 314±27.1 287±23.7 234.9861.39 210.457.93 
H3 4359.07 41316.2 35165.8 3658.26 351±5.06 329±19.9 
Hydroxytyrosol H1 0.90±0.04 0.93±0.04 1.01±0.05 1.02±0.01 0.89±0.19 0.72±0.0 
H2 0.82±0.02 0.85±0.03 1.03±0.06 1.03±0.06 0.82±0.07 0.76±0.01 
H3 1.22±0.13 1.29±0.05 1.26±0.07 1.40±0.02 1.39±0.06 1.09±0.03 
2-(4’-
hydroxyphenyl) 
acetic acid 
 
H1 n.d 0.01±0.2 4.13±0.24 1.40±0.34 20.6±4.19 16.1±1.10 
H2 n.d n.d n.d n.d 1.99±5.78 0.23±2.60 
H3 n.d 0.47±0.18 0.71±0.52 0.40±2.30 n.d 14.4±1.80 
Data are expressed as mean in µmol/L. 
Mean values were calculated subtracting to the average value of the three replicates the control content of the 
respective substance 
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ABSTRACT: The gut metabolism of four thyme phenolics (monoterpenes thymol and carvacrol, 
rosmarinic acid, and eriodictyol) was evaluated in vitro. After the in vitro transformations of the 
individual phenols had been studied, the presence of their microbial metabolites was investigated 
in human feces collected before and after a sustained intake (3 weeks) of 25 mL/day of a thyme 
phenol-enriched olive oil. Results of in vitro fermentation showed low degradation of thymol and 
carvacrol. By contrast, large catabolism was noted when rosmarinic acid and eriodictyol were 
fermented, yielding hydroxyphenylpropionic acid as the main metabolite. In accordance with these 
results, after the in vivo intervention with thyme phenol-enriched olive oil, an increase in the 
concentration of hydroxyphenylpropionic and phenylpropionic acids was observed in human feces, 
confirming the eﬀective in vivo microbial degradation of rosmarinic acid and eriodictyol. Carvacrol 
was detected in fecal samples at trace levels, suggesting that monoterpenes are well absorbed in 
the upper part of the gastrointestinal tract. 
KEYWORDS: colonic metabolites, in vitro colonic fermentation, thyme phenols, thyme 
monoterpenes 
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1. INTRODUCTION
The consumption of aromatic herbs is increasing 
worldwide because of their particular 
characteristics, highly valued by the food and 
pharmaceutical industries. They are commonly 
used in cooking as flavoring agents and for their 
antifungal, antimicrobial, and antioxidant 
properties, capable of delaying undesirables 
changes in food,1,2 with the added advantage of 
being positively perceived by consumers due to 
their “natural” origin. Furthermore, their 
consumption is associated with anti-inflammatory, 
anti-hypertensive, and anti-cancer properties.3−5 
Thyme (Thymus vulgaris) is one of the most used 
aromatic herbs, particularly in the Mediterranean 
countries. Its beneficial eﬀects have been 
attributed to a wide range of chemical compounds 
such as phenolic compounds with terpenoid origin 
(thymol and carvacrol), flavonoids (quercetin, 
eriocitrin, luteolin, eriodictyol, and apigenin), and 
phenolic acids (rosmarinic acid and caﬀeic acid).6 
The bioavailability of phenolic compounds has 
been extensively studied, particularly focused on 
their absorption, distribution, and deposition in 
organs and tissues, plasma concentration, and 
urine excretion.7,8 Because a large portion of 
phenolic compounds are not absorbed in the small 
intestine, recent studies are more focused on the 
polyphenol−gut microbiota interactions and the 
gut microbial bioconversion capability, as it has a 
substantial eﬀect on the phenolic compounds’ 
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bioavailability. Local microbiota converts the 
original compounds in the unabsorbed fraction of 
the digesta to simple phenols with similar or even 
greater bioactivity than their precursors.9 These 
changes in the metabolome may have great 
implications for the gut health10 and, if absorbed, 
beneficial eﬀects throughout the body.11 
In vitro fermentation models, using animal or 
human feces as inocula, have been carried out in 
previous studies to assess the gut metabolism of 
diﬀerent types of phenolic compounds.12,13 
However, these in vitro experiments cannot 
reproduce some phenomena that take place in in 
vivo conditions, such as the enterohepatic 
recirculation (for compounds that enter the 
enterohepatic cycle) or the water and nutrient 
absorption. Therefore, a multidisciplinary 
approach that combines well-established in vitro 
and in vivo studies is essential for understanding 
the nature and extent of the diﬀerent metabolic 
processes of food bioactive compounds. This 
approach may be very useful to predict which 
compounds could reach the molecular targets and 
exert health eﬀects. 
There is limited information about human 
interventions with aromatic herbs or their bioactive 
compounds in the literature. Most of the in vivo 
studies related to monoterpenes have been 
carried out in the veterinary area due to the 
promising overall eﬃcacy of aromatic herbs for 
the benefit of animals and the quality of animal-
derived products. Some authors have even 
proposed these naturally occurring substances as 
substitutes for antibiotic growth promoters.14 In a 
preliminary study conducted by our group, the 
bioaccessibility and phase II metabolism of thyme 
phenols were assessed by an in vitro digestion 
model combined with Caco-2 and HepG-2 cell 
models.15 The results of this study showed 
diﬀerent metabolic profiles depending on the 
phenolic compound. Whereas eriodictyol 
appeared in both its sulfated and glucuronidated 
forms after cell incubation, naringenin was only 
conjugated into its glucuronide form. To 
complement these studies, it becomes essential to 
study the microbial conversion of thyme phenolic 
compounds and the elucidation of their colonic 
pathways. In this sense, the main aim of the 
present study was to provide more complete, 
comprehensive, and convincing results about the 
gut metabolism of thyme phenolic compounds by 
using a combination of in vitro and in vivo 
experiments. For the in vitro fermentation study, 
the most representative compounds from diﬀerent 
subclasses of thyme phenols were selected: (i) 
the monoterpene thymol and its isomer carvacrol; 
(ii) the flavonoid eriodictyol; and (iii) rosmarinic 
acid, a phenolic acid occurring in many common 
aromatic herbs from the Lamiaceae group. After 
studying the in vitro gut metabolism pathways of 
the aforementioned thyme phenols, we 
investigated their colonic metabolites in human 
fecal samples obtained before and after a 3 week 
intervention with a daily administered dose of 25 
mL (23 g) of a thyme phenol-enriched olive oil 
(TPEOO). 
 
2. MATERIALS AND METHODS 
2.1. In Vitro Colonic Fermentation 
Fecal samples were collected from three healthy 
volunteers who followed normal dietary habits and 
declared that they had not taken antibiotics for at 
least 3 months prior to the sample collection. The 
fermentation medium was carbonate− phosphate 
buﬀer. This was prepared according to a 
previously described method16 by mixing (all in 
g/L) 9.240 NaHCO3, 3.542 Na2HPO4·2H2O, 0.470 
NaCl, 0.450 KCl, 0.227 Na2SO4·10H2O, 0.055 
CaCl2 (anhydrous), 0.100 MgCl2·6H2O, and 0.400 
urea with 10 mL/L of added trace element solution 
(in mg/L) 3680 FeSO4·7H2O, 1159 MnSO4·H2O, 
440 ZnSO4·7H2O, 120 CoCl2·6H2O, 98 
CuSO4·5H2O, and 17.4 Mo7(NH4)6O24·4H2O). 
Before its use, the culture medium was 
maintained in an anaerobic chamber for 48 h, 
using gas generator bags (CO2) (Becton 
Dickinson, Sparks, MD, USA) to remove the 
oxygen. The anaerobic conditions were 
continuously monitored by using anaerobic 
indicator strips (Becton Dickinson). Standards of 
thymol, rosmarinic acid, and eriodictyol were 
purchased from Extrasynthese (Genay, France), 
whereas carvacrol was purchased from Sigma-
Aldrich (St. Louis, MO, USA). For the selection of 
the phenolic compounds to carry out the in vitro 
experiments, we took into consideration the 
availability of commercial standards and the 
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occurrence of these substances in the TPEOO. 
The in vitro fermentation procedure used in this 
study was adapted from the method proposed by 
Serra and co-workers.17 For each volunteer, 15 g 
of fresh feces was homogenized for 60 s in a 
stomacher with 300 mL of prereduced culture 
medium to obtain a 5% fecal slurry. Following the 
homogenization, the fecal slurry was filtered and 
left to stand for 30 min. Once done, 10 mL was 
taken and added to 15 mL disposable tubes. After 
the addition of the standard (phenol standard final 
concentration 500 μM for thymol, carvacrol, and 
eriodictyiol, and 200 μM for rosmarinic acid), the 
disposable tubes were incubated in anaerobic 
chambers at 37 °C in an orbital shaker (60 
strokes/min) to mimic colon conditions (anaerobic 
conditions were controlled by anaerobic indicator 
strips). 
 
Table 1. Phenolic Composition of Thyme Phenol-
Enriched Olive Oil (TPEOO)a 
Compound mg phenol/kg oil 
Rosmarinic acid 16.3 ±1.2 
Flavonoids   
Eriodictyol 6.9 ±0.5 
Luteolin 8.5 ±0.8 
Apigenin 3.8 ±0.2 
Naringenin 7.9 ±0.8 
Thymusin 48.6 ±3.6 
Xanthomicrol 21.3 ±2.2 
7-methylsudachitin 21.1 ±3.4 
Monoterpenes   
Thymol 25.4 ±2.1 
Carvacrol 9.1 ±0.8 
aValues are means ± SD (n = 5)  
The high initial concentrations (500 and 200 μM) 
of the parent compounds were chosen to 
determine more clearly the microbial metabolites 
generated, even at relatively low concentrations. 
Aliquots of the fermented fecal samples (500 μL) 
were collected at 0, 2, 6, 12, 24, and 48 h of 
incubation and stored immediately at −80 °C until 
the chromatographic analysis. All of the 
fermentation samples were incubated in triplicate. 
In parallel, a control sample (fecal slurry without 
addition of phenolic standard) was prepared for 
each fermentation time. Also, the phenolic 
standards without feces (blank 1) were incubated 
at each time (0, 2, 6, 12, 24, and 48 h) to take into 
account the possible chemical degradation of 
phenolic compounds. 
2.2. Human Intervention Study 
Fecal samples from 10 volunteers were used to 
determine thyme phenolic metabolites identified in 
the in vitro fermentation model. The feces were 
obtained before and after the consumption (25 
mL/day) of a thyme phenol-enriched olive oil 
(TPEOO) over a period of 3 weeks. The TPEOO 
was prepared by adding a thyme phenolic extract 
to an olive oil according to the methodology 
described by Rubió and co-workers.18 The main 
phenolic compounds that were transferred from 
thyme to the olive oil were flavonoids, such as 
eriodictyol, thymusin, naringenin, and 
xanthomicrol, phenolic acids, such as rosmarinic 
acid, and the monoterpenes thymol and carvacrol 
(Table 1). 
Prior to the TPEOO intervention, there was a 2 
week wash-out period, in which common olive oil 
(a blend of refined olive oil and a small percentage 
of virgin olive oil) was the main fat consumed. To 
avoid an excessive intake of phenolic compounds 
during the intervention period, the participants 
were advised to limit the intake of phenol-rich 
foods. Fecal samples from each volunteer were 
collected after the wash-out period (pre TPEOO 
intake) and at the end of the 3 week intervention 
(post TPEOO intake). The subjects gave their 
written informed consent before participation 
(Ethics Committee for Human Research of the 
IMIM-Hospital del Mar, Barcelona, Spain; CEIC-
PSMAR 2009/3347/I). Freshly voided fecal 
samples were collected by the volunteers into a 
sterile pot and brought to the laboratory under 
anaerobic conditions within 2 h of defecation, 
immediately mixed in a phosphate buﬀer (PBS; 
final concentration 10% of fecal sample), and 
centrifuged for 5 min at 13000 rpm. The 
supernatant was divided into aliquots of 500 μL 
and stored at −20 °C until chromatographic 
analysis of phenol metabolites. 
 
2.3. Treatment of Fecal Samples and 
Chromatographic Analysis of Thyme 
Metabolites 
The in vitro fermentation samples and the 
supernatants obtained from the human 
intervention study were slowly thawed in ice, 
transferred into a disposable tube (15 mL), and 
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acidified with 60 μL of HCl to inactivate the 
microbiota. A liquid−liquid extraction was carried 
out by adding 5 mL of ethyl acetate, and after 
shaking for 10 min in a vortex, samples were 
centrifuged (10 min, 9000 rpm, at room 
temperature). The supernatants resulting from two 
ethyl acetate extractions were combined and 
evaporated under nitrogen flow at 30 °C. The dry 
residue was reconstituted with 
water/acetonitrile/methanol (86:12:2, v/v/v), 
filtered with a 0.22 μm nylon syringe filter, and 
transferred into chromatographic vials for analysis. 
The chromatographic analysis of rosmarinic acid, 
eriodictyol, and their metabolites and thymol and 
carvacrol metabolites was performed with a 
Waters Acquity Ultra-Performance liquid 
chromatography (UPLC-ESI-MS/MS) system 
(Waters, Milford MA, USA), according to the 
previously described method.19 The tandem mass 
spectrometry (MS/MS) analyses were carried out 
on a triple-quadrupole detector (TQD) mass 
spectrometer (Waters) equipped with a Z-spray 
electrospray interface. The analyses were done in 
the negative ion mode, and the data were 
acquired with the selected reaction monitoring 
mode (SRM). The MS/MS parameters were as 
follows: capillary voltage, 3 kV; source 
temperature, 150 °C; cone gas flow rate, 80 L/h; 
desolvation gas flow rate, 800 L/h; desolvation 
temperature, 400 °C. Nitrogen (>99% purity) and 
argon (99% purity) were used as the nebulizing 
and collision gases, respectively. The cone 
voltages and collision energies were optimized for 
each analyte by injection of each standard 
compound in a mixture of acetonitrile/water 
(50:50, v/v) at a concentration of 10 mg/L. Two 
transitions were studied for each compound. The 
most abundant transition was used for 
quantification, whereas the second most abundant 
was used for confirmation purposes. The dwell 
time established for each transition was 30 ms. 
Data acquisition was carried out with MassLynx v 
4.1 software. Catechol, phenylacetic acid, 4-
hydroxybenzoic acid, 3-phenylpropionic acid, 2-
(4′-hydroxyphenyl)acetic acid, 2-(3′-
hydroxyphenyl)acetic acid, 4-coumaric acid, 
protocatechuic acid, 2-(3′,4′-dihydroxyphenyl) 
acetic acid, 3-(4′-hydroxyphenyl)propionic acid, 3-
(3′,4′-dihydroxyphenyl)-propionic, caﬀeic acid, 
rosmarinic acid, and eriodictyol were quantified 
using the calibration curves of their respective 
standards. 
Additionally, all samples were subjected to gas 
chromatography (GC) analyses to identify and 
quantify the volatile monoterpene thymol and 
carvacrol in their native forms. These compounds 
were first extracted from the in vitro fermentation 
samples and from the human fecal supernatants 
to the TPEOO intervention by hexane. For this 
purpose, 500 μL of sample was mixed with 1 mL 
of hexane and shaken during 1 h and then 
centrifuged for 10 min at 9000 rpm at room 
temperature. The volatile material collected from 
the super-natant was analyzed by gas 
chromatography (GC) (Agilent 7890A series) 
coupled to a flame ionization detector (FID) using 
a capillary column TRB-5SM (Teknocroma, 
Barcelona, Spain). The column temperature was 
programmed at 90 °C for 1 min, increased by 15 
°C/ min to 270 °C, and then maintained at 270 °C 
for 10 min (total run time of 25 min). Helium was 
the carrier gas (1 mL/min). Injector temperature 
was 250 °C, the detector temperature was 280 °C, 
and 1 μL of the solution was injected into the GC-
FID system. Thymol and carvacrol were identified 
by comparing the retention times to those for the 
authentic standards and quantified by using the 
calibration curve of the respective standard. 
 
2.4. Statistical Analysis 
Each sample from the in vitro experiment was 
analyzed in triplicate (three replicates from three 
volunteers; n = 9), and the data are presented as 
the mean values of all samples at each time (n = 9 
per each time) minus the concentration of the 
compound in the control (fecal culture medium 
without phenolic compound). In the in vivo study, 
to compare the baseline with the post-treatment 
concentration values of the metabolites in human 
fecal samples, the ANOVA analysis was 
employed using STAT-GRAPHICS Plus 5.1 
software (Manugistics Inc., Rockville, MD, USA). 
The level of significance was 0.05. 
 
3. RESULTS AND DISCUSSION 
3.1. Kinetics of Thyme Phenols. Colonic 
Metabolism in in Vitro Fermentation.  
Results and Discussion 
 Journal of Agicultural and Food Chemistry, 2014, 10954-10961 
85 
 
Changes in the precursor compounds (thymol, 
carvacrol, rosmarinic acid, and eriodictyiol) during 
the in vitro fermentation were monitored from 0 to 
48 h. Results are reported as the average of three 
independent fermentations for each human fecal 
sample, obtaining nine replicates for each 
fermentation time (individual values are shown in 
Tables 1−4 of the Supporting Information). The 
amounts of the phenolic compounds and their 
metabolites were corrected for the endogenous 
levels detected in the control fermentations (fecal 
culture medium without phenolic compound)  
3.2. Monoterpenes: Thymol and Carvacrol. 
On the basis of the volatile nature of thymol and 
carvacrol, these compounds were analyzed by 
GC, whereas colonic metabolites formed during in 
vitro fermentation were analyzed by liquid 
chromatography (UPLC-MS/MS). The kinetics of 
the generated metabolites after thymol and 
carvacrol fermentation is shown in Figure 1, 
panels A and B, respectively. In general, carvacrol 
and thymol showed a similar behavior during the 
48 h incubation, possibly due to the closely related 
chemical structure. Both compounds were poorly 
degraded and remained relatively stable until the 
end-time of the fermentation, indicating the 
nonexistent or low activity of gut microbiota in 
terms of monoterpene utilization. However, some 
metabolites were formed during the in vitro 
fermentation of thymol (Figure 1A): (i) 
phenylacetic acid, which reached its maximum 
concentration (16.91 μM) at 24 h of incubation; (ii) 
2-(4′-hydroxyphenyl)acetic acid with a maximum 
recovery (15.39 μM) also at 24 h of incubation. 
Furthermore, (iii) phenylpropionic acid and (iv) 3-
(4′-hydroxyphenyl)propionic acid reached the 
maximum concentration at 48 h (11.20 μM) and at 
24 h (5.14 μM) of incubation, respectively. 
Interestingly, low concentrations of carvacrol were 
found at diﬀerent times during the thymol 
fermentation (Supporting Information Table 1) 
but were also detected in thymol standard 
samples incubated without fecal slurry (blank 1), 
which may indicate that carvacrol is generated by 
the medium conditions as a consequence of the 
isomerization of thymol. 
Similar results were observed when carvacrol was 
fermented. During the fermentation the main 
metabolites that appeared were (i) 
phenylpropionic acid (10.13 μM) and (ii) 
phenylacetic acid (7.43 μM), both by the end of 
fermentation. After the fermentation of carvacrol, 
(iii) 2-(4′-hydroxyphenyl)acetic acid and (iv) 3-(4′-
hydroxyphenyl)propionic acid wer also detected. 
Both phenolic acids reached their maximum 
concentrations (2.78 and 2.77 μM, respectively) at 
48 h of fermentation. 
 
 
Figure 1. (A) Thymol concentration (solid line) 
and metabolite generation (dotted line) during in 
vitro fermentation. (B) Carvacrol concentration 
(solid line) and metabolite generation (dotted line) 
during in vitro fermentation 
 
In vitro fermentation of monoterpenes using 
animal intestinal content as inocula also showed 
low microbial activity.20,21 Michiels and co-workers 
have reported that thymol and carvacrol were 
degraded by 29% after the fermentation of both 
compounds using piglet cecal as inocula, but no 
degradation products were specified.20 Varel and 
co-workers also observed high stability of thymol 
and carvacrol after anoxic swine waste 
fermentation, recovering close to 95% of both 
monoterpenes at 62 days.21 Therefore, our results 
confirm that phenol terpenes remain stable during 
the fermentation, probably due to the complex 
carbon skeleton that may hamper their microbial 
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degradation. To the best of our knowledge, there 
are no data available in the literature about thymol 
and carvacrol metabolism in human bowel. 
However, cholesterol and bile acids, which also 
have a terpenoid lipid structure, are daily exposed 
to gut microbiota, and their bacterial trans-
formations have been extensively documented in 
humans. 
The reduction of the C7 double bond of the 
cholesterol molecule,22 the 7α-dehydroxylation, 
and the side chain degradation of functional 
groups in the case of bile acids are typically 
caused by bacteria activity, but in any case 
cholesterol, bile acids, and their metabolites suﬀer 
further degradation.23 Similarly, our results 
suggest that thymol and carvacrol (phenolic 
terpenes) may be recalcitrant molecules to 
biodegradation in the human large intestine, 
probably as a consequence of the low number of 
functional groups and/or the lack of intestinal 
bacteria specialized in their metabolism. 
Therefore, the appearance of phenolic acids, 
especially within 24 h of incubation (Figure 1), 
may be explained by the loss of bacteria cell 
integrity due to the modification of membrane 
permeability, which could induce the release of 
endogenous metabolites into the culture medium. 
Linked to this, Thapa and co-workers1 studied the 
eﬀects of diﬀerent essential oils and their pure 
compounds, including thymol, on pathogenic and 
commensal intestinal bacteria. The results 
showed that phenolic monoterpenes were the 
most active class of antibacterial agents and 
caused a dose-dependent loss of cell integrity in 
Gram-positive bacteria, probably by modifying the 
permeability of cellular membranes, thus 
promoting the loss of ATP and intracellular 
metabolites or enzymes.  
Therefore, in our study the release of endogenous 
microbial material could explain the presence of 
diﬀerent phenylacetic and phenylpropionic acids 
in the thyme and carvacrol fermentation media. 
3.3. Rosmarinic Acid and Eriodictyol 
Analyses of the fermentation samples of 
rosmarinic acid and eriodictyol revealed a full 
degradation of the parent compounds and a high 
generation of microbial products over the 
incubation time (0−48 h). The kinetics of the 
rosmarinic acid fermentation showed that this 
compound was insignificant at 12 h of incubation 
(Figure 2A). The first intermediate microbial 
metabolite derived from the hydrolysis of 
rosmarinic acid was caﬀeic acid, which reached 
its maximum concentration at 6 h (17.9 μM) 
(Figure 2A) before declining to trace levels at 48 
h of fermentation. The gut metabolic pathway of 
rosmarinic acid is proposed in Figure 3. A 
previous study has also revealed a rapid 
transformation of rosmarinic acid when it was 
fermented in pure cultures of Lactobacillus 
johnsonii,24 a type of lactic acid bacteria (LAB) 
commonly found in the human gut.25 Degradation 
of rosmarinic acid seems to be mediated by 
microbial chlorogenate esterases.24 
 
 
Figure 2. (A) Rosmarinic acid concentration (solid 
line) and metabolite generation (dotted line) during 
in vitro fermentation. (B) Eriodictyol concentration 
(solid line) and metabolite generation (dotted line) 
during in vitro fermentation 
 
The second intermediate metabolite detected in 
the fecal culture medium was 3-(3′,4′-
dihydroxyphenyl)propionic acid, probably formed 
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as a result of the microbial transformation of 
caﬀeic acid (Figure 3) by the reduction of the 
aliphatic double bond of the second ring of the 
molecule. 3-(3′,4′-dihydroxyphenyl)propionic acid 
reached its highest peak of concentration at 12 h 
(24.2 µM) coinciding with the decrease in the 
concentration of caﬀeic acid in the fermentation 
medium (Figure 2A). An isomer of 3-(4′-
hydroxypehyl)propionic acid was identified as the 
main metabolite formed by the fermentation of 
rosmarinic acid, and this reached the highest 
concentration in the medium (168.2 μM) at 48 h of 
fermentation, parallel to the decrease in the 
concentration of its precursor, 3-(3′,4′-
dihydroxyphenyl)propionic acid. The generation of 
hydroxyphenylpropionic acid probably came from 
the 4 dehydroxylation of 3-(3′,4′-dihydroxyphenyl) 
propionic acid, but we were not able to confirm 
this information. Caﬀeic acid is a 
hydroxycinammic acid widely present in foods, in 
both free and conjugated forms (normally with 
quinic acid to form chlorogenic acid). Microbial 
fermentation of free or conjugated caﬀeic acid has 
been studied, and our findings seem to be in line 
with previous works in which 3-(3′-hydroxyphenyl) 
propionic acid was recovered as the main bacteria 
metabolite. 
.
Figure 3. Proposed colonic pathway of rosmarinic acid. Compounds in bold were detected in the 
fermentation medium between 0 and 48 h. Compounds in gray were detected as minor metabolites in the 
fermentation medium. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chemically, rosmarinic acid is an ester of caﬀeic 
acid and 3-(3′,4′-dihydroxyphenyl)lactic acid. As a 
consequence of its hydrolysis, two molecules are 
released into the medium, but both yield 
hydroxyphenylpropionic acid as the final 
metabolite, which could explain the high molar 
ratio between the parent compound and its formed 
metabolite. In the proposed rosmarinic acid 
colonic pathway (Figure 3), other metabolites 
such as the no hydroxylated form of 
phenylpropionic acid, coumaric acid, benzoic acid, 
and catechol have been described as other 
possible final metabolites. However, the low and 
variable amounts of these metabolites detected 
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during the fermentation suggest that they could be 
attributed to other food precursors, as was 
reported after an in vitro fermentation of coﬀee 
polyphenols.13 With regard to the colonic 
metabolism of eriodictyol, the kinetic response of 
the generated microbial metabolites is shown in 
Figure 2B. Complete degradation of eriodictyiol 
before 48 h of fermentation has been seen in all of 
the samples analyzed, indicating high microbial 
activity. Total degradation of eriodictyol has also 
been reported in previous works using 
Eubacterium ramulus26 and Clostridium 
orbiscindens27 as inocula. On the basis of the 
diﬀerent metabolic compounds detected at 
diﬀerent collection times, we proposed a 
hypothetical colon degradation pathway for 
eriodictyol (Figure 4). Heterocyclic C-ring 
cleavage of eriodictyol was the first evidence of 
microbial action, yielding 3-(3′,4′-dihydroxyphenyl) 
propionic acid as an intermediate metabolite 
probably derived from the B-ring fragment. 3-
(3′,4′-dihydroxyphenyl)propionic acid reached its 
maximum concentration (12.9 μM) at 12 h and 
declined thereafter (Figure 2C). Dehydroxylation 
of 3-(3′,4′-dihydroxyphenyl)propionic acid 
produced an isomer of hydroxyphenylpropionic 
acid, which represents the main phenolic end 
product. There was a progressive increase in the 
concentration of hydroxyphenylpropionic acid over 
the time course of fermentation with the maximum 
peak of concentration at 24 h (344.4 μM). These 
results are in line with those reported by other 
authors, who also detected 3-(3′,4′-
dihydroxyphenyl)propionic acid as a fermentation 
product of eriodictyol.26,27 However, no 
hydroxyphenylpropionic acid was described, 
probably because the experiments were carried 
out with two types of bacteria, E. ramulus and Cl. 
orbiscinders, that may not have dehydroxylation 
activity. 
 
Figure 4. Proposed colonic pathway of eriodictyol. Compounds in bold were detected in the fermentation 
medium between 0 and 48 h. Compounds in gray were detected as minor metabolites in the fermentation 
medium 
 
 
3.4. Human Intervention Study.  
The impact of human intestinal microbiota on the 
transformation of thyme phenols was investigated 
in 10 volunteers after the daily consumption of 25 
Results and Discussion 
 Journal of Agicultural and Food Chemistry, 2014, 10954-10961 
89 
 
mL of TPEOO over 3 weeks. The feces of the 
volunteers were analyzed at baseline and after the 
intervention period to elucidate eventual changes 
in the profile of the microbial metabolites. 
Although we observed that thymol and carvacrol 
were stable over 48 h during the in vitro 
incubation, only carvacrol was quantified in feces 
from one of the volunteers after the intake of 
TPEOO (data not shown). Nevertheless, an 
increment in the instrumental signal corresponding 
to the chromatographic peak of carvacrol 
(Treatment of Fecal Samples and 
Chromatographic Analysis of Thyme Metabolites 
under Material and Methods) was observed in 7 of 
the 10 fecal samples analyzed, although the 
carvacrol concentration was below to the limit of 
quantification (data not shown). This is in line with 
Anderson and co-workers, who failed to detect the 
aforementioned monoterpenes in pig feces after 
the intake of a thyme-rich diet.28
 
Figure 5. Phenolic metabolites detected in human fecal samples before (pre-) and after (post-) intake of 
thyme phenol-enriched olive oil (TPEOO). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In a similar study, only <10% of limonele was 
detected in the feces of animals (dog and guinea 
pig) after a high dose, whereas a high recovery 
was observed in urine.29 In a preliminary human 
intervention study conducted by our research 
group in which hyperlipidemic adults consumed 
thyme-enriched olive oil, a high recovery of thymol 
metabolites (main glucuronide conjugates) in 24 h 
urine was observed.30 The findings of the present 
survey, together with the previous reported data 
regarding the urinary excretion of mono-
terpenes,18 support the hypothesis that phenol 
monoterpenes are eﬀectively absorbed in the 
upper part of the gastrointestinal tract, and 
consequently the trace levels of carvacrol found in 
fecal samples actually represent only 
nonabsorbed remnantsWith regard to rosmarinic 
acid and eriodictyol, these compounds were not 
detected in the human fecal samples as their 
native structure after the sustained intake of 
TPEOO, which is in line with the complete 
degradation of these compounds observed in the 
in vitro study. In accordance with the in vitro 
fermentation, increased in the phenolic acids 
concentrations of 3-(3′,4′-dihydroxyphenyl) 
propionic acid, hydroxyphenylpropionic acid (the 
same isomer of acid reported in the in vitro 
experiments), 3-phenylpropionic acid, and 2-(4′-
hydroxyphenyl)acetic acid were detected in 
human fecal samples after the intake of TPEOO. 
3-(3′,4′-dihydroxyphenyl)propionic acid and 
hydroxyphenylpropionic acid were identified in the 
in vitro colon fermentation study as the 
intermediate and main metabolites of rosmarinic 
acid (Figure 3) and eriodictyol (Figure 4).  
However, the increase in the concentrations of 
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these catabolites was not statistically significant (p 
> 0.05) (Figure 5). Similarly, other in vivo studies 
also noted an increment in the concentration of 
hydroxyphenylpropionic acid in feces after the 
intake of grape seed extract and cranberries. 
Microbial metabolites produced in the large 
intestine could carry out their bioactive activity at a 
local level (intestinal lumen) or, if absorbed, they 
could be distributed by blood circulation to organs 
and tissues where they might accumulate or be 
detoxified by metabolizing enzymes (primarily in 
the liver) before being excreted in the urine.8,12 
Bioactivity assays using human or animal cell 
lines have made extensive use of phenolic 
microbial catabolites to elucidate their possible 
mechanisms of action, and experiments have 
been widely reviewed by Del Rio and co-workers33 
and Rodriguez-Mateos and co-workers,34 From 
this recent literature it is apparent that polyphenols 
and itheir microbial catabolites do not act simply 
as antioxidants in vivo and that their diverse 
eﬀects are, in most instances, based on more 
complex and specific modes of action, mainly 
related to cancer and cardiovascular diseases. In 
this sense, microbial catabolites derived from 
phenylacetic and phenylpropionic acids, which 
were also detected in large amounts in fecal 
samples following TPEOO intake, were proposed 
as anti-inflammatory agents.35 Additional 
experiments were carried out with the advance 
glycation end products (AGEs) model and pointed 
to the glucose-mediated pathway as a likely site of 
action of several microbial catabolites derived 
from hydroxyphenylacetic acid. These minor 
changes in phenol metabolite concentrations 
observed in feces after the sustained intake of 
thyme phenols through TPEOO (Figure 5) could 
indicate a high rate of absorption of thyme 
phenolic compounds in the upper part of the 
gastrointestinal tract. There is in vitro evidence 
that suggests that minor constituents of herb and 
spice extracts could enhance the rate of 
absorption of hydrophilic compounds present in 
the lumen of the small intestine, thus increasing 
paracellular transport by the transient opening of 
tight junctions.37,38 
Recent in vitro studies have proposed that 
aromatic herbs could inhibit the growth of colon 
cancer cells,39 which suggests that these 
compounds might have antitumoral eﬀects in 
contact with colon mucosa. Also, a promising use 
of aromatic herbs as natural antimicrobials of gut 
pathogens was proposed.1 However, in our study 
the thyme phenolic compounds (thymol, carvacrol, 
rosmarinic acid, or eriodictyol) in their native 
structures were not detected in human feces. 
In conclusion, the results of the present study 
provide very useful information regarding the gut 
metabolism of thyme phenols. Although the 
monoterpenes carvacrol and thymol were poorly 
metabolized by gut microbiota in the in vitro model 
fermentation, neither of these compounds, except 
for one volunteer, was quantified in human feces 
after the sustained intake (3 weeks) of a daily 
dose of 25 mL of TPEOO. These results support 
the idea suggested by other authors that thymol 
and carvacrol are well absorbed during small 
intestine passage. In contrast, rosmarinic acid and 
the flavonoid eriodictyol were extensively 
metabolized during in vitro colonic fermentation, 
yielding hydroxyphenylpropionic acid as the main 
metabolite. In accordance with these results, after 
the sustained intake of TPEOO, neither rosmarinic 
acid nor eriodictyol was detected in human feces, 
observing at the same time an increase in the 
concentration of hydroxyphenylpropionic and 
phenylpropionic acids, confirming the eﬀective 
microbial degradation for these compounds. The 
most likely eﬀective absorption in the upper part of 
the gastrointestinal tract, together with the intense 
colonic metabolism of other representative 
compounds of thyme phenolic fraction (rosmarinic 
acid and eriodictyol), opens the possibility of the 
application of technologic resources, such as 
microencapsulation, to facilitate the arrival of this 
type of compound to the colon. Further research is 
needed to understand the physiological eﬀects of 
thyme phenols in the gut and their implications 
when thyme is used as such (dry leaf) or as an 
essential oil for food flavoring. 
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ADDITIOINAL INFORMATION 
 
Table 1. In vitro fermentation of thymol and generation of microbial metabolites 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. In vitro fermentation of carvacrol and generation of microbial metabolites 
Compound  
(M) 
Fecal 
sample 
Incubation time (h) 
0 2 6 12 24 48 
Carvacrol 
H1 21756.4 17619.5 17519.2 2346.28 2433.82 22119.4 
H2 2474.13 18015.4 20126.9 2434.58 2355.58 1788.36 
H3 13720.6 21556.5 1798.83 25653.1 22910.1 18521.2 
2-(3’,4’-dihydroxyphenyl) 
acetic acid 
H1 n.d. 0.220.36 0.150.05 0.060.02 n.d. n.d. 
H2 0.240.14 0.150.09 n.d n.d. 0.530.13 0.380.10 
H3 0.130.12 0.080.03 0.080.06 n.d. n.d. n.d. 
2-(4’-hydroxyphenyl) acetic 
acid 
H1 n.d. 1.211.05 0.150.16 n.d. n.d. 4.561.28 
H2 0.920.13 0.080.11 n.d. n.d. 0.370.10 1.250.39 
H3 0.130.05 0.190.12 n.d. n.d. 7.412.08 2.700.47 
Phenylacetic acid 
H1 1.050.69 2.214.98 2.361.40 n.d. n.d. 9.652.02 
H2 1.200.14 n.d. n.d. n.d. n.d. n.d. 
H3 2.690.62 0.661.01 n.d. n.d. 7.441.64 12.68.29 
3-(4’-hydroxyphenyl) 
propionic acid 
H1 0.140.22 n.d. 1.350.67 0.250.16 n.d. 0.681.54 
H2 15.30.18 4.061.34 n.d. n.d. 43.212.2 16.27.84 
H3 0.070.18 0.970.27 n.d. n.d. 2.600.76 9.521.16 
Phenylpropionic acid 
H1 0.061.07 1.431.82 3.960.50 2.080.80 3.841.40 22.81.33 
H2 n.d. 0.130.49 0.311.55 n.d. n.d. n.d. 
H3 1.781.02 1.160.40 0.371.18 n.d. 5.220.85 7.602.56 
Data are expressed as mean in µmol/L. Mean values were calculated subtracting to the average value of the three 
replicates the control content of the respective substance. n.d.: not detected. Below the limit of detection  Tr.: traces. 
Below the limit of quantification  
 
 
 
Compound 
(M) 
Fecal 
sample 
Incubation time (h) 
0 2 6 12 24 48 
Thymol 
H1 46394.4 49959.9 267105 26789.1 21294.7 17240.4 
H2 23410.1 203166 255162 27625.4 25729.9 450143 
H3 20998.5 192135 261244 21457.4 25734.0 23887.6 
Carvacrol 
H1 n.d. 0.810.04 n.d. 1.32.61 0.690.24 n.d. 
H2 n.d 0.330.07 0.070.22 n.d. n.d. n.d 
H3 n.d n.d. 0.20.38 0.290.76 0.76 n.d 
2-(3’,4’-
dihydroxyphenyl) 
acetic acid 
H1 n.d. n.d. Tr n.d n.d. Tr 
H2 n.d. n.d n.d n.d. 1.060.09 1.500.02 
H3 n.d. n.d n.d n.d. n.d. n.d. 
2-(4’-
hydroxyphenyl) 
acetic acid 
H1 Tr 0.750.10 0.310.08 n.d n.d 11.87.89 
H2 0.230.02 4.353.74 0.950.27 n.d n.d n.d 
H3 n.d 0.700.40 n.d n.d 51.55.30 n.d 
Phenylacetic 
acid 
H1 0.655.15 1.580.78 7.646.06 n.d n.d 44.742.3 
H2 n.d n.d 2.060.89 n.d n.d n.d 
H3 n.d 4.091.91 n.d n.d 50.74.08 1.215.44 
3-(4’-
hydroxyphenyl) 
propionic acid 
H1 0.530.96 3.135.42 2.933.96 n.d 2.892.10 9.708.96 
H2 0.640.05 0.970.23 16.175.47 Tr 0.250.15 6.260.67 
H3 n.d 54.546.8 n.d n.d 13.15.64 6.104.47 
Phenylpropionic 
acid 
H1 3.592.09 n.d 8.254.06 n.d n.d n.d 
H2 n.d n.d 4.481.66 n.d 21.350.0 15.334.1 
H3 n.d 14.710.9 n.d n.d n.d 18.37.49 
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Table 3.  In vitro fermentation of rosmarinic acid and generation of microbial metabolites  
Data are expressed as mean in µmol/L. Mean values were calculated subtracting to the average value of the three 
replicates the control content of the respective substance. n.d.: not detected. Below the limit of detection  Tr.: traces. 
Below the limit of quantification  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compound  
(M) 
Fecal 
sample 
Incubation time (h) 
0 2 6 12 24 48 
Rosmarinic acid 
H1 72.710.6 74.74.18 14.92.24 n.d. n.d. n.d. 
H2 61.9525.03 51.413.6 10.31.68 n.d n.d n.d 
H3 14315.3 12615.4 12.62.84 n.d n.d n.d 
Caffeic acid 
H1 2.110.71 24.74.18 33.22.24 17.97.54 n.d 0.090.18 
H2 2.680.27 11.01.77 20.41.87 17.81.94 0.040.05 0.010.03 
H3 2.091.04 15.11.00 0.100.02 0.080.07 n.d 0.130.02 
p-cumaric acid 
H1 n.d n.d. n.d. n.d. n.d. n.d 
H2 0.910.01 0.050.07 0.560.04 0.400.04 n.d 0.90 
H3 n.d n.d n.d. n.d n.d. n.d. 
3- (3’, 4’-
dihydroxyphenyl) 
propionic acid 
H1 0.030.01 0.130.02 15.80.87 36.25.68 0.330.19 0.060.14 
H2 0.160.02 0.050.01 7.180.86 28.72.73 n.d 0.150.06 
H3 n.d 3.190.27 24.11.10 7.804.86 0.480.10 0.150.06 
Hydroxyphenylpropionic 
acid 
H1 n.d. n.d. 1.480.32 6.454.54 67.95.97 166.24.0 
H2 n.d  n.d 2.751.01 0.190.05 55.77.57 13213.0 
H3 n.d 2.250.87 45.93.42 78.26.59 1016.25 20715.9 
Phenylpropionic acid 
H1 1.093.40 n.d. n.d n.d 4.096.02 18.812.3 
H2 5.470.31 n.d 0.633.69 n.d n.d n.d 
H3 n.d n.d n.d 3.001.11 n.d 3.381.47 
2-(3’,4’-
dihydroxyphenyl) acetic 
acid 
H1 0.040.08 2.260.03 0.300.07 2.520.06 0.310.04 0.240.05 
H2 0.260.05 0.100.03 0.090.01 0.030.03 1.140.36 1.140.38 
H3 n.d 2.090.05 0.120.02 2.220.09 3.040.27 2.180.01 
2-(4’-hydroxyphenyl) 
acetic acid 
H1 0.130.08 0.020.02 0.140.06 0.510.22 0.460.17 0.950.47 
H2 1.070.09 n.d 0.320.13 0.260.06 0.130.01 7.301.25 
H3 n.d, n.d 1.410.68 0.630.22 7.591.07 10.41.86 
Phenylacetic acid 
H1 n.d. 0.890.45 n.d. n.d. 7.603.48 5.736.77 
H2 1.140.38 n.d. 0.411.83 n.d. 0.432.60 14.71.81 
H3 0.031.79 n.d. n.d. n.d. 13.411.50 13.75.29 
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Table 4. In vitro fermentation of eriodictyol and generation of microbial metabolites  
Data are expressed as mean in µmol/L. Mean values were calculated subtracting to the average value of the three 
replicates the control content of the respective substance. n.d.: not detected. Below the limit of detection  Tr.: traces. 
Below the limit of quantification  
 
 
Compound  
(M) 
Fecal 
sample 
Incubation time (h) 
0 2 6 12 24 48 
Eriodyctyol 
H1 13822.1 78.05.80 14.20.73 1.300.41 0.490.43 n.d. 
H2 16335.3 51.322.10 11.73.33 0.980.47 n.d. n.d. 
H3 14943.7 73.232.1 12.01.58 0.500.44 n.d. n.d. 
3- (3’, 4’-dihydroxyphenyl) 
propionic acid 
H1 n.d. n.d. 2.273.29 1.570.18 23.99.23 n.d. 
H2 n.d. 0.050.02 0.380.12 3.090.17 19.55.04 0.070.05 
H3 n.d. n.d. 4.533.27 34.23.08 n.d. 0.050.05 
Hydroxyphenylpropionic 
acid 
H1 n.d. n.d. n.d. 15.640.1 15219.7 37025.8 
H2 n.d. n.d. n.d. 1.070.12 39650.2 35643.1 
H3 n.d. 0.040.10 95.032.2 24015.3 48519.7 40925.0 
Phenylpropionic acid 
H1 3.752.38 1.194.45 n.d. 3.411.96 n.d. n.d. 
H2 n.d. n.d. n.d. 1.082.25 n.d. n.d. 
H3 n.d. n.d. n.d. 1.550.66 19.75.46 19.44.93 
2-(3’,4’-dihydroxyphenyl) 
acetic acid 
H1 0.010.01 n.d. n.d. 2.070.02 n.d. n.d. 
H2 n.d. 0.01 n.d. n.d. 0.070.03 n.d. 
H3 n.d. n.d. n.d. n.d. n.d. n.d. 
2-(4’-hydroxyphenyl) 
acetic acid 
H1 n.d. n.d. 2.570.92 n.d. n.d. n.d. 
H2 n.d. n.d. n.d. n.d. 1.110.10 1.530.45 
H3 n.d. n.d. n.d. n.d. n.d. 0.790.40 
Phenylacetic acid 
H1 2.242.34 1.411.43 n.d. 1.360.81 n.d. n.d. 
H2 0.870.83 n.d. n.d. n.d. n.d. 31.610.5 
H3 n.d. n.d. n.d. n.d. n.d. n.d. 
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ABSTRACT  
Purpose.  To investigate the effect of virgin olive oil phenolic compounds (PC) alone or in combination with 
thyme PC on blood lipid profile from hypercholesterolemic humans, and whether the changes generated 
are related with changes in gut microbiota populations and activities. 
Methods  A randomized, controlled, double-blind, cross-over human trial (n = 12) was carried out. 
Participants ingested 25 mL/day for 3 weeks, preceded by 2-week washout periods, three raw virgin olive 
oils differing in the concentration and origin of PC: (1) a virgin olive oil (OO) naturally containing 80 mg 
PC/kg, (VOO), (2) a PC-enriched virgin olive oil containing 500 mg PC/kg, from OO (FVOO), and (3) a PC-
enriched virgin olive oil containing a mixture of 500 mg PC/kg from OO and thyme 1:1 (FVOOT). Blood 
lipid values and faecal quantitative changes in microbial populations, short chain fatty acids, cholesterol 
microbial metabolites, bile acids, and phenolic metabolites were analysed. 
Results  FVOOT decreased seric ox-LDL concentrations compared with pre-FVOOT, and increased 
numbers of bifidobacteria and the levels of the phenolic metabolite protocatechuic acid compared to VOO 
(P < 0.05). FVOO did not lead to changes in blood lipid profile nor quantificative changes in the microbial 
population analysed but increased the corpostanone compared to FVOOT (P < 0.05), and the levels of the 
faecal hydroxytyrosol and dihydroxyphenylacetic acids, compared with pre-intervention values and to 
VOO, respectively (P < 0.05). 
Conclusion.  The ingestion of a PC-enriched virgin olive oil, containing a mixture of olive oil and thyme PC 
for 3 weeks, decreases blood ox-LDL in hypercholesterolemic humans. This cardio-protective effect could 
be mediated by the increases in populations of bifidobacteria together with increases in PC microbial 
metabolites with antioxidant activities. 
 
Keywords  Bifidobacteria · Gut microbiota · ox-LDL · Cholesterol · Phenolic compounds · Prebiotic · Virgin 
olive oil.  
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1. INTRODUCTION  
Adherence to the Mediterranean diet (MD) has 
shown to be cardio-protective [1]. Consumption of 
virgin olive oil (OO), the main fat of the MD, has 
demonstrated a relevant influence on its beneficial 
effects [2]. Besides oleic acid, the phenolic 
fraction of virgin OO also contributes to the health 
effects associated with virgin OO consumption [3]. 
Its antioxidant and antiinflammatory activities, 
acting as pathway and gene expression 
modulators [4], may explain such health 
properties. However, the mechanisms by which 
virgin olive oil PC influence cardiovascular 
disease (CVD) risk factors are not fully 
understood. Recent insights indicate that gut 
microbiota plays an important role in CVD and 
represents a realistic therapeutic target [5]. Some 
of the reported gut microbiota-related mechanisms 
by which gut bacteria could influence CVD risk 
factors, such as the presence of abnormal levels 
of blood lipids [6], could be one or a combination 
of the following: (1) involvement in cholesterol 
synthesis through generation of short chain fatty 
acids (SCFA) which are generated from microbial 
fermentation of undigested substrates, either 
increasing blood total cholesterol (i.e. acetic) or 
decreasing it (i.e. propionic, butyric) [7]; (2) 
reduction in the amount of cholesterol available for 
re-absorption from the intestine either by 
transforming gut cholesterol to insoluble 
metabolites and, thereby, its uptake from the gut 
[8] or by incorporating cholesterol into the 
microbial cellular membrane [9, 10]; (3) 
deconjugation of bile salts in the gut, generating 
insoluble primary bile acids which are excreted in 
faeces [11], which lead to cholesterol expenditure 
in the liver in order to synthesize new bile acids; 
(4) generation of bioactive metabolites in the gut 
with cardio-protective properties. Diet appears to 
critically influence both, the relative abundance of 
different gut microorganisms and their metabolic 
output. In this sense, high intake of PC from 
different sources appears to regulate some CVD 
risk factors [12, 13], through the modulation of 
microbial populations and activities [14], as many 
plants PC are not totally absorbed and become 
available for microbiota utilization as an energy 
source, which has an impact on nutrient 
bioavailability and host metabolism. Regarding 
virgin olive oil PC, recent studies have 
demonstrated that they are able to reach the gut, 
being transformed by gut microbiota [15]. It has 
also been shown that the bioaccessibility of virgin 
olive oil PC can be increased by combining virgin 
olive oil PC with other PC sources (i.e. thyme) [16, 
17]. Since the interaction of virgin olive oil 
phenolic compounds with gut microbiota and its 
involvement in CVD risk remains to be elucidated, 
the aim of our study was to investigate the effect 
of a sustained consumption of virgin olive oil PC, 
alone or in combination with thyme PC on blood 
lipid levels in hypercholesterolemic subjects, and 
whether this effect is mediated by gut microbiota-
related mechanisms. 
 
2. MATERIAL AND METHODS 
2.1. Study subjects and design 
The present study included a subsample of 12 
hypercholesterolemic (total cholesterol >200 
mg/dL) adults (5 females and 7 males) aged 46–
67 years from the VOHF (Virgin Olive Oil and HDL 
Functionality) study. The VOHF study was a 
randomized, controlled, double-blind, crossover 
clinical trial with 33 hypercholesterolemic 
volunteers, aged 35–80 years. Exclusion criteria 
Abbreviations 
CVD Cardiovascular diseases 
FC Flow cytometry 
FISH Fluorescence in situ hybridization 
FSC Forward scatter detector 
FVOO Phenolic compounds-enriched virgin olive 
oil containing 500 mg  phenolic  
compounds/kg, from olive oil 
 
FVOOT Phenolic compounds-enriched virgin olive 
oil containing a mixture of 500 mg 
phenolic compounds/kg, from olive oil 
and thyme, 1:1 
 
 
MD Mediterranean diet 
PC Phenolic compounds 
PCA Protocatechuic acid 
SCFA Short chain fatty acids 
SSC Side scatter detector 
VOO Virgin olive oil naturally containing 80 mg 
of phenolic compounds/kg 
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included the following: BMI > 35 kg/m2, smokers, 
athletes with high physical activity (>3000 
kcal/day), diabetes, multiple allergies, intestinal 
diseases, or other disease or condition that would 
worsen adherence to the measurements or 
treatments. 
 
Table 1. Chemical characterization of the olive oils used in the study 
Compositiona Olive oils    
 VOO FVOO FVOOT 
Phenolic compounds (mg/25 mL)    
Hydroxytyrosol 0.01 ± 0.00 0.21 ± 0.02 0.12 ± 0.00 
3,4-DHPEA-AC n.d. 0.84 ± 0.06 0.39 ± 0.04 
3,4-DHPEA-EDA 0.04 ± 0.00 6.73 ± 0.37 3.43 ± 0.29 
3,4-DHPEA-EA 0.26 ± 0.04 0.71 ± 0.06 0.36 ± 0.03 
Total hydroxytyrosol derivates 0.30 8.49 4.30 
p-Hydroxybenzoic acid n.d. 0.02 ± 0.00 0.06 ± 0.00 
Vanillic acid n.d. 0.07 ± 0.00 0.13 ± 0.01 
Caffeic acid n.d. 0.00 ± 0.00 0.06 ± 0.00 
Rosmarinic acid n.d. n.d. 0.41 ± 0.03 
Total phenolic acids – 0.09 0.65 
Thymol n.d. n.d. 0.64 ± 0.05 
Carvacrol n.d. n.d. 0.23 ± 0.02 
Total monoterpenes – – 0.86 
Luteolin 0.04 ± 0.00 0.18 ± 0.02 0.21 ± 0.02 
Apigenin 0.02 ± 0.00 0.06 ± 0.00 0.10 ± 0.00 
Naringenin n.d. n.d. 0.20 ± 0.02 
Eriodictyol n.d. n.d. 0.17 ± 0.01 
Thymusin n.d. n.d. 1.22 ± 0.09 
Xanthomicrol n.d. n.d. 0.53 ± 0.06 
7-Methylsudachitin n.d. n.d. 0.53 ± 0.09 
Total flavonoids 0.06 0.23 2.95 
Pinoresinol 0.05 ± 0.00 0.12 ± 0.00 0.10 ± 0.05 
Acetoxipinoresinol 2.47 ± 0.19 3.66 ± 0.31 3.24 ± 0.28 
Total lignans 2.52 3.78 3.34 
Fat-soluble micronutrients (mg/25 mL)    
α-Tocopherol 3.27 ± 0.01 3.40 ± 0.02 3.44 ± 0.01 
Lutein 0.05 ± 0.00 0.06 ± 0.00 0.06 ± 0.00 
β-Cryptoxanthin 0.02 ± 0.00 0.03 ± 0.00 0.02 ± 0.00 
β-Carotene 0.01 ± 0.00 0.02 ± 0.00 0.02 ± 0.00 
Fatty acids (relative area %)    
Palmitic acid 11.21 11.20 11.21 
Stearic acid 1.92 1.92 1.92 
Arachidic acid 0.36 0.36 0.36 
Behenic acid 0.11 0.11 0.11 
Total saturated 13.75 13.74 13.75 
Palmitoleic acid 0.70 0.70 0.69 
Oleic acid 76.74 76.83 76.75 
Gadoleic acid 0.27 0.27 0.27 
Total monounsaturated 77.71 77.80 77.72 
Linoleic acid 7.43 7.36 7.43 
Timnodonic acid 0.36 0.36 0.35 
Linolenic acid 0.43 0.43 0.43 
Total polyunsaturated 8.22 8.15 8.22 
PC and fat-soluble micronutrients are expressed as mean ± SD of mg in 25 mL oil/day. The acidic composition is  
expressed as relative area percentage. n.d. non-detected. VOO, 80 mg/kg of phenolic compounds (PC) from olive oil; 
FVOO, 500 mg/kg of PC from olive oil; FVOOT, 250 mg/kg of PC from olive oil and 250 mg/kg from thyme.a  3,4-
DHPEA-AC, 4-(acetoxyethyl)-1,2-dihydroxybenzene; 3,4-DHPEA-EDA, dialdehydic form of elenolic acid linked to 
hydroxytyrosol; 3,4-DHPEA-EA, oleuropein aglycone 
 
 
 
The study was conducted at IMIM-Mar Insitute of 
Medical Research (Spain) from April 2012 to 
September 2012. Participants ingested 25 mL/day 
for 3 weeks, preceded by 2 week washout 
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periods, of three raw virgin olive oils differing in 
the concentration and origin of phenolic 
compounds (PC): (1) a virgin olive oil naturally 
containing 80 mg PC/kg (VOO), (2) a PC-enriched 
virgin olive oil containing 500 mg PC/kg, from olive 
oil (FVOO), and (3) a PC-enriched virgin olive oil 
containing a mixture of 500 mg PC/kg from olive 
oil and thyme, 1:1 (FVOOT). Participants were 
randomized to one of three orders of 
administration (Order 1: FVOO, FVOOT, and 
VOO, Order 2: FVOOT, VOO, and FVOO, Order 
3: VOO, FVOO, and FVOOT). Elaboration of PC-
enriched olive oils (i.e. FVOO and FVOOT) is 
described by Rubió et al. [18]. Full phenolic 
composition of the three oils is presented in Table 
1. The random allocation sequence was 
generated by a statistician, participant enrolment 
was carried out by a researcher, and participants’ 
assignment to interventions according to the 
random sequence was done by a physician. Due 
to the fact that all participants received each one 
of the three oils, restrictions such as blocking were 
unnecessary. In order to avoid an excessive 
intake of PC other than those provided by the 
intervention’s oils, participants were asked to limit 
the consumption of rich-polyphenol food and 
dietary data were recorded by 3-day dietary 
record at baseline and before and after each 
intervention period. The corresponding 25 mL 
bottles of the corresponding oil for each day of 
consumption were provided to the participants at 
the beginning of each intervention period. The 
participants were instructed to return the bottles in 
order to register the amount of the intervention oil 
consumed. Subjects with <80 % of treatment 
adherence (≥5 full oil containers returned) were 
considered non-compliant for the dietary 
intervention. Blood at fastIng state (of at least 10 
h) and faecal samples were collected before and 
after each intervention period. All participants 
provided written informed consent, and the local 
institutional ethics committees approved the 
protocol (CEIC-IMAS 2009/3347/I). The trial was 
registered with the International Standard 
Randomized Controlled Trial register (www.con-
trolled-trials.com; ISRCTN77500181). 
 
2.2. Dietary adherence 
Twenty-four-hour urine was collected at the start 
of the study and before and after each treatment. 
Urine samples were stored at −80 °C prior to use. 
We measured urinary hydroxytyrosol sulphate and 
thymol sulphate as biomarkers of adherence to 
the type of OO ingested in urine by ultra-HPLC–
ESI–MS/MS [19]. A 3-day dietary record was 
administered to the participants at baseline and 
before and after each intervention period. A 
nutritionist personally advised participants to 
replace all types of habitually consumed raw fats 
with the oils provided, and to limit their 
polyphenol-rich food consumption. 
 
2.3. Serum lipid profile analysis 
Total and HDL cholesterol, and triglyceride 
concentrations were measured by using standard 
enzymatic automated methods. When triglyceride 
concentrations were <300 mg/dL, LDL cholesterol 
was calculated by using Friedewald’s formula. 
Oxidized LDL was determined with an ELISA 
procedure that employed the murine monoclonal 
antibody mAb-4E65 (Mercodia AB). 
 
2.4. Faecal sample collection and pre-
analytical treatment 
For faecal collection, participants were given a set 
containing: a sterile pot, a w-zip plastic pouch 
(AN0010 W, Oxoid, Basingstoke, UK), two 
anaerobic sachets (Anaero-Gen Compact 
AN0025, Oxoid), and one anaerobic indi-cator 
(BR0055, Oxoid). Freshly voided faecal samples 
were collected by the volunteers in the sterile pot 
and kept under anaerobic conditions by 
introducing them into the plastic pouch, together 
with the anaerobic sachets and the anaerobic 
indicator. In order to avoid changes in microbial 
populations, faecal samples were brought to the 
laboratory within 2 h after defecation. 
For quantitative analysis of gut microbiota, faeces 
were diluted with sterile 0.1 M, pH 7.0, phosphate-
buffered saline (PBS, Sigma-Aldrich Co. LLC., St. 
Louis, USA) (1:10, w/v), mixed in a Stomacher 
400 (Seward, Thetford, Norfolk, UK) for 2 min and 
faecal slurries homogenized. After centrifugation 
(1300g, 3 min), hexane (Sigma-Aldrich, UK) was 
added to the faecal homogenate supernatant (4:1, 
v/v), mixed by inversion for 2 min and removed 
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after centrifugation (15,500g, 5 min) and 
evaporation. Pellets were washed in 1 mL of 
filtered sterile PBS and centrifuged (15,500g, 5 
min). Afterwards, pellets were diluted in 375 µL of 
PBS and fixed in ice-cold 4 % (w/v) 
paraformaldehyde (PFA) (1:4, v/v) for 4 h at 4 °C. 
PFA was discarded after centrifugation (15,500g, 
5 min) and washed twice in 1 mL of sterile PBS.  
 
2.5. Quantification of faecal microbiota by 
FISH-FC 
Bacterial hybridizations were based on the 
method described by Massot-Cladera et al. [20] 
with some modifications. Briefly, 5 µL of fixed cell 
suspensions were centrifuged at 15,500g for 5 
min. 30 µL of a mixture (1:10, v/v) of synthetic 
oligonucleotide probes (50 ng/µL) targeting 
specific diagnostic regions of 16S rRNA and 
labelled with the fluorescent Cy3 dye (Ato291 [21], 
Bac303 [26], Bif164 [27], Chis150 [22], Erec482 
[22], Fprau645 [23], Lab158 [24], Prop853 [25] 
and Rrec584 [25]), plus pre-heated hybridization 
buffer (0.9 M NaCl, 20 mM Tris–HCl pH 8, 0.01 % 
sodium dodecyl sulphate), were added to the 
pellets, homogenized, and incubated in a 
thermocycler for 4 h at each specific probe 
hybridization temperature, in the dark. After 
hybridization, samples were washed by adding 2 
mL of a mixture of preheated wash buffer (0.9 M 
NaCl, 20 mM Tris–HCl, pH 8) where 0.04 % of 6-
diamidino-2-phenylindole dihydrochloride (50 
ng/µL; Sigma-Aldrich) was added, for 15 min at 
each specific probe hybridization temperature in 
the dark. Washed samples were then centrifuged 
at 15,500g for 5 min. Pellets were homogenized in 
200 µL of PBS solution and kept in the dark at 4 
°C overnight. Immediately before the flow 
cytometry analysis, 30 µL of Commercial Flow 
CheckTM Fluorospheres (Beckman Coulter, Inc. 
FL, USA) were added to the samples in order to 
calculate total counts of bacteria. 
An LSRFortessa flow cytometer (Becton–
Dickinson, New Jersey, USA) was used for 
bacteria quantifications. The flow cytometer 
parameters were adjusted for bacterial counts. 
Bacteria morphology was selected according to 
their FSC/SSC signal. For this purpose, selected 
bacteria (Leibniz-Institut DSMZ collection, 
Germany) representative of each bacterial group 
hybridized by each probe (Collinsella aerofaciens 
for Ato291; Bacteroides caccae for Bac303; 
Bifidobacterium bifidum for Bif164; Clostridium 
acetobutyl-icum for Chis150; Clostridium 
saccharolyticum for Erec482; Faecalibacterium 
praustnizii for Fprau645; Lactobacillus plantarum 
for Lab158; Megasphaera elsdenii for Prop853; 
Roseburia intestinalis for Rrec584) were grown, 
fixed, and hybridized as described above. Bacteria 
hybridized with Cy3-labelled probes were detected 
using a yellow and green laser (561 nm filter), and 
DAPI bacteria stained DNA was detected using 
violet one (405-nm filter). Both lasers worked at 
50-mW power. An acquisition gate of 2500 
fluorospheres was established. Analysis was 
performed using the FACS-Diva software version 
6.1.2 (Becton–Dickinson). Microbiota composition 
results were expressed as the log faecal cells/g 
dry faeces for each sample.  
 
2.6. Analysis of faecal SCFA 
For the analysis of SCFA, freeze-dried samples 
were diluted 10-fold with milli-Q water and 
centrifuged, first at 1800g for 5 min and afterwards 
at 8784g for 4 min at 4 °C. Supernatants were 
filtered through a 0.22 µm filter and subjected to 
GC analysis (Agilent 7890A Series, Santa Clara, 
EEUU) using a capillary BP-21 column (SGE, 
Cromlab SL, Barcelona, Spain) (30 m, 0.25 mm, 
0.25 µm) coupled to a flame ionization detector 
(FID) [28]. 4-methyl valeric acid (Sigma-Aldrich) 
was used as internal standard. Concentrations of 
SCFA were calculated from calibration curves 
using standard solutions with known 
concentrations of acetic, propionic, butyric, 
isobutyric, isovaleric, and valeric acids (Sigma-
Aldrich). Results were expressed as µmol/g dry 
faeces. 
 
2.7. Analysis of faecal cholesterol microbial 
metabolites (neutral sterols) and bile acids 
Freeze-dried milled faeces were diluted in milli-Q 
water (0.1:4, w/v) and homogenized. A volume of 
400 µL of faecal homogenate was used for the 
extractions, following the method described by 
Santas et al. [29] with some modifications. For 
cholesterol and its microbial metabolites, sterol 
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mixtures were prepared as calibrators. 5-α-
Cholestane (10 µg, Sigma-Aldrich) was used as 
internal standard. Samples were hydrolysed with 1 
mL of NaOH (1 N, in ethanol) for 1 h at 70 °C. 
After cooling the tubes at room temperature, 0.5 
mL of water was added and tubes were sonicated 
for 5 min. After two extractions with cyclohexane 
(3 mL each), mixed organic phases were 
evaporated under a 15-psi nitrogen stream at 30 
°C. 
For bile acid analysis, bile acid mixtures were 
prepared. 5-β-Cholanic acid (Sigma-Aldrich) was 
used as internal standard. Samples were 
hydrolysed with 1 mL NaOH 1 N at 70 °C for 1 h. 
After cooling the tubes, liquid–liquid extraction 
with 3 mL of tert-butylmethyl ether was done 
twice. Organic phases were further cleaned with 2 
mL of NaCl 1 %. The organic phase was 
evaporated under a 15-psi nitrogen stream at 30 
°C. 
Derivatization of both sterols and bile acids was 
car-ried out by addition of 50 µL of N-methyl-bis 
(trifluoro-acetamide)/NH4I/2-mercaptoethanol 
(1000/2/6) (Mach-erey–Nagel, Düren, Germany) 
and dry heated at 60 °C for 20 min. A gas 
chromatograph (6890 N; Agilent Tech-nologies, 
Wilmington, DA, USA) equipped with a mass 
selective detector (5973 Network, AT) and an 
autosampler injector (7683 series, AT) was used 
for analysis and performed in a 100 % 
methylsiloxane column (Agilent Ultra 1) in all 
cases. After derivatization, both neutral sterols 
and bile acids were quantified with their respective 
standards, expressed as µmol/g and µmol/10 g 
dry faeces, respectively. 
 
2.8. Analysis of faecal phenolic microbial 
metabolites 
For PC metabolite analysis, freeze-dried faeces 
(0.1 g) were mixed with 1 mL of milli-Q water. 
Samples were shaken for 30 min and centrifuged 
(13,200g, 10 min, 4 °C). Supernatants were 
centrifuged (13,200g, 10 min, 4 °C) and filtered 
through a membrane (0.22 µm pore size) and 
transferred to chromatographic vials. PC 
metabolites analysis was performed as previously 
described [15, 17] and was quantified using the 
calibration curve of their respective standard. PC 
metabolites concentration results were expressed 
as µmol/100 g dry faeces. 
 
2.9. Sample size 
The sample size for this study was calculated with 
the free software GRANMO 
(http://www.imim.cat/ofertadeserveis/ software-
public/granmo/) by selecting 80 % power (5 % α 
level) to detect a 0.4 log10/g dry faeces difference 
between treatments in the primary outcome 
variable (Bif164 counts/g of dry faeces), with a 
standard deviation of treatment differences <0.48 
(log10 scale). 
 
2.10. Statistical analysis 
Normality of continuous variables was assessed 
with normal probability plots and the Shapiro–Wilk 
test. Non-normally distributed variables were log 
transformed previous to the analysis. Paired t test 
was used for intra-intervention comparisons. 
Adjusted general linear mixed models with a 
period-by-treatment interaction term were used for 
inter-intervention comparisons, given results as 
adjusted means. P ≤ 0.05 was considered 
significant. Statistical analyses were performed 
with an R software version 2.11.1. 
 
3. RESULTS 
3.1. Compliance  
Urine compliance markers (hydroxytyrosol 
sulphate and thymol sulphate) indicated good 
adherence to the oil interventions (Table 1 of 
Supplementary). The three intervention oils were 
well tolerated by all participants, and no adverse 
events were reported. 
 
3.2. Blood lipid profile 
Serum concentrations of cholesterol, triglycerides, 
HDL cholesterol, and LDL cholesterol did not 
present any statistical change with any of the 
dietary interventions (data not shown). Oxidized 
LDL concentrations decreased after FVOOT 
intervention compared to pre-FVOOT values (P = 
0.049) (Fig. 1).  
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Fig. 1 Changes in serum oxidized LDL (after–
before interventions values) with olive oil 
interventions. Values are given as means of mg/ 
dL and SE bars n = 12 subjects. *P < 0.05, for the 
differences within the same olive oil intervention. 
 
3.3. Analysis of quantitative changes in gut 
microbiota 
Quantitative changes in faecal microbiota before 
and after interventions are presented in Table 2. 
Consumption of virgin olive oil PC alone (FVOO) 
did not have a significant effect on bacterial 
counts. Only a decrease in numbers of 
Clostridium cluster IX (Prop853) compared to 
VOO intervention was observed, although this 
decrease did not reach statistical significance (P = 
0.066). 
When virgin olive oil PC were combined with 
thyme PC (FVOOT), the numbers of the bacterial 
groups hybridized by Bif164 probe (most 
Bifidobacterium spp and Paras-cardovia 
denticolens) significantly increased compared to 
VOO (P = 0.044). PC combination also increased 
the numbers of Roseburia–Eubacterium rectale 
group (Rrec584 probe) compared to FVOO 
intervention, but this increment did not reach 
statistical significance (P = 0.085). 
Table 2. Bacterial enumerations determined by FISH-flow cytometry in faecal samples collected before (B) 
and after (A) each olive oil intervention 
Probe  VOO FVOO FVOOT 
Pa 
VOO–FVOO VOO–FVOOT FVOO–FVOOT 
Ato291 B 8.80 ± 0.09 8.86 ± 0.11 8.72 ± 0.10    
 A 8.78 ± 0.09 8.64 ± 0.09 8.72 ± 0.09 0.319 0.947 0.293 
Bac303 B 8.68 ± 0.38 8.87 ± 0.42 8.64 ± 0.40    
 A 8.75 ± 0.39 8.73 ± 0.39 8.73 ± 0.40 0.423 0.917 0.373 
Bif164 B 8.33 ± 0.25 8.29 ± 0.27 8.14 ± 0.26    
 A 8.10 ± 0.25 8.11 ± 0.26 8.32 ± 0.26 0.818 0.044 0.073 
Fprau645 B 8.90 ± 0.06 9.03 ± 0.07 8.96 ± 0.06    
 A 8.90 ± 0.06 8.92 ± 0.06 8.93 ± 0.06 0.420 0.831 0.558 
Lab158 B 8.30 ± 0.20 8.43 ± 0.22 8.24 ± 0.21    
 A 8.44 ± 0.20 8.32 ± 0.21 8.27 ± 0.21 0.145 0.512 0.427 
Prop853 B 8.81 ± 0.08 8.99 ± 0.10 8.81 ± 0.09    
 A 8.98 ± 0.08 8.79 ± 0.08 8.80 ± 0.08 0.066 0.338 0.364 
Rrec584 B 8.74 ± 0.08 8.81 ± 0.10 8.63 ± 0.09    
 A 8.76 ± 0.09 8.61 ± 0.09 8.79 ± 0.09 0.303 0.461 0.085 
Values are given as adjusted means of log10 bacteria/g dry faeces ± SE; n = 12 subjects 
VOO, 80 mg/kg of phenolic compounds (PC) from olive oil; FVOO, 500 mg/kg of PC from olive oil; FVOOT, 250 mg/kg 
of PC from olive oil and 250 mg/kg from thyme. aP values for inter-dietary intervention comparison.
3.3. Analysis of changes in faecal microbial 
activities 
The analysis of the main SCFA generated by gut 
microbial fermentation (acetic, butyric, propionic, 
and branched acids) did not show significant 
changes with any of the interventions (Table 3).  
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Table 3.  Faecal short chain fatty acids (SCFA), neutral sterols, and bile acids determined before (B) and 
after (A) each olive oil intervention. 
Values are given as adjusted means and CI; n = 12 
25 mL/day extra virgin olive oil containing: VOO, 80 mg/kg of phenolic compounds (PC) from olive oil; FVOO, 500 mg/kg 
of PC from olive oil; FVOOT, 250 mg/kg of PC from olive oil and 250 mg/kg from thyme 
df dry faeces  
a  Sum of isobutyric, isovaleric, and valeric acids  
b  P values for inter-dietary intervention comparisons. 
 
 
Their relative amounts remained constant along 
the trial irrespective of the intervention (54–58, 
15–18, 16–18, and 8–10 %, respectively). 
From the faecal concentrations of cholesterol and 
microbial cholesterol metabolites (coprostanol, 
coprostanone, cholestanone) analysed, only 
coprostanone changed with the dietary 
interventions, by increasing with FVOO compared 
to FVOOT (P = 0.028) (Table 3). Changes in 
concentrations of faecal bile acids after dietary 
interventions did not reach statistical significance 
(Table 3). However, the relative proportion of 
 
Olive oil interventions Pb 
 VOO FVOO FVOOT 
VOO 
–FVOO 
VOO 
–FVOOT 
FVOO 
–FVOOT 
SCFA (µmol/g df) 
Acetic B 195 (102, 372) 144 (73.8, 281) 148 (80.5, 272)    
 A 178 (94.0, 337) 168 (94.5, 294) 160 (74.7, 341) 0.364 0.547 0.772 
Butyric B 64.3 (26.2, 157) 42.4 (19.7, 91.3) 44.4 (21.1, 93.5)    
 A 58.0 (22.2, 151) 52.6 (25, 109) 42.3 (16.8, 106) 0.264 0.854 0.347 
Propionic B 62.9 (32.6, 121) 48.5 (24.0, 97.9) 48.0 (23.9, 96.4)    
 A 50.8 (26.7, 96.7) 51.7 (26.9, 99.3) 48.6 (21.0, 113) 0.333 0.444 0.858 
Brancheda B 28.2 (14.7, 54.0) 25.8 (16.8, 39.7) 25.3 (14.8, 43.0)    
 A 24.6 (14.2, 42.7) 29.9 (17.7, 50.6) 23.4 (15.0, 36.4) 0.117 0.751 0.207 
Neutral sterols (µmol/g df) 
Cholesterol B 4.18 (2.06, 8.50) 2.17 (0.29 16.1) 4.57 (1.72, 12.2)    
 A 3.61 (1.28, 10.2) 3.33 (0.72, 15.4) 3.53 (1.28, 9.73) 0.176 0.798 0.103 
Coprostanol B 89.0 (38.8, 204) 79.7 (17.9, 354) 110 (42.1, 285)    
 A 74.0 (27.0, 203) 111 (29.4, 423) 116 (39.0, 348) 0.266 0.622 0.559 
Cholestanone B 0.21 (0.01, 6.99) 0.07 (0.01, 0.33) 0.17 (0.02, 1.74)    
 A 0.28 (0.01, 6.74) 0.11 (0.03, 0.35) 0.21 (0.03, 1.37) 0.723 0.904 0.631 
Coprostanone B 0.73 (0.25, 2.16) 0.39 (0.04, 4.03) 1.02 (0.25, 4.12)    
 A 0.78 (0.17, 3.62) 0.82 (0.22, 2.97) 0.75 (0.23, 2.43) 0.155 0.440 0.028 
Bile acids (mmol/10 g df) 
Chenodeoxycholic B 2.42 (0.14, 40.8) 2.39 (0.37, 15.3) 1.68 (0.18, 15.5)   
 A 2.78 (0.23, 33.3) 4.54 (0.99, 20.9) 1.55 (0.34, 7.15) 0.493 0.776 0.319 
Cholic B 1.10 (0.16, 7.68) 0.65 (0.14, 3.05) 0.64 (0.09, 4.35)    
 A 1.22 (0.24, 6.18) 1.46 (0.27, 7.76) 0.99 (0.17, 6.00) 0.356 0.666 0.621 
Lithocholic B 9.07 (1.73, 47.7) 11.0 (2.15, 56.2) 8.67 (1.47, 51.1)    
 A 9.81 (3.21, 30.0) 19.0 (7.09, 51.0) 11.6 (4.05, 33.1) 0.407 0.721 0.644 
Isolithocholic B 2.34 (0.52, 10.5) 3.98 (0.72, 21.9) 2.10 (0.25, 17.8)    
 A 2.17 (0.48, 9.81) 3.42 (1.18, 9.89) 2.80 (0.90, 8.79) 0.895 0.556 0.450 
Deoxycholic B 32.8 (11.4, 94.7) 34.4 (12.0, 99.0) 27.9 (3.37, 230)    
 A 40.0 (11.4, 139) 54.7 (20.0, 149) 48.2 (8.15, 285) 0.604 0.519 0.870 
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isolithocholic acid, referred to the total of faecal 
bile acids analysed, decreased after FVOO 
compared with pre-FVOO [from 6.29 % CI (5.81, 
6.80) to 3.47 % CI (3.20, 3.75); P = 0.020]. The 
analysis of faecal phenolic metabolites is 
presented in Table 4. Hydroxytyrosol increased 
and tended to increase after FVOO (P = 0.034) 
and FVOOT (P = 0.064), respectively. FVOO 
increased dihydroxyphenylacetic acid compared 
to VOO (P = 0.014). Protocatechuic acid with 
FVOOT compared to VOO (P = 0.003). Two 
unknown phenolic metabolites increased after 
FVOO compared with VOO (P = 0.027 and P = 
0.042, respectively. 
 
 
 
Table 4  Phenolic metabolites determined by LC in faecal samples collected before (B) and after (A) each 
olive oil intervention 
Values are given as adjusted means of µmol/100 g dry faeces and CI; n = 12 subjects  VOO, 80 mg/kg of phenolic compounds (PC) from 
olive oil; FVOO, 500 mg/kg of PC from olive oil; FVOOT, 250 mg/kg of PC from olive oil and 250 mg/kg from thyme. * 0.05 < P < 0.1; ** P 
≤ 0.05 for intra-dietary intervention differences a  P values for inter-dietary intervention comparisons. b  M1: unknown metabolite. (M–H)− = 
187 m/z. MS2 fragments = 125, 117, 89 m/z; M2: unknown metabolite. (M–H)− = 243 m/z. MS2 frag-ments = 227, 207, 119 m/z 
 
 
4. DISCUSSION 
The aim of this study was to elucidate whether the 
possible cardio-protective effects of a sustained 
consumption of virgin olive oil phenolic 
compounds (PC) alone or in combination with 
thyme PC are mediated by changes in gut 
Phenolic metabolite  VOO FVOO FVOOT 
Pa 
VOO–
FVOO 
VOO–
FVOOT 
FVOO-
FVOOT 
Hydroxytyrosol B 0.19 (0.02, 2.28) 0.15 (0.02, 1.13) 0.08 (0.01, 1.16)    
 A 0.16 (0.02, 1.50) 0.74 (0.10, 5.76)** 0.33 (0.01, 10.3)* 0.108 0.140 0.928 
Dihydroxypheny B 46.6 (39.0, 55.6) 30.1 (25.3, 35.7) 30.5 (25.3, 36.7)    
lacetic acid A 23.3 (19.1, 28.3)** 40.9 (34.4, 48.7) 30.6 (25.5, 36.8) 0.014 0.092 0.435 
Hydroxyphenylacetic 
acid 
B 31.8 (24.6, 41.1) 18.7 (14.6, 23.9) 23.7 (17.9, 31.5)    
A 14.3 (10.5, 19.4)* 17.9 (14.0, 23.0) 28.7 (22.0, 37.6) 0.226 0.129 0.708 
Phenylacetic acid B 247 (236, 262) 234 (222, 247) 232 (219, 246)  
A 206 (194, 219) 263 (249, 277) 203 (192, 215) 0.194 0.818 0.281 
Dihydroxyphenyl-
propionic acid 
B 0.01 (0.00, 0.02) 0.00 (0.00, 0.01) 0.00 (0.00, 0.02)   
A 0.01 (0.00, 0.05) 0.00 (0.00, 0.01) 0.01 (0.00, 0.02) 0.690 0.617 0.913 
Hydroxyphenyl 
-propionic acid 
B 102 (56.9, 185) 42.2 (23.2, 76.8) 36.8 (19.5, 69.4)  
A 65.6 (33.4, 128.6) 33.1 (18.6, 58.7) 39.1 (21.2, 72.1) 0.796 0.534 0.703 
Phenylpropionic acid B 165 (149, 184) 122 (111, 136) 128 (114, 143)   
A 143 (127, 161) 138 (125, 153) 117.8 (106, 131) 0.394 0.847 0.510 
Rosmarinic acid B 2.60 (1.40, 4.83) 1.80 (1.01, 3.23) 2.76 (1.57, 4.87)   
 A 2.83 (1.41, 5.68) 1.85 (1.13, 3.04) 2.22 (1.29, 3.82) 0.938 0.684 0.733 
Protocatechuic acid B 0.55 (0.03, 9.15) 0.11 (0.00, 3.01) 0.07 (0.00, 1.45)   
A 0.04 (0.00, 0.68)** 0.11 (0.00, 3.41) 0.10 (0.01, 1.80) 0.008 0.003 0.652 
Coumaric sulphate 
acid 
B 2.92 (1.74, 4.89) 3.96 (2.40, 6.53) 2.93 (1.64, 5.24)     
A 1.50 (0.83, 2.70) 4.46 (2.70, 7.37) 3.81 (2.22, 6.54) 0.288 0.231 0.842  
Caffeic acid B 1.94 (1.68, 2.24) 2.18 (1.89, 2.51) 2.41 (2.07, 2.81)    
 A 2.74 (2.35, 3.19) 2.68 (2.32, 3.09) 2.16 (1.87, 2.49) 0.247 0.597 0.110 
Ferulic acid B 1.01 (0.61, 1.67) 0.58 (0.40, 0.85) 0.89 (0.52, 1.52)    
A 1.81 (1.10, 2.97) 0.93 (0.65, 1.31) 1.30 (0.81, 2.09) 0.881 0.817 0.924 
Hydroxyphenyl- 
valerolactone 
B 2.52 (1.77, 3.60) 4.94 (3.48, 7.00) 3.93 (2.55, 6.06)    
A 3.61 (2.32, 5.63) 3.42 (2.41, 4.84) 7.80 (5.39, 11.3) 0.401 0.718 0.231 
M1b B 141 (104, 192) 106 (78.0, 144) 127 (92.7, 173)    
 A 106 (77.8, 146) 135 (99, 183) 127 (93, 172) 0.027 0.236 0.295 
M2 B 1.61 (1.18, 2.20) 1.00 (0.73, 1.37) 1.40 (1.01, 1.95)    
 A 0.88 (0.63, 1.25)* 1.50 (1.11, 2.04) 1.58 (1.15, 2.18) 0.042 0.152 0.559 
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microbiota populations and metabolic activities, in 
hyper-cholesterolemic humans. The combination 
of olive oil and thyme PC exerted a cardio-
protective effect, by decreasing blood levels of ox-
LDL. The antioxidant activity of some microbial 
phenolic metabolites such as hydroxytyrosol and 
protocatechuic acid, generated after gut microbial 
fermentation of phenolic compounds contained in 
FVOOT, could be involved in the observed effects 
on ox-LDL. After oxidation, LDL becomes more 
toxic and plays a primary role in the development 
and progression of atherosclerosis [30]. It has 
been reported that oxidation of LDL decreases 
with increasing phenolic content of olive oil [3, 31, 
32]. In fact, the European Food Safety Authority 
approved a claim concerning the benefits of olive 
oil polyphenols for the protection of LDL from 
oxidation [33]. We observed quantitative 
significant changes in gut microbiota only when 
virgin olive oil PC were ingested together with 
thyme PC, by increasing Bifidobacterium group 
numbers. The gut microbial usage of virgin olive 
oil and thyme PC has been recently reported in a 
linear non-controlled study, by Mosele et al. [15,  
17]. They observed the generation of PC 
metabolites after microbial transformation of virgin 
olive oil and thyme parental PC, concluding that 
some of the investigated parental PC were able to 
reach the gut, afterwards being transformed by 
gut microbiota. Increases in gut bifidobacteria 
have been reported with other sources of phenolic 
compounds such as wine [34], wild blueberry [35], 
pomegranate peel [36] and cocoa [7]. However, 
this is the first time that a potential bifidogenic 
effect is reported for a combination of virgin olive 
oil and thyme PC. Since prebiotic is defined as “a 
selectively fermented ingredient that allows 
specific changes, both in the composition and/or 
activity in the gastrointestinal microflora that 
confers benefits upon host well-being and health” 
[37], a potential prebiotic activity of the 
combination of PC in FVOOT is suggested and 
should be further investigated.  
Since recent studies in animals and humans have 
shown improvements in blood lipid profile with the 
ingestion of bifidobacteria and lactobacilli mixtures 
[38, 39], the increase in Bifidobacterium could be 
responsible at least in part for the decrease in ox-
LDL levels observed with the ingestion of FVOOT. 
Regarding blood cholesterol levels, hardly any 
effects were observed on the cholesterol-lowering 
mechanisms investigated. This is in accordance 
with the lack of changes reported in blood 
cholesterol levels. First, we investigated whether 
microbial usage of PC was able to generate 
changes in SCFA production, related to 
cholesterol synthesis. In our study, neither faecal 
amounts of acetic, propionic, and butyric acids nor 
their relative amounts changed with any of the 
interventions. Grapefruit PC have been shown to 
increase amounts of SCFA in rats [40], whereas 
black tea and red wine PC decreased them in vitro 
[41]. The lack of effects observed in our study 
could be due to the fact that, contrary to what 
occurs in an in vitro system, SCFA generated are 
also absorbed in vivo, making difficult to observe 
any difference at faecal level. Different results 
could also indicate that the influence on the 
microbial generation of SCFA depends on the PC 
source. The second mechanism analysed was the 
insolubilization of gut cholesterol by its 
transformation into non-soluble metabolites by gut 
microbiota. Gut bacteria are able to metabolize 
cholesterol by two pathways [11]. One of them 
transforms cholesterol directly into coprostanol 
and the other implies the transformation of 
cholesterol into cholestanone, coprostanone, and 
finally coprostanol. Few studies have investigated 
this gut microbiota-mediated blood cholesterol-
lowering mechanism after dietary interventions 
with PC [42]; most of them focusing on changes in 
total faecal cholesterol or total faecal lipids. In our 
study, faecal concentrations of cholesterol 
remained constant with the dietary interventions 
besides the increase in coprostanone observed 
with FVOO. This could be due to the fact that we 
performed faecal analysis in the whole faecal 
residue, containing bacteria that could be also 
either assimilating cholesterol or including it in the 
bacterial cell wall or both. The absence of any 
impact on faecal cholesterol could be also related 
to the PC source. Whereas PC sources such as 
horseradish [42], apple skin [43] and sesame flour 
[44] have been shown to increase faecal 
cholesterol in murine models, other sources such 
as peanut skin [45] or oolong tea [46] decreased 
or had no effect on faecal cholesterol levels. 
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The third mechanism studied was the increase in 
liver cholesterol expenditure due to microbial 
generation of insoluble bile acids in the gut. Bile 
acids are synthesized in the liver from cholesterol, 
conjugated and excreted to the biliary system. 
From them, 200 to 800 mg/day passes to the 
colon. Probiotic bacteria, such as bifidobacteria, 
encode bile salt hydrolase (BSH) enzymes, which 
deconjugate bile salts [47]. Deconjugated bile 
acids are not absorbed and are excreted in 
faeces. As synthesis of new bile acids rises in 
compensation, blood cholesterol levels fall [14]. In 
our study, faecal concentrations of primary bile 
acids did not change with any of the interventions. 
This is in concurrence with other authors [48] who 
were not able to detect any effect of black tea PC 
on faecal bile acids in humans. Other PC sources 
such as peanuts, hazelnut skin, and sesame flour 
[44, 49] have shown increases in bile acid 
excretion in murine models. Different sources of 
PC would have a different effect on BSH 
producing bacteria. In our study, the increase in 
populations of bifidobacteria with FVOOT, 
although significant, could have been not enough 
to significantly increase the concentrations of 
deconjugated bile acids. A novel bile acid-related 
mechanism has been published recently [50], 
which suggest that Lactobacillus could reduce 
blood cholesterol by lowering absorption of fat 
from the intestine via FXR activation by 
deconjugated bile acids absorbed from the 
intestine. Nevertheless, in the present work, no 
decrease in the systemic cholesterol has been 
observed and further studies are needed to 
elucidate the mechanisms and their degree of 
involvement. 
Besides the absence of changes in the amounts 
of faecal bile acids, we found a potential 
detoxificating effect of FVOO, which reduced the 
relative proportions of the toxic isolithocholic acid. 
Deconjugated forms are the substrate for 7-
dehydroxylation, which generates toxic secondary 
bile acids. Consumption of common dietary 
polyphenols has shown to reduce toxic faecal 
deoxycholic acid and lithocholic acids in rats [51]. 
Probiotic bacteria are not capable of 
dehydroxylate deconjugated bile salts [52], and so 
the majority of the breakdown products of BSH 
activity by a probiotic strain may be precipitated 
and excreted in faeces. Only certain strains of 
Clostridium and Eubacterium spp. have been 
shown to possess dehydroxylating activity [53]. In 
our study, the decrease in the relative proportions 
of isolithocholic acid could be related to the 
decrease in populations of Clostridium cluster IX 
observed with FVOO. 
The last mechanism investigated in the present 
study was related to the microbial generation of 
bioactive PC metabolites in the gut. It has been 
demonstrated that bioactivity of some microbial 
metabolites from undigested phenolic compounds 
is physiologically more relevant on CVD risk than 
the native form present in the diet. Some 
representative examples are enterolignans from 
lignans [54] and protocatechuic acid (PCA) from 
flavonoids [55]. PCA promotes reverse cholesterol 
transport in mice [56] and inhibits LDL oxidation 
[57], suggesting a remarkable antiatherogenic 
effect. These and other microbial phenolic 
metabolites with antioxidant activity, such as 
hydroxytyrosol, generated after gut microbial 
fermentation of phenolic compounds ingested with 
the oils, can be further absorbed and enter into 
the blood stream. In our study, faecal PCA 
increased in FVOOT compared to VOO, which 
could be due to the microbial transformation of 
PCA precursors, vanillic and p-hydroxybenzoic 
acids, present in FVOOT and absent in VOO. We 
found also increase in hydroxytyrosol after FVOO 
and FVOOT, which could be due to microbial 
transformation of OO secoiridoids and 
demonstrates a high stability of hydroxytyrosol in 
the gut, which is considered to have the highest 
antioxidant power compared to other olive 
polyphenols [58]. The increase in the levels of free 
hydroxytyrosol in faeces after FVOO and FVOOT 
ingestion confirms early observations suggesting 
that a fraction goes via faeces [59] and recent 
observations in a parallel in vivo trial [15]. In this 
regard, although the increase in hydroxytyrosol 
with FVOOT did not reach statistical significance, 
it could be behind, in combination with the 
increase in PCA, the decrease in LDL oxidation 
observed after the FVOOT intervention. 
Although effects on gut microbiota and ox-LDL 
were observed with the combination of both 
sources of PC (olive oil and thyme, FVOOT), it is 
not clear the relevance of each PC source in the 
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results obtained. The lack of effects observed in 
FVOO would not necessary mean that these PC 
are not able to exert an effect on gut microbiota 
growth and metabolism. It would be probably due 
to the high amount used (500 ppm in FVOO 
compared to 250 ppm in FVOOT), which could 
exert an inhibitory effect on gut microbiota growth 
and metabolism. Furthermore, another advantage 
of the combination of both PC sources is that the 
pro-oxidant activity observed in with PC-rich foods 
containing unique PC sources could be eliminated 
with the use of complementary PC sources; a 
functional oil with complementary antioxidants 
(FVOOT), according to their structure/activity 
relationship, could be a suitable option to obtain 
PC’s beneficial effects avoiding those harmful 
ones [60]. 
In conclusion, the ingestion of a PC-enriched 
virgin olive oil, containing a mixture of olive oil and 
thyme PC for 3 weeks, decreases blood ox-LDL in 
hypercholesterolemic humans. This cardio-
protective effect could be mediated by the 
increases in populations of bifidobacteria together 
with increases in PC microbial metabolites with 
antioxidant activities such as protocatechuic acid 
and hydroxytyrosol. The specific growth 
stimulation of bifidobacteria in human gut 
suggests for the first time a potential prebiotic 
activity of an olive oil enriched in virgin olive oil 
and thyme PC. 
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ADDITIONAL INFORMATION 
 
Table 1. Compliance markers before (B) and after (A) each olive oil interventiona 
Compound  VOO FVOO FVOOT 
Pb 
VOO-FVOO VOO-FVOOT FVOO-FVOOT 
Hydroxytyrosol B 5.26±4.87 7.12±4.06 5.35±4.76    
sulfate  A 8.95±5.05 14.3±5.54* 10.1±8.40* 0.210 0.709 0.371 
Thymol sulfate B 141±144 72.5± 16 219±386    
 A 74.6±132 106±121 804±370* 0.466 <0.001 <0.001 
Values are given as adjusted means of µmol/24h ± SE; n=12 subjects 
a) 25 mL/day extra virgin olive oil containing: VOO, 80 mg/kg of phenolic compounds (PC) from olive oil; FVOO, 
500mg/kg of PC from olive oil; FVOOT, 250 mg/kg of PC from olive oil and 250 mg/kg from thyme.  
b) P values for inter-interventions comparisons. 
*P<0.05 for intra-intervention comparison 
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Abstract 
Pomegranate fruit contains a wide range of phenolic compounds that have been related to several health 
benefits. The stability of pomegranate phenols during digestion was tested by the application of in vitro 
gastrointestinal digestion (GID) to different pomegranate products: juice (PJ), pulp (PP) and peel extract 
(PE). The resulting non-absorbable fractions were submitted to in vitro colonic fermentation with human 
faeces to monitor the generation of microbial metabolites. During the duodenal step, we observed a low 
stability of anthocyanins and flavonoids and an important release of ellagic acid, especially after PE 
digestion. The poor potential absorption of the studied phenolic compounds led to their high exposure to 
colonic metabolism. After colonic fermentation, PE appeared to be the best source of microbial 
substrates leading to a larger generation of gut microbial catabolites in terms of absolute amounts. We 
suggest that using PE might be a good strategy to enrich food products with potential health benefits in 
the prevention of chronic diseases. 
Keywords: In vitro gastrointestinal digestion In vitro fermentation Microbial metabolites Phenolic 
compounds Pomegranate 
1. INTRODUCTION
The daily intake of fruits and vegetables is 
associated with a lower risk of cancer, 
cardiovascular diseases, metabolic syndrome and 
other degenerative diseases, as well as with the 
maintenance of optimal body functions (Boeing et 
al., 2012). Therefore, recent trends propose diet 
management as a useful strategy to reduce the 
incidence and progression of chronic diseases 
(Akbaraly et al., 2011). The pomegranate (Punica 
granatum L.) is an ancient and highly distinctive 
fruit which, in addition to its historical uses, is 
found in several medicinal systems for a variety of 
diseases. The high phenolic content of 
pomegranate when compared to other fruits, 
along with its anti-inflammatory and antiobesity 
properties (Viladomiu, Hontecillas, Lu, & 
Bassaganya-Riera, 2013), has increased the 
interest in investigating its potential nutraceutical 
and functional food applications Ellagitannins, also 
known as hydrolyzable tannins, correspond to the 
main pomegranate phenolic fraction (Fischer, 
Carle, & Kammerer, 2011; Madrigal-Carballo, 
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Rodriguez, Krueger, Dreher, & Reed, 2009), and 
an important number of studies have focused on 
their metabolism, absorption and excretion (Espín 
et al., 2007; García-Villalba, Beltrán, Espín, 
Selma, & Tomás-Barberán, 2013; González-
Barrio, Borges, Mullen, & Crozier, 2010; Tomás-
Barberán, García-Villalba, González-Sarrías, 
Selma, & Espín, 2014). These studies indicate 
that hydrolyzable tannins and ellagic acid are 
poorly absorbed, and therefore they reach the 
large intestine, where they are largely metabo-
lized by local microbiota. The resulting catabolites 
have been identified as urolithins, considered as 
microbial metabolites with potential bioactivity. 
Other types of phenolic compounds present in 
pomegranate are flavonoids, such as 
anthocyanins and flavan-3-ols, phenolic acids and 
lignans (Mena et al., 2012), which may also 
contribute to the beneficial properties of 
pomegranate. However, little is known about the 
digestion stability and metabolism of these minor 
phenolic compounds of pomegranate (Pérez-
Vicente, Gil-Izquierdo, & García-Viguera, 2002), 
suggesting that a large percentage of this phenolic 
fraction also reaches the colon and is submitted to 
microbial transformations. 
Polyphenol-rich foods have gained a key position 
in the attempt to include new food ingredients that 
offer potential therapeutic properties. Health 
claims associated with pomegranate intake have 
stimulated the production of pomegranate-based 
products. Commercial juices have emerged as an 
alternative to fresh fruit consumption due to their 
practical use and close similarity in composition 
and sensory characteristics to the natural fruit. 
Pomegranate peel extract has also been subject 
of numerous studies and its potential use as a 
nutraceutical or functional food ingredient is well 
documented (Akhtar, Ismail, Fraternale, & Sestili, 
2015). Faced with this variety of pomegranate-
derived products, it is important to consider the 
different food matrices. Food matrix will determine 
the stability during gastric and intestinal digestion 
and will affect the intact proportion of phenolic 
compounds that reach the colon or that will 
potentially be absorbed. 
In view of all the above, in the present study, an in 
vitro gastrointestinal digestion (GID) model was 
used to evaluate the stability and the potential 
bioaccessibility of phenols from pomegranate in 
three different pomegranate products: juice (PJ), 
pulp (PP) and peel extract (PE). The non-digested 
fraction resulting from in vitro digestion was then 
submitted to in vitro fermentation. The main 
objective was to determine the effect of different 
pomegranate products submitted to digestion on 
phenol recovery after GID and the nature of the 
catabolites formed after colonic fermentation. 
Results might be used in the development of 
future food formulations, representing a prior step 
in functional food development to select the most 
suitable delivery system 
2. MATERIALS AND METHODS 
2.1. Chemicals and reagents  
Ultrapure water was obtained from a Milli-Q water 
purification system (Millipore Corp., Bedford, MA, 
USA). Alpha-amylase, pepsin, pancreatin, bile 
salts, KH2PO4 and Na2HPO4·2H2O were obtained 
from Sigma Aldrich (St. Louis, MO, USA). 
Acetoni-trile, methanol, ethanol (all HPLC-grade), 
hydrochloric acid (37%), glacial acetic acid 
(99.8%), NaHCO3, KCl, CaCl2, MgCl2·6H2O, 
FeSO4·7H2O, MnSO4·H2O, ZnSO4·7H2O, 
CoCl2·6H2O, Mo(NH4)6O24·4H2O were purchased 
from Pancreac Quimica S.A. (Barcelona, Spain) 
and CuSO4·5H2O, NaCl, Na2SO4·10H2O from 
Scharlau S.L. (Barcelona, Spain). 
For the identification and quantification of 
pomegranate phenolic compounds, different 
commercial standards were used. Ellagic acid, 
punicalagin, p-coumaric acid, vanillic acid and 
kaempferol were purchased from Fluka (Buchs, 
Switzerland); protocatechuic acid, catechin, 
epicatechin, p-hydroxybenzoic acid, catechol, and 
ferulic acid from Sigma Aldrich; caffeic acid, rutin, 
myricetin, quercetin, cyanidin-3-O-glucoside and 
cyanidin-3,5-O-diglucoside from Extrasynthese 
(Genay, France). Gallic acid and malic acid were 
purchased from Panreac (Barcelona, Spain) and 
pinoresinol and secolariciresinol were purchased 
from Arbonova (Turku, Finland). Standards of 
urolithin A (dihydroxyurolithin), urolithin B 
(hydroxyurolithin) and urolithin C 
(trihydroxyurolithin) were kindly provided by Dr. 
Thasana from Chulabhorn Research Institute, 
Laksi, Bangkok, Thailand (Nealmongkol, 
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Tangdenpaisal, Sitthimonchai, Ruchirawat, & 
Thasana, 2013). These standard phenolic 
compounds were prepared in methanol 
 
2.2. Pomegranate products preparation  
The pomegranate fruits (Punica granatum L. 
Mollar de Elche cv.) (growing area of Alicante, 
Spain) were purchased from a local market in 
Lleida (Catalonia, Spain) in November 2013. 
Fruits were washed and manually peeled. The 
pomegranate juice (PJ) was prepared by blending 
the entire arils without the peel using a 
commercial blender with an incorporated filter 
(Molinex, France) in which pulp and intact seeds 
were retained. The pomegranate pulp (PP), which 
represented the whole pomegranate fruit intake, 
was prepared by blending the entire arils without 
any filtration. Thirty grams of fresh PJ and PP 
were aliquoted under nitrogen flux in dark bottles 
and immediately stored at −80 °C until the in vitro 
study. Part of PJ and PP were freeze-dried and 
maintained also at −80 °C for the chromatographic 
analysis. The residual peels resulting from the PJ 
and PP preparation were used to obtain the 
pomegranate peel extract (PE). Peels were dried 
(40 °C) overnight, reduced to small pieces and 
powdered using a domestic grinder (particle size 
<0.5 mm). The PE was obtained by accelerated 
solvent ex-traction ASE 100 (Dionex, Voisins le 
Bretonneaux, France). An aqueous solution 
containing 50% ethanol (50:50, v/v) was selected 
as extraction solvent after optimizing the 
extraction conditions. The resulting extract was 
rotary-evaporated to eliminate the ethanol, freeze-
dried and stored in dark bottles at −80 °C for two 
weeks. 
 
2.3. Simulated in vitro gastrointestinal 
digestion (GID)  
The in vitro digestion procedure was adapted from 
the method proposed by Ortega, Reguant, 
Romero, Macià, and Motilva (2009), which 
consisted of three-steps to mimic the digestive 
process in the mouth, stomach (gastric digestion) 
and small intestine (dynamic duodenal digestion) 
with a slight variation in the time course of the 
gastric incubation (1 h in the present study) (Fig. 
1). Briefly, the method consisted of a continuous-
flow dialysis system performed with a dialysis tube 
through which the duodenal mixture flowed by 
using a peristaltic pump with a flow rate of 1 
mL/min and a phosphate buffer solution (pH 7.4) 
covering the dialysis tub. Distilled water was 
pumped from a bath through the water jacket to 
keep the system’s temperature around 37 °C. 
After the dynamic duodenal digestion two fractions 
were collected, the “IN” and the “OUT” fractions. 
IN is considered as the non-absorbable fraction 
that reaches the colon, while the OUT represents 
the absorbable fraction. Each in vitro digestion 
was performed in the absence of light and in 
triplicate. Samples obtained from the different 
digestion steps were lyophilized and stored at −80 
°C in dark bottles until the time of their 
chromatographic analysis. 
To evaluate the effect of pomegranate product on 
the polyphenol stability during digestion, a 
percentage of variation (% var) was calculated for 
each phenol compound. This index provides the 
amount of each phenol (µmols) present in the 
complete digesta after gastric or duodenal (IN + 
OUT) digestions in relation to the amount (µmols) 
quantified per gram of pomegranate product 
submitted to in vitro digestion. 
 
2.4. In vitro colonic fermentation by human 
microflora  
Fresh faecal samples were collected from three 
healthy adults (25–35 years) who declared no 
gastrointestinal diseases and no intake of 
antibiotics at least 3 months before the beginning 
of the study. Faeces were collected 2 h maximum 
from defecation and maintained at 4 °C in 
anaerobic conditions until the moment of the 
experiment. The fermentation medium was a 
carbonate–phosphate buffer and was prepared 
according to Durand, Dumay, Beaumatin, and 
Morel (1988). The medium was adjusted to pH 6.5 
using HCl and reduced in an anaerobic chamber 
for 48 h prior to the fermentation. A 0.5:10 (w/v) 
dilution of the faecal samples with the anaerobic 
buffer was prepared and homogenized in a 
stomacher (1 min). The resulting faecal 
suspension was filtered, distributed in disposable 
tubes (10 mL/tube/incubation time) and 0.1 g of 
the IN fraction collected after the duodenal 
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digestion of PJ, PP and PE were added. The 
mixtures were fermented at 37 °C with continuous 
shaking (60 rpm) under anaerobic conditions. In 
parallel, two different controls were conducted 
under the applied conditions: (i) the IN fraction 
was incubated in buffer solution without faeces to 
determinate possible chemical degradation, and 
(ii) the faecal suspension was incubated without 
the IN fraction as a negative control. All 
incubations were performed in triplicate and both 
the samples and the controls were collected at 0, 
2, 8, 24, 48 and 72 h. The tubes obtained at each 
time of fermentation were freeze-dried and stored 
at −80 °C until their analysis (Fig. 1). 
 
 
 
Figure 1 – Graphic representation of the in vitro procedure carried out with the different pomegranate 
products (PJ: juice, PP: pulp and PE: peel extract) 
 
2.5. Sample preparation  
Freeze-dried PJ, PP and PE (0.5 g) were mixed 
with 8 mL of methanol/HCl/water (79.9:0.1:20, 
v/v/v), shaken during 30 min, centrifuged (13,200 
g, 10 min, room temperature), filtered (0.22 µm 
pore size) and dispensed in chromatographic 
vials. For the analysis of digestion and 
fermentation samples, freeze-dried samples were 
homogenized in 10 volumes of methanol/ 
HCl/water (79.9:0.1:20, v/v/v) following the same 
conditions as the pomegranate products. 
 
2.6. Chromatographic analysis  
The analysis of the phenolic fraction of PJ, PP, 
PE, the digestion and fermentation products were 
performed by using a Waters Acquity Ultra-
Performance™ liquid chromatography system 
(Waters, Milford, MA, USA), equipped with a 
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binary pump system (Waters). The 
chromatographic column was an Acquity BEH 
C18 (100 mm × 2.1 mm i.d.) with a 1.7 mm 
particle size (Waters). A binary mobile phase with 
a gradient elution was used. For the analysis of 
anthocyanins, eluent A was Milli-Q water/acetic 
acid (90:10, v/v) and eluent B was acetonitrile. 
The gradient was performed as follows: 0–10 min, 
3%B; 10–10.1 min, 3–25%B; 10.1–11 min, 25–
80%B; 11–11.1 min, 80–80%B; 11.1– 12.5 min, 
80–3%B. In the case of the other phenolic 
compounds, the eluent A was Milli-Q water/acetic 
acid (99.8:0.2, v/v) and eluent B was acetonitrile. 
The gradient was performed as follows: 0–5 min, 
5%B; 5–10 min, 5–10%B; 10–18 min, 10– 
12.4%B; 18–23 min, 12.4–28%B; 18–23 min, 28–
70%B; 23–25 min, 70%B; 25–27 min, 70–5%B 
and 27–30 min, 5%B. For the analy-sis of all the 
phenolic compounds, the flow rate was 0.4 mL/ 
min and the injection volume was 2.5 µL. The 
tandem mass spectrometry (MS/MS) analysis was 
carried out on a triple quadrupole detector (TQD) 
mass spectrometer (Waters) equipped with a Z-
spray electrospray interface. The analysis was 
done in the positive ion mode for anthocyanins 
and urolithins and in the negative ion mode for the 
rest of phenolic compounds and the data were 
acquired with the selected reaction monitoring 
mode (SRM). The MS/MS parameters were as 
follows: capillary voltage, 3 kV; source 
temperature, 150 °C; cone gas flow rate, 80 L/h 
and desolvatation gas flow rate, 800 L/h; 
desolvatation temperature, 400 °C Nitrogen 
(>99% purity) and argon (99% purity) were used 
as nebulizing and collision gases, respectively. 
Cone voltages and collision energies were 
optimized for each analyte by injection of each 
standard compound in a mixture of 
acetonitrile/water (50:50, v/v) at a concentration of 
mg/L. Two transitions were studied for each 
compound. The most abundant transition was 
used for quantification, while the second most 
abundant was used for confirmation purposes. 
The dwell time established for each transition was 
30 ms. Data acquisition was carried out with the 
MassLynux v 4.1 Soft-ware (Supplementary 
Table S1 shows the SRM transition, cone voltage 
and energy collision used for quantification. In this 
table it is also specified the standards used for 
quantification). So, malic acid, p-hydroxybenzoic 
acid, protocatechuic acid, p-coumaric acid, vanillic 
acid, gallic acid, caffeic acid, ferulic acid, 
quercetin, kaempferol, catechin epicatechin, 
ellagic acid, myricetin, pinoresinol, 
secolariciresinol, dimer B2, rutin, punicalagin, 
cyanidin-3-O-glucoside and cyanidin-3,5-O-
diglucoside were quantified using their own 
calibration curve. The phenol-glycoside 
compounds were tentatively quantified using the 
calibration curves of their respective aglycones. 
Syringaldehyde was tentatively quantified with the 
calibration curve of gallic acid. Syringic and 
chlorogenic acid were tentatively quantified as 
caffeic acid equivalents. Pinocembrin, naringenin, 
phloretin and eriodyctiol were tentatively 
quantified as quercetin equivalents. Ellagitannins 
were tentatively quantified as ellagic acid 
equivalents and the anthocyanins glucoside and 
diglucoside were tentatively quantified as 
cyanidin-3-O-glucoside equivalents and cyanidin-
3,5-O-diglucoside equivalents, respectively. 
Urolithins tetrahydroxyurolithin and 
pentahydroxyurolithins were tentatively quantified 
as trihydroxyurolithin equivalents (Data regarding 
LOD and LOQ of each compound are available in 
Supplementary Table S2). 
 
 
3. RESULTS AND DISCUSSION  
3.1. Phenolic composition of pomegranate 
products  
Phenolic composition of PJ, PP and PE is 
presented in Table 1. Data are expressed as 
µmols of phenolic compound per gram of 
lyophilized pomegranate product submitted to in 
vitro digestion. PE presented the highest total 
phenolic concentration (155 ± 21.4 µmol/g of PE) 
ahead of PJ and PP, which presented similar 
concentrations (1.41 ± 0.43 and 1.17 ± 0.08 
µmol/g of PJ and PP, respectively). Ellagitannins 
and free and glycosylated ellagic acid were the 
main phenolic compounds in the three 
pomegranate products studied, followed by 
anthocyanins in PJ or flavonoids in the case of 
PP and PE. Differences in the phenolic 
composition between PP and PJ could be 
attributed to the manufacturing process of both 
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products. In this respect, the presence of pulp 
and seeds in PP could be associated with the 
presence of a higher concentration of certain 
phenolic compounds.  
 
3.2. Stability of pomegranate phenolic 
compounds during in vitro gastric step 
In order to test the stability of each individual 
phenol during gastric digestion, their 
concentration was measured after digestion, 
expressing the results as µmols of each phenolic 
compound per gram of pomegranate product and 
as percentage of variation (% var) between the 
initial phenolic concentration and the 
concentration detected after digestion (Table 1).  
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To a greater or lesser extent, all the individual 
pomegranate phenolic groups were modified after 
acidic incubation. Recovery of ellagic acid and its 
glycosides after gastric digestion varied 
depending on the type of pomegranate product, 
observing a greater release in the case of PE 
(+71.0%) compared to PJ (+21.7%) and PP 
(+29.1%). Parallel to this generation of free and 
glycosylated ellagic acid, we observed a decrease 
in the ellagitannin concentration. However, the 
reduction of ellagitannins (% var) did not 
correspond to the ellagic acid generation. 
Considering our results and the low degree of 
ellagitannin hydrolysis at pH 3 observed by 
Tuominen and Sundman (2013), the extra amount 
of free and glycosylated ellagic acid recovered 
could be explained by the sum of both: 
ellagitannins degradation and the release of 
ellagic acid from the food matrix during in vitro 
gastric digestion. Accordingly, higher recovery of 
total phenolic compounds was observed after 
gastric digestion of pomegranate extract (Sengul, 
Surek, & Nilufer-Erdil, 2014). In another study, a 
slight modification in total phenolic content was 
noticed after the acidic incubation of a wild 
chokeberry commercial juice (Bermúdez-Soto, 
Tomás-Barberaán, & García-Conesa, 2007). 
After gastric digestion, anthocyanins were slightly 
increased in PJ (+4.39 %) and PP (+1.75 %), 
whereas in the case of PE they were slightly 
reduced (−6.31 %) (Table 1). Accordingly, 
previous studies reported that anthocyanins from 
red cabbage and wild blueberry juice were stable 
under acidic gastric conditions (Correa-Betanzo et 
al., 2014; McDougall, Fyffe, Dobson, & Stewart, 
2007), which was attributed to the low pH that 
would favour the stability of these molecules 
(Mazza & Brouillard, 1978). With regards to 
phenolic acids, flavonoids and lignans, all of them 
showed a slight decrease in their concentration 
after the gastric digestion of the three 
pomegranate products, varying from −5.53 to 
−26.7 % (Table 1). In relation to these com-
pounds, previous studies have noticed low 
stability of phenolic acids under gastric incubation 
(Kamiloglu & Capanoglu, 2013; Vallejo, Gil-
Izquierdo, Paez-Vicente, & Gasrcía-Viguera, 
2004), while flavonoids (Bouayed, Deußer, 
Hoffmann, & Bohn, 2012; Vallejo et al., 2004) and 
lignans (Eeckhaut et al., 2008) were not affected 
under the same conditions. These discrepancies 
might be related to different chemical structures of 
the phenolic compounds studied, the food matrix 
characteristics or the in vitro conditions of 
digestion. Vallejo et al. (2004), for example, 
noticed different degrees of acidic degradation 
depending on the phenolic acid type after gastric 
digestion of broccoli inflorescence. 
 
3.5. Stability of pomegranate phenolic 
compounds during duodenal in vitro 
digestion step 
Results from the duodenal step are shown in 
Table 1. Under the intestinal conditions, an 
important decrease in the total phenolic content 
was observed in PJ (−42.2 %) and PP (−27.2 %). 
In contrast, after PE digestion the total phenolic 
content increased by 36.9%, mainly due to the 
large amounts of ellagic acid released (+271 %). 
In previous studies, generation of ellagic acid from 
hydrolysis of ellagitannins was also observed in 
the lumen of pigs fed with oak acorns (Espín et 
al., 2007). 
Accordingly, almost double amounts of ellagic 
acid were detected after a middle alkaline 
incubation of dried pomegranate peel extract 
during 3 h (Liu, Li, Hu, & Zhao, 2013). Punicalagin 
(a pomegranate ellagitannin) was quickly 
hydrolyzed, yielding ellagic acid in a cell culture 
medium both in absence and in presence of Caco-
2 cells, supporting that alkaline pH promotes 
ellagitannin breakdown (Larrosa, Tomás-
Barberán, & Espín, 2006). The major increase in 
the concentration of ellagic acid after the 
gastrointestinal incubation of PE observed in the 
present study may be linked to its liberation from 
the complex phenols present in the food matrix. 
Unlike the juice and pulp, PE appears to be a 
more complex matrix that might contain greater 
amounts of non-extractable ellagitannins linked to 
cell wall constituents (polysaccharides and 
protein) or trapped within the food matrix. This 
non-extractable phenolic fraction cannot be 
detected in the original test foods with the 
common extraction procedures with organic 
solvents (Saura-Calixto, 2012), and although they 
are mainly hydrolyzed in the colon, some 
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ellagitannins could have also been hydrolyzed 
during digestion under acidic (gastric phase) and 
alkaline (duodenal phase) conditions resulting in 
the concentration increase of ellagic acid in the 
digesta. These results suggest that pomegranate 
peel could be considered as a source of great 
interest to obtain pomegranate phenolic extracts. 
Together with the release of ellagic acid during 
intestinal digestion, an elevated liberation of gallic 
acid was also expected, as it is also part of the 
ellagitannin structure. However, no important 
increase of gallic acid was observed after 
digestion (Table 1), which could be explained by 
the reported instability of gallic acid under alkaline 
conditions (Liu et al., 2013) or the possible 
generation of ellagic acid from monogalloyl 
derivatives (Tuominen & Sundman, 2013). In 
contrast to the gastric step, anthocyanins 
underwent an important decrease after duodenal 
digestion, being less intense than the reduction in 
PE (Table 1). Accordingly, different degrees of 
instability of anthocyanins under alkaline 
conditions were previously described in red 
cabbage and wild blueberry pulp (Correa-Betanzo 
et al., 2014; McDougall et al., 2007). 
 
 
Figure. 2 – Microbial metabolites generation during the in vitro fermentation of non-digested fraction of PJ 
(pomegranate juice). (A) Time course of urolithins and gallic acid generation and (B) time course of 
catechol, coumaric acid and protocatechuic acid generation 
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The higher stability of anthocyanins when PE was 
digested could be explained by the food matrix 
composition, which could play a protective role as 
some components of the peel, such as soluble 
and insoluble fibre, could interact with 
anthocyanins during the digestion process, 
increasing their stability. In a previous study, a 
higher recovery of anthocyanins was observed in 
whole fruits in relation to liquid products, indicating 
the importance of the food matrix in their stability 
during digestion (Parada & Aguilera, 2007). The 
decreasing trend in the concentration of flavonoids 
after the duodenal step was in accordance with 
Vallejo et al. (2004), who also detected important 
losses of these compounds after a simulated in 
vitro intestinal digestion of broccoli inflorescence. 
On the other hand, a greater recovery of lignans 
was observed specially in the PE, which was also 
reported after in vitro gastrointestinal digestion of 
a flax seed complex (Eeckhaut et al., 2008). 
Regarding the absorbable fraction (OUT fraction 
in the dialysis tube), in general our results 
revealed that the concentration of pomegranate 
phenolics detected was low (Table 1) compared 
with the initial amounts presented in the 
pomegranate products. These results indicate a 
low potential bioavailability of pomegranate 
phenolic compounds, which are in accordance 
with previous in vivo studies. A study by Espín et 
al. (2007) with Iberian pigs after a continued 
intake of ellagitannin rich-food (fresh acorns from 
Quercus ilex and Quercus suber) showed that 
under in vivo conditions ellagic acid is released 
from ellagitannins and then ellagic acid is 
gradually metabolized in the intestine, and finally 
transformed into urolithins, with no detection of 
ellagitannins in plasma and urine. In another study 
in which healthy humans consumed 300 g of 
raspberries, low concentrations of anthocyanins 
and ellagic acid were detected in urine from 0 to 7 
h after ingestion, indicating low absorption rate of 
these compounds (González-Barrio et al., 2010).
 
3.4. In vitro colonic fermentation of 
pomegranate phenolic compounds 
After in vitro digestion of the three pomegranate 
products, the respective IN fractions (non-
absorbable) were submitted to in vitro colonic 
fermentation using human faeces inoculum from 
three healthy volunteers. The generation of 
phenolic catabolites was monitored at different 
incubation times: 0, 2, 8, 24, 48 and 72 h (Fig. 1). 
After analyzing the fermentation media, a wide 
range of phenolic catabolites was detected. 
Because of the quantitative and qualitative 
differences observed among volunteers, the 
microbial metabolite generation during the in vitro 
fermentation of non-digested fraction of PJ (Fig. 
2) (numerical data are available in 
Supplementary Table S3), PP (Fig. 3) (numerical 
data are available in Supplementary Table S4) 
and PE (Fig. 4) (numerical data are available in 
Supplementary Table S5) was presented 
individually for each volunteer. In line with other 
studies that investigated the microbial conversion 
of ellagic acid and ellagitannins (Cerdá, Periago, 
Espín, & Tomás-Barberán, 2005; García-Villalba 
et al., 2013), in our study urolithins were not 
detected in controls (i) and (ii) (Section 2.4), 
indicating their specificity as microbial metabolites. 
The efficiency of the faecal microbiota from the 
three volunteers to generate urolithins from ellagic 
acid and ellagitannins after the in vitro 
fermentation of PJ (Fig. 2A) and PP (Fig. 3A) was 
highly variable; however, these quantitative 
differences were reduced after PE incubation (Fig. 
4A). Volunteer 1 was the most effective urolithin 
producer, reaching maximum concentrations of 
urolithin A (dihydroxyurolithin) after fermentation 
of the IN fraction of PJ (0.17 µmols/g PJ) 
(numerical data are available in Supplementary 
Table S3) and PP (0.25 µmols/g PP) (numerical 
data are available in Supplementary Table S4). 
Differences between volunteers were minimized 
after fermentation of the IN fraction of PE, and in 
this case the concentrations of urolithin A were 
from 10 to 15 µmols/g PE (72 h) (Fig. 4A) 
(numerical data are available in Supplementary 
Table S5). 
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Figure. 3 – Microbial metabolites generation during the in vitro fermentation of non-digested fraction of PP 
(pomegranate pulp).(A) Time course of urolithins and gallic acid generation and (B) time course of 
catechol, coumaric acid and protocatechuic acid generation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Regarding other urolithins, urolithin B 
(hydroxyurolithin) was only produced by volunteer 
2, being the main metabolite detected in PJ and 
PP faecal suspensions. On the other hand, tri-and 
tetrahydroxyurolithins were detected in faecal 
suspension of volunteer 1 after fermentation of the 
three pomegranate products and after PE 
fermentation in volunteers 2 and 3. 
Pentahydroxyurolithin was detected only in the 
faecal suspensions of volunteer 1 after 
fermentation of PE. These results confirm that 
colonic microflora is critically involved in the 
interindividual variability of the excretion of 
microbial metabolites (Tomás-Barberán et al., 
2014). In the case of PE faecal suspensions (Fig. 
4A), this variability was markedly lower, which 
could be due to the enhanced urolithin excretion 
by the low urolithin producer (volunteer 3). 
Another explanation could be the saturation 
caused by the higher microbial substrate or its 
products (urolithins) that could probably hamper 
the transformation of ellagic acid to urolithins. 
Previous studies have proposed the metabolic 
colonic pathway of ellagitannins and ellagic acids 
in which penta-, tetra- and trihydroxyurolithins 
were described as intermediate products of major 
final metabolite urolithins A and B (García-Villalba 
et al., 2013). In the present study, volunteer 3 
produced very small amounts of urolithin A after 
the incubation of PJ (Fig. 2A) and PP (Fig. 3A) 
and no type of urolithin was detected until 48 h of 
fermentation, which suggests that, apart from 
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higher amounts of precursors, more time is 
needed to start the microbial conversion. Thus, 
the transit time might also be a crucial factor in 
determining the colonic metabolic profile, which 
varies considerably depending on individual 
characteristics (age, sex, health status) 
(McClements, Decker, & Park, 2009). 
 
Figure 4 – Microbial metabolites generation during the in vitro fermentation of non-digested fraction of PE 
(pomegranate peel extract). (A) Time course of urolithins and gallic acid generation and (B) time course of 
catechol, coumaric acid and protocatechuic acid generation 
 
In relation to other pomegranate phenolic 
catabolites identified, gallic acid and catechol 
were not detected in controls (i) and (ii), indicating 
their specificity as microbial metabolites of 
pomegranate, similarly to urolithins. Although 
detected in control (i), coumaric and 
protocatechuic acid concentration increased after 
incubation. In contrast to the generation of 
urolithins, catechol, gallic acid, coumaric acid and 
protocatechuic acid production did not show 
considerable interindividual variability, which is 
probably related to the non-specific bacteria 
needed for the precursor’s degradation, as 
required for the conversion of ellagic acid into 
urolithins (Selma, Beltrán, García-Villalba, Espín, 
& Tomás-Barberán, 2014). 
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Due to the simple structure of these phenolic 
acids and catechol, these catabolites could be 
formed by the degradation of multiple phenolic 
precursors (Dall’Asta et al., 2012). Indeed, one 
could be a product of the other (Cueva et al., 
2013; González-Barrio, Edwards, & Crozier, 
2011). Despite this aparent complex scenario, 
evidence exists that may help to determine their 
origin. Gallic acid could be generated by the 
hydrolysis of ellagitannins (Liu et al., 2013), but 
also by the breakdown of glycosylated gallic acid 
present in the IN fraction of pomegranate 
products. The gradual increase in its 
concentration observed during the first period of 
incubation (0 to 48 h) of the three pomegranate 
products studied could indicate the hydrolysis of 
ellagitannins and the liberation of gallic acid from 
the food matrix to the fermentation media as a 
consequence of the microbial activity (Saura-
Calixto et al., 2010). The microbial 
dehydroxylation of gallic acid might be the 
explanation for protocatechuic acid generation, 
although this phenolic metabolite was also 
proposed as a product of anthocyanins 
(González-Barrio et al., 2011) and flavonoid 
degradation (Sánchez-Patán, Monagas, Moreno-
Arribas, & Bartolomé, 2011). In addition, catechol 
has previously been suggested as a product of 
protocatechuic acid bacteria metabolism 
(González-Barrio et al., 2011). In regard to 
coumaric acid, its generation could result from the 
early degradation of flavonoids (Sánchez-Patán et 
al., 2011) present in high concentration in the IN 
fractions of PE (Table 1). Taking into account the 
initial concentration of anthocyanins and 
flavonoids in the IN fractions of the three 
pomegranate products (Table 1), the generation 
of higher amounts of gallic acid, catechol, 
coumaric acid and protocatechuic acid after PE 
fermentation could be attributed to the flavonoid 
metabolism while, in the case of PJ and PP, 
anthocyanins seem to be the main precursors for 
the generation of these phenolic metabolites  
 
4. CONCLUSION  
Results of the present study showed that 
differences in the stability of pomegranate 
phenolic compounds during in vitro digestion may 
not be only associated with the initial phenolic 
composition, but also with the food matrix. After 
the duodenal step, most of the pomegranate 
phenolic compounds remained in the IN fraction 
(non-absorbable), indicating a poor potential 
absorption and consequently a high exposure of 
these compounds to colonic metabolism. Results 
of in vitro colonic fermentation with human faeces 
inoculum revealed that urolithins (mainly urolithin 
A), and different simple phenols such as catechol, 
and gallic, coumaric and protocatechuic acids, 
were the main microbial metabolites after 
pomegranate products were submitted to in vitro 
digestion. Our results confirm that, depending on 
the colonic microflora of each individual, high or 
low ellagitannin metabolism can occur and, thus, a 
high or low amount of urolithin derivatives can be 
formed. This should be taken into account in 
intervention studies with ellagitannins containing 
foodstuffs because, depending on the individual 
microflora, a different biological activity could be 
expected. Among the three pomegranate 
products, pomegranate peel extract (PE) 
appeared to be the best source of microbial 
substrates at colonic level, leading to a larger 
generation of microbial catabolites in terms of 
absolute amounts. Therefore, the use of 
pomegranate peel extracts obtained as a sub-
product of the pomegranate juice industry could 
be a good strategy to enrich or fortify 
pomegranate products or other fruit-based 
products that would allow the enhancement of the 
pomegranate’s therapeutic effect, especially for 
those subjects with a low capacity to produce 
urolithins. 
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ADDITIONAL INFORMATION 
 
Table 1. Microbial metabolites generation during PJ in vitro fermentation. Results are expresed in umol/1 g 
of PJ for each fermentation time (0, 2, 8, 24, 48 and 72 h) 
 
 
Data are expressed as mean in µmol/L. Mean values were calculated subtracting to the average value of the three 
replicates the control content of the respective substance. 
n.d.: not detected. Below the limit of detection  
tr.: traces. Below the limit of quantification  
 
 
 
Compound Volunteer 0 h 2 h 8 h 24 h 48 h 72 h 
5-OH urolithin 
 1 n.d. n.d. n.d. n.d. n.d. n.d. 
 2 n.d. n.d. n.d. n.d. n.d. n.d. 
 3 n.d. n.d. n.d. n.d. n.d. n.d. 
4-OH urolithin 
 1 n.d. tr 0.01±0.00 0.06±0.01 0.08±0.01 0.05±0.01 
 2 n.d. n.d. n.d. n.d. n.d. n.d. 
 3 n.d. n.d. n.d. n.d. n.d. n.d. 
3-OH urolithin 
 1 n.d. n.d. tr tr n.d. n.d. 
 2 n.d. n.d. n.d. n.d. n.d. n.d. 
 3 n.d. n.d. n.d. n.d. n.d. n.d. 
2-OH urolithin 
 1 n.d. tr 0.05±0.00 0.07±0.00 0.25±0.04 0.25±0.06 
 2 n.d. tr tr tr 0.01±0.00 0.01±0.00 
 3 n.d. n.d. n.d. n.d. tr tr 
OH urolithin        
 1 n.d. n.d. n.d. n.d. n.d. n.d. 
 2 n.d. n.d. 0.02±0.00 0.02±0.00 0.03±0.00 0.03±0.00 
 3 n.d. n.d. n.d. n.d. n.d. n.d. 
Gallic acid        
 1 0.01±0.00 0.02±0.00 0.12±0.01 0.08±0.01 n.d. n.d. 
 2 0.02±0.00 0.02±0.00 0.10±0.01 0.10±0.01 n.d. n.d. 
 3 n.d. n.d. 0.01±0.00 0.01±0.00 n.d. n.d. 
Protocatechuic acid 
 1 n.d. tr tr 0.01±0.00 0.01±0.00 0.01±0.00 
 2 n.d. n.d. tr tr 0.01±0.00 0.03±0.00 
 3 tr tr tr 0.02±0.00 0.02±0.00 0.02±0.00 
Coumaric 
acid 
       
 1 tr tr tr n.d. n.d. n.d. 
 2 0.01±0.00 0.01±0.00 tr n.d. n.d. n.d. 
 3 0.01±0.00 0.01±0.00 n.d. n.d. n.d. n.d. 
Catechol        
 1 n.d. tr tr tr tr tr 
 2 n.d. n.d. n.d. n.d. n.d. tr 
 3 n.d. n.d. n.d. n.d. n.d. tr 
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Table 2. Microbial metabolites generation during PP in vitro fermentation. Results are expresed in umol/1 
g of PP for each fermentation time (0, 2, 8, 24, 48 and 72 h) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are expressed as mean in µmol/L. Mean values were calculated subtracting to the average value of the three 
replicates the control content of the respective substance. 
n.d.: not detected. Below the limit of detection  
tr.: traces. Below the limit of quantification  
 
 
 
 
 
Compound Volunteer 0 h 2 h 8 h 24 h 48 h 72 h 
5-OHurolithin 
 1 n.d. n.d. n.d. n.d. n.d. n.d. 
 2 n.d. n.d. n.d. n.d. n.d. n.d. 
 3 n.d. n.d. n.d. n.d. n.d. n.d. 
4-OH urolithin 
 1 n.d. n.d. tr tr tr n.d. 
 2 n.d. n.d. n.d. n.d. n.d. n.d. 
 3 n.d. n.d. n.d. n.d. n.d. n.d. 
3-OH urolithin        
 1 n.d. 0.03±0.00 0.06±0.00 0.07±0.01 0.1±0.01 0.08±0.01 
 2 n.d. n.d. n.d. n.d. n.d. n.d. 
 3 n.d. n.d. n.d. n.d. n.d. n.d. 
2-OH urolithin        
 1 n.d. 0.01±0.00 0.07±0.00 0.27±0.00 0.37±0.04 0.35±0.06 
 2 n.d. n.d. n.d. 0.01±0.00 0.03±0.00 0.01±0.00 
 3 n.d. n.d. n.d. n.d. tr tr 
OH urolithin        
 1 n.d. n.d. n.d. n.d. n.d. n.d. 
 2 n.d. n.d. 0.02±0.00 0.02±0.00 0.02±0.00 0.03±0.00 
 3 n.d. n.d. n.d. n.d. n.d. n.d. 
Gallic acid        
 1 0.01±0.00 0.02±0.00 0.12±0.01 0.10±0.01 n.d. n.d. 
 2 0.02±0.00 0.02±0.00 0.10±0.01 0.10±0.01 n.d. n.d. 
 3 n.d. n.d. 0.01±0.00 0.01±0.00 n.d. n.d. 
Protocatechuic 
acid 
 
      
 1 n.d. tr tr 0.01±0.00 0.01±0.00 0.01±0.00 
 2 n.d. n.d. tr tr 0.01±0.00 0.03±0.00 
 3 tr tr tr 0.02±0.00 0.02±0.00 0.02±0.00 
Coumaric acid 
 1 n.d. tr tr tr tr tr 
 2 n.d. 0.01±0.00 tr n.d. n.d. n.d. 
 3 tr 0.01±0.00 tr n.d. n.d. n.d. 
Catechol        
 1 n.d. 0.01±0.00 tr tr tr tr 
 2 n.d. n.d. n.d. n.d. n.d. tr 
 3 n.d. n.d. n.d. n.d. n.d. n.d. 
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Table 3. Microbial metabolites generation during PE in vitro fermentation. Results are expresed in umol/1 
g of PE for each fermentation time (0, 2, 8, 24, 48 and 72 h) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Data are expressed as mean in µmol/L. Mean values were calculated subtracting to the average value of the three 
replicates the control content of the respective substance. 
n.d.: not detected. Below the limit of detection  
tr.: traces. Below the limit of quantification  
 
 
 
 
 
 
 
Compound Volunteer 0 h 2 h 8 h 24 h 48 h 72 h 
5-OH urolithin        
 1 n.d. n.d. n.d. n.d. 0.11±0.04 n.d. 
 2 n.d. n.d. n.d. n.d. n.d. n.d. 
 3 n.d. n.d. n.d. n.d. n.d. n.d. 
4-OH urolithin        
 1 n.d. n.d. n.d. 0.01±0.00 1.26±0.46 n.d. 
 2 n.d. n.d. n.d. 0.02±0.00 n.d. n.d. 
 3 n.d. n.d. n.d. n.d. 0.03±0.00 n.d. 
3-OH urolithin       
 1 n.d. 0.02±0.00 0.18±0.01 0.54±0.02 3.74±0.35 3.45±0.29 
 2 n.d. n.d. 0.08±0.01 0.23±0.01 0.29±0.01 0.08±0.01 
 3 n.d. n.d. n.d. 0.02±0.00 0.45±0.03 0.04±0.00 
2-OH urolithin       
 1 n.d. 0.07±0.00 0.82±0.08 0.96±0.09 5.32±0.5 20.84±0.68 
 2 n.d. 0.01±0.00 0.04±0.00 0.31±0.04 14.01±1.50 17.51±0.82 
 3 n.d. n.d. n.d. n.d. 14.54±0.75 21.89±1.65 
OH urolithin        
 1 n.d. n.d. n.d. n.d. n.d. n.d. 
 2 n.d. n.d. 0.04±0.00 0.11±0.01 0.33±0.02 0.12±0.01 
 3 n.d. n.d. n.d. n.d. n.d. n.d. 
Gallic acid        
 1 n.d. 0.02±0.00 0.02±0.00 0.55±0.02 4.03±0.68 n.d. 
 2 n.d. 0.01±0.00 0.66±0.01 1.30±0.05 0.37±0.02 0.04±0.00 
 3 n.d. 0.01±0.00 0.60±0.04 0.70±0.04 0.35±0.03 n.d. 
Protocatechuic 
acid 
      
 1 n.d. 0.03±0.00 0.03±0.00 0.04±0.00 0.06±0.00 0.11±0.01 
 2 n.d. n.d. n.d. 0.03±0.00 0.06±0.00 0.16±0.01 
 3 n.d. 0.01±0.00 0.03±0.00 0.08±0.00 0.11±0.01 0.11±0.01 
Coumaric acid        
 1 n.d. 0.20 n.d. 0.08±0.00 0.03±0.00 n.d. 
 2 0.07 0.13±0.01 0.06±0.00 n.d. n.d. n.d. 
 3 0.15±0.01 0.16±0.01 0.23±0.02 0.01±0.00 n.d. n.d. 
Catechol        
 1 n.d. n.d. n.d. n.d. n.d. 0.01±0.00 
 2 n.d. n.d. n.d. n.d. n.d. 0.01±0.00 
 3 n.d. n.d. n.d. n.d. n.d. n.d. 
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EFFECT OF DAILY INTAKE OF POMEGRANATE JUICE ON FECAL MICROBIOTA AND 
FECES METABOLITES FROM HEALTHY VOLUNTEERS 
 
Juana I. Mosele1, María-Jose´ Gosalbes2,3, Alba Macià1, Laura Rubió4, Jorge F. Vazquéz-Castellanos2,3, 
Nuria Jimenéz Hernandez2,3, Andrés Moya2,3, Amparo Latorre2,3 and María-José Motilva1 
 
5 Food Technology Department, Agrotecnio Center, University of Lleida, Lleida, Spain  
6 Unidad Mixta de Investigacion´ en Genomica´ y Salud de la Fundacion´ para el Fomento de la Investigacion´ Sanitaria 
y Biomedica´ (FISABIO-Salud Publica)´ y del Instituto Cavanilles de Biodiversidad y Biolog´ýa Evolutiva (Universitat de 
Valencia),` Valencia,` Spain  
7 CIBERESP (Consorcio de Investigacion´ Biomedica´ de Epidemiolog´ýa y Salud Publica),´ Madrid, Spain  
8 Functional Nutrition, Oxidation and Cardiovascular Diseases Group (NFOC-Salut), Unit of Lipids and Atherosclerosis 
Research (URLA), Centro de Investigacion´ Biomedica´ en Red de Diabetes y Enfermedades Metabolicas´ Asociadas 
(CIBERDEM), Hospital Universitari Sant Joan, IISPV, Technological Center of Nutrition and Health (CTNS), Faculty of 
Medicine and Health Sciences, Universitat Rovira i Virgili, Reus, Spain  
 
Scope: The purpose of the study was to evaluate the effect, regarding the metabolic and microbial profile 
of feces, of diet supplementation of healthy adults with pomegranate juice (PJ). 
Methods and results: Twelve healthy adults were recruited to the study, which consisted of the intake of 
200 mL/day of PJ during 4 weeks. Feces were collected before and after the supplementation with PJ. 
Metabolites (phenolic catabolites, short-chain fatty acids, and fecal steroids) and microbial profile were 
analyzed at baseline and at 4 weeks. Fecal phenolic metabolites, 3-phenylpropionic acid, catechol, 
hydroxytyrosol, and urolithin A, showed a significant increase in their concentration after supplementation 
with PJ. Among fecal steroids, parallel to the significant increase of cholesterol concentration, a significant 
decrease of coprostanol was observed. Although no significant changes in the microbiota profile were 
observed, different relationships between initial microbiota and the metabolites produced were found. 
Catechol showed positive and negative correlation with Oscillospora and Paraprevotella genera, 
respectively, and 3-phenylpropionic acid was positively correlated with Odoribacter genus.  
Conclusion: Inclusion of PJ in the diet did not significantly alter the gut microbiota composition in healthy 
adults, but the individual bacterial composition could contribute to the generation of potential health-
promoting phenolic metabolites. 
 
Keywords: Fecal steroids / Microbiota / Phenolic compounds / Pomegranate / Short-chain fatty acids 
 
 
1. INTRODUCTION 
Gut microbiota represents the largest microbial 
environment of the human organism and its 
composition and interplay with the host are closely 
connected to healthy conditions [1]  
Intestinal microbiota markedly depends on diet 
and numerous nutritional interventions have been 
shown to selectively modify specific bacterial 
groups [2,3]. Although some studies have been 
conducted on the effect of dietetic fiber as 
prebiotic [3], little is known about the ability of 
other components of fresh fruit, such as phenolic 
compounds, which are also important contributors 
to modulate the gut microbiota composition. Some 
studies have revealed that gut microbiota is able 
to transform intact phenolic compounds into 
bioactive metabolites and the accumulation of 
these microbial metabolites may be a key factor to 
promote changes in the gut ecosystem, including 
modifications of microbial population [4–6]. In 
general, human studies evidence that dietary 
polyphenols may contribute to the maintenance of 
intestinal health by preserving the gut microbial 
balance through the stimulation of the growth of 
beneficial bacteria (i.e. Lactobacilli and 
Bifidobacteria) and the inhibition of pathogenic 
bacteria, exerting prebiotic-like effects [5, 7]. 
Therefore, the analysis of fecal composition not 
only provides valuable information regarding the 
unabsorbed diet components, but also clarifies 
whether the functional stability of the gut 
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ecosystem could undergo modifications after 
dietary interventions. 
Apart from the study of the gut microbiota 
modulation through diet, recent studies have also 
revealed that fecal sterols might exert a much 
wider range of biological activities than initially 
recognized [8]. In this sense, it has been 
established that secondary metabolites of fecal 
sterols produced by the gut microbiota may 
promote health or favor disease development 
depending on the quantity and type produced. 
Specifically, increased concentrations of 
secondary bile acids (BAs) and cholesterol 
microbial metabolites in feces are involved in 
colorectal carcinogenesis [8, 9]. 
Therefore, it is interesting to study whether the 
fecal excretion of these metabolites can be 
modulated into a healthier profile through dietary 
intervention, as has already been demonstrated 
for phenolic compounds in rats [10]. On the other 
hand, the presence of other microbial products 
formed from non-digestible carbohydrates (dietary 
fiber), such as short chain fatty acids (SCFAs) 
[11], could serve as a protector factor of 
gastrointestinal disease, limiting the generation of 
pathogenic bacteria as well as promoters of the 
growth of beneficial bacteria [12], and maintain 
optimal bowel balance [11, 13].  
Pomegranate is one of the most polyphenol-rich 
fruits with many associated health benefits such 
as antiinflammatory [14], anticarcinogenic [15] and 
cardioprotective effects [16] and are mainly 
attributed to its phenolic content [17]. Ellagitannins 
and anthocyanins are the most representative 
phenolic groups, followed by variable amounts of 
lignans, flavonoids, and phenolic acids [18, 19].  
Most of these compounds are poorly absorbed in 
the small intestine and reach the large intestine, 
where they are subjected to catabolic 
transformations, being the urolithins derived from 
ellagic acid the most studied microbial phenolic 
metabolites [19, 20]. The microbial metabolites 
are thus likely to be responsible for the health 
benefits of pomegranate rather than the original 
compounds. However, to date no human studies 
have revealed whether pomegranate polyphenols 
could possess specific qualities to modulate the 
bacterial gut population and other steroid 
metabolites related to colonic health. 
  
 
  
Figure 1. Graphic representation of the study design and sample collection 
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The purpose of the present study was to evaluate 
possible beneficial effects regarding the microbial 
and metabolic profile of feces from healthy adults 
after the addition of pomegranate juice (PJ; 200 
mL/day) to the habitual diet during a period of 4 
weeks.  
Changes in the microbial phenolic metabolites, 
SCFAs, and fecal steroids were evaluated. The 
modulation of the intestinal microbial population 
after the intervention was also evaluated, studying 
the relationship between possible changes in 
microbial metabolite profile and microbial 
composition for each individual. To our 
knowledge, this is the first study that evaluates the 
microbiota profile of healthy volunteers and the 
phenol metabolic profile of human feces after a PJ 
intervention. 
 
2. MATERIALS AND METHODS 
2.1. Pomegranate juice 
The pomegranate fruits (Punica granatum L. 
Mollar de Elche cv.; growing area of Alicante, 
Spain) were purchased from a local market in 
Lleida (Catalonia, Spain). Fruits were washed and 
manually peeled. The PJ was prepared by 
blending the entire arils without the peel using a 
commercial blender with an incorporated filter 
(Molinex, France) in which pulp and intact seeds 
were retained. The juice was immediately divided 
into daily doses of 200 mL in amber glass bottles 
and stored at −20°C, and on the day of 
consumption the juice was defrosted at 4°C. The 
phenolic composition analysis was carried out by 
using Ultra-performance LC MS/MS methodology 
on the basis of the protocol of Mosele et al. [19]. 
The average phenolic content in the daily intake of 
200 mL of PJ was: 878.9 mg ellagic acid and 
ellagitannins, 41.5 phenolic acids and its 
derivates, 38.0 anthocyanins, 4.21 lignans, 3.39 
flavonols, 1.19 flavan-3-ols, 0.50 flavanones, and 
minor phenols as syringaldehyde and phloretin 
glucoside; Supporting Information Table 1). 
Two hundred milliliters of PJ contributed 
approximately 968 mg/day of phenolic compounds 
to the habitual diet of the volunteers. Values 
correspond to the average concentration of 
different aliquots (n = 5) collected over the 4 
weeks of juice preparation  
 
2.2. Study design 
The diet intervention study was approved by the 
Ethical Committee of Clinical Research of Arnau 
Vilanova University Hospital, Lleida, Spain 
(Approval Number: CEIC-1326). Twelve healthy 
adults (4 men and 8 women, aged 26–40, BMI < 
25 kg/m2) were recruited to participate in the 
study. Inclusion criteria included healthy men and 
women aged between 26 and 40 years, not taking 
antibiotics at least 3 months before the study and 
reported to be in good health conditions before 
and during the study. After successful completion 
of screening, participants provided informed 
consent, including authorization to use their feces 
for analysis of microbiota and metabolites. 
Participants were instructed to maintain their 
regular diet, with the exception of probiotic 
consumption, in order to elucidate the gut 
metabolic profile and changes in microbiota 
population in a conventional diet complemented 
with the daily intake of PJ. They were also asked 
to complete a 3-day dietary record before and 
during the 4 weeks of PJ supplementation period 
which included 1 day of the weekend in order to 
consider all the dietary habits of volunteers. Mean 
total kilocalories of the volunteer diets and their 
composition in proteins, carbohydrates, and fat 
were estimated using Spanish food composition 
sheets (www.bedca.net), and the total intake of 
phenolic compounds was estimated using the 
information supplied by www.phenolexplored.eu. 
No significant differences were detected in 
energy, carbohydrate, protein, fat, and phenolic 
compound intake between baseline and the study 
period (see Supporting Information Table 2). 
Before the intervention period with PJ, participants 
received detailed instructions to collect fecal 
samples and were provided with two different 
containers: a sterile pot and a falcon tube 
containing 10 mL of RNAlater® solution (Life 
Technologies). The volunteers were asked to 
transfer approximately 10 g of fresh feces from the 
sterile pot to the falcon tube immediately after 
defecation. Weekly, each volunteer received a box 
with seven bottles containing the daily PJ dose. 
During the intervention period, the volunteers 
consumed 200 mL/day of PJ with breakfast during 
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4 weeks. Each volunteer collected the feces 
sample in fasted state before (Pre; day 0) and 
after (Post; day 28) the intervention period. The 
same day of collection, fecal samples were 
lyophilized and stored at −80°C until the 
chromatographic analysis to determinate phenolic 
microbial metabolites, SCFAs, and fecal steroids 
(BAs and sterols). The feces preserved in falcon 
tubes, also stored at −80°C, were used for the 
analysis of microbiota composition  
 
2.3. Phenolic quantification in feces 
Lyophilized feces (0.1 g) were mixed in 1 mL of 
MeOH/HCl/H2O (79.9:0.1:20, v/v/v) and 
centrifuged (8784 × g, 5 min, 4°C) after 15 min of 
shaking. The supernatant was collected and re-
centrifuged under the same conditions. The 
resulting supernatant was filtered (0.22 µm filter 
pore size) and analyzed by ultra-high LC coupled 
to MS/MS (Supporting Information Method). All 
phenolic compounds present in the PJ and their 
potential catabolites formed by microbiota 
fermentation were studied. To avoid differences in 
the water content of feces, depending on the 
individual, the results are expressed in mg or ng of 
compound per gram of dry feces. 
 
 
 
Table 1. Changes in the phenolic compounds and their metabolites in human feces before (Pre) and after 
(Post) the supplementation period (4 weeks) with pomegranate juice (200 mL/day) 
Compound Pre Post n (%)  
     
Urolithins (mg/g dry feces)     
Urolithin D (tetrahydroxy-urolithin) n.d. t.r. 1 (8)  
Urolithin C (trihydroxy-urolithin) 0.07 ± 0.05 0.69 ±  0.31 6 (50)  
Urolithin A (dihydroxy-urolithin) 7.00 ± 6.74 35.9 ±  11.3* 8 (67)  
Isourolithin A (dihydroxy-urolithin) n.d. 0.57 ±  0.57 1 (8)  
Urolithin B (monohydroxyl-urolithin) 2.23 ± 2.02 9.47 ±  5.74 3 (23)  
Anthocyanins (ng/g dry feces)     
Cyanidin-O-3,5-diglucoside n.d. 112 ±  87.5 3 (25)  
Cyanidin-O-3-glucoside 0.89 ± 0.89 27.5 ±  14.7 9 (70)  
Cyanidin pentoside n.d. 4.35 ±  2.98 3 (25)  
Phenolic acids (mg/g dry feces) 
5.80 ± 3.33 
   
Phenylpropionic acid 10.98 ±  3.69* 8 (67)  
Protocatechuic acid 0.13 ± 0.03 0.18 ±  0.03 9 (75)  
Other phenolic compounds (mg/g dry 
feces) 
0.02 ± 0.01 
   
Catechol 0.05 ±  0.01** 10 (83)  
Hydroxytyrosol 0.06 ± 0.01 0.13 ±  0.03* 10 (83)  
Unidentified metabolites (mg/g dry feces) 
1.25 ± 0.63 
   
Unkown: m/z−  333 MS2 285, 259 54.4 ±  16.8** 12 (100)  
Total phenolic metabolites (mg/g dry feces) 16.6 ± 7.24 112 ±  19.1** 12 (100)  
a) All values are 
means (n = 12) ± SE. Compared with corresponding Pre-value, *p < 0.05, **p < 0.01. n.d., 
no detected; t.r., traces level. 
n is number of volunteers who presented an increase in the concentration for each compound after pomegranate juice, and the 
percentage of the total 12 volunteers who presented an increase for each compound
 
 
 
2.4. Determination of SCFAs in feces 
Lyophilized feces (0.1 g) were mixed with 1 mL of 
acidified aqueous solution (1% phosphoric acid) 
containing 4-methyl valeric acid (Sigma-Aldrich, 
St. Louis, MO, USA) as internal standard (IS, final 
concentration 500 µM). Samples were shaken for 
15 min and centrifuged (10 min, 1800 × g, 4°C). 
Before filtration (0.22 µm pore size filter), the 
supernatants were centrifuged (4 min, 8784 × g, 
4°C) once more. 
The analysis of acetic, propionic, butyric, 
isobutyric, isovaleric, and valeric acids was 
performed by GC (Agilent 7890A Series) using a 
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capillary BP-21 column (30 m, 0.25 mm, 0.25 m; 
SGE, Cromlab SL, Barcelona, Spain), coupled to 
a flame ionization detector (FID). The column 
temperature was programed at 90°C, rising by 
15°C/min until it reached 150°C, then 5°C/min to 
170°C, and then 20°C/min to 240°C, and 
maintained 3 min (total run time 14.5 min). Helium 
was the carrier gas (1 mL/min). Injection was 
carried out with a split injector (1:100) at 220°C, 
detector temperature was 250°C, and 1 L of the 
solution was injected into the GC/FID system. 
Identification of the SCFAs was carried out 
according to the retention time of standard 
compounds (acetic acid, propionic acid, butyric 
acid, isobutyric acid, valeric acid, and isovaleric 
acid; Sigma-Aldrich) and their quantification was 
determined with reference to the peak side of IS 
(4-methyl valeric acid; Supporting Information 
Fig. 1). All samples were analyzed in duplicate. 
 
2.5. Analysis of fecal steroids: BAs and sterols 
Silylation of sterols and BAs was carried out 
simultaneously. For this, 100 L of pyridine and 100 
L of N-methyl-N-(trimethylsilyl) trifluoroacetamide 
(both from Sigma-Aldrich) were added to a vial 
containing 10 mg of feces and two ISs (1000 µM 
of 5α-cholestane and 500 µM 5β-cholanic acid; 
Sigma-Aldrich) and then maintained during 30 min 
at 60°C. After silylation, samples were centrifuged 
10 min at 8784 × g at room temperature. The 
supernatants were analyzed by GC system 
(Agilent 7890A) coupled to an FID. Samples were 
injected into a capillary column DB-1 (30 m × 0.25 
mm × 0.25 i.d.) and the simultaneous 
quantification of sterols and BAs was performed 
as follows: the column temperature was set at 
240–290°C (20°C/min) and maintained 2 min; 
290–295°C (1°C/min) and 295–310°C (25°C/min) 
maintained during 5 min, total run time 16.1 min. 
The temperature of the injector was 280°C, the 
volume of injection was 1 L and the FID 
temperature was 200°C. Peak identification was 
based on comparison of retention times with 
reference compounds. All quantifications were 
performed using calibration curves generated from 
different know concentrations of commercial 
standards. For fecal sterols quantifications, 
commercial standards of 5α-cholestane (IS), 
cholesterol, coprostanol, cholestanol, and 
cholestanone acid (Sigma-Aldrich) were used. In 
the case of fecal BAs commercial standards of 5β-
cholanic acid (IS), cholic acid, deoxycholic acid, 
chenodeoxycholic acid, and lithocholic acid 
(Sigma-Aldrich) were used (Supporting 
Information Fig. 2). 
 
 
 
Table 2. Changes in the SCFAs composition in human feces before (Pre) and after (Post) the 
supplementation during 4 weeks with pomegranate juice (200 mL/day)a). 
 Concentration (mg/g dry feces) Molar ratio (% mol of total) 
SCFAs Pre Post Pre Post 
Acetic acid 11.98 ±  1.78 13.53 ±  1.70 57.48 ±  1.24 57.63 ±  1.80 
Propionic acid 5.05 ±  0.82 4.94 ±  0.64 19.19 ±  1.47 17.15 ±  0.90 
Butyric acid 5.05 ±  1.38 5.37 ±  1.01 15.31 ±  1.31 18.08 ±  0.96 
Isobutyric acid 0.63 ±  0.09 0.68 ±  0.10 2.46 ±  0.29 2.14 ±  0.38 
Isovaleric acid 1.05 ±  0.14 0.93 ±  0.19 3.37 ±  0.46 2.68 ±  0.60 
Valeric acid 0.73 ±  0.12 0.82 ±  0.12 2.19 ±  0.25 2.35 ±  0.42 
Total 24.49 ±  4.00 26.26 ±  3.17   
a) All values are means (n = 12) ± SE 
 
 
 
2.6. Fecal microbiota composition analysis 
2.6.1. DNA purification, amplicons, and 
sequencing 
Fecal samples stored in RNAlater® were treated 
following Vázquez et al. [21]. Briefly, the samples 
were diluted with 5 mL of PBS solution. To 
remove fecal debris, the samples were centrifuged 
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at 600 × g at 4°C for 2 min and then the 
supernatant was centrifuged at 25 364 × g for 5 
min to pel-let the cells. Total DNA was extracted 
from bacterial pellet with QIAamp® DNA Stool Kit 
(Qiagen, Hilden, Germany) according to the 
manufacturer’s instructions. A region of the 16S 
rRNA gene was amplified by PCR with the 
universal primers E8F (5_ -AGAGTTT 
GATCMTGGCTCAG-3_) and 530R (5_ -
CCGCGGCKGCTGGCAC-3_) using the sample-
specific Multiplex Identifier (MID) for 
pyrosequencing, and attached to the 454 Roche 
adaptors. The amplified region comprises hyper-
variable regions V1, V2, and V3. PCR was run 
under the following conditions: 95° for 2 min 
followed by 28 cycles of 95° for 30 s, 52° for 1 min 
and 72° for 1 min and a final extension step at 72° 
for 10 min. After purification using NucleoFast® 96 
PCR Clean-Up Kit (Macherey-Nagel), the PCR 
products were pooled and directly pyrosequenced 
using a Roche GS FLX sequencer and Titanium 
chemistry in the Centre for Public Health 
Research (FISABIO-Salud Publica,´ Valencia, 
Spain). All sequences were deposited in the public 
European Nucleotide Archive server under 
accession number PRJEB7859. 
 
 
 
 
Table 3. Changes in the bile acids (BA) and sterols composition in human feces before (Pre) and after 
(Post) the supple-mentation during 4 weeks with pomegranate juice (200 mL/day)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a) All values are means (n = 12) ± SE; compared with correspond-ing Pre-value, *p < 0.05 
 
2.6.2. Composition, biodiversity, and 
interactions of fecal microbiota  
16S rRNA gene reads with low-quality score (<20 
out of 40 quality units assigned by the 454) and 
short read lengths (<170 nt) were removed. 
Potential chimeras were also re-moved from the 
remaining sequences using uchime in Qiime v1.8 
pipe line [22]. Usearch tool in Qiime software was 
used to denoise data and to create the operational 
taxonomic unit (OTU) clusters (97%). Taxonomic 
information of the 16S rDNA sequences was 
obtained by comparison with the Ribosomal 
Database Project-II [23], using the 
pick_otus_through_otu_table.py pipe line avail-
able in QIIME v1.8.0 software. We considered 
only annotations that were obtained with a 
bootstrap value greater than 0.8, leaving the 
assignation at the last well-identified level and 
consecutive levels as unclassified (uc). To 
statistically assess the effect of the PJ on the 
bacterial composition, the Permutational 
Multivariate Analysis of Variance Using Distance 
Matrices (Adonis) was applied, as implemented in 
Compound 
Concentration (mg/g dry feces)  
Pre Post  
Primary BA    
Cholic acid 0.11 ±  0.07 0.19 ±  0.13  
Chenodeoxycholic acid 0.09 ±  0.03 0.15 ±  0.06  
Total 0.20 ±  0.08 0.33 ±  0.18  
Secondary BA    
Lithocholic acid 1.54 ±  0.20 1.55 ±  0.21  
Desoxycholic acid 1.99 ±  0.40 1.82 ±  0.35  
Total 3.53 ±  0.57 3.37 ±  0.50  
Primary + secondary BA 3.73 ±  0.61 3.70 ±  0.55  
Sterols  ±    
Cholesterol 1.88 ±  0.53 5.60 ± 1.56*  
Colestanol 0.54 ±  0.12 0.51 ±  0.19  
Coprostanol 20.33 ±  4.32 13.9 ±  4.12*  
Total 22.7 ±  4.32 19.8 ±  3.48  
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the Vegan package of the R software (Avail-able 
from: http://CRAN.R-project.org/package=vegan 
and http://www.R-project.org/. Accessed October 
14, 2013). 
The association between the microbiota before PJ 
intervention period (Pre-treatment) and metabolite 
production was determined by applying a 
generalized linear regression model, using glmnet 
function in the “glmnet” R package [24]. The 
models were estimated by setting the genus 
frequencies before PJ as the predictor matrix, 
transformed by the Arcsin square root 
transformation, and the increment of the 
metabolites as the response vector. The Least 
Absolute Shrinkage and Selection Operator was 
used as the regression method to penalize the 
absolute size of the regression coefficients. The 
performance of the predictive model was validated 
by means of the k-mean cross-validation using cv. 
glmnet function in the "glmnet" R package. Those 
bacterial taxa that gave a good fit within the linear 
regression model were validated using the 
Spearman correlation index. Those genera that 
matched both criteria were selected as bacteria 
involved in the metabolite production 
 
2.6.3. Functional prediction 
Functional prediction was performed using the 
PICRUSt pipeline [25]. Usearch software was 
used to cluster the OTU sequences at 97% of 
identity, using the GreenGenes OTU database 
(version 13.5) as reference. OTUs were 
normalized by copy number using the 
normalize_by_copy_number.py script (version 
1.0.0), and the functional predictions were 
estimated running the script 
predict_metagenomes.py, taking the KEGG 
database as reference. The resulting 
metagenomic prediction was then entered into the 
HUMAnN pipeline [26] in order to determine the 
abundance and coverage of putative microbial 
pathways. In the present study, we only predict 
the functional composition of all the OTUs whose 
taxonomic an-notation includes Oscillospira, 
Odoribacter, or Paraprevotella genera. 
 
2.7. General statistical analysis 
The results were presented as mean values ± SE. 
Paired Student’s t-test was used to analyze 
changes of phenolic compounds and their 
metabolites, SCFAs, BA, sterols, and tocopherol, 
in the feces before and after PJ intake. The 
biodiversity Shannon index was estimated with the 
Kruskal–Wallis rank sum test. The p-values in the 
correlation analysis were adjusted using the 
Benjamini–Hochberg correction. 
 
3 RESULTS 
3.1. Effect of PJ intake on phenolic metabolite 
profile in human feces  
Changes in some phenolic metabolite amounts 
were assessed in fecal samples of all volunteers 
before and after PJ intervention during 4 weeks 
(Table 1). It is most remarkable that five types of 
urolithins with different hydroxyl substitutions were 
detected in variable concentrations and high 
individual variability was observed in the fecal 
metabolism of pomegranate phenols. Urolithin A 
(p < 0.05) was the most abundant urolithin 
detected in larger amounts in eight out of 12 
subjects, while isourolithin A 
(dihydroxyisourolithin) was quantified in the feces 
of one subject after the PJ intervention. Three 
volunteers produced higher amounts of urolithin B 
(hydroxyurolithin), especially in the isourolithin A 
producers. The excretion of urolithin C 
(trihydroxyurolithin) was detected in feces of six 
volunteers and urolithin D (tetrahy-droxyurolithin) 
only in one volunteer. In three volunteers no class 
of urolithins was detected. Apart from urolithins, 
the phenolic acids 3-phenylpropionic acid (p < 
0.05), catechol (p < 0.01), and hydroxytyrosol (p < 
0.05) were also detected in significantly higher 
concentrations after the PJ intervention. 
Native anthocyanins from PJ were detected with a 
large variability in concentrations (Table 1). 
Cyanidin 3-O-glucoside was present in nine out of 
12 volunteers after the intake of PJ (Post) while 
cyanidin pentoside and cyanidin 3,5-O-diglucoside 
were detected in the feces of the same three 
volunteers. The detection of an unknown 
compound (m/z− 333, MS2 285, 259) in the feces 
of all volunteers is noteworthy, a significant 
increase of this metabolite being observed 
following the PJ intake (p < 0.01). Neither ellagic 
acid nor ellagitannins were recovered in their 
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native form present in PJ in any of the feces 
analyzed. 
3.2. Effect of PJ intake on SCFAs and 
steroid (BAs and sterols) composition 
in feces  
Results of SCFAs (acetic, propionic, butyric, 
isobutiric, valeric, and isovaleric acids) 
concentrations are reported in Table 2. No 
significant statistical differences were observed 
between Pre and Post PJ intake in the 
concentration of total and individual SCFAs (mg/g 
dry feces). However, when the data were 
normalized to molar ratio (percentage of individual 
SCFAs in relation to total SCFAs) differences 
were observed between Pre and Post PJ intake. 
Changes in fecal BA concentration are shown in 
Table 3. Although no significant changes were 
observed after the PJ consumption period, an 
increasing trend of primary BA was observed. 
Regarding the fecal sterols, cholesterol increased 
its concentration in feces (p < 0.05) and the 
concentration of coprostanol suffered a significant 
reduction (p < 0.05; Table 3). 
  
Figure 2. Fecal microbiota composition in the individuals analyzed before and after PJ. The phylum and 
the genus level are shown for the most abundant bacterial groups (>1%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.3. Effect of PJ intake on gut microbiota 
composition  
Despite some intraindividual differences, the 
bacterial composition of all the fecal samples, 
before and after PJ intervention during 4 weeks, 
was rather homogeneous since the distribution of 
genus abundance was similar (Shannon index, p 
value = 0.386). Bacteroides (20.372 ± 9.128%) 
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and Faecalibacterium (23.138 ± 12.279%) were 
the most abundant genera. We also found that 
commensal members of intestinal community, 
such as Prevotella (3.913 ± 6.76%), Oscillospira 
(3.4824.075%), Lachnospira (2.99 ±  2.571%), 
Roseburia (2.615 1.964%), Parabacteroides 
(2.398 ± 3.345%), Ruminococcus between 
metabolites produced and initial microbiota (Pre 
PJ), we performed a generalized linear regression 
model analysis. We identified three genera that 
showed significant correlation with two phenolic 
metabolites detected in feces. Catechol was 
positively correlated with Oscillospira genus and 
negatively correlated with Paraprevotella genus, 
while 3-phenylpropionic acid showed a positive 
correlation with Odoribacter genus (Table 4). Both 
phenolic metabolites presented a significant 
increase after the PJ supplementation (4 weeks). 
These three genera, Oscillospira, Paraprevotella, 
and Odoribacter, were low abundant in the initial 
microbiota (4.021 ± 4.245%, 0.821 ± 1.174%, and 
0.123 ± 0.169%). 
Table 4. Significant interactions between bacterial genera and phenolic metabolites in feces 
 
 
 
 
 
 
q-Value is the p-value adjusted using the Benjamini–Hochberg correction. GLM, generalized linear regression model 
 
 
Table 5. Metabolic pathways related to the cathecol in Oscillospira and Paraprevotella 
 
 
 
The relative abundance is expressed as 
percentage based on the total pathways 
predicted. The coverage represents the 
percentage of the pathway that has been found in 
the prediction. 
For Paraprevotella, we obtained a functional 
prediction in eight of the 12 samples, the same 
metabolic pathways being represented. Table 5 
shows the relative abundance and coverage of 
each pathway. The 3-phenylpropionic acid could 
be involved in three KEGG pathways: 
phenylalanine metabolism, degradation of 
aromatic compounds, and microbial metabolism in 
diverse environments. In the Odoribacter genome, 
we found only the phenylalanine metabolism 
pathway with a relative abundance and coverage 
of 0.3456 ± 0.0675 and 17 ± 8.00, respectively. 
To determine if the metabolic pathways involved 
in the production of these phenolic metabolites are 
present in these members of fecal microbiota, we 
obtained a prediction of metagenome functional 
content from each genera using bioinformatic 
Phenolic metabolite Genus 
GLM 
coefficient 
Spearman rho 
coefficient 
p-Value q-Valuea) 
Catechol Paraprevotella −6.809 −0.822 0.001 0.012 
Catechol Oscillospira 3.297 0.685 0.012 0.087 
3-phenylpropionic acid Odoribacter 2.179 0.643 0.0278 0.093 
 Oscillospira Paraprevotella 
Pathways Abundance (%) Coverage (%) Abundance (%) Coverage (%) 
ko00361: Chlorocyclohexane and 
chlorobenzene  
degradation 
0.0497 ± 0.0485 5.701755 ± 1.5193 0.0343 ± 0.0339 5.2631 ± 2.8132 
ko00362: Benzoate degradation 0.4946 ± 0.1152 12.0000 ± 0.0000 0.1347 ± 0.1021 8.9999 ± 4.0158 
ko00621: Dioxin degradation 0.3339 ± 0.0948 7.6923 ± 0.0000 0.0112 ± 0.0234 5.7692 ± 7.9622 
ko00624: Polycyclic aromatic 
hydrocarbon degradation 
0.2293 ± 0.0489 2.9412 ± 0.0000 0.1718 ± 0.1274 3.3088 ± 1.0398 
ko00626: Naphthalene degradation 0.6160 ± 0.0604 13.6905 ± 1.3902 0.3072 ± 0.2328 16.0714 ± 3.3064 
ko00627: Aminobenzoate degradation 0.2922 ± 0.1044 7.3446 ± 0.8345 0.1308 ± 0.0980 7.86128 ± 2.5255 
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PICRUSt and HUMAnN tools [25, 26]. Thus, for 
Oscillospira, the functional category “Xenobiotics 
Biodegradation and Metabolism” contained the 
different pathways (benzoate degradation, 
naphthalene degradation, aminobenzoate 
degradation, polycyclic aromatic hydrocarbon 
degradation, dioxin degradation, and 
chlorocyclohexane and chlorobenzene 
degradation) where cathecol could be 
synthesized. 
 
4 DISCUSSION 
To our knowledge, this is the first study that 
evaluates the interaction between the gut 
microbiota composition, the nature of the 
biotransformation products of pomegranate 
polyphenols, and the modulation of other 
fermentation products such as fecal steroids and 
SCFAs. Regarding the fecal microbial metabolism 
of pomegranate polyphenols, the main 
metabolites detected in feces after the intervention 
period with PJ were urolithins, which is in 
accordance with previous works where the 
predominant fecal metabolites after 
ellagitanninrich food administration were urolithins 
[20]. Besides that, other phenolic metabolites such 
as 3-phenylpropionic acid and catechol have been 
described for the first time in human feces after 
pomegranate consumption which could be 
products from the anthocyanin colonic 
metabolism, as previously described in an in vitro 
colonic fermentation of a red wine extract [27] and 
cyanidin [28]. Hydroxytyrosol, which has normally 
been associated with the intake of virgin olive oil 
phenols [29], presented a significant increase in 
feces after PJ consumption in the present study. 
In a previous study, tyrosol appeared as a 
phenolic catabolite after an in vitro colonic 
fermentation of raspberry anthocyanins [28], so 
we hypothesize that hydroxytyrosol could also 
derive from pomegranate anthocyanins colonic 
metabolism. Related to the native structures of 
anthocyanins present in PJ, an important increase 
in their concentration in feces was observed after 
the intervention period with PJ, which indicated 
that these phenolic compounds could resist the 
digestion conditions and reach the large intestine. 
As demonstrated in the present study, urolithins, 
together with the phenolic acid metabolites and 
the non-degraded anthocyanins, are able to 
persist in the intestinal lumen and their contact 
with the gut epithelium and other compounds from 
diet could modulate some of the mechanisms 
involved in intestinal diseases The biological 
mechanisms proposed for these phenolic 
catabolites have been previously described, being 
the maintenance of adequate organic antioxidant 
status, the increase in antiinflammatory defense 
and the protection against intestinal pathologies 
[30,31]. Remarkable activities associated with 
antioxidant effects against radical oxygen species 
have been noticed for urolithins [32, 33], catechol 
[34], hydroxytyrosol [35], and cyanidin [36]. The 
capacity of phenolic compounds to regulate the 
signaling pathways, such as nuclear factor-kappa 
B (NF-kB) and mitogen-activated protein kinases, 
responsible for the regulation of proinflammatory 
modulators, has been the central topic in recent 
studies [36–39]. In the case of the fecal phenolic 
catabolites of pomegranate, urolithins A and C 
were effective in the inhibition of cytokine-induced 
proinflammatory markers TNF-alfa and IL-6, 
respectively, in THP-1 cell line-derived 
macrophages [38]. In addition, urolithin A was also 
effective at reducing the levels of PGE2, PAI-1, 
and IL-8 in parallel with the inhibition of colon 
fibroblast migration and monocyte adhesion to 
fibroblast [39]. Catechol also showed a reduction 
in the expression of adhesion molecules in a 
microvascular endothelial cell line [40], in addition 
to NF-κB factor inhibition [41]. Cytokine-stimulated 
human HT-29 cells treated with cyanidin 3-
glucoside also reduce the production of the 
proinflammatory mediators as well as the amounts 
of activated STAT1 [42]. Several studies based on 
rodents induced inflammatory bowel disease (IBD) 
highlighted the properties of rich-ellagic acid [43] 
and hydroxytyrosol [44] based diets, observing a 
reduction in intestinal inflammation promoters and 
decreasing colon epithelial damage. All these data 
suggest that, apart from the classical urolithins 
derived from pomegranate, other fecal metabolites 
described in the present study, such as phenolic 
acids or intact anthocyanins, might also be 
potential candidates to keep down the 
inflammatory response, especially in IBD 
pathogenesis. 
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As inflammation is a manifestation of oxidative 
stress and the intensity and duration of the 
inflammation process were also linked to the 
development of cancer [45, 46], the phenolic 
compounds detected in feces in our study could 
play a role in the prevention of the proliferation of 
cancer cells by control of oxidative stress and 
inflammation episodes. In this sense, several in 
vitro studies have described specific 
anticarcinogenic effects of urolithin A [47], 
catechol [48], and hydroxytyrosol [49]. Molecular 
mechanisms, such as inhibition of COX-2 in the 
case of 3-phenylpropionic acid [50] and down 
regulation of AP-1 and NF-κB activity by 
anthocyanins [36], were proposed as 
chemopreventive activity. We hypothesize that a 
broad spectrum of the latter-mentioned functions 
could occur, not only due to urolithins, but as a 
consequence of the synergistic combination of all 
the microbial phenolic metabolites detected after 
PJ intake in our study. The sustained intake of PJ 
could also potentiate their effects, increasing the 
time of their exposure to gut epithelium, with a 
consequent restriction of the oxidative damage 
and limiting the inflammatory episodes, 
contributing to reducing the risk of colon cancer 
and IBD development as well as to achieving 
remission of symptoms. 
There is limited information regarding the ability of 
dietary components, including phenolic 
compounds, to influence the gut microbial 
population. To address this, we investigated the 
influence of pomegranate intake on the 
composition of human fecal microbiota. Only one 
study has been performed in animals suggesting 
that pomegranate polyphenols can be very active 
at the gut level, modulating the gut microbial 
population [51]. Contrary to this study, we 
showed, using high-throughput sequencing, that a 
4 weeks daily ingestion of 200 mL of PJ that 
represented a daily intake of around 968 mg of 
pomegranate phenols (Supporting Information 
Table 1) did not significantly modify the 
composition of the individual gut microbiota in 
healthy humans. In another study, no differences 
in fecal microbiota profile were detected after 
consumption of a probiotic-enriched yogurt [52]. 
These results are in good agreement with our 
observations. This may be related to the microbial 
resilience reported under normal physiological 
conditions, which contributes to maintaining 
homeostasis in healthy adults [53]. Moreover, 
Espin et al. [54] observed the conversion of ellagic 
acid to urolithins in the jejunum of pigs fed with 
oak acorns (rich source of ellagitannins), 
associated with special ellagic acid converter 
microbial groups situated in upper segments of 
the gastrointestinal tract. Due to the difficulty in 
obtaining internal human samples, microbial 
analyses are normally carried out in feces, whose 
bacteria profile may differ from the microbial 
population of the intestinal mucosa and small 
intestine segments [55]. This could explain that no 
relation between the bacteria profile and urolithin 
production was inferred in our study. 
However, we identified catechol that was 
positively correlated with Oscillospora genus and 
negatively correlated with Paraprevotella, while 3-
phenylpropionic acid showed a positive correlation 
with Odoribacter genus. Since none of these 
genera are abundant members of the fecal 
microbiota, they were poorly described in human 
studies and scarce information is available in 
terms of reference genomes. However, by 
bioinformatics we detected several pathways 
involved in the production of catechol in 
Oscillospira. Thus, the positive correlation 
between this genus and catechol in feces 
indicates that Oscillospira could be involved in the 
conversion of pomegranate phenolics into 
catechol based on metabolic predictions and, 
therefore, volunteers presenting higher 
proportions of this specific genus could also 
present higher concentrations of catechol. Despite 
the fact that Paraprevotella presented the same 
pathway profile as Oscillospira, we found a 
negative correlation between the fecal catabolite 
and this genus. This result may indicate 
differences in enzymatic com-position within the 
catechol pathways involved. Thus, this bacterium 
could transform the phenolic compounds from PJ 
in a different manner, yielding other products. 
Furthermore, Ododribacter genus was positively 
correlated with 3-phenylpropionic acid. We found 
that this compound is only synthesized in the 
phenylalanine metabolism pathway, as occurred 
in Odoribacter splanchnicus, whose genome has 
been recently sequenced [56]. Further studies are 
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needed to obtain direct evidence of metabolic 
capabilities of these genera. 
The modulation observed in the sterols profile and 
the slight changes in BAs and SCFAs might mean 
that pomegranate phenolic compounds are not 
directly involved in their formation or excretion rate 
but may interfere with the activity of some 
microbial enzyme, as has been reported after fiber 
fermentation [57]. This may explain the 
differences among molar ratios of butyrate, less 
conversion of secondary BAs, and less conversion 
of cholesterol to coprostanol. According to recent 
studies [57], these changes in the propor-tions 
and profile of fecal SCFAs, BAs, and sterols could 
contribute to the health status of the gut. Butyric 
acid, the main energy source of intestinal cells, 
supports metabolic health by preventing the 
development of abnormal intestinal cells as well 
as by the selective induction of apoptosis of 
cancer cells [58]. High fecal secondary BAs and 
coprostanol enhance the lumen toxicity, which 
increased the incidence of colorectal cancer, and 
it is therefore expected that the change in the 
profile of these compounds after PJ intake could 
potentially exert protective action against colon 
cancer. 
In conclusion, although the inclusion of PJ in the 
diet did not significantly alter the gut microbiota 
composition, specific genera, as Oscillospira and 
Odoribacter, could contribute to the generation of 
potential health-promoting phenolic metabolites in 
the individuals that harbor these bacteria. Besides 
that, we found that the inclusion of PJ in the diet 
modulates the concentration in feces of fecal 
metabolites of interest, as SCFAs, sterols, and 
secondary BAs. Further research should be 
undertaken to unravel the bacterial mechanisms 
involved in metabolite production. The 
comprehensive identification of bacteria groups 
associated with certain food components, such as 
the case of phenolic compounds, is a pending 
task and must be considered essential to establish 
dietetic recommendation, functional food design, 
or provide information to develop a therapeutic 
target to prevent or treat intestinal diseases. 
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ADDITIONAL INFORMATION 
 
Table 1. Phenolic composition of pomegranate juice (PJ)1 
Phenolic compounds Cumulative daily 
intake (mg / 200 mL 
PJ) 
Ellagic acid and ellagitannins (Total) 878.9  75.13 
Ellagic acid 2.28  0.44 
Ellagic acid pentoside 48.21  4.15 
Ellagic acid deoxyhexoside 80.69  7.18 
Ellagic acid hexoside 144.04  10.29 
Valoneic acid bilactone 9.91  1.37 
Dehydrogalloyl HHDP hexoside 3.16  0.52 
Galloyl HHDP glucoside 39.18  4.52 
Bis-HHDP glucoside 78.50  6.08 
Digalloyl HHDP glucoside 12.95  2.26 
Ellagic acid derivate 75.36  5.04 
Punigluconin 61.42  6.05 
2-O-galloylpunicalin 5.42  1.07 
Tris-galloyl HHDP glucose isomer 21.25  2.18 
Punicalagin A, B, isomer 86.95  7.82 
Di-(HHDP galloyl glucoside) 
pentoside 
0.48  0.05 
Digalloyl tri-HHDP diglucoside 
isomer 
87.27  2.15 
Brevifolin carboxylic acid 3.04  0.77 
Galloyl HHDP gluconate isomer 97.59  9.51 
Punicalin 21.15  3.68 
Phenolic acids and its derivates 
(Total) 
41.5  5.56 
Malic acid 6.94  1.19 
p-hydroxybenzoic acid 0.13  0.16 
Hydroxybenzoic acid hexoside 1.12  0.17 
Protocatechuic acid 0.03  0.03 
Protocatechuic acid hexoside 0.17  0.27 
Protocatechuic acid pentoside 0.20  0.01 
Citric acid 12.4  1.01 
Chlorogenic acid glucoside 0.03  0.01 
Gallic acid 0.20  0.05 
Gallic acid glucoside 2.24  0.68 
Gallic acid diglucoside 0.04  0.04 
p-Coumaric acid 0.02  0.01 
Coumaric acid glucoside 1.10  0.20 
Coumaric acid derivate 3.68  0.13 
Caffeic acid glucoside 2.75  0.68 
Vanillic acid hexoside 1.60  0.22 
Vanillic acid derivate 6.06  0.45 
Ferulic acid hexoside 2.13  0.08 
Ferulic acid derivate 0.47  0.00 
Ferulic acid hexoside derivate 0.21  0.16 
Anthocyanins (Total) 38.0  16.2 
Cyanidin-3-O-glucoside 1.29  0.20 
Cyanidin-3,5-O-diglucoside 26.7  7.8 
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Cyanidin pentoside 0.02  0.00 
Cyanidin pentoside hexoside 0.05  0.02 
Delphinidin-3-O-glucoside 0.03  0.02 
Delphinidin-3,5-O-diglucoside 0.13  0.03 
Pelargonidin-3-O-glucoside 0.41  0.33 
Pelargonidin-3,5-O-diglucoside 9.30  7.80 
Pelargonidin pentoside hexoside 0.01  0.01 
(epi)afzelechin cyanidin hexoside 0.01  0.00 
Lignans (Total) 4.21  0.45 
Pinoresinol 0.64  0.08 
Secoisolariciresinol glucoside 2.65  0.10 
Cyclolariciresinol 0.92  0.27 
Flavonols (Total) 3.39  1.07 
Kaempferol glucoside 0.62  0.43 
Kaempferol rutinoside 0.23  0.08 
Kaempferol coumaroyl glucoside 0.28  0.34 
Mirycetin rhamnoside 0.01  0.00 
Mirycetin glucoside 0.21  0.14 
Quercetin rutinoside (rutin) 0.01  0.00 
Quercetin coumaroyl glucoside 0.01  0.00 
Syringetin glucoside 2.02  0.07 
Flavan-3-ols (Total) 1.19  0.64 
Catechin 0.31  0.19 
Epicatechin 0.28  0.11 
Dimer 0.47  0.26 
Trimer 0.13  0.08 
Flavanones (Total) 0.50  0.10 
Naringenin 0.19  0.01 
Eriodictyol glucoside 0.11  0.07 
Phenolic aldehydes  
Syringaldehyde  0.38  0.11 
Dihydrochalcones  
Phloretin glucoside 0.20  0.02 
Total phenolic compounds 968.00  99.36 
1 All values are means  SDs (n=5) 
HHDP: hexahydroxydiphenic acid 
 
 
Table 2. Calculated daily nutrient composition of the volunteers’ diets before (Pre) and after (Post) the 4 
wk of the pomegranate juice (PJ) supplementation (n=12)1. 
 
Diet basic composition Pre Post 
Total energy (kcal) 2263 ± 522 2263 ± 522 
Total protein (g) 88.1 ± 22.2 88.1 ± 22.2 
Total carbohydrates (g) 243 ± 37.3 243 ± 37.2 
Fiber (g) 27.2 ± 9.7 27.23 ± 9.72 
Total fat (g) 84.1 ± 47.4 84.08 ± 47.38 
Saturated fat 34.5 ± 14.2 34.53 ± 14.16 
Monounsaturated fat (g) 39.5 ± 14.0 39.48 ± 14.01 
Polyunsaturated fat (g) 10.9 ± 3.7 10.94 ± 3.68 
Cholesterol (mg) 333 ± 215 333.3 ± 215.1 
Total phenolic compounds (mg) 1927 ± 346 1928 ± 345 
1 All values are means SDs 
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Methods 
 
Chromatographic analysis of phenolic 
metabolites in feces 
 
The chromatographic analysis of phenol 
metabolites was performed by a Waters Acquity 
Ultra-PerformanceTM liquid chromatography 
system (Waters, Milford, MA, USA), equipped with 
a binary pump system (Waters, Milford, MA, 
USA). The chromatographic column was an 
Acquity BEH C18 (100 mm x 2.1 mm i.d.) with a 
1.7 µm particle size (Waters, Milford, MA, USA). A 
binary mobile phase with a gradient elution was 
used. For the analysis of anthocyanins, eluent A 
was Milli-Q water:acetic acid (90:10, v/v) and 
eluent B was acetonitrile. The flow-rate was 0.4 
mL/min. The gradient was performed as follows: 
0-10 min, 5-35%B; 10-10.1 min, 35-80%B; 10.1-
11 min, 80%B isocratic; 11-11.1 min, 80-5%B; 
11.1-12.5 min, 5%B isocratic. In the case of the 
other phenolic compounds, the eluent A was Milli-
Q water:acetic acid (99.8:0.2, v/v) and eluent B 
was acetonitrile. The flow rate was 0.3 mL/min. 
The gradient was performed as follows: 0-5 min, 
5-10%B; 5-10 min, 10-12.4%B; 10-18 min, 12.4-
28%B; 18-23 min, 28-100%B; 23-25.5 min, 100 
%B isocratic; 25.5-27 min, 100-5%B; 27-30 min, 
5%B isocratic. The injection volume was 2.5 µL. 
The tandem mass spectrometry (MS/MS) analysis 
were carried out on a triple quadrupole detector 
(TQD) mass spectrometer (Waters, Milford, Ma, 
USA) equipped with a Z-spray electrospray 
interface. The analysis was done in the positive 
ion mode for anthocyanins and urolithins and in 
the negative ion mode for the rest of phenolic 
compounds and the data was acquired with the 
selected reaction monitoring mode (SRM) (Table 
1SM). The MS/MS parameters were as follows: 
capillary voltage, 3 kV; source temperature, 
150ºC; cone gas flow rate, 80 L/h and 
desolvatation gas flow rate, 800 L/h; desolvatation 
temperature, 400ºC Nitrogen (>99% purity) and 
argon (99% purity) were used as nebulizing and 
collision gases, respectively. Cone voltages and 
collision energies were optimized for each analyte 
by injection of each standard compound in a 
mixture of acetonitrile/water (50:50, v/v) at a 
concentration of 10 mg/L. Two transitions were 
studied for each phenolic compound. The most 
abundant transition was used for quantification, 
while the second most abundant was used for 
confirmation purposes. The dwell time established 
for each transition was 30 ms. Data acquisition 
was carried out with the MassLynux v 4.1 
software. The concentration of each compound 
was measured by using an external calibration 
curve produced with the use of authentic 
standards (Table 1SM). 
Ellagic acid, punicalagin, p-coumaric acid, vanillic 
acid, kaempferol, p-hydroxyphenylacetic acid, 
phenylpropionic acid,  3-(4-
hydroxyphenyl)propionic acid and 3-(2,4-
dihydroxyphenyl)propionic acid were purchased 
from Fluka (Buchs, Switzerland); protocatechuic 
acid, catechin, epicatechin, p-hydroxybenzoic 
acid, catechol, ferulic acid, 3,4-
dihydroxyphenylacetic acid,  phenylacetic acid 
and hippuric acid from Sigma Aldrich (St. Louis, 
MO, USA); caffeic acid, rutin, myricetin, quercetin, 
dimer B2, hydroxytyrosol, tyrosol, cyanidin-3-O-
glucoside and cyanidin-3,5-O-diglucoside from 
Extrasynthese (Genay, France). Gallic acid and 
malic acid were purchased from Panreac 
(Barcelona, Spain) and pinoresinol and 
secolariciresinol were purchased from Arbonova 
(Turku, Finland). Standards of urolithin A 
(dihydroxy urolithin), urolithin B (hydroxy urolithin) 
and urolithin C (trihydroxy urolithin) were kindly 
provided by Dr. Thasana from Chulabhorn 
Research Institute, Laksi, Bangkok (Nealmongkol 
et al., 2013*). These standard phenolic 
compounds were prepared in methanol. 
p-hydroxybenzoic acid, protocatechuic acid, p-
coumaric acid, vanillic acid, gallic acid, caffeic 
acid, ferulic acid, quercetin, kaempferol, catechin 
epicatechin, ellagic acid, myricetin, pinoresinol, 
seicolariciresinol, dimer B2, rutin, punicalagin, 
cyanidin-3-O-glucoside and cyanidin-3,5-O-
diglucoside were quantified using their own 
calibration curve. The phenol-glycoside 
compounds were tentatively quantified using the 
calibration curves of their respective aglycones. 
Syringaldehyde was tentatively quantified with the 
calibration curve of gallic acid. Chlorogenic acid 
was tentatively quantified as caffeic acid. 
Pinocebrin, naringenin, phloretin and eriodictyol 
were tentatively quantified as quercetin.  
(*) Nealmongkol P, Tangdenpaisal K, 
Sitthimonchai S, Ruchirawat S, Thasana N. Cu(I)-
mediated lactone formation in subcritical water: A 
benign synthesis of benzopyranones and 
urolithins A-C. Tetrahedron 2013;69:9277-83 
Ellagitannins were tentatively quantified as ellagic 
acid and the anthocyanins glucoside and 
diglucoside were tentative quantified as cyanidin-
3-O-glucoside and cyanidin-3,5-O-diglucoside, 
respectively. Urolithins tetrahydroxy urolithin and 
pentahydroxy urolithins were tentatively quantified 
as trihydroxy urolithins. 
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Table 1 Method. Optimized SRM conditions and commercial standards used for the quantification analysis 
of the studied phenolic compounds and their colonic fermentation products in feces.  
Phenolic compound 
MW  
(g/mol) 
SRM quantification 
Standard used for 
quantification 
Transition 
Cone voltage 
(V) / Collision 
energy (eV) 
 
Anthocyanins 1     
Pelargonidin-3-O-glucoside 434 433  271 40 / 20 Cyanidin-3-O-glucoside 
Pelargonidin pentoside 434 403  271 40 / 15 Cyanidin-3-O-glucoside 
Pelargonidin-3,5-O-diglucoside 594 595  271 40 / 30 Cyanidin-3,5-O-diglucoside 
Pelargonidin pentoside hexoside 564 565  271 40 / 30 Cyanidin-3-O-glucoside 
(epi)afzelechin pelargonidin hexoside 704 705  543 40 / 20 Cyanidin-3-O-glucoside 
(epi)gallocatechin pelargonidin hexoside 736 737  575 40 / 30 Cyanidin-3-O-glucoside 
Cyanidin pentoside 418 419  287 40 / 20 Cyanidin-3-O-glucoside 
Cyanidin-3-O-glucoside 448 449  287 40 / 20 Cyanidin-3-O-glucoside 
Cyanidin-3,5-O-diglucoside 610 611  287 40 / 30 Cyanidin-3,5-O-diglucoside 
Cyaniding pentoside hexoside 580 581  287 40 / 35 Cyanidin-3-O-glucoside 
Cyanidin rutinoside 594 595  287 40 / 25 Cyanidin-3-O-glucoside 
Delphinidin-3-O-glucoside 464 465  303 40 / 20 Cyanidin-3-O-glucoside 
Delphinidin-3,5-O-diglucoside 626 627  303 40 / 30 Cyanidin-3,5-O-diglucoside 
(epi)afzelechin cyanidin hexoside 720 721  559 40 / 25 Cyanidin-3-O-glucoside 
Phenolic acids and its derivates 2     
Malic acid 134 133  115 20 / 10 Malic acid 
p-hydroxybenzoic acid 138 137  93 30 / 15 p-hydroxybenzoic acid 
Hydroxybenzoic acid hexoside 300 299  137 40 / 15 p-hydroxybenzoic acid 
Protocatechuic acid 154 153  109 45 / 15 Protocatechuic acid 
Protocatechuic acid hexoside 316 315  153 45 / 15 Protocatechuic acid 
Protocatechuic acid pentoside 286 285  153 40 / 25 Protocatechuic acid 
Citric acid 192 191  111 40 / 10 Malic acid 
Chlorogenic acid 516 515  353 60 / 15 Caffeic acid 
Gallic acid 170 169  125 35 /10 Gallic acid 
Gallic acid glucoside 332 331  169 35 / 15 Gallic acid 
Gallic acid diglucoside 484 483  331 40 / 20 Gallic acid 
p-coumaric acid 164 163  119 35 / 10 p-coumaric acid 
Coumaric acid glucoside 326 325  145 40 / 15 p-coumaric acid 
Coumaric acid derivate 430 429  163 40 / 15 p-coumaric acid 
Caffeic acid 180 179  135 35 / 15 Caffeic acid 
Caffeic acid glucoside 342 341  179 60 / 20 Caffeic acid 
Vanillic acid 168 167  123 30 / 10 Vanillic acid 
Vanillic acid hexoside 330 329  167 40 / 15 Vanillic acid 
Vanillic acid derivate 364 363  167  40 /15 Vanillic acid 
Ferulic acid 194 193  134 30 / 15 Ferulic acid 
Ferulic acid hexoside 356 355  193 40 / 25 Ferulic acid 
Ferulic acid derivate 390 389  193 40 / 20 Ferulic acid 
Ferulic acid hexoside derivate 450 449  355 40 / 20 Ferulic acid 
Phenolic aldehydes     
Syringaldehyde  182 181  166 35 / 10 Gallic acid 
Flavan-3-ols 2     
Catechin 290 289  245 45 / 10 Catechin  
Epicatechin  290 289  245  45 / 10 Epicatechin  
Dimer  578 577  289 40 / 20 Dimer B2 
Trimer  866 865  287 60 / 30 Catechin 
Flavonol 2     
Kaempferol  286 285  151 35 / 15 Kaempferol  
Kaempferol glucoside 448 447  284 45 / 15 Kaempferol 
Kaempferol rutinoside 594 593  285 50 / 25 Kaempferol 
Kaempferol coumaroyl glucoside 594 593  285  Kaempferol 
Mirycetin  318 317  179 40 / 15 Myricetin  
Mirycetin rhamnoside  464 463  316 50 / 25 Myricetin  
Mirycetin glucoside 480 479  316 45 / 20 Myricetin 
Quercetin  302 301  151 40 / 15 Quercetin  
Quercetin rutinoside (rutin) 610 609  300 40 / 20 Rutin  
Quercetin coumaroyl glucoside 610 609  463 40 / 20 Quercetin 
Syringetin  346 345  315 60 / 25 Quercetin 
Syringetin glucoside 508 507  327 60 / 30 Quercetin 
Flavanone 2     
Pinocembrin 256 255  213 40 / 25 Quercetin 
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MW: Molecular weight. Ionisation mode: 1 negative mode, 2 positive mode. HHDP: hexahydroxydiphenic acid  
 
 
 
 
 
 
 
 
 
Naringenin  272 271  151 40 / 15 Quercetin 
Eriodictyol glucoside 450 449  287 45 / 10 Quercetin 
Dihydrochalcone 2     
Phloretin hexoside 436 435  273 40 / 15 Quercetin 
Lignans 2     
Pinoresinol  358 357  151 40 / 10 Pinoresinol 
Secoisolariciresinol  362 361  346 50 / 15 Secoisolariciresinol 
Secoisolariciresinol glucoside 524 523  361  Secoisolariciresinol 
Cyclolariciresinol  522 521  359 40 / 25 Secoisolariciresinol 
Ellagic acid and ellagitannins 2     
Ellagic acid 302 301  245 45 / 25 Ellagic acid 
Ellagic acid pentoside 434 433  300 40 / 30 Ellagic acid 
Ellagic acid deoxyhexoside 448 447  301 40 / 25 Ellagic acid 
Ellagic acid hexoside 464 463  301 40 / 25 Ellagic acid 
Dimethyl ellagic acid 330 329  285 45 / 15 Ellagic acid 
Valoneic acid bilactone 470 469  425 60 / 20 Ellagic acid 
Dehydrogalloyl HHDP hexoside 616 615  301 60 / 25 Ellagic acid 
Galloyl HHDP glucoside 634 633  301 60 / 30 Ellagic acid 
Bis-HHDP glucoside 784 783  301 60 / 30 Ellagic acid 
Digalloyl HHDP glucoside 786 785  301 70 / 35 Ellagic acid 
Ellagic acid derivative  800 799  301 60 / 25 Ellagic acid 
Punigluconin  802 801  301 50 / 30 Ellagic acid 
2-O-galloylpunicalin 934 933  721 70 / 35 Ellagic acid 
Tris-galloyl HHDP glucose isomer 952 951  301 65 / 35 Ellagic acid 
Punicalagin A, B, isomer 1084 1083  601 70 / 40 Punicalagin 
di(HHDP galloil glu) pentoside 1416 1415  1397 70 / 35 Ellagic acid 
Digalloyl tri-HHDP diglucoside isomer 1568 1567  765 70 / 35 Ellagic acid 
Brevifolin carboxylic acid 292 291  247 45 / 20 Ellagic acid 
Galloyl HHDP gluconate isomer 650 649  301 55 / 25 Ellagic acid 
Punicalin  782 781  601 50 / 35 Punicalagin  
Galloyl bis HHDP hexoside 936 935  633 60 / 25 Ellagic acid 
Castalagin derivate 966 965  933 60 / 25 Ellagic acid 
Urolithins 1     
Hydroxy urolithin 212 213  141 40 / 20 Hydroxy urolithin 
Di-hydroxy urolithin 228 229  157 40 / 20 Di-hydroxy urolithin 
Tri-hydroxy urolithin 244 245  155 40 / 30 Tri-hydroxy urolithin 
Tetra-hydroxy urolithin 260 261  171 40 / 25 Tri-hydroxy urolithin 
Penta-hydroxy urolithin 278 277  259 40 / 30 Tri-hydroxy urolithin 
Other fermentation products 2     
Catechol  110 108.9  90.9 40 / 15 Catechol 
Phloroglucinol   126 125  83 20 / 10 Catechol 
Tyrosol  138 137  106 40 / 10 Tyrosol  
Hydroxytyrosol  154 153  123 35/10 Hydroxytyrosol  
Hippuric acid 179 178  134 40 / 10 Hippuric acid 
Hydroxyhippuric acid 195 194  100 40 / 10 Hippuric acid 
Phenylacetic acid 136 135  91 20 / 5 Phenylacetic acid 
p-Hydroxyphenylacetic acid 152 151  107 20 / 10 p-Hydroxyphenylacetic acid 
3,4-Dihydroxyphenylacetic acid 168 167  123 20 / 10 3,4-Dihydroxyphenylacetic 
acid 
Phenylpropionic acid 150 149  105 20 / 5 Phenylpropionic acid 
3-(4-Hydroxyphenyl)propionic acid 166 165  121 20 / 10 3-(4-Hydroxyphenyl)propionic 
acid 
3-(2,4-Dihydroxyphenyl)propionic acid 182 181  137 20 / 15 3-(2,4-
Dihydroxyphenyl)propionic 
acid 
Unkown  334 333  259 40 / 20 Hydroxytyrosol  
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Table 2 Method. Retention time (min), linearity, calibration curves, LOQs and LODs of the standard 
phenolic compounds used to quantity the pomegranate juice and the generated fermentation metabolites 
 
Phenolic compound 
tr 
(min) 
Linearity 
(mg/l) 
Calibration curve 
LOQ 
(µg/l) 
LOD 
(µg/l) 
Sample 
matrix 
Anthocyanins       
Cyanidin-3,5-O-diglucoside 0.82 0.01-12.5 y = 85913x – 131.25 10 3.5 PJ 
Cyanidin-3-O-glucoside 1.85 0.001-
1.25 
y = 716214x – 141.1 1 0.4 PJ 
Rest of phenolic 
compounds 
      
Malic acid 0.94 0.099-9.9 y = 4536.8x – 642.5 99 35 PJ 
Gallic acid 1.51 0.009-9 y = 19793.3x – 103.6 9 3 PJ, 
feces 
Protocatechuic acid 2.35 0.059-5.9 y = 3708.8x – 246.9 59 20 PJ, 
feces 
Hydroxytyrosol  2.72 0.01-
10.00 
y = 3787.3x – 172.9 10 3 Feces  
3,4-dihydroxyphenylacetic 
acid  
3.27 0.01-
10.00 
y = 19717.0x – 241.9 10 3 Feces  
Tyrosol  4.05 0.098-9.8 y = 995.7x + 348.0 98 30 Feces  
p-hydroxybenzoic acid 4.25 0.001-
10.5 
y = 8142.7x – 23.4 1 0.3 PJ, 
feces 
Punicalagin  4.75 30-1000 y = 231.8x – 7255.3 30000 10000 PJ 
p-hydroxyphenylacetic acid 4.95 0.017-1.7 y = 13972.7x + 222.9 17 6 Feces  
Catechin  5.01 0.098-10 y = 648.5x – 81.9 98 32.5 PJ 
3-(2,4-
dihydroxyphenyl)propionic 
acid 
5.16 0.009-10 y = 32136.3x – 99.9 9 2.5 Feces  
Vanillic acid 5.49 0.0099-10 y = 4565.3x + 1742.8 9.9 3.0 PJ 
Caffeic acid 5.67 0.009-5.0 y = 67897.3x – 792.5 9 3 PJ 
Dimer B2 6.35 0.1-10 y = 1641.9x – 355.7 100 35 PJ 
Epicatechin  7.21 0.098-10 y = 814.7x – 184.6 98 30 PJ 
3-(4-hydroxyphenyl)propionic 
acid 
7.64 0.018-20 y = 7496.7x + 92.2 18 5 Feces  
p-coumaric acid 8.57 0.009-10 y = 80072.0x – 5.7 9 3 PJ, 
feces 
Ferulic acid 10.60 0.0099-10 y = 17006.7x – 33.9 9.9 3.0 PJ 
Ellagic acid 12.02 0.99-10 y =344.9x – 65.3 990 350 PJ 
Rutin  12.25 0.0008-8 y = 34110.0x + 642.1 0.8 2.5 PJ 
Phenylacetic acid 12.47 0.002-17 y = 28169.7x + 1006.0 2 0.6 Feces  
Urolithin C 13.53 0.0007-2 y = 100772x + 231.5 0.7 0.25 Feces  
Myricetin  15.22 0.06-6 y = 4473.3x – 625.5 60 22 PJ 
Seicolariciresinol  15.85 0.099-10 y = 1943.4 + 271.8 99 35 PJ 
Urolithin A 16.64 0.008-10 y = 24816.7x + 3098.9 8 2.5 Feces  
Phenylpropionic acid 17.06 0.10-10 y = 560.6x + 288.5 100 30 Feces  
Quercetin  18.08 0.007-7 y = 8978.7x + 2164.7 7 2.5 PJ 
Pinoresinol  18.62 0.009-9 y = 4544.7x + 87.4 9 3 PJ 
Urolithin B 19.96 0.016-30 y = 6878.7x + 769.1 16 5.0 Feces  
Kaempferol  20.07 0.05-5.64 y = 1499.7x + 291.5 50 15 PJ 
tr: retention time. LOQ: quantification limit. LOD: detection limit 
PJ: pomegranate juice 
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Figure 1Method. Extracted ion chromatograms of the anthocyanins determined in PJ by UPLC-MS/MS. 
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Figure 2Method. Extracted ion chromatograms of the main phenolic compounds (the rest of phenolic 
compounds) determined in PJ by UPLC-MS/MS. 
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Figure 1S: GC/FID chromatogram of the SCFA (Acetic acid, propionic acid, butyric acid, isobutyric acid, 
isovaleric acid, valeric acid and 4-methylvaleric acid as internal standard, IS) quantified in feces.  
 
 
 
 
Figure 2S: GC/FID chromatogram of sterols (cholesterol, coprostanol, cholestenol, cholestanone and α-
cholestane as internal standard, IS) and bile acids (cholic acid, deoxycholic acid, chenodeoxycholic acid, 
lithocholic acid and 5β-cholanic acid as internal standard, IS) 
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STABILITY AND METABOLISM OF ARBUTUS UNEDO BIOACTIVE COMPOUNDS 
(PHENOLICS AND ANTIOXIDANTS) UNDER IN VITRO DIGESTION AND COLONIC 
FERMENTATION 
Juana I. Mosele, Alba Macià, Mari-Paz Romero, María-José Motilva* 
Food Technology Department, Agrotecnio Research Center, University of Lleida, Av/Alcalde Rovira Roure 191, 25198-
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Abstract 
The natural antioxidants of Arbutus unedo highlight the importance of this fruit as natural source of 
bioactive compounds. In the present study, to evaluate the stability of phenolic compounds, ascorbic 
acid and fat-soluble antioxidants (α-tocopherol, β-carotene and lutein), in vitro gastrointestinal digestion 
was applied to Arbutus unedo fruit. After that, the non-absorbable fraction was anaerobically incubated 
with human faeces and the metabolic pathway for gallotannins, ellagitannins, flavan-3-ols and 
anthocyanins from Arbutus unedo fruit was proposed. The results showed that the presence of pectin 
from the fruit hampered the solubilisation of the phenolic compounds (with exception of gallic and ellagic 
acids) and fat-soluble vitamins during gastric digestion. Degradation of pectin-gel during the duodenal 
digestion favoured the release of the phenolic compounds and fat-soluble antioxidants to the media. The 
catabolic activity of human microbiota led to the generation of a wide range of simple phenols, such as 
p-hydroxybenzoic acid and catechol, derived from the catabolism of gallotannins, ellagitannins, flavan-3-
ols and anthocyanins. 
 
Keywords: antioxidants; Arbutus unedo; in vitro fermentation; in vitro gastrointestinal digestion; phenolic 
compounds 
 
1. INTRODUCTION  
Over recent years, a general scientific consensus 
has supported the association between the high 
intake of fruit and vegetables and the lower risk of 
chronic diseases; particularly, cardiovascular 
diseases (CVD), type-2 diabetes, and certain 
cancers (Mohamed, 2014). As a result, increasing 
fruit and vegetable consumption became a priority 
for international organisations as well as national 
governments, which have promoted different 
awareness campaigns. Fresh fruit constitute an 
important dietary source of such natural 
antioxidants as vitamins, fibre and certain minor 
compounds often known as phytochemicals 
(including phenolic compounds) or secondary 
plant metabolites, which are potentially associated 
with the prevention of chronic diseases (Del Rio et 
al., 2013). In response to unfavourable 
environmental conditions and to ensure survival, 
plants synthesize an important amount and variety 
of secondary metabolites, which participate in 
numerous mechanism of protection. Adaptation to 
the ecosystem may involve competition with other 
plants, soil nutrient availability, droughts or 
weather fluctuations, mould or bug infestation, 
amount of accessible sunlight and other factors 
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(Quideau, Deffieux, Douat-Casassus & Pouységu 
et al., 2011).  
As result of these resilient and adaptive 
mechanisms, a wide range of protective 
compounds with antioxidant properties are 
accumulated in plants and fruits. So, the named 
“superfruits” are becoming increasingly popular 
among consumers for their accumulated 
phytochemicals that can be included in the diet. 
The promotion of their consumption could provide 
the food industry with possible new products and 
ingredients, while also stimulating local 
production. A. unedo L. (strawberry tree) is a 
Mediterranean shrub with a circum-Mediterranean 
Sea distribution, being found in western, central 
and southern Europe, north-eastern Africa 
(excluding Egypt and Libya), the Canary Islands 
and western Asia (Miguel, Faleiro, Guerreiro, & 
Antunes, 2014). The fruit of the A. unedo is 
generally used for preparing alcoholic beverages 
(wines, liqueurs and brandies), jams, jellies and 
marmalades, and less frequently eaten fresh 
(Santo, Galego, Gonçalves, & Quintas, 2012). It 
can also be added to yoghurts either in pieces or 
as flavours and be used, like other berries, in 
confectionery, such as for pie and pastry fillings 
and cereal products, among other applications 
(Miguel et al., 2014). 
Several components belonging to diverse phenolic 
groups have been reported in the fruit of A. unedo. 
Gallotannins, such as mono-, di-, and tri-O-
galloylshikimic acids and mono-, di-, and tri-O-
galloylquinic acids have been described as being 
exclusive to this fruit, which gives it an extra 
added value. Other phenolic groups, such as 
flavan-3-ols, ellagitannins and anthocyanins, have 
also been described in A. unedo fruit in 
considerable amounts (Guimarães et al., 2013). 
This complex phenolic composition of A. unedo 
seems to be connected to antioxidant and 
anticarcinogenic effects (Del Rio et al., 2013). In 
addition, the particular composition in gallotannins 
could convert this singular fruit into an interesting 
source of antiviral agents against influenza (Ge et 
al., 2014; Saha et al., 2010) and HIV (Junior et al., 
2013). Besides phenolic compounds, A. unedo 
fruit also contains considerable amounts of other 
antioxidants, such as ascorbic acid, and fat-
soluble antioxidants like α-tocopherol, β-carotene 
and lutein (Oliveira et al., 2011; Pallauf, Rivas-
Gonzalo, del Castillo, Cano, & de Pascual-Teresa, 
2008), increasing its interest as a dietary source of 
multiple bioactivities related to the reduction of 
CVD risk. 
From a nutritional and commercial point of view, 
the chemical composition of a fresh fruit is an 
important quality attribute. However, the total 
phenolic compounds and natural antioxidants 
present in food do not always reflect the total 
amount that can be absorbed and metabolized by 
the human body (bioavailability). During digestion, 
food components are constantly exposed to 
different physical (temperature), chemical (pH) 
and biochemical (enzymes) conditions. As a 
consequence of this, the bioavailability and 
bioactivity of the potential food bioactive 
compounds are affected (Hur, Lim, Decker, & 
McClements, 2011). Besides the stability, it is 
crucial to understand how the complex phenolic 
compounds found in A. unedo fruit, mainly 
gallotannins and ellagitannins, are released from 
the fruit matrix, solubilised in the digesta media 
and finally absorbed through the intestinal 
epithelium. These changes are a key point for 
elucidating the capability of food bioactive 
phytochemicals to be used by the human body, 
which is a key condition to achieve the levels at 
which health benefits have been observed. 
Moreover, part of the ingested phenolic 
compounds are not absorbed in the small intestine 
and pass to the large intestine, where the 
structural modifications promoted by gut 
microbiota result in the generation of specific 
active metabolites (González-Barrio, Edwards, & 
Crozier, 2011; Mosele, Macià, Romero, Motilva, 
Rubiò, 2015). Although A. unedo fruit has been 
proposed as a potential source of bioactive 
compounds, there is no information about their 
stability and changes in their molecular structure 
during the different steps of gastrointestinal 
digestion and subsequent colonic fermentation. In 
order to predict the stability of phenolic 
compounds, ascorbic acid and fat-soluble 
antioxidants (α-tocopherol, β-carotene and lutein), 
in vitro gastrointestinal digestion was carried out. 
As the large intestine is an active place where 
phytochemicals could be transformed and 
absorbed, it is also important to consider this 
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segment in in vitro assays. Therefore, the non-
absorbable fraction obtained from the in vitro 
gastrointestinal digestion was anaerobically 
incubated with human faeces and the metabolic 
pathway for gallotannins, ellagitannins, flavan-3-
ols and anthocyanins from A. unedo fruit was 
proposed. 
 
2. MATERIALS AND METHODS   
2.1. Standards and reagents 
Ultrapure water was obtained from a Milli-Q water 
purification system (Millipore Corp., Bedford, MA, 
USA). Alpha-amylase, pepsin, pancreatin, bile 
salts, KH2PO4 and Na2HPO4·2H2O were obtained 
from Sigma Aldrich (St. Louis, MO, USA). 
Methanol, ethanol, hexane (all HPLC-grade), 
hydrochloric acid (37%), glacial acetic acid 
(99.8%) and methyl-terta-butyl-ether (MTBE) 
were from Scharlau S.L. (Barcelona, Spain). 
Trifluoroacetic acid (TFA), NaHCO3, KCl, CaCl2, 
MgCl2·6H2O, FeSO4·7H2O, MnSO4·H2O, 
ZnSO4·7H2O, CoCl2·6H2O, Mo(NH4)6O24·4H2O, 
and CuSO4·5H2O, NaCl, Na2SO4·10H2O were 
purchased from Pancreac Quimica S.A. 
(Barcelona, Spain). Acetonitrile (HPLC-grade) 
was purchased from Romil (Teknokroma, 
Barcenola, Spain)  
For the identification and quantification of the 
phenolic compounds and antioxidants from A. 
unedo fruit, different commercial standards were 
used. Ellagic acid, 3-(2,4-dihydroxyphenyl) 
propionic acid and β-carotene were purchased 
from Fluka (Buchs, Switzerland); p-
hydroxybenzoic acid, protocatechuic acid, 
catechin, epicatechin, α-tocopherol, lutein, 3’,4’-
(dihydroxyphenyl)acetic acid, p-(hydroxyphenyl) 
acetic acid, phenylacetic acid, 3-(4’-
hydroxyphenyl)propionic acid, phenylpropionic 
acid, and catechol were from Sigma Aldrich (St. 
Louis, MO, USA); cyanidin-3-O-glucoside and 
dimer B2  from Extrasynthese (Genay, France). 
Gallic acid was purchased from Panreac 
(Barcelona, Spain) and ascorbic acid from Sharlau 
(Barcelona, Spain). Standards of hydroxyl-6H-
benzopyran-6-one derivatives (urolithins), such as 
urolithin A (dihydroxyurolithin), urolithin B 
(hydroxyurolithin) and urolithin C 
(trihydroxyurolithin) were kindly provided by Dr. 
Thasana from Chulabhorn Research Institute, 
Laksi, Bangkok (Nealmongkol, Tangdenpaisal, 
Sitthimonchai, Ruchirawat, & Thasana, 2013). 
 
2.2. In vitro gastrointestinal digestion 
Fruit from A. unedo was picked in December of 
2013 in the vicinity of Lleida (Catalonia, Spain) 
(Figure 1 of Supplementary information). The 
fruit arrived in the laboratory on the same day it 
was picked and it was immediately washed by 
hand and cut into slices with a maximum 
thickness of 1.5 cm before being lyophilized 
(LyoBeta 15, Telstar, Netherlands). The 
lyophilisation cycle consisted in two phases, a first 
drying at 0.5 mbar (from -20 ºC to -5 ºC within 19 
h) and a second drying performed at total vacuum 
(from 0 ºC to 15 ºC within 37 h). The freeze-dried 
samples were maintained at -80 ºC in amber 
containers until the day of the experiment. For the 
in vitro gastrointestinal digestion, the freeze-dried 
samples were grinded with a commercial coffee 
mill (Moulinex, France) until obtain a fine and 
visually homogenous powder (particle size < 2.5 
mm). The in vitro gastrointestinal digestion was 
performed to imitate the physiological conditions 
during human oral, gastric and intestinal steps 
(Mosele et al., 2015). For this, 1.5 g of ground 
lyophilized A. unedo was incubated at 37ºC in a 
Gallenkamp IOI400.XX2.C orbital shaker 
(Lancashire, UK) for 5 min at 200 rpm in presence 
of artificial saliva (phosphate buffer 0.005 M at pH 
6.9 with 0.04% of NaCl and 0.044% of CaCl2) 
contained α-amylase (15 mg/1.5 g of lyophilized 
fruit). After the oral step, the sample was 
incubated under gastric conditions. For this, the 
pH of the digesta was adjusted to a value 2.0 by 
adding HCl 37% and incubated at 37ºC for 60 min 
under continuous shaking (200 rpm) in presence 
of pepsin (22.5 mg/1.5 g of lyophilized fruit). Then, 
to imitate intestinal digestion, the pH of the gastric 
digesta was corrected to 6.5 with NaHCO3 (0.5 N) 
and pancreatin (30 mg/1.5 g of lyophilized fruit) 
and bile salts (200 mg/1.5 g of lyophilized fruit) 
were added. The resulted mixture was circulated 
(1 mL/min) in darkness for two hours thought a 
dialysis membrane (Sigma-Aldrich) immersed in 
phosphate buffer (pH 7.5) (Mosele et al., 2015). 
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The temperature was maintained at 37 ºC during 
the digestion using a close circuit of distilled water 
(at 37 ºC), which surrounded the in vitro digestion 
system. After the dynamic duodenal digestion, two 
fractions were collected, the “IN” and the “OUT” 
fractions. The IN fraction (dialysis tube content) 
was considered the part of the digesta that reach 
the colon, whereas the OUT fraction (phosphate 
buffer), which contained the compounds capable 
of crossing the membrane, was considered as the 
bioavailable fraction of the A. unedo. Each in vitro 
digestion was performed in the absence of light 
and in triplicate. The samples obtained from the 
different digestion steps were lyophilized and 
stored at -80 °C in dark bottles until their 
chromatographic analysis for phenolic compounds 
and antioxidants (ascorbic acid, α-tocopherol, β-
carotene and lutein). To evaluate their stability 
during digestion, a percentage of variation (%var) 
was calculated for each compound. This index 
provides the amount of each compound (ìmols) 
present in the complete digesta after gastric or 
duodenal (IN + OUT) digestions in relation to the 
amount (ìmols) quantified per 100 g of lyophilized 
A. unedo submitted to in vitro digestion. The 
percentage of absorption (%abs) defines the 
percentage of each compound (µmols) quantified 
in the OUT fraction in relation to the amount 
(µmols) quantified per 100 g of lyophilized A. 
unedo submitted to in vitro digestion. 
 
2.3. In vitro colonic fermentation 
The IN fraction obtained after the in vitro intestinal 
digestion was incubated in vitro in the presence of 
human gut microbiota, which was achieved with 
donations of faeces from three healthy females 
(27-35 years, BMI 18.5-24.9 kg/m2). The protocol 
of the study was approved by the Ethical 
Committee of Clinical Research of Arnau Vilanova 
University Hospital, Lleida, Spain (Approval 
Number: CEIC-1326). Volunteers, who reported 
no intestinal alterations, no consumption of 
prebiotics and probiotics products and have 
declared no antibiotic treatment during the last 
three month previous to the donation day, 
transported the faecal samples in an airtight 
container provided with a gas generation sachet 
(BD GasPackTM). In the laboratory, faecal samples 
were maintained in the containers at 4 ºC and 
used within the 2 h of defecation. For the 
fermentation procedure, a media (5% faeces) was 
prepared mixing the faeces with a pre-reduced 
carbonate-phosphate buffer prepared according to 
Mosele, et al., 2015. Ten millilitres of faecal 
inocula (5% faeces) were aliquoted in dispensable 
tubes (15 mL), mixed with 0.1 g of IN and 
incubated for different times (0, 2, 8, 24 and 48 h). 
These samples were prepared in parallel with two 
controls: Control 1, which was faecal medium 
without IN, and Control 2, which was carbonate-
phosphate buffer with the IN fraction but without 
faeces. The incubation was carried out under 
anaerobic conditions in an orbital shaker (60 rpm) 
at 37 ºC and all incubations were performed in 
triplicate. Samples obtained from each time were 
freeze-dried and stored at -80 ºC until the 
chromatographic analysis of their phenolic 
compounds and antioxidants.  
 
2.4. Chromatographic analysis of phenolic 
compounds  
For the extraction of phenolic compounds, 0.25 g 
lyophilized A. unedo fruits, 0.25 g of the different 
fractions of the gastrointestinal digestion (oral, 
gastric, IN and OUT) and 0.1 g of the in vitro 
fermentation samples were diluted in 2.5 mL, 2.5 
mL and 500 µL of methanol/H2O/acetic acid 
(79.9:20:0.1, v/v/v), respectively. After 10 min of 
vigorous shacking, the samples were centrifuged 
for 10 min at 9000 rpm at room temperature. The 
supernatant was filtered with a 0.22 m nylon 
syringe filter and injected into the column. 
The analysis of the phenolic compounds in the A. 
unedo fruit, digestion and fermentation samples 
was performed by ultra-performance liquid 
chromatography (UPLC) coupled to tandem mass 
spectrometry (MS/MS) as the detector system 
(Waters, Milford, MA, USA). The chromatographic 
column was an Acquity BEH C18 (100 mm x 2.1 
mm i.d.) with a 1.7 µm particle size (Waters). The 
UPLCTM system was equipped with a binary 
pump system, and a gradient elution was used. 
Two different mobile phases were used, one for 
the analysis of anthocyanins, and the second one 
for the other phenolic compounds. For the 
analysis of anthocyanins, eluent A was Milli-Q 
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water/acetic acid (90:10, v/v) and eluent B, 
acetonitrile. The gradient was performed as 
follows: 0-10 min, 3-25%B; 10-10.1 min, 25-
80%B; 10.1-11 min, 80%B; 11-11.1 min, 80-3%B; 
11.1-12.5 min, 3%B. On the other hand, for the 
analysis of the other phenolic compounds, eluent 
A was Milli-Q water/acetic acid (99.8:0.2, v/v) and 
eluent B, acetonitrile. The gradient was 
performed as follows: 0-5 min, 5-10%B; 5-10 min, 
10-12.4%B; 10-18 min, 12.4-28 %B; 18-23 min, 
28-100%B; 23-25.5 min, 100 %B; 25.5-27 min, 
100-5%B; and 27-30 min, 5%B. For all the 
phenolic compounds, the flow-rate was 0.4 
mL/min and the injection volume was 2.5 L. 
Tandem MS (MS/MS) analyses were carried out 
on a triple quadrupol detector (TQD) mass 
spectrometer (Waters) equipped with a Z-spray 
electrospray interface. The analyses were done in 
the positive ion mode for anthocyanins and 
urolithins and in the negative ion mode for the 
rest of the phenolic compounds. The data were 
acquired with the selected reaction monitoring 
mode (SRM). The MS/MS parameters were as 
follows: capillary voltage, 3 kV; source 
temperature, 150 ºC; cone gas flow-rate, 80 L/h 
and desolvatation gas flow-rate, 800 L/h; 
desolvation temperature, 400 ºC. Nitrogen (>99% 
purity) and argon (99% purity) were used as 
nebulizing and collision gases, respectively. The 
cone voltages and collision energies were 
optimized for each analyte by injecting each 
standard compound into a mixture of 
acetonitrile/water (50:50, v/v) at a concentration 
of 5 mg/L 
Two transitions were studied for each compound, 
the most abundant was used for quantification, 
and the second one for confirmation purposes. 
The dwell time established for each transition was 
30 ms. Data acquisition was carried out with the 
MassLynux v 4.1 Software. Table 1 shows the 
SRM conditions used for quantification purposes, 
as well as the cone voltage and collision energy 
for each phenolic compound. 
Gallic acid, ellagic acid, catechin, epicatechin, 
dimer, cyanidin glucoside, catechol, p-
hydroxybenzoic acid, protocatechuic acid, 
phenylpropionic acid, hydroxyphenylpropionic 
acid, dihydroxyphenylpropionic acid, phenylacetic 
acid, p-hydroxyphenylacetic acid, dihydroxy 
phenylacetic acid, hydroxyurolithin, dihydroxy-
urolithin, trihydroxyurolithin were quantified by 
their own calibration curves. Gallic acid hexoside, 
galloylshikimic acid, galloylquinic acid, di-O-
galloylshikimic acid, di-O-galloylquinic acid, tri-O-
galloylquinic acid and tetra-O-galloylquinic acid 
were tentatively quantified as gallic acid. Ellagic 
acid arabinoside and strictinin ellagitannin were 
tentatively quantified as ellagic acid. 
Epigallocatechin and gallocatechin + catechin 
were tentatively quantified as catechin while 
epicatechin gallate and epigallocatechin gallate 
were tentatively quantified as epicatechin. 
Hydroxyphenylvaleric acid was tentatively 
quantified as hydroxyphenylpropionic acid, and 
dihydroxyphenyl-γ-valerolactone and trihydroxy 
phenyl-γ-valerolactone were tentatively quantified 
as dihydroxyphenylpropionic acid. All the 
anthocyanins were tentatively quantified as 
cyanidin-3-O-glucoside. Tetrahydroxyurolithin and 
pentahydroxyurolithin were tentatively quantified 
as trihydroxyurolithin. Table 1 also provides the 
information regarded the commercial standards 
used to quantify each phenolic compound. 
 
2.5. Analysis of antioxidants: ascorbic acid, á-
tocopherol, â-carotene and lutein   
For the determination of the antioxidants in the A. 
unedo fruit, digestion and fermentation samples, 
high-performance liquid chromatography (HPLC) 
coupled to photodiode-array detector (DAD) 
(Waters, Milford, MA) was used. The HPLC-DAD 
system included a Waters 600 E pump, a Waters 
column heater (column temperature 22 ºC), a 
Waters 717 Plus autosampler and a Waters 996 
DAD detector. Empower software was used. 
Before injection, all the samples were filtered with 
a 0.22 m nylon syringe filter. All the compounds 
were quantified by their own calibration curve. 
 
2.5.1. Ascorbic acid analysis 
To determine ascorbic acid from the Arbutus 
unedo fruit, oral and gastric digestions, 0.1 g of 
freeze dried samples was diluted in 10 mL of an 
aqueous solution of 0.1% TFA. The solutions 
obtained were vigorous shaken in a vortex for 1 
min, and centrifuged for 5 min at 3500 rpm at 
room temperature. The supernatant was reserved 
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in dark bottles at 4 ºC and the process was repeated with the residue twice more. 
Table 1. Optimized SRM conditions used for quantification purposes for the analysis of phenolic 
compounds by UPLC-MS/MS 
MW: Molecular weight 
* Positive ionization mode
Phenolic compound 
MW 
(g/mol) 
SRM quantification 
Standard used for quantification 
Transition  
Cone 
voltage 
(V)  
Collision 
energy 
(eV) 
Anthocyanins *           
Cyanidin arabinoside 418 419  287 40 20 Cyanidin-3-O-glucoside 
Cyanidin glucoside 448 449  287 40 25 Cyanidin-3-O-glucoside 
Delphinidin arabinoside 434 435  303 40 20 Cyanidin-3-O-glucoside 
Delphinidin glucoside 464 465  303 40 25 Cyanidin-3-O-glucoside 
Pelargonidin arabinoside 402 403  271 40 20 Cyanidin-3-O-glucoside 
Pelargonidin glucoside 432 433  271 40 20   
Peonidin arabinoside 432 433  301  40 20 Cyanidin-3-O-glucoside 
Peonidin glucoside 462 463  301 40 25 Cyanidin-3-O-glucoside 
            
Rest of the phenolic compounds           
Gallic acid 170 169  125 35 10 Gallic acid 
Gallic acid hexoside 332 331  169 40 15 Gallic acid 
Galloylshikimic acid 326 325  169 40 20 Gallic acid 
Galloylquinic acid 344 343  191 40 15 Gallic acid 
Di-O-galloylshikimic acid 478 477  325 40 20 Gallic acid 
Di-O-galloylquinic acid 496 495  191 40 25 Gallic acid 
Tri-O-galloylquinic acid 648 647  495 40 15 Gallic acid 
Tetra-O-galloylquinic acid 630 629  477 40 15 Gallic acid 
Ellagic acid 302 301  245 45 25 Ellagic acid 
Ellagic acid arabinoside 434 433  300 40 30 Ellagic acid 
Strictinin ellagitannin 634 633  301 40 30 Ellagic acid 
Catechin 290 289  245 45 15 Catechin 
Epicatechin  290 289  245 45 15 Epicatechin  
Dimer  578 577  289 40 20 Dimer B2 
Epigallocatechin 306 305  125 40 15 Catechin  
Gallocatechin + catechin 594 593  289 40 30 Catechin  
Epicatechin gallate 442 441  169 40 20 Epicatechin  
Epigallocatechin gallate 458 457  169 40 15 Epicatechin  
Catechol  110 108.9  90.9 40 15 Catechol  
p-Hydroxybenzoic acid  138 137  93 30 15 p-Hydroxybenzoic acid  
Protocatechuic acid 154 153  109 45 15 Protocatechuic acid 
Phenylpropionic acid 150 149  105 20 5 Phenylpropionic acid 
Hydroxyphenylpropionic acid 166 165  121 20 10 Hydroxyphenylpropionic acid 
Dihydroxyphenylpropionic acid 182 181  137 20 10 Dihydroxyphenylpropionic acid 
Phenylacetic acid 136 135  91 20 15 Phenylacetic acid 
p-hydroxyphenylacetic acid 152 151  107 20 10 p-hydroxyphenylacetic acid 
Dihydroxyphenylacetic acid 168 167  123 15 5 Dihydroxyphenylacetic acid 
Hydroxyphenylvaleric acid 194 193  175 40 15 Hydroxyphenylpropionic acid 
Dihydroxyphenyl--valerolactone  208 207  163 40 25 Dihydroxyphenylpropionic acid 
Trihydroxyphenyl--valerolactone  224 223  179 40 10 Dihydroxyphenylpropionic acid 
Hydroxy urolithin (urolithin B) * 212 213  141 40 20 Urolithin B 
Dihydroxy urolithin (urolithin A) * 228 229  157 40 20 Urolithin A 
Trihydroxy urolithin (urolithin C) * 244 245  155 40 30 Urolithin C 
Tetrahydroxy urolithin *  260 261  171 40 25 Urolithin C 
Pentahydroxy urolithin *  278 277  187 40 30 Urolithin C 
Results and Discussion 
 Food Chemistry, 2016, 120-130 
 
173 
 
Then, the supernatants were combined and TFA 
solution was added until reaching 50 mL and 
analysed. In the case of the intestinal fractions (IN 
and OUT) and fermentation samples, 0.1 g was 
diluted in 1 mL and 500 µL of TFA solution, 
respectively, and the supernatant obtained after 
centrifugation was filtered and injected into the 
column. For the chromatographic determination of 
ascorbic acid, the analytical column was a BEH 
C18 column (100 x 4.6 mm, 2.5 ìm) (Waters), and 
the mobile phase was 0.1% TFA. An isocratic 
mode was used and the run time was 8 min. The 
chromatograms were obtained at 243 nm. The 
flow-rate was 0.4 mL/min, and the injection 
volume was 20 L 
 
Table 2. Content of phenolic compounds and antioxidants (mol) in Arbutus unedo lyophilized fruit and in 
fractions of the gastric and duodenal (OUT + IN) steps of the in vitro gastrointestinal digestion of Arbutus 
unedo 
Compound (ìmols) 
Arbutus 
unedo 
Gastric  % var Duodenal % var IN OUT 
% 
abs 
Gallic acid and gallotannins         
Tetra-O-galloylquinic acid  21.9  19.5  -11.8 0.43  -98.0 0.40  n.q. 0.00 
Tri-O-galloylquinic acid 2.44  2.05  -16.0 0.14  -94.3 0.10  n.q. 0.00 
Di-O-galloylquinic acid 84.7  26.2  -69.1 7.43  -91.2 7.01  0.42  0.50 
Di-O-galloylshikimic acid 201  122  -39.1 10.6  -94.7 10.2  0.38  0.19 
Galloylquinic acid 1425  281  -80.2 1275  -10.5 943  332  23.3 
Galloyl shikimic acid 104  42.9  -59.1 272  159 216  55.3  52.8 
Gallic acid hexoside 189  24.5  -87.0 263  39.2 161  102  54.1 
Gallic acid 17.2  150  772 156  807 91.0  65.5  379 
Total gallotannins 2046  669  -67.3 1985  -3.00 1429  556  27.2 
Flavan-3-ols         
Dimer 26.8  n.q. -100 23.5  -12.0 20.1  3.47  13.0 
Gallocatechin 12.1  n.q. -100 6.07  -50.1 5.54  0.53  4.37 
Epigallocatechin gallate 2.06  0.23  -88.8 0.1  -31.9 0.99  n.d. n.d. 
Catechin 78.5  0.60  -99.2 53.4  169 34.5  18.9  24.1 
Epicatechin 0.72  n.q. -100 1.93  161 0.94  0.99  137 
Epigallocatechin 0.93  n.q. -100 15.9  -57.2 12.9  3.01  324 
Epicatechin gallate 16.7 n.q. -100 7.16  -51.5 6.12  1.05  6.25 
Total flavan-3-ols 137  0.83  -99.4 109  -20.9 81.1  28.0  20.3 
Ellagic acid and ellagitannins         
Strictinin ellagitannin 184  29.1  -84.2 104  -43.3 99.2  4.80  2.61 
Ellagic acid arabinoside (xyloside) 434  86.4  -80.1 289  -33.5 238  50.6  11.6 
Ellagic acid 9.44  26.4  179 9.17  -2.80 7.25  1.92  20.4 
Total ellagitannins 628  142  -77.4 402  -35.9 345  57.3  9.13 
Anthocyanins         
Pelargonidin arabinoside 0.03  0.02  -41.9 0.01  -62.0 0.01  0.01 15.8 
Pelargonidin glucoside 0.19  0.10  -46.7 0.04  -76.9 0.03  0.01 6.02 
Cyanidin arabinoside 2.89  1.52  -47.3 0.55  -80.9 0.45  0.1 3.49 
Cyanidin glucoside 15.5  13.6  -12.7 2.53  -83.7 2.08  0.45 2.89 
Peonidin arabinoside 0.01  0.01  15.9 0.01  -36.1 0.01 n.q. 0.00 
Peonidin glucoside 0.03  0.10  261 0.04  28.5 0.03 0.01 22.5 
Delphinidin arabinoside 0.38  0.14  -64.5 0.16  -58.5 0.07 0.09 24.0 
Delphinidin glucoside 0.64  0.25  -60.7 0.43  -32.8 0.34 0.09 13.7 
Total anthocyanins 19.7  15.7  -20.3 3.78  -80.8 3.02 0.75 3.82 
ToTotal phenolic compounds 2832  828  -70.8 2500  -11.7 1858 642 22.7 
Other Antioxidants          
Ascorbic acid 2496 2481 -0.58 846 -66.1 386 460 18.4 
α-tocopherol 32.6 14.6 -54.7 13.2 -59.1 12.7 0.60 1.87 
β-carotene 3.80 1.77 -53.4 5.03 -32.3 5.03 n.q. 0.00 
Lutein  1.45 n.q. -100 1.84 10.3 1.84 n.q. 0.00 
The results are expressed as umol of compounds in relation to the content in 100 g of lyophilized fruit submitted to digestion 
n.d.: no quantified (lower than the detection limit ( LOD)). n.q.: its concentration between its LOD and LOQ  
% var and % abs: see Materials and methods (section 2.2) 
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2.5.2. α-tocopherol analysis 
One gram of lyophilized A. unedo and digestion 
fractions (oral, gastric, IN and OUT) and 0.2 g of 
fermentation samples were vigorously mixed for 1 
min with hexane and centrifuged at 9000 rpm, for 
10 min at 4 ºC. The extraction procedure was 
repeated (n=3) until the -tocopherol was not 
detected in the last extraction supernatant by 
chromatographic analysis. Then, the supernatants 
were combined and the mixture was rotavapored 
(Rotavapor R-205, Büchi, Switzerland) at 20 ºC 
(Heating bath B-490, Büchi, Switzerland) until fully 
dry. The A. unedo fruit and digestion samples 
were reconstituted in 1 mL of hexane whereas the 
fermentation samples were reconstituted in 200 
L.  
For the chromatographic determination of -
tocopherol, the analytical column was Sulpelcosil 
LC-NH2 (250 x 4.6 mm, 5µm) (Supelco, 
Bellefante, PA, USA), and the mobile phase was 
70% hexane as eluent A, and 30% ethyl acetate 
as eluent B. An isocratic mode was used and the 
run time was 20 min. The chromatograms were 
obtained at 295 nm. The flow-rate was 1 mL/min, 
and the injection volume was 20 L. 
 
2.5.3. -carotene and lutein analysis 
One g of the lyophilized A. unedo and digestions 
(oral, gastric, IN and OUT fractions) and 0.2 g 
fermentation samples were vigorous mixed for 1 
min with a mixture of ethanol/hexane (60:40, v/v) 
and centrifuged at 9000 rpm, for 10 min at 4 ºC. 
The extraction procedure was repeated (n=3) until 
a colourless supernatant was obtained and the 
studied compounds were not detected in the last 
extraction supernatant by chromatographic 
analysis. The combined supernatants were 
rotavapored and the dry residue was redissolved 
in 2 mL of ethanol in the case of the fruit and 
digestions, and 200 L for the fermentation 
residues.  
For the chromatographic determination of -
carotene and lutein, the analytical column was an 
YMC C30 (150  4.6 mm, 3 m) (Waters), and 
the mobile phase was methanol as eluent A, 
MTBE as eluent B, and Milli-Q water as eluent C. 
The gradient elution was of B into A with a 
constant 2%C, as follows: 0-27 min, 2-80 %B; 
 27-31 min, 80-2 %B; 31-35 min, 2 %B isocratic. 
The chromatograms were obtained at 450 nm. 
The flow-rate was 1 mL/min, and the injection 
volume was 20 L. 
 
2.6. Total pectin content 
Total pectin was determined in the lyophilized A. 
unedo fruit according to the method described by 
Maran, 2015, which is based on gravimetric 
determination. The results are expressed as g the 
pectin/100 g of lyophilized A. unedo fruit. 
 
2.7. Statistical analysis 
All data are expressed as the average of the 
three replicates of the different digested fractions. 
To simplify the results shown in Tables 1 and 2, 
the standard deviations were omitted because 
they were lower than 10% of the values 
 
3. RESULTS AND DISCUSSION 
3.1. Phenolic and antioxidants content in 
Arbutus unedo fruit 
The content of extractable polyphenols, ascorbic 
acid and fat-soluble antioxidants (α-tocopherol, β-
carotene and lutein) in the A. unedo fruit is 
presented in Table 2. The data are expressed as 
mols of compound per 100 g of lyophilized fruit 
submitted to in vitro digestion. Regarding the 
phenolic composition, the fruit of the A. unedo 
contains a wide variety of phenolic groups, 
including anthocyanins, flavan-3-ols, phenolic 
acids and hydrolysable tannins, such as 
ellagitannins and gallotannins. It is worth 
highlighting that the gallotannin tetra-O-
galloylquinic acid is described for the first time in 
A. unedo fruit. As it is shown in Table 2, the 
gallotannins were the most abundant phenolic 
compounds in A. unedo fruit (2046 µmol/100 g 
lyophilized fruit) followed by ellagitannins (628 
mol/100 g lyophilized fruit). Nevertheless, other 
authors found flavan-3-ols to be the most 
abundant phenolic compounds in A. unedo 
(Guimarães et al., 2013; Pallauf, Rivas-Gonzalo, 
del Castillo, Cano, & de Pascual-Teresa, 2008). 
Considering the total phenolic content quantified 
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in the present study (2832 µmol/100 g lyophilized 
fruit), this was lower than the content determined 
in A. unedo fruit harvested in Portugal (Fortalezas 
et al., 2010).. This fact could be associated with 
the analytical technique used for determining the 
total phenols. These authors applied the Folin-
Ciocalteau method (colorimetric), which is 
considered a non-specific analytical method that 
results in an overestimation of phenolic 
compounds due to the presence of ascorbic acid 
as a powerful reducing agent (Singleton, Orthofer, 
& Lamuela-Raventós, 1999). Regarding 
antioxidants, the A. unedo fruit could be 
considered an interesting dietary source of 
ascorbic acid (2496 µmol/100 g lyophilized fruit) 
and a lesser source of fat-soluble antioxidants 
such as α-tocopherol and carotenoids, β-carotene 
and lutein 
The concentrations of these compounds detected 
in A. unedo fruit in the present study were also in 
agreement with previous data (Oliveira, Baptista, 
Malheiro, Casal, Bento, & Pereira, 2011), with the 
exception of lutein, which was found at higher 
concentration than that reported previously 
(Pallauf, Rivas-Gonzalo, del Castillo, Cano, & de 
Pascual-Teresa, 2008). It is important to highlight 
the high concentration of ascorbic acid in A. 
unedo fruit. Its concentration is higher than in 
other fruit commonly thought of as rich sources of 
vitamin C, such as oranges, strawberries and 
kiwis (Proteggente et al., 2002; Szeto, Tomlinson, 
& Benzie, 2002). In addition, when the 
concentrations of the fat-soluble antioxidants were 
compared to other fruits, such as apples, 
bananas, kiwis and oranges, A. unedo also 
presented higher levels of α-tocopherol (Chun, 
Lee, Ye, Exler, & Eitenmiller, 2006), β-carotene 
and lutein (USDA, 2015). 
In order to test the stability of each individual 
phenolics and ascorbic acid and fat-soluble 
antioxidants during gastrointestinal digestion, an 
in vitro digestion model, mimicking the oral, gastric 
and duodenal conditions, was applied to A. unedo 
fruit samples. 
3.2. Stability of Arbutus unedo fruit phenolic 
compounds and antioxidants during in 
vitro gastric step 
After 5 min of oral digestion, minimal modifications 
were observed in the concentration of the phenolic 
compounds and vitamins (results not shown). No 
relevant differences were also observed in 
pomegranate juice, pulp and extract after oral 
digestion (Mosele et al., 2015) 
The short exposure time and marginal effects of α-
amylase could explain the lack of changes in the 
phytochemical profile of A. unedo, which would 
justify the omission of this step in other studies 
(Bouayed, Hoffmann, & Torsten 2011; Carnachan, 
Bootten, Mishra, Monro, & Sims, 2012; Green, 
Murphy, Schulz, Watkins & Ferruzzi, 2007; Vallejo 
et al., 2004). By contrast, simulated gastric 
digestion (pH 2.0 in presence of pepsin) caused 
an important decrease in the recovery of the 
phenolic compounds and fat-soluble vitamins 
(Table 2). 
To perform a real balance of the effect of gastric 
digestion, the concentration of each individual 
compound was expressed as ìmols per 100 g of 
lyophilized A. unedo fruit, and as a percentage of 
variation (%var) between the initial µmols 
submitted to in vitro digestion and the µmols 
recovered in the total digesta after the 
incubationAs shown in Table 2 and Figure 1, 
important differences were observed in the 
recovery (%var) of phenolic compounds and fat-
soluble antioxidants after gastric digestion. The 
stability and potential absorption of low molecular 
weight compounds, such as gallic, ellagic and 
ascorbic acids, was slightly affected during gastric 
digestion. In fact, gallic and ellagic acids were 
recovered in larger amounts compared to the 
initial values (772 and 179 %var, respectively), 
and this could be due to the partial hydrolysis of 
the gallotannins and ellagitannins, respectively. By 
contrast, the most heavily-affected phenolic group 
was flavan-3-ols (-99.4 %var), followed by 
ellagitannins (-77.4 %var), gallotannins (-67.3 
%var) and anthocyanins (-20.3 %var). High 
recovery of anthocyanins after gastric digestion 
was also observed in previous studies, this 
phenomena was attributed to their chemical 
characteristics that convert the anthocyanin in an 
acidic-tolerant molecule (Bouayed, Hoffmann, & 
Torsten 2011; Mosele et al., 2015). Regarding the 
fat-soluble antioxidants, the recovery after gastric 
digestion of α-tocopherol (-54.7 %var), β-carotene 
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(–53.4 %var), and lutein (-100 %var) was lower 
than the recovery of ascorbic acid, which showed 
a high stability under the pH (2.0) and temperature 
(37 ºC). 
 
 
 
 
 
Figure 1. Schematic representation of the metabolic pathway of gallotannins from Arbutus unedo fruit after 
the simulated in vitro steps, stomach, small intestine and large intestine. The red down arrows represent a 
decrease in the recovery of compounds compared with the raw A. unedo. The green up arrows represent 
an increase in the recovery of compounds compared with the raw A. unedo. 
To understand the low recovery of the some 
compounds studied in the digesta after gastric 
incubation, the composition of the food matrix 
submitted to digestion should be considered. 
Some studies have suggested that the presence 
of pectin could interact with bioactive compounds 
and affect their release into the digestive media 
due to their intragastric gelation properties 
(Padayache et al., 2012a; Padayache et al., 
2012b). Thus, in order to connect the low 
recovery of bioactive compounds after gastric 
digestion, observed in the present study, with the 
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content of pectin in A. unedo fruit, this type of 
water-soluble fibre was measured and its average 
concentration was 4.1%. This amount was 
reported to be enough to promote the formation 
of gel under acidic conditions (Zhang, & 
Vardhanabhuti, 2014), which could explain the 
low recovery of gallotanins, ellagitannins and 
flavan-3-ols (Table 2). Similarly, a minor release 
of phenolic compounds was also observed after 
gastric incubation of whole apples (Bouayed, 
Hoffmann, & Torsten 2011), fruit with high 
amounts of pectin in its skin (Billy et al., 2008). 
Summarizing, the differences in the recovery of 
phenolic compounds and fat-soluble antioxidants 
could be attributed to the stability of the molecule 
under acidic conditions as well as their ease of 
entrapment in the pectin-gel. 
 
3.3. Stability of A. unedo fruit phenolic 
compounds and antioxidants during in 
vitro intestinal digestion 
After the intestinal digestion step, the two 
fractions were collected and analyzed separately. 
These were the outside dialysis solution (OUT), 
which was considered the dialyzable fraction, and 
the inside dialysis tub content (IN), referring to the 
non-dialyzable fraction. To study the effect of the 
intestinal conditions on the stability of the studied 
compounds, the µmols quantified in the IN and 
OUT fractions were summed (Table 2). Despite 
the low recovery of some of the compounds 
studied after gastric incubation, their recovery 
increased after simulated duodenal digestion. As 
can be seen in Table 2, the negative value 
(%var) of galloylquinic and galloyl shikimic acids, 
gallic acid hexoside, catechin and carotenoids 
observed after gastric digestion showed a 
positive value after duodenal digestion, the ìmols 
quantified in the total digesta (IN fraction plus 
OUT fraction) being similar to the ìmols quantified 
in 100 g of lyophilized A. unedo fruit prior to 
digestion. This behaviour could be explained by 
the link between some phenolic structures and 
the pectin-gel formed under the acidic conditions 
of the gastric digestion (pH 2.0), which could 
explain the low recovery of the main phenolic 
compounds. By contrast, the pH conditions of the 
duodenal phase (pH 6.5) could disrupt the gel 
structure due to depolymerisation by β-elimination 
(Carnachan, Bootten, Mishra, Monro, & Sims, 
2012). The time and the speed at which the 
phenolics were released from the gel-structure 
could vary significantly according to the nature of 
the molecule, and this could influence their 
stability. Higher quantities of gallic acid, 
galloylshikimic acid, epicatechin and 
epigallocatechin were recovered compared with 
the initial amounts detected in the raw A. unedo 
fruit (prior to digestion) and the product obtained 
after gastric incubation. This fact could be 
explained by the partial hydrolysis (pH 6.5) of 
gallotannins and oligomeric flavan-3-ols, 
respectively. Based on the results observed after 
gastric and duodenal in vitro digestion of A. 
unedo fruit, we proposed the metabolic pathway 
of gallotannins based on the hydrolysis of tetra-O-
galloylshikimic to tri-, di-, and mono-O-
galloylshikimic until the simplest phenolic and 
gallic acids quantified in duodenal digesta (small 
intestine conditions) (Figure 1).  
Besides gallotannins, anthocyanins also suffered 
an intense degradation after the duodenal step 
compared with the high recovery observed after 
gastric digestion (Table 2). This fact could 
suggest that anthocyanins were not embedded 
and hence protected by the pectin web, which 
could enhance the exposition of these flavonoids 
to the media. Previous studies where 
anthocyanins bioaccessibility was investigated 
under in vitro conditions have also observed 
important losses in the final amount recovered 
(Bouayed, Hoffmann, & Torsten 2011; Mosele et 
al., 2015). This was attribute to the sensitivity of 
anthocyanins to the medium-alkaline conditions 
of the intestinal environment (pH>6). 
Deglycosylation and subsequent liberation of the 
anthocyanins algycone to the media to explain 
the disappearance of anthocyanins should be 
discarded since β-deglycosylation activity has not 
been described for pancreatic enzymes. The 
presence of ascorbic acid has been described to 
confer protection to some phenolic classes such 
as flavan-3-ols during in vitro intestinal digestion 
(Green, Murphy, Schulz, Watkins & Ferruzzi, 
2007). Probably, stability of anthocyanins was 
also negative affected by the parallel degradation 
of ascorbic acid during the duodenal step. 
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As far as antioxidants are concerned, ascorbic 
acid degradation through the gastric portion of the 
in vitro digestive model was not significant and 
degradation occurred primarily during the small 
intestinal phase (IN plus OUT fractions) (Table 
2). The sensitivity of ascorbic acid to small 
intestinal conditions has been previously reported 
(Vallejo et al., 2004). By contrast, the α-
tocopherol instability occurred primarily during the 
gastric phase. Interestingly, β-carotene and lutein 
were recovered in higher amounts after the 
duodenal step compared to their values in the A. 
unedo fruit prior to digestion (Table 2). These 
results suggest that fat-soluble vitamins could be 
retained by pectin-gel during gastric incubation 
and released when the media conditions 
changed, as is the case of the change from 
gastric (pH 2.0) to intestinal digestion (pH 6.5). 
After the intestinal digestion step, the dialyzable 
fraction (OUT) was considered to be the fraction 
that could be available for absorption into the 
systematic circulation by passive diffusion. For 
each compound, the bioaccessibility (%abs) is 
defined as the percentage of compound that is 
quantified (µmols) in the soluble/dialyzable 
fraction (OUT) after the intestinal step (Table 2). 
The phenolic compounds recovered in major 
proportion in this fraction were gallic acid and 
gallotannins (27.2 %abs) and flavan-3-ols (20.3 
%abs), followed by ellagic acid and ellagitannins 
(9.13 %abs) and anthocyanins (3.82 %abs). This 
tentative approach to predict the degree of 
intestinal epithelium absorption is in agreement 
with human studies where the bioavailability of 
phenolic compounds was studied after the intake 
of vegetable products (Clifford, Van Der Hooft, & 
Crozier, 2013; Stoner et al., 2005). Gallic acid 
and flavan-3-ols and their generated metabolites 
were detected in human plasma and urine after 
green tea intake (Clifford, Van Der Hooft, & 
Crozier, 2013). The poor efficiency of the ellagic 
acid and anthocyanins intestinal absorption was 
reported in human biological fluids after the intake 
of lyophilized black raspberries (Stoner et al., 
2005). 
  
Table 3. Phenolic precursors, phenolic microbial metabolites and antioxidants content (µmol compound / 
100 g lyophilized A. unedo fruit) detected in the non dialyzable IN fraction and in the fecal media at 
different incubation times (2, 8, 24 and 48 h) for each fecal donor (Volunteers 1, 2 and 3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vol.: volunteer 
n.d.: no quantified (lower than the detection limit ( LOD)) 
n.q.: its concentration between its LOD and LOQ  
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Regarding the antioxidants in the OUT fraction, 
only ascorbic acid (18.4 %abs) and α-tocopherol, 
at a very low level (1.87 %abs), were quantified. 
Furthermore, β-carotene and lutein were not 
detected, indicating no diffusion through the 
dialysis membrane during the intestinal digestion 
phase. Although pectin could be considered a 
protector agent for some phenolic groups during 
the digestion process, its presence seemed to 
affect the bioavailability of β-carotene, lutein 
(Aschoff et al., 2015) and tocopherols (Richelle et 
al., 2004). In addition, the solubility of fat-soluble 
vitamins also depends on the presence of lipids 
(Read, Wright, & Abdel-Aal, 2015), but these are 
very limited in A. unedo fruit (Ruiz-Rodriguez et 
al., 2011), which could also explain the low 
recovery of fat-soluble vitamins in the OUT 
fraction. It could be concluded that most phenolic 
compounds present in the A. unedo fruit reach 
the large intestine. The non-absorbable fraction of 
phenolic compounds (non dialyzable IN fraction), 
which was susceptible to be catabolised by the 
gut microbiota, was composed mainly of gallic 
acid and gallotannins, ellagic acid and 
ellagitannins, and to a lesser extent, flavan-3-ols 
and anthocyanins (Table 2). 
 
3.4. In vitro colonic fermentation of Arbutus 
unedo  
After the gastric and intestinal in vitro digestion 
phases, the IN fraction (non dialyzable) was 
submitted to in vitro colonic fermentation using a 
human faeces inoculum from three healthy 
volunteers. The generation of phenolic catabolites 
was monitored at different incubation times from 0 
to 48 h, considering the IN fraction as time-point 0 
h. Table 3 shows the microbial metabolites 
generated for each faecal donor at different 
fermentation times. The metabolites described in 
Table 3 were those that appeared in major 
concentration in faecal media incubated with the 
IN fraction compared to control 1 and control 2; 
control 1 being faecal medium without IN, and 
control 2, carbonate-phosphate buffer with the IN 
fraction but without faeces. As was expected, 
different metabolites were generated at different 
fermentation times. Although an evident 
intervariability between the volunteers was 
observed, some behaviour patterns were 
repeated. 
Since the IN fraction post-intestinal digestion of A. 
unedo contained gallic acid, gallotannins, flavan-
3-ols, ellagic acid, ellagitannins and 
anthocyanins, a wide range of different microbial 
metabolites derived from their microbial 
catabolism were detected (Table 3). Based on 
the metabolites quantified at different incubation 
times, we proposed the colonic pathways for 
gallotannins, ellagitannins, flavan-3-ols and 
anthocyanins (Figure 2). Dihydroxyphenyl--
valerolactone and trihydroxyphenyl--
valerolactone were associated with the microbial 
catabolism of (epi)catechin and (epi)gallocatechin 
moieties, respectively (Jiménez-Girón, Muñóz-
González, Martín-Álvarez, Moreno-Arribas, & 
Bartolomé, 2014; Serra et al., 2011). Then, 
dihydroxyphenylvaleric acid was generated from 
dihydroxyphenyl--valerolactone (Jiménez-Girón, 
Muñóz-González, Martín-Álvarez, Moreno-
Arribas, & Bartolomé, 2014). In the present study, 
we proposed that in the last phases of the colonic 
catabolism, the hydroxyphenylpropionic and 
hydroxyphenylacetic acids could be synthesised 
from dihydroxyphenylvaleric acid, followed by the 
simplest phenolic compounds, such as 
protocatechuic and p-hydroxybenzoic acids 
(Figure 2). Phenylpropionic and phenylacetic 
acids, in their hydroxylated forms, were 
determined at the final incubation times (24 and 
48 h) (Table 2), and apart from being generated 
from flavan-3-ols, these have also been reported 
as coming from anthocyanins (González-Barrio, 
Edwards, & Crozier, 2011). In addition of these 
acids, protocatechuic and gallic acids have also 
been reported as coming from cyanidin-3-O-
glucoside (Hanske et al., 2013; Vitaglione et al., 
2007), this being the main anthocyanin detected 
in the IN fraction in the present study. 
The other phenolic compounds detected in the 
faecal media were the urolithins. These 
compounds have been reported to be exclusive 
to ellagic acid microbial metabolism (García-
Villalba et al., 2013). The kinetic generation of the 
different hydroxylated forms of urolithins detected 
in the present study (Table 3) was similar to that 
described after ellagic acid in vitro fermentation 
(García-Villalba et al., 2013). The more 
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hydroxylated urolithins were found at the initial 
fermentation times. Then, the bacterial 
metabolism was increased and led to the 
formation of the more lipophilic urolithins, such as 
dihydroxylated urolithins (urolithin A) and 
monohydroxylated urolithins (urolithin B). These 
two urolithin metabolites have been described as 
the main ellagic acid microbial metabolites 
(García-Villalba et al., 2013). 
There is little information in the literature 
regarding the microbial colonic metabolism of 
flavan-3-ols, ellagitannins and anthocyanins. 
Nevertheless, no data is reported about the 
metabolic pathway of gallotannins. In order to fill 
this gap in the information, the gastrointestinal 
and colonic metabolic fate of gallotannins from 
the A. unedo fruit is proposed in Figure 1, while 
the colonic pathways of flavan-3-ols, ellagitannins 
and anthocyanins are represented in Figure 2.  
Degradation of the gallotannins remaining in the 
IN fraction continued in the presence of human 
microbiota with an accumulation of gallic acid at 
early stages of incubation (2 h). At this same time 
(2 h), protocatechuic acid, p-hydroxybenzoic acid 
and catechol began to be detected in the faecal 
media. The maximum concentration of 
protocatechuic acid was detected at 8 h of 
incubation in the faecal media from the three 
volunteers. However, the maximum peak of the 
other microbial metabolites, p-hydroxybenzoic 
acid and catechol, depended on the faecal donor 
(Table 3). p-hydroxybenzoic acid was at 8 h for 
volunteers 1 and 2, and at 24 h for volunteer 3. 
Regarding catechol, its maximum concentration 
was at 8 h for volunteer 1, and at 48 h for 
volunteers 2 and 3. The microbial metabolites of 
gallotannins generated: gallic acid, 
protocatechuic acid and p-hydroxybenzoic acid, 
were also described for flavan-3-ols and 
anthocyanins (Figure 2) (Hanske et al, 2013; 
Serra et al., 2011). The gut microbiota 
composition, together with the quantity and 
quality profile of the phenolic compounds 
interacting with microorganisms (Cueva et al., 
2013), are probably implicated in the types of 
microbial metabolites generated in the present 
study. 
As far as antioxidants are concerned, a rapid 
degradation of ascorbic acid was observed in the 
faecal media, since this compound was no 
detected after any incubation time. On the other 
hand, α-tocopherol and β-carotene remained very 
stable, even after 48 h of incubation. Their 
resistance to microbial metabolism and media 
conditions was also observed in human faeces 
(Pierre et al., 2013). 
 
4. CONCLUSIONS 
The results obtained in the present study provide 
further evidence about the in vitro digestion 
stability and colonic metabolism of A. unedo 
antioxidants from the fruit to the colon. Depending 
on the phenolic groups and the antioxidant 
compound, different behaviour was observed 
under in vitro gastric and intestinal digestive 
conditions. The presence of pectin from the A. 
unedo fruit hampered the solubilisation of the 
phenolic compounds (with exception of gallic and 
ellagic acids) and fat-soluble vitamins during 
gastric digestion. The increase in the viscosity of 
bulk could lead to a slowdown in gastric emptying 
and this favour the gradual release of phenolic 
compounds from the pectin gel network into the 
small intestine. Therefore, a large proportion of 
the phenolic compounds and antioxidants from the 
A. unedo fruit remained in the non-absorbable 
fraction of the digesta (IN fraction), indicating that 
these compounds could reach the colon, where 
they are susceptible of further microbial 
transformations. The catabolic activity of human 
microbiota led to the generation of different 
phenolic microbial metabolites derived from the 
gallotannins, ellagitannins, flavan-3-ols and 
anthocyanins that remained stable after the in 
vitro intestinal digestion. These were urolithins, 
hydroxyphenylvalerolactones, hydroxyphenyl 
propionic acid, hydroxylphenylacetic acid, and the 
simplest phenols, such as gallic acid, p-
hydroxybenzoic acid, protocatechuic acid and 
catechol.  
Therefore, while these in vitro results cannot be 
fully extended directly to in vivo conditions, these 
data provide evidence that the fruit of the A. 
unedo may be interesting as a rich dietary source 
of a wide range of phenolic compounds, together 
with ascorbic acid and fat-soluble antioxidants. 
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Abstract 
Arbutus unedo is a small Mediterranean fruit, commonly named strawberry tree, which is a rich source of 
different sub-classes of phenolic compounds, the more representative being the gallic acid derivatives, 
including its mono and oligomeric forms esterified with quinic and shikimic acids. In addition, galloyl 
derivatives, particularly gallotannins, described in A. unedo, are part of a very selective phenolic group, 
present in a reduced number of plant-products. The aim of the present study is to provide a better 
understanding of human metabolic pathways of different sub-classes of phenols from the A. unedo fruit 
after an acute intake by healthy adults. Therefore, the A. unedo phenolic metabolites were studied in whole 
blood samples (0 to 24 h), urine (24 h) and feces (12 and 24 h). Special focus was placed on the 
application of dried blood spot (DBS) cards for the sample collection and for the analysis of phenolic 
metabolites in whole blood samples. The results of the blood analysis revealed two peaks for the 
maximum concentrations of the main phenolic metabolites. Furthermore, it is appropriate to highlight the 
application of DBS cards as an efficient and accurate way to collect blood samples in post-prandial 
bioavailability studies. The analysis of urine (24 h) gave a wide range of phenolic metabolites showing the 
extensive metabolism that A. unedo phenolic compounds underwent in the human body. The results of the 
study provide a relevant contribution to the understanding of the in vivo human bioavailability of phenolic 
compounds, especially galloyl derivatives, a singular phenolic sub-group present in the A. unedo fruit..   
 
Key words: Arbutus unedo, human phenol bioavailability, dried spot cards, phenolic metabolism 
 
1. INTRODUCTION  
An eagerness to raise the value of local products 
rich in bioactive compounds has stimulated 
interest in the characterization of little-known plant 
products. Arbutus unedo (A. unedo) is a small 
Mediterranean fruit, commonly named strawberry 
tree that reaches it optimal ripeness at the end of 
autumn. A. unedo belongs to the Ericaceae family, 
native to the Mediterranean region and from the 
northeast of Europe to western France and 
Ireland. The macro- and micro- components of A. 
unedo have been previously characterized.1-4 
Between the minority fraction, phenolic 
compounds cover a broad range of different sub-
classes, the more representative being the gallic 
acid derivatives, including its mono and oligomeric 
forms esterified with quinic and shikimic acids. In 
addition, galloyl derivatives, particularly 
gallotannins, described in A. unedo, are part of a 
very selective phenolic group, found in a limited 
number of plant products.2,4-6 Other phenolic 
compounds, such as flavan-3-ols, ellagic acid 
derivatives, flavonols and anthocyanins, have also 
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been found in A. unedo in different 
concentrations.1,2,4  
Diet phytochemicals, such as phenolic 
compounds, have been recognized as a natural 
defense against chronic disorders. This biological 
property has been related to an improvement in 
the antioxidant status of the body and modulation 
of the inflammatory response, which contribute to 
reducing the risks of suffering type-2 diabetes, 
cardiovascular diseases, cancer and degenerative 
diseases.2,6-8 After intake, phenolic compounds 
undergo several transformations, which closely 
depend on their absorption and metabolism. In 
addition, over the last decade, many authors have 
highlighted the relevant role of diet phenols in the 
large intestine where these compounds are 
metabolized and can interact with local 
microbiota.9-12 
The in vitro digestion models are useful resources 
for predicting chemical and structural changes, but 
do not fully cover the physiological conditions 
phenolic compounds are exposed to in the 
gastrointestinal tract of living organisms. In vitro 
digestion models should be considered as a 
preliminary evaluation in the bioavailability studies 
and it would be appropriate to combine these with 
in vivo studies. For in vivo studies, humans are 
preferred and the absorption and metabolism of 
bioactive compounds is normally studied through 
the analysis of such biological fluids as plasma 
and urine.13-15 The identification of phenolic 
compounds and/or their biological metabolites in 
human biospecimens has been successfully used 
as markers of food intake and to associate their 
presence with disease preventive effects. 
Biological samples, such as urine and faeces, can 
be collected directly by the individuals involved, 
since no further training is required and the 
volunteers need not remain under clinical 
surveillance in special rooms for extended periods 
of time.  
The analysis of food bioactive metabolites in blood 
is a good predictor of their absorption and 
metabolism and allows a reasonable estimate of 
the exposure of the target organs and/or tissues to 
these compounds. Nevertheless, qualified 
personnel and special supervision are required to 
obtain blood samples, and this could limit the 
objectives and increase the cost of the 
bioavailability studies. For this reason, it is 
necessary to find alternative solutions to simplify 
the blood sampling, especially in post-prandial 
bioavailability kinetic studies. In order to reduce 
these downsides, a simplified method using dried 
blood-spot (DBS) cards could be considered for 
the direct blood sampling and sample pre-
treatment prior to the chromatographic analysis of 
phenolic metabolites. This sample pre-treatment 
strategy was previously applied by our group for 
the analysis of olive oil phenolic metabolites in 
human urine.16 The successful results obtained 
and the simplified sampling technique encouraged 
us to apply this method to the analysis of blood 
samples.  
The aim of the present study is to provide a better 
understanding of human metabolic pathways of 
different phenolic sub-classes from A. unedo fruit 
after an acute intake by healthy adults. Therefore, 
the purpose of this study was to determine A. 
unedo phenolic compounds and their generated 
metabolites in whole blood (0 to 24 h), urine (24 h) 
and faeces (12 and 24 h). Special focus was 
placed on the use of DBS cards for the direct 
analysis of phenolic metabolites in whole blood 
samples. To our knowledge, this is the first study 
in which DBS cards are applied to the analysis of 
blood phenolic metabolites. 
 
2. MATERIALS AND METHODS 
2.1. Chemicals and reagents 
Ultrapure water was obtained from a Milli-Q water 
purification system (Millipore Corp., Bedford, MA, 
USA). Acetonitrile (HPLC-grade) was from Romil 
(Tecknokroma, Barcelona, Spain). Methanol and 
acetone (all HPLC-grade), hydrochloric acid (HCl) 
(37%), phosphoric acid (85%) and glacial acetic 
acid (99.8%) were from Scharlau S.L. (Barcelona, 
Spain).  
Different commercial standards were used to 
identify and quantify the phenolic compounds from 
A. unedo fruit. Ellagic acid, syringic acid, 3-(4-
hydroxyphenyl)propionic acid and 3-(2’,4’-
dihydroxyphenyl)propionic acid were purchased 
from Fluka (Buchs, Switzerland); p-
hydroxybenzoic acid, protocatechuic acid, 
catechin, epicatechin, hippuric acid, myricetin and 
catechol were from Sigma Aldrich (St. Louis, MO, 
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USA); cyanidin-3-O-glucoside, quercetin, 
kaempferol, taxifolin (as internal standard (IS)), 
and dimer B2 were from Extrasynthese (Genay, 
France). Gallic acid was purchased from Panreac 
(Barcelona, Spain). Standards of hydroxyl-6H-
benzopyran-6-one derivatives (urolithins), such as 
urolithin A (dihydroxyurolithin), urolithin B 
(hydroxyurolithin) and urolithin C 
(trihydroxyurolithin) were kindly provided by Dr. 
Thasana from Chulabhorn Research Institute, 
Laksi, Bangkok.17 
 
2.2. Arbutus unedo phenolic composition  
A. unedo fruit were manually harvested in 
November 2014 in the vicinity of Lleida (Catalonia, 
Spain). The fruit were delivered to the laboratory 
on the same day they were picked. There, after 
being washed manually and cut radially (1 cm 
sized pieces), they were lyophilized (Telstar 
Lyobeta 15). The freeze-dried fruit was maintained 
in a desiccator protected for the light. The acute 
intake assay was run on the following week 
harvest. For the extraction of phenolic compounds 
from A. unedo, 0.1 g of ground lyophilized fruit 
was mixed with 5 mL of an acidified aqueous 
methanol solution (methanol/Milli-Q water/acetic 
acid, 79.9:20:0.1, v/v/v) and shaken for 10 min. 
After this time, the samples were centrifuged 
(9000 rpm for 10 min at room temperature), and 
the supernatant was filtered through a 0.22 µm 
nylon syringe filter (Tecknokroma, Barcelona, 
Spain) and transferred to the autosampler vial 
before the chromatographic analysis.  
 
Fgure 1. Schematic representation of the study design of acute intake of A. unedo by healthy volunteer. 
 
2.3. Study design 
Three healthy humans with normal weight (IBM 
18.5–24.9 kg m−2) participated in the study. They 
were in good health, with no declared 
gastrointestinal disorders and not having received 
antibiotic treatment during the three months prior 
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to the study. The subjects gave written informed 
consent before starting the experiment protocol. 
The experiment was performed in compliance with 
the Helsinki Declaration and good clinical practice 
guidelines of the International Conference of 
Harmonization (ICH GCP). The protocol of the 
study was approved by the Ethical Committee of 
Human Clinical Research of Arnau Vilanova 
University Hospital, Lleida, Spain (approval 
number: CEIC-1326). Fig. 1 shows a schematic 
depiction of the study design. After 2 days of 
wash-out and fasting overnight, the three 
volunteers consumed a single helping of 50 g of 
the lyophilized A. unedo fruit (equivalent to 163 g 
of fresh weight). Fasting samples of blood, urine 
and feces were collected before the acute intake. 
Following the A. unedo consumption, blood (0.5, 
1, 2, 4, 12 and 24 h), urine (24 h) and feces (12 
and 24 h) were collected. The intake of the single 
dose of A. unedo was preceded by a two-day 
wash-out period consisting of restriction on the 
consumption of fruit, vegetables, tea, red wine, 
chocolate, cocoa, whole grain foods and coffee. 
The same diet limitations were also respected on 
the day of the study, in which volunteers received 
low polyphenol meals for lunch and dinner, which 
consisted of refined carbohydrates, cheese, ham 
and plain yoghurt. Detailed information of food 
intake during the two days of the wash-out period 
and the day of the study was gathered from each 
volunteer in order to confirm dietary compliance. 
 
2.4. Biological samples pre-treatment 
The sample pre-treatment for the extraction of 
phenolic compounds and their generated 
metabolites in urine, blood and feces was carried 
out as follows. 
Blood analysis. Blood samples at baseline (0 h) 
and different post-intake times (0.5, 1, 2, 4, and 24 
h) were collected in the laboratory. The blood 
samples at 12 h were taken by each volunteer at 
home, stored at -20 ºC and transported to the 
laboratory the next day in refrigerated containers. 
The whole blood was taken by pricking the 
volunteers’ fingers with disposable lancets 
(Unistik®, Owen Mumford Ltd, Woodstock, UK). 
Then, the blood drops were directly collected with 
micro-capillary blood collection tubes that 
contained lithium-heparin as anticoagulant 
(Microvette® CB 300 LH, sample volume 300 μL 
Sarstedt, Numbrecht, Germany). 20 μL of this 
whole blood was spotted onto a pre-marked circle 
on the FTA DMPK cards (DBS filter paper) (GB 
Healthcare, Buckinghamshire, UK). The cards 
were then dried in the dark at room temperature 
for 2 h in a desiccator. After this time, 7 disks of 2 
mm diameter were punched out from the card and  
were placed into an Eppendorf with 100 L of 
methanol/water (50:50, v/v) (Figure 1). The Harris 
Uni-Core punch and a Cutting Mat were supplied 
by Whatman Inc. (Sanford, ME, USA). The 
Eppendorf was then vortexed for 5 min and 
centrifuged at 9000 rpm for 10 min at room 
temperature. The supernatant was filtered through 
a 0.22 µm nylon syringe filter and directly injected 
into the chromatographic system. Each blood 
sample was analyzed in triplicate. 
Urine analysis. Urine samples were collected by 
the volunteers in appropriate containers at the 
baseline (0 h) and over 24 h after the A. unedo 
fruit intake. After measuring the total urine volume, 
aliquots of 6 mL were freeze-dried. Before the 
chromatographic analysis, the dry residue was 
reconstituted with 200 µL of an aqueous solution 
of 4% phosphoric acid. 100 µL of this solution was 
mixed in an Eppendorf containing 50 µL of 
taxifolin (IS) (at the concentration of 10 mg/L and 
prepared with 4% phosphoric acid) and 50 µL of 
4% phosphoric acid. This solution was then 
centrifuged at 9000 rpm for 10 min at room 
temperature and the supernatant was cleaned up 
with µElution solid-phase extraction (µSPE). 
OASIS hydrophilic-lipophilic balance (HLB) 
µElution plates 30 µm (Waters, Milford, MA, USA) 
were used. These were activated with 250 L of 
methanol and equilibrated with 250 L of 0.2% 
acetic acid. 100 µL of urine supernatant with IS 
(50 µL) and 50 µL of 40% phosphoric acid were 
loaded into the plate. The retained phenolic 
compounds were then eluted with 2 x 50 µL of the 
solution acetone/Milli-Q water/acetic acid 
(70:29.5:0.5, v/v/v). 2.5 µL of the eluted solution 
were directly injected into the chromatographic 
system (UPLC-MS/MS). Each urine sample was 
analyzed in triplicate. 
Feces analysis. Feces collected by volunteers 
before and after the acute intake of A. unedo were 
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freeze-dried in order to avoid possible variability 
due to the water content. Before the 
chromatographic analysis, freeze-dried feces (0.1 
g) were mixed with 1 mL of an acidified aqueous 
methanol solution (methanol/Milli-Q water/HCl, 
79.9:20:0.1, v/v/v) and shaken in vortex for 10 
min. Then, the solution was centrifuged at 9000 
rpm for 10 min at room temperature. The 
supernatants were collected and filtered with a 
syringe with a 0.2 um filter pore size and analyzed 
by UPLC-MS/MS. The fecal samples were 
analyzed in triplicate.  
.
  
Table 1. Phenolic content in the single dose of A. unedo lyophilized fruit consumed by the volunteers 
(mean value ± standard deviation).  
Phenolic compound 
µmol/50 g lyophilized 
A. unedo fruit 
Phenolic compound 
µmol/50 g lyophilized 
A. unedo fruit 
Galloyl derivatives   Flavonols  
Gallic acid 72.5 ± 9.41 Myricetin 0.18 ± 0.00 
Gallic acid hexoside 327 ± 25.0 Dihydroquercetin  0.8 ± 0.17 
Galloyl shikimic acid 340 ± 25.0 Quercetin arabinoside 8.32 ± 0.34 
Digalloyl shikimic acid 181 ± 17.0 Quercetin rhamnoside 16.1 ± 1.33 
Galloyl quinic acid 618 ± 80.1 Quercetin glucoside 5.73 ± 0.53 
Digalloyl quinic acid 64.9 ± 7.16 Quercetin-3-O-glucoside 0.07 ± 0.04 
Trigalloyl quinic acid 3.22 ± 0.15 Quercetin galloyl hexoside 4.03 ± 0.60 
Tetragalloyl quinic acid 25.4 ± 1.69 Dihydroxykaempferol 9.01 ± 0.59 
Total 1632 ± 144 Kaempferol-3-O-rhamnoside 1.17 ± 0.33 
Ellagic acid derivatives   Kaempferol-3-O-glucoside 0.11 ± 0.07 
Ellagic acid 8.1 ± 0.59 Kaempferol-3-O-rutinoside 0.61 ± 0.27 
Ellagic acid arabinoside 657 ± 76.9 Dihydrokaempferol hexoside 23.3 ± 3.30 
Strictinin ellagitannin 371 ± 51.0 Myricetin rhamnoside 21.3 ± 0.59 
Total 1036±122 Myricetin glucoside 7.25 ± 0.58 
Flavan-3-ols   Total 98 ± 5.34 
Catechin 48.1 ± 3.11 Anthocyanins  
Epicatechin gallate 11.2 ± 1.04 Cyanidin glucoside 20.6 ± 2.76 
Epigallocatechin gallate 3.97 ± 0.61 Cyanidin arabinoside 7.31 ± 1.16 
Gallocatechin-catechin 12.4 ± 1.26 Delphinidin arabinoside 1.71 ± 0.29 
Dimer B2 0.28 ± 0.06 Delphinidin glucoside 2.1 ± 0.33 
Other dimers 30.4 ± 2.02 Pelargonidin glucoside 0.25 ± 0.04 
Trimer 1.37 ± 0.16 Pelargonidin arabinoside 0.09 ± 0.01 
Total 108 ± 7.94 Peonidin glucoside 0.12 ± 0.01 
  Peonidin arabinoside 0.07 ± 0.01 
  Total 32.2 ± 3.92 
  Total phenolic content 2905 ± 276 
 
2.5. Liquid-chromatography coupled to tandem 
mass spectrometry (UPLC-MS/MS) 
The analysis of phenolic compounds in samples of 
A. unedo fruit, and in the biological samples 
(blood, urine and faeces) was performed by ultra-
performance liquid chromatography (UPLC) 
coupled to tandem mass spectrometry (MS/MS) 
as the detector system (Waters, Milford, MA, 
USA). The chromatographic column was an 
Acquity BEH C18 (100 mm x 2.1 mm i.d.) with a 
1.7 µm particle size (Waters). The UPLCTM 
system was equipped with a binary pump system, 
and a gradient elution was used. Two different 
mobile phases were used, one for the analysis of 
anthocyanins, and the second one for the other 
phenolic compounds. For the analysis of 
anthocyanins, eluent A was Milli-Q water/acetic 
acid (90:10, v/v) and eluent B, acetonitrile. The 
gradient was performed as follows: 0-10 min, 3-25 
%B; 10-10.1 min, 25-80 %B; 10.1-11 min, 80 %B; 
11-11.1 min, 80-3 %B; 11.1-12.5 min, 3 %B. On 
the other hand, eluent A for the analysis of the 
rest of the phenolic compounds was Milli-Q 
water/acetic acid (99.8:0.2, v/v) and eluent B, 
acetonitrile. The gradient was performed as 
follows: 0-5 min, 5-10 %B; 5-10 min, 10-12.4 %B; 
10-18 min, 12.4-28 %B; 18-23 min, 28-100 %B; 
23-25.5 min, 100 %B; 25.5-27 min, 100-5 %B; and 
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27-30 min, 5%B. For all the phenolic compounds, 
the flow-rate was 0.4 mL/min and the injection 
volume was 2.5 L. Prior to chromatographic 
analysis, the samples were filtered with a 0.22 m 
nylon syringe filter. 
Tandem MS (MS/MS) analyses were carried out 
on a triple quadrupol detector (TQD) mass 
spectrometer (Waters, Milford, MA, USA) 
equipped with a Z-spray electrospray interface. 
Ionization was achieved using electrospray (ESI) 
interface operating in the negative mode [M-H]- 
and the data was acquired through selected 
reaction monitoring (SRM). The ionization source 
parameters were capillary voltage 3 kV, source 
temperature 150 ºC and desolvation gas 
temperature 400 ºC, with a flow rate of 800 L/h. 
Nitrogen (99.99% purity, N2LCMS nitrogen 
generator, Claind, Lenno, Italy) and argon (≥ 
99.99% purity, Aphagaz, Madrid, Spain) were 
used as cone and collision gases respectively. 
Two SRM transitions were studied, selecting the 
most sensitive transition for quantification and a 
second one for confirmation purposes. The SRM 
transition for quantification and the individual cone 
voltage and collision energy for each phenolic 
compound and metabolite are shown in Table 1 of 
Supplementary Information. In this table is also 
shown in which standard compound is quantified 
or tentatively quantified each phenolics and 
metabolites. The dwell time established for each 
transition was 30 ms. Data acquisition was carried 
out with the MassLynx 4.1software. 
The calibration curves were prepared by spiking 
blank blood, urine and faeces samples, obtained 
from volunteers under fasting conditions, with 
known concentrations of the standard compounds. 
Gallic acid, catechin, dimer B2, ellagic acid, 
myricetin, cyanidin-3-O-glucoside, p-hydroxy 
benzoic acid, catechol, hippuric acid, 
protocatechuic acid, 3-(4-hydroxyphenyl) 
propionic acid, mono-, di-, and tri-hydroxy 
urolithins were quantified with their own calibration 
curves. On the other hand, gallic acid hexoside, 
mono-, di-, tri- and tetra-O-galloylquinic acid, 
mono- and di-O-galloylshikimic acid, gallic acid 
sulfate and gallic acid glucuronide were tentatively 
quantified by using the calibration curve of gallic 
acid. Pyrogallol sulfate, methyl pyrogallol 
sulphate, pyrogallol glucuronide, and pyrogallol 
glucuronide-sulfate, catechol sulfate, and catechol 
glucuronide were tentatively quantified as 
catechol. Ellagic acid arabinoside, ellagic acid 
glucuronide and strictinin ellagitannin were 
tentatively quantified as ellagic acid. 
Gallocatechin-catechin, catechin glucuronide, 
methyl catechin glucuronide and catechin sulfate 
were tentatively quantified as catechin. 
Epigallocatechin, epicatechin gallate, 
epigallocatechin gallate, epicatehin glucuronide, 
methyl epicatechin glucuronide and methyl 
epicatechin sulfate were tentatively quantified as 
epicatechin. Dimer and trimer were tentatively 
quantified as dimer B2. Dihydroquercetin, 
quercetin arabinoside, quercetin rhamnoside, 
quercetin glucoside, quercetin-3-O-glucoside and 
quercetin galloyl hexoside were tentatively 
quantified as quercetin. Dihydroxykaempferol, 
kaempferol-3-O-rhamnoside, kaempferol-3-O-
glucoside, kaempferol-3-O-rutinoside and dihydro 
kaempferol hexoside were tentatively quantified 
as kaempferol. Myricetin rhamnoside and 
myricetin glucoside were tentatively quantified as 
myricetin. All the anthocyanins were tentatively 
quantified as cyanidin-3-O-glucoside. Hydroxy 
phenylpropionic acid was tentatively quantified as 
4-hydroxyphenylpropionic. Hydroxyurolithin 
glucuronide was tentatively quantified as 
hydroxyurolithin; and dihydroxyurolithin 
glucuronide as dihydroxyurolithin. Tetra 
hydroxyurolithin, pentahydroxyurolithin, and tetra 
hydroxyurolithin sulfate were tentatively quantified 
as trihydroxyurolithin. 
 
2.6. Method validation  
The instrumental quality parameters of the 
method, such as linearity, repeatability, accuracy, 
detection limits (LODs), and quantification limits, 
as well as the extraction recovery (%R) and matrix 
effect (%ME) for the determination of phenolic 
compounds in biological samples, were 
determined by spiking blank biological samples 
(blood, urine and faeces obtained prior to A. 
unedo intake) with known concentrations of 
standard compounds. These instrumental quality 
parameters, as well as the %R and %ME, were 
determined as reported in our previous study.16 
The results obtained are shown in Table 1 of the 
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Supplementary Information. The %R for all the 
phenolic compounds studied was higher than 75% 
and the %ME was lower than 15%. 
 
3. RESULTS 
Table 1 shows the dose of A. unedo phenols 
ingested thought 50 g of lyophilized fruit 
(expressed as µmols of phenolic compound). As 
can be seen, the main phenolic compounds are 
galloyl and ellagic acid derivatives whereas minor 
fractions correspond to flavan-3-ols, flavonols and 
anthocyanins. After the intake of the single dose 
of 50 g of lyophilized A. unedo fruit (equivalent to 
approximately 2900 µmols phenolic compounds), 
the phenolic metabolism was studied through the 
analysis of  blood, urine and faeces  
 
. 
 Figure 2. Pharmacokinetic representation of the main phenolic metabolites detected in blood samples at 
different times (0, 0.5, 1, 2, 4, 12 and 24 h) of healthy adults after the intake of a single dose of 50 g of 
lyophilized A. unedo. 
 
3.1. Phenolic metabolites in blood samples 
Figure 2 shows the individual kinetics of the main 
phenolic metabolites detected in the blood 
samples of the three volunteers after the acute 
intake of 50 g of lyophilized A. unedo (numerical 
data is available in Table 2 of the Supplementary 
Information). In general, a progressive increase 
with time (with small oscillations) and two 
maximum peaks were observed for the main of 
the phenolic metabolites generated, one at 4 h, 
and a second one between 12-24 h (Figure 2). 
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The blood concentration of catechol, pyrogallol 
and methyl pyrogallol, all in their sulfate forms, 
reached a maximum at 4 h post-intake of A. 
unedo in the three volunteers. On the other hand, 
the concentration of the hydroxybenzoic acid, 
hydroxyphenylpropionic acid and hippuric acid 
showed a maximum at 12 h post-intake, with 
except in volunteer 2 who showed the maximum 
concentration at 24 h. No native or conjugated 
forms of gallotannins, flavan-3-ols, ellagic acid, 
flavonols and anthocyanins were detected in the 
whole blood. One aspect to be noted is the 
person-to-person variability, which was particular 
obvious in terms of the concentrations and the 
time when the different phenolic metabolites reach 
their maximum peak, especially between 12 and 
24 h after the intake of the A. unedo fruit (Figure 2 
and Table 2 of the Supplementary Information).  
 
Table 2. Phenolic compounds and their metabolites (μmol/day) detected in the volunteer’s 24 h urine 
after the acute intake of 50 g of lyophilized Arbutus unedo 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results are expressed as mean (n=3)  SD: standard deviation n.d.: no detected (Its concentration is below its detection 
limit (LOD)). Vol.: Volunteer 
 
3.4. Urinary excretion of phenolic compounds 
Table 2 shows the mean urinary concentrations of 
phenolic metabolites detected in the three 
volunteers followed the intake of the single dose 
of lyophilized A. unedo fruit (μmols excreted/24 h). 
The high number of phenolic compounds and their 
metabolites detected in urine show the extensive 
metabolism that the A. unedo phenols underwent 
in the human body. A total of 28 phenolic 
Phenolic metabolites 
Concentration (μmol/day) ± SD 
Vol. 1 Vol. 2 Vol. 3 
Gallic acid and its derivatives       
Gallic acid 0.66 ± 0.06 1.66 ± 0.76 n.d. 
Gallic acid sulfate 4.37 ± 1.73 12.7 ± 5.04 0.78 ±0.12 
Gallic acid glucuronide 0.17 ± 0.09 0.86 ± 0.37 0.14 ±0.07 
Galloylshikimic acid 0.94 ± 0.40 2.29 ± 0.30 0.49 ± 0.07 
Galloylquinic acid n.d. 0.26 ± 0.13 0.01 ± 0.01 
Phenolic acids     
Protocatechuic acid 0.54 ± 0.09 0.82 ± 0.25 n.d. 
Syringic acid 0.14 ± 0.01 0.12 ± 0.03 0.07 ± 0.02 
Syringic acid sulfate 0.13 ± 0.04 0.49 ± 0.21 0.04 ± 0.03 
Hydroxyphenylpropionic acid 3.18 ± 0.30 1.57 ± 0.22 0.54 ± 0.06 
Hippuric acid 31.3 ± 3.58 48.6 ± 5.25 18.3 ± 9.67 
Flavan-3-ols and their metabolites    
Catechin 0.18 ± 0.00 0.45 ± 0.14 0.08 ± 0.05 
Catechin sulfate 3.92 ± 0.58 10.5 ± 1.40 1.69 ± 0.57 
Catechin glucuronide 0.05 ± 0.01 0.16 ± 0.06 0.03 ± 0.00 
Epicatechin glucuronide 0.11 ± 0.01 0.35 ± 0.23 0.03 ± 0.00 
Methyl catechin sulfate 0.66 ± 0.09 1.49 ± 0.24 0.26 ± 0.02 
Methyl catechin glucuronide 0.08 ± 0.02 0.30 ± 0.06 0.07 ± 0.01 
Methyl epicatechin sulfate 0.22 ± 0.05 0.57 ± 0.06 0.08 ± 0.02 
Methyl epicatechin glucuronide 0.43 ± 0.07 0.94 ± 0.17 0.23 ± 0.03 
Catechol and pyrogallol and their metabolites    
Catechol sulfate 89.1 ± 14.7 65.7 ± 22.0 12.3 ± 3.89 
Catechol glucuronide 6.72 ± 1.02 6.88 ± 2.79 1.05 ± 0.14 
Pyrogallol sulfate 56.4 ± 14.5 169 ± 43.5 27.1 ± 17.2 
Methyl pyrogallol sulfate 8.78 ± 1.79 28.2 ± 7.19 18.0 ± 23.1 
Pyrogallol glucuronide 12.6 ± 2.75 29.0 ± 11.2 6.45 ± 1.86 
Pyrogallol glucuronide sulfate 0.30 ± 0.04 0.50 ± 0.16 0.31 ± 0.04 
Ellagic acid and its metabolites    
Ellagic acid glucuronide 17.0 ± 0.25 19.9 ± 3.96 10.2 ± 1.63 
Hydroxyurolithin glucuronide 0.01 ± 0.01 0.03 ± 0.01 0.04 ± 0.00 
Dihydroxyurolithin glucuronide 0.14 ± 0.01 n.d. 0.55 ± 0.05 
Tetrahydroxyurolithin sulfate 0.01 ± 0.00 0.02 ± 0.00 n.d. 
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metabolites were selected and quantified after 
comparing their concentrations (μmol/L) between 
the baseline (0 h) and the cumulative urinary 
excretion (24 h). Among these, gallic acid, galloyl-
derivatives, protocatechuic acid, syringic acid 
(including its sulfate form), flavan-3-ols (including 
sulfate and glucuronide metabolites) and urolithin 
metabolites, could be characterized as exclusive 
to the A. unedo fruit intake, since they were not 
detected in the urine at 0 h (Table 2).
 
 
Table 3. Concentration of the microbial phenolic metabolites (nmol/g lyophilized feces) after 12 h 
(volunteer 1) and 24 h (volunteers 1, 2 and 3) the intake of 50 g of lyophilized A. unedo (results are 
expressed as mean ± standard deviation 
  
Phenolic metabolites  
Concentration (nmol/g lyophilized feces) 
12 h 24 h 24 h 24 h 
Vol 1 Vol 1 Vol 2 Vol 3 
Gallic acid 8.85 ± 1.75 n.d. n.d. n.d. 
Hippuric acid n.d. 5.35 ± 0.71 27.4 ± 2.11 n.d. 
p-hydroxybenzoic acid 12.3 ± 0.62 15.2 ± 4.73 133 ± 7.52 7.91 ± 1.45 
Hydroxybenzoic acid 0.06 ± 0.07 0.21 ± 0.36 n.d. n.d. 
Protocatechuic acid 1.37 ± 1.26 n.d. n.d. n.d. 
Catechol 397 ± 19.9 206 ± 19.2 71.5 ± 3.06 16.3 ± 1.15 
Phenylpropionic acid n.d. n.d. n.d. 2.42 ± 1.39 
3-(4’-hydroxyphenyl)propionic acid n.d. n.d. 92.6 ± 11.9 n.d. 
Hydroxyphenylpropionic acid 1069 ± 23.7 297 ± 6.35 15158 ± 1042 547 ± 173 
3-(2’,4’-dihydroxyphenyl)propionic acid n.d. n.d. 2.58 ± 2.86 n.d. 
Dihydroxyphenylpropionic acid n.d. n.d. 529 ± 34.6 42.9 ± 7.50 
Hydroxyurolithin n.d. n.d. n.d. n.d. 
Dihydroxyurolithin n.d. 33.81 ± 12.5 46.0 ± 22.7 84.6 ± 1.91 
Trihydroxyurolithin 0.07 ± 0.06 n.d. 5.94 ± 5.14 n.d. 
Tetrahydroxyurolithin 0.17 ± 0.04 n.d. 0.26 ± 0.22 n.d. 
Pentahydroxyurolithin 0.34 ± 0.02 1.61 ± 0.24 0.16 ± 0.10 n.d. 
n.d.: no detected (its concentration is below its LOD) 
Vol.: volunteer  
 
 
 
 
Of these compounds, galloyl shikimic acid (2.29-
0.49 μmols excreted/24 h) and gallic acid sulfate 
(12.7-4.37 μmols excreted/24 h) were the most 
predominantly excreted. Other phenolic 
metabolites were detected in urine at the baseline 
(0 h), but a large increase in their concentration 
was observed after the intake of A. unedo fruit. 
The most abundant were catechol sulfate (89.1-
12.3 μmols excreted/24 h), pyrogallol sulfate (169-
27.1 μmols excreted/24 h) and hippuric acid (48.6-
18.3 μmols excreted/24 h). Other metabolites that 
contributed considerably to the urinary phenolic 
pool were pyrogallol glucuronide (29.0-6.54 μmols 
excreted/24 h), ellagic acid glucuronide (19.9-10.2 
μmols excreted/24 h) and methyl pyrogallol sulfate 
(28.2-8.78 μmols excreted/24 h).  
3.3. Phenolic metabolites in fecal samples  
The three volunteers provided the fecal samples 
24 h after the A. unedo fruit intake, but only one of 
them (Vol. 1) was able to provide an extra sample 
after 12 h. The post-intake concentration of fecal 
metabolites, expressed in nmol/g lyophilized 
feces, is shown in Table 3. Similarly to what was 
observed in the blood and urine samples, 
important inter-individual variability was observed 
in the feces obtained 24 h post-intake. The results 
showed an intense colonic metabolism of A. 
unedo phenolic compounds since no native 
structures detected in the fruit (Table 1) were 
found in the feces taken 24 h after ingestion 
(Table 3). Hydroxyphenylpropionic acid (297 to 
15158 nmols/g lyophilized feces) was the main 
microbial metabolite quantified in the feces of the 
three volunteers. Despite notable differences 
between individuals, other metabolites, such as p-
hydroxybenzoic acid, hippuric acid, catechol, 
dihydroxyphenylpropionic acid and urolithins 
(especially urolithin A), were also detected at 
higher concentration levels (nmols/g lyophilized 
faeces) compared with the baseline (t = 0 h)  
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Figure 3. Possible phenol metabolic pathways for the generation of the phenolic metabolites (only the 
aglycones) detected in blood, urine and feces after the acute intake of A. unedo fruit 
 
 
4. DISCUSSION 
Human studies regarded the evaluation of the 
absorption, metabolism and excretion of phenolic 
compounds are highly appreciated because the 
results obtained are useful for tentatively 
determining their effective bioavailability. The 
bioavailability studies are based on the collection 
of biological samples, normally blood and urine, 
after the acute intake of a specific food or pure 
compound. Although the urine samples can be 
collected by volunteers themselves, the collection 
of blood/plasma has serious limitations as it 
requires qualified staff and special infrastructures 
where volunteers must spend a long time. During 
this period, the subjects have numerous blood 
samples taken and where it is sometimes 
necessary to use a cannula for hours to facilitate 
the procedure. Beyond the discomfort this means, 
some people have a particular aversion to 
needles, which could be a reason to refuse to 
participate in a study like this and consequently 
making it more difficult to find enough volunteers. 
The satisfactory results obtained previously by our 
group with the application of DBS cards for the 
sample-pretreatment to determine olive oil 
phenolic metabolites in urine samples16 gave us 
the motivation to extend the use of this easy 
strategy for the volunteers to collect their own 
samples for bioavailability studies using whole 
blood.  
It is highly desirable to promote phytochemical-
rich products because this would be an effective 
way to increase opportunities to enrich the variety 
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and nutritional value of the diet. Moreover, 
bioavailability studies, especially those with 
human subjects, are required to determine the 
way the body uses the phenolic compounds. In an 
effort to investigate whether the phenolic 
compounds from A. unedo fruit are bioavailable in 
the human body, for the first time, we conducted 
an acute study to determine the possible potential 
of this fruit as a rich source of phenolic 
compounds for a healthy population. A special 
feature of the A. unedo fruit is that it ripens in the 
autumn-winter period of generally low availability 
of fruit with high phenolic antioxidant contents. 
The analysis of the phenolic composition of the 
blood, urine and faeces revealed an increase in 
the concentrations of a wide variety of phenolic 
metabolites (including phase-II metabolites and 
microbial catabolism), which suggests the active 
metabolism that A. unedo phytochemicals 
undergo in the human body. The results of the 
present study also demonstrate, for the first time, 
that the phenolic compounds from A. unedo are 
bioavailable in healthy adults and, in addition, the 
main phenolic compounds absorbed can be 
quantified in blood samples by using DBS cards 
for the self-management of blood collection and 
easy sample-pretreatment before the 
chromatographic analysis. 
Over the last few years, the use of DBS cards has 
gained ground in studies concerning drug 
pharmacokinetics and other applications, such as 
the detection of prohibited substances 
(doping),18,19 therapeutic drug monitoring, 
assessing adherence to medications and 
preventing toxicity.20 In contrast, to the best of our 
knowledge, this is the first time that DBS cards 
have been used for the determination of phenolic 
metabolites in whole blood. Easy sample 
collection, the possibility of self-management of 
blood collection, easy sample pre-treatment and 
the reduction of invasive techniques could convert 
the use of this method into a promising way to 
increase the number of human studies in the area 
of phytochemical bioavailability. One downside of 
DBS cards could be the low sensitivity when trace 
metabolites are determined. In our study, in order 
to enhance the sensitivity of this sample pre-
treatment, the entire blood circle was punched out 
from the card and analyzed, which was equivalent 
to 7 disk extractions, instead of only one 
extraction (disk). 
Two transient maximum concentrations of 
phenolic metabolites were noticed in blood 
samples after the intake of A. unedo fruit. The 
maximum concentrations of catechol sulfate, 
pyrogallol sulfate and methyl pyrogallol sulfate 
were found in the blood of the three volunteers 4 h 
after the A. unedo fruit intake. By contrast, the 
maximum concentration of hydroxyphenyl 
propionic acid, hippuric acid and hydroxybenzoic 
acid was detected at 12 or 24 h after the A. unedo 
fruit intake, depending on the volunteer. 
Discrepancies between volunteers in the 
concentration and time when each metabolite 
reached its maximum blood concentration could 
be related to individual differences in the 
dynamics of gastrointestinal transit time, diverse 
absorption efficiency and particular microbiota 
composition. An increase in the plasma 
concentration of the sulfated forms of catechol 
and pyrogallol have also been described by 
Pimpao et al. (2015)15 after an acute intake of 500 
mL of a mixture of fruit (including A. unedo) by 
healthy adults. Considering the delay appearance 
(4 h) of sulfated pyrogallol in blood, this metabolite 
probably originated from the hydrolysis of galloyl 
phenol derivates (galloylshikimic acid, galloyl 
quinic acid, gallotannins, galloyl flavan-3-ols) in 
the proximal large intestine through the action of 
microbial esterases and carboxilases.21 Microbial 
dehydroxilation, previous described in in vitro 
incubations,9,12 could explain the appearance of 
catechol from pyrogallol. Based on the 
compounds detected in the blood, we proposed 
the possible human metabolic pathways of A. 
unedo phenolic compounds (Figure 3). This 
includes the generation of phase-II metabolites 
(sulfo-conjugates), probably originated in the liver 
after intestinal absorption. The microbial 
catabolism in the distal colon could explain the 
second peak observed in blood after 12-24 h of A. 
unedo intake, in which hydroxyphenylpropionic, 
hippuric and hydroxybenzoic acids were detected 
as the main metabolites. Gonthier et al. (2003)22 
assumed that quinic acid could be the precursor of 
hippuric acid, probably via the gut microbial 
shikimate pathway in the gastrointestinal tract.23 
Hippuric acid has also been described as a 
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hepatic and renal metabolite resulting from the 
conjugation of benzoic acid and glycine.24 The 
presence of hydroxyphenylpropionic and 
hydroxybenzoic acids may be due to the microbial 
metabolism of flavan-3-ols10,12,14,25 and/or 
flavonols11,12,26 (Figure 3). 
In the present study, a greater diversity of the 
phenolic spectrum was noticed in urine than in the 
blood. This ties well with the results reported by 
other authors, where the phenolic profile of human 
or animal urine reaches a greater complexity than 
that of the plasma.22,27 Nevertheless, catechol and 
pyrogallol, the larger compounds excreted in urine 
after the intake of A. unedo fruit, were also the 
predominant phenolic compounds detected in 
whole blood in our study. Free galloyl shikimic and 
quinic acids were found in the urine, which 
indicates that they could be absorbed in their 
intact form by the intestinal epithelium. Therefore, 
in view of the fact that these galloyl derivatives are 
the most representative phenolic compounds of A. 
unedo, their presence in biological fluids make 
them particularly suitable markers for monitor the 
dietary exposure. Further consideration should be 
given to galloylshikimic acid since it appeared in 
the urine of all the volunteers. 
The chromatographic analysis of the urine 
revealed the presence of other phenolic 
compounds and their phase-II and microbial 
metabolites. Most of these compounds have been 
described before in human bioespeciments and 
their origin could be from a combination of 
phenolic metabolic pathways (Figure 3). 
Protocatechuic acid could be formed by the 
microbial degradation of cyanidin glucoside,13 
since this is the most abundant anthocyanin in the 
A. unedo fruit. In the case of syringic acid and its 
sulfated form, these could be generated by the 
methylation of gallic acid (phase-II metabolism). 
Epicatechin and catechin metabolites could 
originate from flavan-3-ols (Table 1) through the 
hepatic metabolism (in the case of conjugates) 
and microbial catabolism (hydrolysis of galloyl 
derivatives).25 Several studies have described 
urolithins as exclusively microbial products of 
ellagic acid colonic metabolism.12 
In the present study, we detected a relationship 
between the phenolic metabolites detected in the 
blood, urine and feces. Simpler compounds, 
derived from microbial metabolism, were the most 
abundant phenolic metabolites found in the 
human fluids. This highlights the importance of the 
full screening of bioespeciments to establish the 
bioavailability of dietary compounds, since these 
could sometimes be underestimated, especially 
because the analyses mainly focused on the 
detection of the native phenolic compounds of the 
food.28 In accordance with our results, Pimpao et 
al. (2015)15 and Margalef et al. (2015)25 observed 
that microbial phenolic metabolites contribute an 
important percentage of the absorbed and 
circulated phenolic structures in humans and 
animals.  
 
5. CONCLUSIONS 
The results of the present study, based on the 
analysis of biological fluids, like whole blood and 
urine, together with the analysis of faeces, have 
allowed us to establish the metabolic pathways of 
different phenolic groups of A. unedo fruit in 
humans for the first time. Unsupervised sampling 
of blood by volunteers at home was found to be 
suitable for the analysis of blood phenolic 
metabolites using the DBS card methodology. The 
analysis of whole blood revealed two peaks in the 
maximum concentrations of the main phenolic 
metabolites. In parallel, the analysis of urine (24 h) 
displayed a wide range of phenolic metabolites 
showing the extensive metabolism that A. unedo 
phenolic compounds underwent in the human 
body. Galloylshikimic and galloylquinic acids could 
be selected as exclusive to the A. unedo intake 
since they were not detected in the analysis of 
urine at 0 h. We believe our results provide a 
relevant contribution to the understanding of the in 
vivo human bioavailability of phenolic compounds, 
especially galloyl derivatives, a singular phenolic 
sub-group present in A. unedo fruit.   
Additionally, the use of DBS cards offers the 
advantage of easy sample pre-treatment before 
the chromatographic analysis, where a low 
volume of blood (up to 20 μL), obtained from 
minimally invasive techniques, is needed. The 
proposed use of DBS cards might be considered 
in future studies, with the possibility of extending 
the analysis with the inclusion of other 
micronutrients for simultaneous determination. 
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ADDITIONAL INFORMATION 
Table 1 Supplementary Information. Optimized SRM conditions used for quantification for the analysis of 
phenolic compounds by UPLC-MS/MS. 
Phenolic compound MW 
Quantification Standard used for quantification 
SRM 
Cone 
voltage (v) 
Collision 
energy (eV) 
 
Catechol   110 108.9  90.9 40 15 Catechol  
Catechol sulfate 190 189  109 20 15 Catechol 
Catechol glucuronide 286 285  123 40 15 Catechol 
Pyrogallol sulfate 206 205  125 20 15 Catechol 
Methyl pyrogallol sulfate 220 219  124 20 25 Catechol 
Pyrogallol glucuronide 302 301  125 20 10 Catechol 
Pyrogallol glucuronide-sulfate 382 381  125 20 10 Catechol 
p-Hydroxybenzoic acid 138 137  93 30 15 p-Hydroxybenzoic acid 
Hydroxybenzoic acid 138 137  93 30 15 p-Hydroxybenzoic acid 
Protocatechuic acid 154 153  109 40 15 Protocatechuic acid 
Gallic acid 170 169  125 35 10 Gallic acid 
Gallic acid hexoside 332 331  169 40 15 Gallic acid 
Mono-O-galloylquinic acid 344 343  191 40 15 Gallic acid 
Di-O-galloylquinic acid 496 495  191 40 25 Gallic acid 
Tri-O-galloylquinic acid 648 647  495 40 15 Gallic acid 
Tetra-O-galloylquinic acid 630 629  477 40 15 Gallic acid 
Mono-O-galloylshikimic acid 326 325  169 40 20 Gallic acid 
Di-O-galloylshikimic acid 478 477  325 40 20 Gallic acid 
Gallic acid sulphate 250 249  169 35 15 Gallic acid 
Gallic acid glucuronide 346 345  169 35 15 Gallic acid 
Syringic acid 198 197  182 30 10 Syringic acid 
Ellagic acid arabinoside 434 433  300 40 30 Ellagic acid 
Ellagic acid glucuronide 478 477  301 40 20 Ellagic acid 
Strictinin ellagitannin  634 633  301 40 30 Ellagic acid 
p-Hydroxyphenylacetic acid  152 151  107 20 10 p-Hydroxyphenylacetic acid 
Dihydroxyphenylacetic acid 168 167  123 20 10 3,4-Dihydroxyphenylacetic acid 
3-(4-Hydroxyphenyl)propionic acid  166 165  121 20 10 3-(4-Hydroxyphenyl)propionic acid 
Hydroxyphenylpropionic acid 166 165  121 20 10 3-(4-Hydroxyphenyl)propionic acid 
3-(2’,4’-Dihydroxyphenyl)propionic acid 181 181  137 20 15 3-(2’,4’-Dihydroxyphenyl)propionic acid 
Dihydroxyphenylpropionic acid  181 181  137 20 15 3-(2’,4’-Dihydroxyphenyl)propionic acid 
Hippuric acid 179 178  134 40 10 Hippuric acid 
Catechin  290 289  245 45 15 Catechin  
Gallocatechin – catechin  594 593  289 40 30 Catechin 
Catechin sulfate 370 369  289 40 20 Catechin 
Catechin glucuronide 466 465  289 40 20 Catechin 
Methyl catechin glucuronide 480 479  303 40 25 Catechin 
Epicatechin  290 289  245 45 15 Epicatechin  
Epigallocatechin  306 305  125 40 15 Epicatechin 
Epicatechin gallate 442 441  169 40 20 Epicatechin 
Epigallocatechin gallate 458 457  169 40 15 Epicatechin 
Methyl epicatechin sulfate 384 383  303 45 15 Epicatechin 
Methyl epicatechin glucuronide 480 479  303 40 25 Epicatechin  
Dimer  578 577  289 45 20 Dimer B2 
Trimer  865 865  287 60 30 Dimer B2 
Quercetin-3-O-glucoside 464 463  301 45 25 Quercetin 
Quercetin glucoside 464 463  301 45 25 Quercetin 
Quercetin arabinoside  434 433  300 45 20 Quercetin 
Quercetin rhamnoside 448 447  301 40 15 Quercetin 
Dihydroquercetin  304 303  285 45 15 Quercetin 
Quercetin galloyl hexoside 616 615  463 40 30 Quercetin  
Kaempferol-3-O-glucoside 448 447  285 45 15 Kaempferol 
Kaempferol-3-O-rhamnoside 432 431  285 45 20 Kaempferol 
Kaempferol-3-O-rutinoside 594 593  285 50 25 Kaempferol 
Dihydrokaempferol  288 287  259 45 10 Kaempferol 
Dihydrokaempferol hexoside 450 449  269 40 15 Kaempferol  
Myricetin glucoside  480 479  317 45 20 Myricetin  
Myricetin rhamnoside  464 463  317 50 25 Myricetin  
Cyanidin-3-O-glucoside * 450 449  287 40 20 Cyanidin-3-O-Glucoside 
Cyanidin arabinoside * 420 419  287 40 20 Cyanidin-3-O-Glucoside 
Delphinidin arabinoside * 436 435  303 40 20 Cyanidin-3-O-Glucoside 
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Delphinidin glucoside *  466 465  303 40 20 Cyanidin-3-O-Glucoside 
Pelargonidin arabinoside * 404 403  271 40 20 Cyanidin-3-O-Glucoside 
Pelargonidin  glucoside * 434 433  271 40 20 Cyanidin-3-O-Glucoside 
Peonidin arabinoside * 434 433  301 40 20 Cyanidin-3-O-Glucoside 
Peonidin glucoside * 464 463  301 40 20 Cyanidin-3-O-Glucoside 
Hydroxy urolithin (urolithin B) * 212 213  141 40 20 Hydroxy urolithin (urolithin B) 
Dihydroxy urolithin (urolithin A) *  230 229  157 40 20 Dihydroxy urolithin (urolithin A) 
Trihydroxy urolithin (urolithin C)  *  246 245  155 40 30 Trihydroxy urolithin (urolithin C) 
Hydroxy urolithin glucuronide 388 387  211 40 20 Hydroxy urolithin (urolithin B) 
Dihydroxy urolithin glucuronide 404 403  227 40 30 Dihydroxy urolithin (urolithin A) 
Tetrahydroxy urolithin * 262 261  171 40 25 Trihydroxy urolithin (urolithin C)   
Tetrahydroxy urolithin sulfate 340 339  259 40 20 Trihydroxy urolithin (urolithin C)   
Pentahydroxy urolithin * 278 277  187 40 30 Trihydroxy urolithin (urolithin C)   
MW: molecular weight (g/mol) 
* ESI positive 
 
 
Table 2 of Supplementary Information. Instrumental quality parameters for the determination of phenolic 
compounds in biological samples after the Arbutus unedo intake. 
Phenolic compound 
Linearity 
range (µM) 
Calibration curve 
RSD 
(%)  
(25 
µM), 
n=3 
Accuracy 
(%) 
(25 µM), 
n=3 
LOD 
(µM) 
LOQ 
(µM) 
Blood samples       
Catechol  0.10-110 y = 239.47 x – 17.75 104 104 0.04 0.10 
Hippuric acid 0.10-70 y = 96.07 x + 202.89 99 98 0.03 0.10 
p-Hydroxybenzoic acid 0.10-90 y = 174.15 x + 424.29 98 102 0.03 0.10 
3-(4-hydroxyphenyl)propionic acid 0.10-80 y = 170.21 x + 127.05 103 99 0.03 0.10 
Urine samples       
Catechol  0.9-50 y = 473.25 x – 30.27 102 103 0.3 0.9 
3-(4-hydroxyphenyl)propionic acid 0.06-35 y = 346.51 x + 253.21 100 99 0.02 0.06 
Protocatechuic acid 0.06-30 y = 891.56 x – 15.21 105 98 0.02 0.06 
Gallic acid 0.06-30 y = 1247.39 x + 34.30 101 96 0.02 0.06 
Hippuric acid 0.05-50 y = 949.4 x + 795.26 101 97 0.03 0.08 
Syringic acid 0.05-25 y = 1189.2 x + 710.42 95  104 0.03 0.05 
Catechin  0.03-25 y = 625.25 x – 203.77 95  105 0.01 0.03 
Epicatechin  0.03-25 y = 413.75 x – 181.54 98 101 0.01 0.03 
Hydroxy urolithin (urolithin B)  0.07-100 y = 4373 x + 230.70 99 102 0.03 0.07 
Dihydroxy urolithin (urolithin A)  0.03-50 y = 15862 x + 730.52 102 104 0.01 0.03 
Trihydroxy urolithin (urolithin C)   0.003-30 y = 64963 x + 5420.5 103 99 0.001 0.003 
Faeces samples       
Catechol  14-710 (1) y = 12.46 x + 318.28 (2) 102 (1)   103 (1)     4.5 (2) 14 (2) 
3-(2’,4’-dihydroxyphenyl)propionic acid 0.9-500 (1) y = 112.31 x + 2638.5 (2) 101 (1)   98 (1)    0.3 (2)  0.9 (2) 
3,4-dihydroxyphenylacetic acid 1.0-500 (1) y = 85.67 x + 448.35 (2) 98 (1) 97 (1)   0.3(2)  1.0 (2) 
3-(4-hydroxyphenyl)propionic acid 1.0-500 (1) y = 375.56 x + 409.94 (2) 97 (1)   102 (1)   0.3 (2)  1.0 (2) 
Dihydroxy urolithin (urolithin A)   0.3-500 (1) y = 1697.5 x + 929.66 (2) 102 (1)    96 (1)   0.1 (2) 0.3 (2) 
Gallic acid 0.7-400 (1 y = 108.46 x + 13.63 (2) 96 (1)   95 (1)   0.2 (2) 0.7 (2) 
Hippuric acid 0.7-400 (1) y = 111.32 x + 92.88 (2) 99 (1)   98 (1)   0.2 (2) 0.7 (2) 
p-Hydroxyphenylacetic acid 1.0-560 (1) y = 54.56 x – 6516.4 (2) 97 (1)   104 (1)   0.3 (2) 1.0 (2) 
p-Hydroxybenzoic acid 1.0-500 (1) y = 303.59 x + 2205.1 (2) 100 (1)   99 (1)   0.3 (2) 1.0 (2) 
Protocatechuic acid 0.9-500 (1 y = 74.02 x + 27.07 (2) 104 (1)   105 (1)   0.3 (2) 0.9 (2) 
Trihydroxy urolithin  0.03-300 (1) y = 5988.2 x + 678.26 103 (1)   102 (1)   0.01 (2) 0.03 (2) 
(1): Linearity range, calibration curve, LODs and LOQs in feces are nmols/g lyophilized feces. 
(2): %RSD and %accuracy in feces are 100 nmols/g lyophilized feces 
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The inclusion of plant-based products, especially fruit and vegetables, as part of everyday 
diet, has been linked to a reduced risk of chronic disease (Del Rio et al., 2013; Johnson et 
al., 2004; Liu et al., 2003). This association appears to be related to their composition, 
based on moderate amounts of carbohydrates, fibre, vitamins, minerals and other minor 
compounds commonly known as phytochemicals (Liu et al., 2003). Regarding 
phytochemicals, phenolic compounds have attracted much attention in the last few 
decades in view of their antioxidant, anti-inflammatory and anticarcinogenic properties (Del 
Rio et al., 2013).  
The present Doctoral Thesis proposes a series of works concerning in-vitro and in-vivo 
studies in order to evaluate the colonic fate of different groups of phenolic compounds as 
well as their possible repercussion on the local ecosystem (microbial and metabolic 
implications). Three different plant-based products were selected for this purpose: enriched 
olive oil with olive and olive/thyme phenolic extracts, pomegranate and Arbutus unedo (A. 
unedo) fruit (Figure 14). Each of these products has its distinctive phenolic spectrum 
whose behaviour during digestion does not necessarily have to be equal; therefore, they 
deserve individual evaluation.  
 
Figure 14. Rich-phenolic sources selected to study the colonic fate of their phenolic 
compounds 
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The results derived from each study comprising this Doctoral Thesis could be analyzed 
from different perspectives (Figure 15). On the one hand, by comparing the data obtained 
from in-vitro and in-vivo models to establish possible correlations. On the other hand, the 
discussion could also be formulated from a cross-sectional approach, based on the 
comparison of the colonic metabolism between the different types of phenolic compounds 
tested. In addition, a short review associated with the possible implication of phenolic 
compounds in the gut ecosystem should be mentioned. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Different perspectives to face the discussion of the results obtained from the 
individual works that comprises the core of the present Doctoral Thesis. 
 
Phenol colonic metabolism: from in vitro to in vivo approaches 
In-vitro digestion models are valuable sources of preliminary results to screen and predict 
the metabolic behaviour of several food components that, in many cases, represent the first 
entry point for further investigations (Guergoletto et al., 2016; Hur et al., 2011; Bode et al., 
2013). For example, the identification of a specific metabolite generated during colonic 
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fermentation by in-vitro model can be subjected to further tests to confirm its in-vivo 
generation and its possible physiological relevance. It is rather enigmatic how the 
observations from in-vitro digestion models can be extended to humans. However, 
comparing results might help to discriminate which considerations are more relevant in in-
vitro experiments if is intended to extrapolate to in-vivo systems (Bode et al., 2013).  
The most common elements that make up artificial digestion are in-vitro gastrointestinal 
digestion combined with in-vitro colonic fermentation. According to the desired end points 
of the study, there are considerable differences between the parameters measured. These 
may include structural changes in the native molecule, stability, release from the food 
matrix (bioaccessibility), prediction of the potential bioavailability, and interference with 
other food components (competitive process) (Coates et al., 2007; Hur et al., 2011; Rubió 
et al., 2014a; Saura-Calixto et al., 2007). The pursued objective of this Doctoral Thesis was 
the qualitative and quantitative characterization of the phenolic fraction that presumably 
reaches the colon (Mosele et al., 2015a; Mosele et al., 2016a) after the gastro-intestinal 
digestion process.  
On the other hand, in-vitro fermentations were implemented to study the time-based 
biotransformation of the most representative phenolic compounds of the three phenolic 
sources selected: phenol-rich olive oils, pomegranate and A. unedo fruit, in order to 
propose their colonic metabolic pathways (Mosele et al., 2014a; Mosele et al., 2014b; 
Mosele et al., 2015a; Mosele et al., 2016a). Using the information obtained from in-vitro 
and in-vivo studies, an overall picture of the colonic pathways of various phenolic 
compounds has been proposed. Unfortunately, due to ethical issues, the in-situ study of the 
digestive process in humans was not considered. Therefore, the phenolic composition of 
faeces collected after the sustained intake of phenol-rich olive oils and pomegranate juice, 
and obtained following the acute intake of A. unedo fruit, was explored in order to 
understand the colonic metabolism of their respective phenolic components. Interestingly, 
the global results of this Doctoral Thesis revealed a suggestive relationship between those 
colonic metabolites detected after in-vitro fermentation and those increased in the faeces 
after the phenolic human diet intervention (Table 5). 
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Table 5. Common observations between in vitro fermentations and the phenolic profile of 
human faeces after dietary supplementation. 
 
HY: hydroxytyrosol; OLE: oleuropein; w: weeks 
 
It is also worth mentioning the similarity existing between the time of defecation and the in-
vitro fermentation kinetic. Those metabolites detected only at initial times of in-vitro 
fermentation of A.unedo (gallic and protocatechuic acids) were detected in the faeces 
excreted after more than 12 h after A. unedo fruit intake, but not in those excreted after 
more than 24 h (Mosele et al., 2016a; Mosele et al., 2016b). This fact is in accordance with 
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the previous conclusion of Stephen et al. (1987), who associated a rapid transit time with 
increased amounts of unmetabolized dietary products in faeces. 
Diverse categories of human metabolizers (inter-individual variability) were distinguished in 
both in-vitro and in-vivo models. Differences were not only in the amount of metabolites 
produced but also in their nature (Mosele et al., 2015a; Mosele et al., 2015b; Mosele et al., 
2016a; Mosele et al., 2016b). Based on the different profile of urolithins detected in human 
biological fluids, Tomás-Barberán et al., 2014, differentiated between three phenotypes of 
urolithin converters. These include phenotype A (produces only urolithin A), phenotype B 
(produces urolithin A and/or isourolithin A plus urolithin B) and phenotype 0 (non-urolithin 
producer). Something similar occurs with the isoflavones, since there is a percentage of 
individuals who do not have the capacity to convert daidzein into equol (Decroos et al., 
2005; Guadamuro et al., 2015). 
Despite the commonalities, some discordance between in-vitro and in-vivo outcomes was 
also noted (Table 6). The metabolic profile of faeces after phenolic treatment did not 
completely reproduce the same spectra as in-vitro samples. These contradictions, which 
may seem trivial, can lead to over or underestimations of in-vivo metabolism. Over-
estimation can occur when certain metabolites increase considerably after in-vitro 
fermentation, but their presence in faeces after phenolic treatment lacks significance. This 
is the case of the olive oil enriched with a combination of olive and thyme phenolic extracts. 
After diet supplementation with olive oil enriched with olive and thyme phenols (500 mg 
total phenols/kg oil) during 3 weeks at a dose of 25 mL/day), the analysis of human faeces 
did not show changes in the concentration of hydroxyphenylpropionic acid (Martín-Peláez 
et al., 2015), despite the fact that this compound was the main metabolite formed from 
rosmarinic acid and eriodictyol after the in-vitro colonic fermentation (Mosele et al., 2014b). 
In the same way, p-coumaric and protocatechuic acids were not significantly increased in 
human faeces after the diet supplementation with pomegranate juice (200 mL/day during 4 
weeks) (Mosele et al., 2015b), although results from in-vitro fermentation of pomegranate-
based products showed an intense colonic metabolism (Mosele et al., 2015a). In the case 
of A. unedo fruit, valerolactones and phenylacetic acids do not make an outstanding 
contribution to the phenolic content of faeces after acute ingestion (Mosele et al., 2016a; 
Mosele et al., 2016b). 
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Table 6. Discrepances between results from in vitro fermentation of phenolic compounds 
and the phenolic profile of human faeces after dietary supplementation. 
 
 
Contrary to the latter perspective, the presence of non-described in-vitro phenolic 
compounds in biological specimens after phenolic treatment can lead to omissions of in-
vivo metabolism. This has been noted after the daily dietary supplementation with olive oil 
enriched with olive/thyme phenols (Martín-Peláez et al., 2015), resulting in an increase in 
the concentration of protocatechuic acid in faeces, while this phenolic metabolite was not 
detected as a consequence of the in-vitro colonic fermentation of olive or thyme phenolic 
extracts (Mosele et al., 2014a; Mosele et al., 2014b). In this respect, phenylpropionic acid 
and hydroxytyrosol were detected in considerable amounts in human faeces after a daily 
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diet supplementation with pomegranate juice (200 mL/day, 4 weeks), but these compounds 
were not detected after in-vitro fermentation of pomegranate products (Mosele et al., 
2015a; Mosele et al., 2015b). Similar to the latter was the increase of hippuric acid in 
faeces of some volunteers after the acute intake of A. unedo fruit, which was not observed 
after the in-vitro fermentation of A. unedo fruit (Mosele et al., 2016a; Mosele et al., 2016b). 
Certain reasons explain differences in the phenolic metabolism when in-vitro models are 
compared with the metabolism in living beings. Firstly, the difficulty to reproduce the 
microbiota associated with the colon mucosa and other mammalian contributions, such as 
active intestinal absorption, effect of brush border enzymes, cellular efflux and the 
contribution of enterohepatic recirculation, and other compounds present in the diet.  
Collectively, the results of the Doctoral Thesis maintain the previous opinions set out by 
other authors who insist on the necessity to contrast in-vitro data with animal or human 
monitoring (Hur et al., 2011). In-vitro data is obtained mainly from chemical analyses, and 
the lack of many factors present in in-vivo systems could be crucial in some physiological 
aspects. This does not mean that in-vitro assessments should be discarded to study the 
behaviour of phenolic compounds during digestion. Further, in-vitro gastrointestinal 
digestion and fermentation could be considered as a valuable approach to (1) determine 
the metabolites generated from the action of gut microbiota to elucidate the metabolic 
pathways involved in colon metabolism, (2) distinguish between different phenotypes of 
metabolizers, (3) establish the potential stability of parent compounds present in food and 
their microbial derivatives during the digestion process, (4) identify potential biomarkers of 
consumption, and (5) promote the identification and subsequent study of phenolic 
derivatives based on their chemical and physiological properties. In synthesis, information 
derived from in-vitro experiments can be used as the basis for the design of proper human 
studies, in which the definition of biomarkers and therapeutic targets may be necessary. 
 
Colonic metabolism according to the type of phenolic structure and the 
food matrix composition  
To associate the improvement of specific physiological responses with the intake of 
phenolic compounds, it is crucial to determine the chemical structure and the concentration 
that reach the target tissues. For this purpose, researchers are making increasing use of 
 Genereal Discussion 
214 
 
data derived from urine and plasma analysis, paying particular attention to the native 
structure of phenols present in the food (Bergmann et al., 2010; Rubió et al., 2014b; Serra 
et al., 2010). Apart from a limited number of exceptions, the balance between the amount 
of phenolic compounds ingested and that detected in biological fluids (urine and plasma) is 
far from satisfactory, suggesting limited bioavailability (Bergmann et al., 2010; Rubió et al., 
2014b; Serra et al., 2010). In this context, the beneficial effects associated with phenolic 
ingestion are perhaps related to structures derived from diverse metabolic pathways, with 
special regard to the colon metabolism (Bergmann et al., 2010; Del Rio et al., 2013; 
Guadamuro et al., 2015; Johnson et al., 2004; Martín-Peláez et al., 2015; Tomás-Barberán 
et al., 2014; Verbeke et al., 2015).  
The three different phenolic sources studied in the Doctoral Thesis, phenol-rich olive oils, 
pomegranate and A. unedo fruit, are particularly rich in one or two phenolic subclasses and 
have modest concentrations of others. The addition of pomace phenolic extract (waste 
product of virgin olive oil extraction) to olive oil increases and standardizes the 
concentration of the main virgin olive oil phenols, such as phenolic alcohols (hydroxytyrosol 
and tyrosol) and secoiridoids (oleuropein derivatives) with minor sensorial modifications 
(Rubió et al., 2012; Rubió et al., 2014b). Additionally, the incorporation of the thyme 
phenolic extract provides supplementary phenols, such as monoterpenes (thymol and 
carvacrol), rosmarinic acid and flavonoids (Rubió et al., 2012; Rubió et al., 2014b). The 
analysis of the pomegranate products reported high concentration of ellagitannins, ellagic 
acid related compounds and anthocyanins (in juice and pulp), besides other minor phenols 
(Mosele et al., 2015a; Mosele et al., 2015b). A. unedo fruit possesses a singular phenolic 
composition characterized by high amounts of gallotannins (Mosele et al., 2016a; Mosele et 
al., 2016b). 
In accordance with previous studies by other authors, our results have shown that, during 
in-vitro digestion, the stability of phenolic compounds depends on their chemical 
characteristics (Bergmann et al., 2010; Coates et al., 2007; Kahle et al., 2005; Rubió et al., 
2014a; Serra et al., 2010; Tagliazucchi et al., 2010). Anthocyanins and polymeric phenols 
(ellagitannins, gallotannins and proanthocyanins) are especially sensitive to small intestine 
conditions. The native phenols present in the food are degraded to unknown compounds 
(probably chalcones), while the latter are recovered as monomers or minor polymerized 
forms (Bergmann et al., 2010; Coates et al., 2007; Kahle et al., 2005; Mosele et al., 2015a; 
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Mosele et al., 2016a; Tagliazucchi et al., 2010; Serra et al., 2010). The food matrix 
characteristics also have an impact on the phenolic stability during digestion, particularly 
delaying the rate of release to the digesta, which confers some resistance to degradation 
(Mosele et al., 2015a; Mosele et al., 2016a). The characteristics of the alimentary bolus that 
reaches the colon will depend on how much the phenolic fraction is affected during 
gastrointestinal digestion (Coates et al., 2007; Kahle et al., 2005; Mosele et al., 2015a; 
Mosele et al., 2016a; Rubió et al., 2014a). 
Once phenolic species are in contact with the gut microbiota, many of them suffer further 
degradation with the concomitant generation of microbial derivatives in parallel with the 
decrease of the parent compounds (Mosele et al., 2014a; Mosele et al., 2014b; Mosele et 
al., 2015a; Mosele et al., 2016a). The degree of microbial degradation also seems to be 
influenced by the characteristics of the molecule. For example, low molecular weight 
phenols are less affected. This is the case of hydroxytyrosol, tyrosol and phenolic 
monoterpenes (Mosele et al., 2014a; Mosele et al., 2014b) detected in human faeces. 
Moreover, it could be expected that hydroxytyrosol was transformed to tyrosol by 
dehydroxylation. Nevertheless, this reaction was not observed under in-vitro conditions 
(Mosele et al., 2014a), corresponding to the absence of tyrosol in faeces after olive oil 
intake (Martín-Peláez et al., 2015). Nevertheless, other minor compounds, such as 
phenolic acids (e.g. gallic acid), that can initially be present in the food (pomegranate and 
A. unedo fruit) or else generated by the catabolism of more complex precursors, are easily 
degraded (Mosele et al., 2015a; Mosele et al., 2016b). This fact could be explained by the 
characteristics of the side chain of the phenolic molecule that may govern the affinity as 
microbial substrate.   
The colonic fermentation of phenolic compounds is a gradual process of degradation in 
which intermediate metabolites are generated early. In turn, these intermediate or initial 
metabolites are subsequently catabolized, promoting the accumulation of simpler end 
products of fermentation in the gut lumen. Some of these intermediate or end microbial 
derivatives can be exclusive or common to several precursors (Table 7). Ellagitannins (or 
ellagic acid derivatives) and other phenolic compounds, such as isoflavones, lignans and 
resveratrol, have been described as producing exclusive microbial metabolites (Bode et al., 
2013; Decroos et al., 2005; Guadamuro et al., 2015; Heinonen et al., 2001; Mosele et al., 
2015a; Tomás-Barberán et al., 2014). On the other hand, there is a wide range of phenolic 
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compounds that produce common metabolites. This was reported for eriodictyol and 
rosmarinic acid, which produced hydroxyphenylpropionic acid as the main microbial 
metabolite (Mosele et al., 2014b). Hydroxyphenylpropionic acid was also generated after 
the in-vitro fermentation of coffee (rich in chlorogenic acid) (Ludwig et al., 2013). 
The dominance of colonic metabolism intermediate products over end-products in faeces is 
influenced by host-intrinsic features, such as transit time, rate of absorption, and 
composition and activity of microbiota. Different phenolic compounds sharing common 
microbial metabolites certainly do not guarantee a specific biomarker of consumption. 
 
Table 7. Microbial metabolites generated from different phenolic sources. 
 
 
A more complex picture emerges when the food matrix composition and food structure is 
considered. The behaviour in the phenolic metabolism resulting from the in-vitro 
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gastrointestinal digestion of pomegranate juice and pulp was quite similar, and some 
differences were observed with respect to the pomegranate peel extract (Mosele et al., 
2015a). The metabolites formed during in-vitro digestion did not differ in nature, but some 
aspects relative to their amount were evident. Although major quantities of urolithins were 
collected during in-vitro fermentation of the extract, the relative rate of urolithin generation 
respect to the initial precursors (ellagitannins) was greater for juice and pulp (Mosele et al., 
2015a). Seeram et al., 2008, observed that the administration of liquid, semi-liquid and 
solid pomegranate extracts with the same phenolic concentration did not promote 
significant differences in the concentration of plasmatic urolithin A. Only the time of 
maximum concentration was delayed for the solid pomegranate extract compared to liquid 
and semiliquid preparations. Based on the knowledge of matrix effects, food and 
nutraceuticals could be designed to be focused on a particular mission. The delivery of 
parent compounds could be manipulated to fit the needs of each specific individual. For 
example, promoting the generation of microbial metabolites in different segments of the 
colon may be possible with a food material that controls the release of parent compounds. 
 
 
Methods of phenolic analysis in in vitro models and human biological 
samples 
Prior to the qualitative and quantitative characterization of in-vitro digestion samples and 
human faeces, phenolic compounds and their microbial metabolites need to be extracted 
from the sample. Several pre-treatment sample methods, including water or chemical 
solvents (e.g. methanol), alone or in combination, have been used (Martín-Peláez et al., 
2015; Mena et al., 2015; Mosele et al., 2014a; Mosele et al., 2014b; Mosele et al., 2015a; 
Mosele et al., 2016a; Tagliazucchi et al., 2010). Marked contrast with the reality is the main 
justification put forward for rejecting the use of chemical solvents, since extractions 
performed with water (or aqueous buffers) adjust better to the physiological conditions 
(Pierre et al., 2013). However, the use of chemical solvents is the most favourable 
approach since, if chosen correctly, they are best suited to the characteristics of the matrix 
and selectively retain the compounds of interest (Mena et al., 2015; Saura-Calixto et al., 
2007). The use of chemical solvents for the analysis of samples obtained from in-vitro 
 Genereal Discussion 
218 
 
and/or in-vivo digestion is not considered to be physiological, since the major effects of 
extraction are achieved due to the digestion process itself. In addition, the isolation of those 
phenolic compounds that remain closely associated with the food matrix require far more 
aggressive treatments that include high temperatures in the presence of strong acids for 
long periods of time (Saura-Calixto et al., 2007). 
In-vitro gastrointestinal digestion and colonic fermentation have been widely used to study 
stability, bioaccessibility and transformation of several individual phenolic compounds 
(Mena et al., 2015; Mosele et al., 2014a; Mosele et al., 2014b) and whole food (Saura-
Calixto et al., 2007; Mosele et al., 2015a; Mosele et al., 2016a). Study-to-study 
comparisons may become risky due to the lack of harmonized protocols between the 
digestion models, the experimental conditions and the modality used for phenolic detection 
and quantification. In the current situation, it is unrealistic to expect all the laboratories to 
use the same digestion model, since each one should be adapted to the available 
resources. Certain parameters, such as the experimental conditions, may be easy to apply 
in an attempt to harmonize inter-laboratory procedures. Some of them could be: (1) the 
time-course of incubation in each individual digestion step, (2) the pH values of each 
compartment, (3) the ratio between the amount of buffer and food (or compound), (4) the 
amount and type of enzymes and bile acids, (5) the extraction procedures, (6) the 
proportion of faeces in faecal slurries, (7) the composition of buffers and (8) the expression 
of results.   
The analysis of faeces before and after a dietary intervention based on the ingestion of 
phenolic-rich products is not a common practice (Rubió et al., 2014b; Seeram et al., 2008; 
Serra et al., 2010; Tomás-Barberán et al., 2014). The composition of faeces is a reflection 
of the intra-colonic environment and their characterization before and after phenolic 
treatment includes information regarding the impact of the local residence of phenolic 
compounds. Collection of faeces is easy and does not pose any particular risk, since it 
does not require any invasive technique, but it can be somewhat embarrassing for 
volunteers. Handling of fresh faeces for analysis may be impracticable and unpleasant; 
therefore, lyophilization was conducted in most of the in-vitro and human biological fluids 
analyzed in the present work. A free water material permits better homogenization and the 
reduction of sample-to-sample variability. In addition, the results can be expressed based 
on dry weight or also on fresh weight, if required.  
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In parallel, the analysis of bioactive food metabolites in plasma is a good predictor of their 
absorption and metabolism, and allows a reasonable estimation of their body distribution 
and lifespan (Rubió et al., 2014b). Nevertheless, qualified personnel and special 
supervision are required for blood extraction, which could limit the objectives and increase 
the cost of the bioavailability studies. For this reason, with the aim of developing an 
alternative solution to simplify blood sampling, we proposed the use of dry blood spot 
(DBS) cards as a simple sample-pre-treatment for the analysis of phenolic compounds in 
whole blood. This original approach was sufficient to detect and quantify the most abundant 
phenolic species in blood after the acute intake of A. unedo fruit (Mosele et al., 2016b). We 
observed that the main circulating metabolites detected were of colonic origin, which is in 
accordance with previous findings that also noticed the important contribution of colonic 
metabolites to total oral bioavailability of dietary phenolic compounds (Rubió et al., 2014b; 
Tomás-Barberán et al., 2014).  
 
The role of dietary phenolic compounds in the large intestine 
Phenolic compounds - microbiota interactions-faeces metabolites 
Modulation of gut microbiota is a concept associated with positive modifications due to the 
influence of external factors (diet and antibiotics). These changes range from the increasing 
abundance of beneficial microorganisms to the lower number of harmful inhabitants 
(Cammarota et al., 2014). With regard to foodstuff, the term “prebiotic” has emerged to 
define those compounds that possess the capacity to increase health-promoting probiotic 
bacteria (especially Bifidobacterium and Lactobacillus). Gibson et al., 1994 defined a 
prebiotic as “a non-digestible food ingredient that beneficially affects the host by selectively 
stimulating the growth and/or activity of one or a limited number of bacteria in the colon, 
and thus improves host health”. Considering this, phenolic compounds, if they increase the 
concentration of beneficial bacteria, would automatically be included in this group. 
However, the prebiotic concept has mutated over recent years and currently there is not an 
agreed definition. In general, only alimentary fibre and certain non-digestible carbohydrates 
are considered as potential candidates (Cammarota et al., 2014; Hutkins et al., 2004).  
From a global point of view, data obtained from in-vitro fermentations and animal studies 
have shown positive responses to phenolic treatments (Appendix; Guergoletto et al., 2016). 
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Nevertheless, the latter expectations are not really encouraging in human trials due to the 
low amount of studies and the incongruence between results (Appendix). Another objective 
of this Doctoral Thesis was to study the ability of different phenolic dietary treatments 
(enriched olive oil and pomegranate juice) to reshape the human gut microbiota. This is 
intended to provide extra data obtained from human studies in order to stimulate the debate 
about the possibility of including phenolic compounds in dietary therapies to promote gut 
microbiota homeostasis.  
Analyzing the results of the present work together, we observed two different scenarios. 
First, an increase in the abundance of Bifidobacterium after 3 weeks of sustained intake of 
25 mL of enriched olive oil with thyme and olive extracts (Martín-Peláez et al., 2015). On 
the other hand, substantially higher amounts of phenolic compounds supplied by 200 
mL/day of pomegranate juice during 4 weeks did not produce any change in the gut 
community (Mosele et al., 2015b). The incongruence in the responses to dietary treatments 
between enriched olive oil and pomegranate juice may be related to the health status of 
volunteers. The participants in the study of dietary supplementation with phenol-enriched 
olive oil were hypercholesterolaemic subjects, while participants in the study of dietary 
supplementation with pomegranate juice were healthy and younger subjects. Healthy gut 
microbiota promotes colon homeostasis, and different strategies could be employed by 
microorganisms to maintain this stable state for short or medium-term periods (Lozupone et 
al., 2012). Hypercholesterolaemia has been associated with an altered microbiota, which 
may be more susceptible to dietary changes (Martínez et al., 2009). Whether a phenolic 
treatment is capable of promoting changes in the gut microbiota may depend on the 
resilience of the microorganism to the type and amount of phenolic compounds and the 
length of treatment (Lozupone et al., 2012).  
In any case, differences between studies in the techniques used to assess the gut 
microbiota unfortunately make any comparison incompatible. Pyrosequencing is a large-
scale high-throughput screening method used for the characterization of the general 
composition of the gut community (Sekirov et al., 2010; Mosele et al., 2015). On the other 
hand, the fluorescence in situ hybridization (FISH) technique utilizes specific probes to 
target distinct groups of bacteria, and hence identified certain bacterial groups previously 
selected with the researcher’s criteria (Martín-Peláez et al., 2015).  
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The characterization of faecal metabolites can subsequently be analyzed to establish 
possible connections with certain gut inhabitants. The relationship between phenolic 
microbial metabolites, faecal sterols and short chain fatty acids (SCFAs) and intestinal 
microorganisms was studied. Metabolic-microbial associations displayed both positive and 
negative correlations and were only detected for catechol and phenylpropionic acid, two 
microbial metabolites that increased significantly after the intake of pomegranate juice 
(Mosele et al., 2015b). All this confirms the existence of a relationship between phenolic 
compounds and certain bacteria groups at colon level. Metatranscriptomic as well as the 
introduction of proteomic studies in phenolic interventions could be an interesting approach 
to understand how the microbiota functionality responds to dietary phenolic interventions 
(Lozupone et al., 2012).  
It is very difficult to select a single connecting factor that explains the association between 
phenolic compounds from the diet and microbial modulation, due to the large heterogeneity 
between individuals’ responses. Different factors, such as dose administered, treatment 
time, form of administration, and number and characteristics of the volunteers (healthy or 
presenting certain risk of disease), add even more complexity.  
Regarding the faecal metabolites other than phenolic metabolites, the gut epithelium is 
continuously exposed to a varied amount and type of substances. The overall balance of 
the lumen composition is determined by non-absorbed food and internal secretions 
(enzymes, bile acids, mucus and shedding of cells). Due to the high density of 
microorganisms in the large intestine, most of these products are successfully 
biotransformed (Appendix; Verbeke et al., 2015). The result is the generation of a wide 
range of metabolites. Some microbial metabolites, such as those derived from proteins and 
sterols (cholesterol and bile acids), are likely to play a role in many different intestinal 
diseases, whereas SCFAs maintain the gut homeostasis (Appendix; Verbeke et al., 2015). 
In spite of some shortcomings, the analysis of faecal samples is a suitable alternative to 
estimate, by the regulation of the abundance of toxic/beneficial compounds, the potential 
impact that dietary phenolic compounds may have on the intra-colonic environment (Pierre 
et al., 2013). Verbeke et al. (2015) propose that “analyzing the activity of the microbiota 
rather than its composition and structure may be more relevant to assess the impact of 
prebiotic interventions”. 
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The present Doctoral Thesis includes innovative aspects of dietary phenolic compounds in 
the regulation of SCFAs and faecal sterols (Martín-Peláez et al., 2015; Mosele et al., 
2015b), since these parameters have been poorly explored in previous human dietary 
interventions with phenols. We observed that the concentration of SCFAs and primary and 
secondary bile acids did not undergo modification after the intervention with phenol-rich 
olive oils and with pomegranate juice, respectively. Therefore, the microbial metabolism of 
luminal cholesteroll was, in both cases, modified due to the dietary intervention (Martín-
Peláez et al., 2015; Mosele et al., 2015b).  
It is worth mentioning that the existence of statistical significance in the faecal metabolic 
profile does not necessarily indicate clinical significance and vice versa. Normally, in clinical 
medicine, clinical significance is estimated based on a cutoff value (on occasions 
represented by a range including low and high values) (Colodner et al., 2006). Regarding 
the parameters studied in the present work, there is no consensus about the range of 
faecal SCFAs and sterols in order to discriminate between “healthy” and “unhealthy” state. 
Once the healthy composition of faeces has been defined, the impact of dietary 
interventions on intestinal homeostasis will be more realistic and precise. However, the 
complexity of the gut ecosystem and the intra and inter-individual variability complicate the 
definition of cutoff values of faecal metabolites (Verbeke et al., 2015). To make this 
possible, the inclusion of a larger number of individuals is necessary in order to better 
adjust the range of plausible values. 
The third volume of the Word Cancer Report prepared in 2014 by the International Agency 
for Research on Cancer (which forms part of the World Health Organization –WHO-) 
includes a controversial issue in which processed meat and meat products are categorized 
as group 1 (carcinogenic to humans) and group 2A (probably carcinogenic) carcinogenics, 
respectively (www.who.int). The decision of the committee was made based on the results 
reported by numerous epidemiological studies that associate consumption of these 
products with an increased risk of cancer development, especially colorectal cancer.  
Several components present in meat and processed meat foods may explain the 
association between their consumption and the risk of colorectal cancer. Among them, 
positive association of risk was described for N-nitroso compounds (Pierre et al., 2013), fat 
(Van Hecke et al., 2014), proteins (Appendix; Belobrajdic et al., 2003), heme iron (Bastide 
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et al., 2015; Pierre et al., 2013), heterocyclic amines and polycyclic aromatic hydrocarbons 
(Helmus et al., 2013). Their mechanisms of action include increase of oxidation, 
genotoxicity and cytotoxicity that promote the appearance of pre-carcinogenic lesions 
(Bastide et al., 2015; Pierre et al., 2013; Van Hecke et al., 2014). Some compounds, such 
as heme iron, heterocyclic amines and polycyclic aromatic hydrocarbons, are originally 
present in the food, whereas N-nitroso compounds and other toxic products derived from 
fat and proteins are formed endogenously through the action of microbiota (Van Hecke et 
al., 2014). In addition, the presence of fat in meat and processed meat products promotes 
the secretion of bile acids, which increase the pool of potential carcinogens in the gut 
(Ajouz et al., 2014; Appendix).  
Reduction of certain colorectal cancer biomarkers has been observed after the 
simultaneous consumption of processed meat products, and -tocopherol may reveal an 
important role of dietary antioxidants as protector agents (Pierre et al., 2013). In addition, 
Arts et al. (2002) observed that a diet rich in proteins and iron reduced the absorption of 
flavonoids, which would increase the presence of protective molecules in the lumen. The 
contribution of dietary phenolic compounds should be studied experimentally to evaluate 
the possible reduction of cancer risk in meat eaters. For this, the implementation of studies 
concerning the effectiveness of phenolic compounds to reduce the formation of harmful 
substances by gut microbiota and/or to block the pro-carcinogenic mechanism activated by 
toxic compounds is needed. 
 
 
Development of phenolic-rich products to improve colonic health status 
The natural occurrence of phenolic compounds in the diet and their healthy properties 
have converted these phytochemicals into an attractive ingredient for the design, 
development and production of high value-added foods and nutraceuticals (Rubió et 
al., 2014b). Phenolic compounds are part of the minor fraction of plant-based foods 
but, despite their low concentration, it has been noticed that they confer protection 
against colonic injuries (Appendix; Coates et al., 2007; Johnson et al., 2004; Martín et 
al., 2015). The lumen enrichment with phenolic species provides a wide assortment of 
compounds associated with antioxidant, anti-inflammatory and antiproliferative 
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purposes (Appendix; Coates et al., 2007). This phenolic cocktail is expected to protect 
the gut from several toxic substances formed during gastro-intestinal digestion and to 
promote the development of a healthy gut microbiota (Appendix; Guergoletto et al., 
2016 Johnson et al., 2004) 
 
Considering the potential and growing applications of phenol-rich foods for the 
maintenance of an optimal colonic metabolism, there are regulatory policies that hinder 
their commercialization, including claims associated with health. The European Food 
Safety Agency (EFSA) is the authority responsible for conducting and verifying compliance 
with the strict rules that foods must fulfil to be placed on the European market as health 
Figure 16. Applicants who wish submit an application for authorizations of a health claim under 
Articles 13.5 or 14 or Regulation EC 1924/2006 or for modification of an existing authorizations 
should consult the guidance documents and complete the relevant application forms. Applications 
should be submitted to the national competent authority of a Member State. The competent authority 
passes the application and any supplementary information supplied by the applicant to EFSA, which 
carries out the scientific evaluation. From www.efsa.europa.eu 
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claim products (Figure 16). The idea is to protect consumers from unscrupulous traders or 
industries. However, at the same time, the high standards may not stimulate the scientific 
and industrial advancement in the study of phenolic compounds and their repercussion on 
human health, which may have a negative impact on the development of functional foods 
(Katan et al., 2012). 
Substantial information from in-vitro and in-vivo animal studies is available in the literature 
to explain the positive impact of phenolic compounds on the colon metabolism (Appendix; 
Del Rio et al., 2013; Guergoletto et al., 2016; Martin et al., 2015). However, the lack of 
consistent results obtained from human clinical trials is usually the main reason that 
conditioned the recognition of health claims for phenol-rich foods (Katan et al., 2012). Much 
remains to be done to demonstrate the importance of phenolic compounds in human 
health. In the case of colonic metabolism, there are a number of outstanding issues that 
need to be resolved. For this, the establishment of multidisciplinary groups of experts could 
be optimal in order to establish:  
i. The amount of phenolic compounds that needs to reach the colon intact to produce 
the expected effects. 
ii. The amount of phenolic compounds that should be ingested to reach the effective 
concentration in the colon. 
iii. The active form of the molecule (parent compound or microbial metabolites). 
iv. The possible interactions with the food matrix or other dietary components that may 
be ingested simultaneously. 
v. The different profile of metabolizers to design specific dietary strategies (for 
example the oral administration of the microbial metabolite).  
vi. The identification of specific biomarkers of colonic disease progression and their 
control by diet phenolic compounds.  
In synthesis, the potential of the phenol-rich products and the biological activity of the 
metabolites formed as a consequence of digestion and colonic catabolism must be 
confirmed through more studies (especially involving humans) in which specific biomarkers 
of colonic disease progression are identified. 
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The main conclusions drawn from the results obtained from this Doctoral Thesis are 
presented below. The structure of the Conclusion section has been organized based on the 
proposed objectives, from phenolic characterization (phenol-enriched olive oil, 
pomegranate and A. unedo fruit) to the colonic metabolism of phenolic compounds. 
 
Objective 1. Phenolic characterization of enriched olive oils, pomegranate products 
(juice, pulp and peel extract) and A. unedo fruit.  
Conclusion 1. The present Doctoral Thesis offers relevant information that 
contributes to expanding the existing data regarding the phenolic composition of 
plant-based products, including some indigenous fruits. The phenolic sources studied 
present a distinctive phenolic spectrum normally dominated by a specific group of 
phenolic compounds. 
Olive oil enriched with its own phenolic compounds possesses large amounts of 
hydroxytyrosol derivatives, mainly oleuropein aglycone derivatives (secoiridoids). 
The incorporation of thyme phenolic extract into olive oil enriched the product with 
complementary phenols, mainly phenolic monoterpenes (thymol and carvacrol), 
flavonoids and rosmarinic acid. 
The main phenolic sub-classes of the pomegranate products (juice, pulp and 
phenolic extract) are ellagitannins and ellagic acid derivatives. 
The Arbutus unedo fruit is a rich source of gallotannins.  
 
Objective 2. Application of the in-vitro colonic fermentation model to define the 
behaviour of phenolic compounds in the large intestine. 
Conclusion II. The in-vitro colon fermentation of the most representative phenols of 
virgin olive oil (tyrosol, hydroxytyrosol, hydroxytyrosol acetate and oleuropein) 
revealed that (i) phenolic acids are the main catabolites formed after the fermentation 
of tyrosol and hydroxytyrosol, (ii) hydroxytyrosol and tyrosol are very stable during 
colonic fermentation, and (iii), by contrast, hydroxytyrosol acetate and oleuropein are 
completely degraded during colonic fermentation, generating hydroxytyrosol as the 
main microbial metabolite.  
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Conclusion III: The thyme phenolic monoterpenes thymol and carvacrol are not 
degraded by human microbiota after in-vitro colonic fermentation. Other phenols from 
thyme extract, such as rosmarinic acid and the flavonoid eridictyol are completely 
degraded and generate hydroxyphenylpropionic acid as the main microbial 
metabolite. 
Conclusion IV. The application of in-vitro gastrointestinal digestion to pomegranate 
products (juice, pulp and peel extract) and to A. unedo fruit allows the stability of 
phenolic compounds to be predicted according to their particular chemical structures 
and the influence of the food matrix during digestion. The in-vitro colonic fermentation 
model is a useful tool to probe the affinity of phenolic compounds as microbial 
substrates (rate of metabolism) and the main metabolites generated as a 
consequence of the faecal microbiota metabolism.  
The absence of native phenolic compounds (ellagitannins and ellagic acid 
derivatives) present in the pomegranate products at final times of incubation indicates 
good microbial affinity. The in-vitro fermentation of the three pomegranate products 
(juice, pulp and peel extract) results in the same metabolic products, urolithins being 
the main microbial metabolites. 
The in-vitro fermentation of A. unedo fruit promotes the total disappearance of native 
phenolic compounds (mainly gallotannins) phenylacetic and phenylpropionic acids 
being the main catabolites formed. 
 
Objective 3. Colonic metabolic pathways of phenolic compounds 
Conclusion V. In-vitro fermentation models offer the possibility of assessing the 
degradation rate of phenolic compounds according to the time of exposure to faecal 
microorganisms. This allows pictures to be captured that represent the different 
states of phenolic compound degradation. Putting all the pictures together allows the 
metabolic pathways of phenolic compounds in the colon to be defined. Following this 
premise, the present Doctoral Thesis proposes the colonic pathways of the main 
phenolic compounds present in enriched olive oils, pomegranate products and A. 
unedo fruit. The human colonic pathways of oleuropein, hydroxytyrosol, tyrosol, 
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hydroxytyrosol acetate, thymol, carvacrol and gallotannins constitute a valuable 
source of information, since they had not previously been described.  
 
Objective 4. In-vivo colonic metabolism of phenolic compounds: human studies. 
Conclusion VI. Daily dietary supplementation with phenol-enriched olive oils and 
pomegranate juice during three and four weeks, respectively, as well as the acute 
intake of A. unedo fruit, increases the amount of phenolic compounds and their 
microbial metabolites in faeces. 
Three weeks of sustained intake of olive oil enriched with its own phenolic 
compounds increases the concentration of hydroxytyrosol and dihydroxyphenylacetic 
acid in human faeces. Similarly, the sustained intake of olive oil enriched with a 
mixture of olive and thyme phenols increases the concentration of protocatechuic 
acid in human faeces. 
Daily supplementation of pomegranate juice during four weeks increases the amount 
of urolithins, hydroxytyrosol, phenylpropionic acid, catechol and an unknown 
metabolite in the faeces of healthy volunteers.  
The acute intake of A.unedo fruit increases most but not all the phenolic metabolites 
generated during in-vitro fermentation.  
 
Objective 5. Changes in the gut ecosystem (microbial and metabolic modifications) 
promoted by the intake of enriched olive oil and pomegranate juice 
Conclusion VII. Daily moderate consumption of olive oil enriched with phenolic 
compounds from olive and thyme during three weeks increases the amount of gut 
beneficial bacteria (bifidobacteria) in hypercholesterolaemic human volunteers. By 
contrast, no changes in the microbiota composition of healthy volunteers are 
observed after daily diet supplementation with pomegranate juice. 
Conclusion VIII. Regarding faecal metabolites, diet supplementation with olive oil 
enriched with its own phenolic compounds interferes with the gut microbial 
metabolism of cholesterol, increasing the amount of coprostanone in human faeces. 
In a similar way, the sustained intake of pomegranate juice affects the colonic 
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metabolism of cholesterol, decreasing the generation rate of coprostanol and 
increasing the presence of unmetabolized cholesterol in faeces. Neither the 
sustained intake of enriched olive oils nor that of pomegranate juice modifies the 
concentration of short chain fatty acids and bile acids in human faeces. 
 
Objective 6. Comparison between in-vitro and in-vivo results  
Conclusion IX. The phenolic profile of human faeces after daily dietary 
supplementation during a period of three-four weeks with phenol-enriched olive oils 
and pomegranate juice, after the acute intake of A. unedo fruit, is partly aligned with 
the results obtained from the in-vitro fermentations. However, the use of in-vitro 
colonic fermentation models could be proposed as a useful tool to elucidate the 
colonic pathways of dietary phenols; therefore, they must necessarily be combined 
with dietary intervention studies in humans. 
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Abstract: Phenolic compounds represent a diverse group of phytochemicals whose intake is associated 
with a wide spectrum of health benefits. As consequence of their low bioavailability, most of them reach 
the large intestine where, mediated by the action of local microbiota, a series of related microbial 
metabolites are accumulated. In the present review, gut microbial transformations of non-absorbed 
phenolic compounds are summarized. Several studies have reached a general consensus that unbalanced 
diets are associated with undesirable changes in gut metabolism that could be detrimental to intestinal 
health. In terms of explaining the possible effects of non-absorbed phenolic compounds, we have also 
gathered information regarded their influence on the local metabolism. For this purpose, a number of 
issues are discussed. Firstly, we consider the possible implications of phenolic compounds in the 
metabolism of colonic products, such as short chain fatty acids (SCFA), sterols (cholesterol and bile acids), 
and microbial products of non-absorbed proteins. Due to their being recognized as affective antioxidant 
and anti-inflammatory agents, the ability of phenolic compounds to counteract or suppress pro-oxidant 
and/or pro-inflammatory responses, triggered by bowel diseases, is also presented. The modulation of gut 
microbiota through dietetic maneuvers including phenolic compounds is also commented on. Although the 
available data seems to assume positive effects in terms of gut health protection, it is still insufficient for 
solid conclusions to be extracted, basically due to the lack of human trials to confirm the results obtained 
by the in vitro and animal studies. We consider that more emphasis should be focused on the study of 
phenolic compounds, particularly in their microbial metabolites, and their power to influence different 
aspects of gut health. 
 
Keywords: colon metabolites; gut fermentation; microbiota; phenolic compounds 
 
1. INTRODUCTION 
Most of the beneficial health properties of fruit, vegetables, and whole grains have been attributed to 
bioactive non-nutritional chemical compounds commonly named phytochemicals, which include phenolic 
compounds. Plant phenols embrace a wide range of secondary metabolites that are synthesized from 
carbohydrates via the shikimate pathway, occurring as soluble conjugated (glycosides) and insoluble or 
bound forms [1]. Based on the extensive intake of these kinds of phytochemicals through the diet, a 
complex mixture of hundreds of phenolic compounds enters the gastrointestinal tract where they can be 
partially released and absorbed, or survive stomach and intestinal digestion and reach the colon until 
excretion via feces. Several studies have reported that an important part of the ingested phenolic 
compounds reaches the large intestine where it undergoes a series of microbial transformations that leads 
to the generation of related metabolites [2–4]. 
On occasion, gut microbiota has been defined as a biological reactor since it possesses powerful 
metabolic functions which include the transformation of many compounds that reach the colon. This 
activity is possible through the capacity of microorganisms to produce a huge and varied range of 
enzymes. In the particular case of phenolic compounds, their intestinal transformations include several 
steps. First, aglycones must be released to the media. For this, different classes of enzymes are needed to 
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deconjugate the specific moiety associated to the molecule or, in the case of polymeric forms, to break 
phenolic polymers into individual monomers. Phenolic compounds are also strongly linked to some 
components of the food matrix, and this interaction is also disrupted by microbiota [1]. The released 
aglycones undergo subsequent microbial transformations which may include ring fission, α or β-oxidation, 
dehydrogenation, dehydroxylation, and demethylation, and these result in the generation of simpler related 
compounds. 
An overview of the bioactivity that is probably carried out by phenolic compounds in the large intestine is 
represented in Figure 1. The passage of digesta through the small intestine is estimated to take around 2–
4 h, but the transit time increases considerably in the large intestine, extending to as long as 24 h or more 
[4,5]. This time is probably long enough to accumulate substantial amounts of phenolic compounds and 
induce metabolic and microbial changes in the gut lumen. Phenolic compounds are recognized 
antioxidants and anti-inflammatory agents which can protect intestinal cells from pro-oxidant and 
inflammatory injuries [6–8]. The presence of luminal phenolic compounds could also impact the metabolic 
profile, enhancing or inhibiting the generation of fermentation products derived from endogenous and 
dietary compounds. In turn, changes in the metabolic profile of the gut are sometimes associated with the 
modification of the shape of the intestinal inhabitants. In fact, some authors have associated the phenolic 
compounds–gut microbiota interaction with a presumable modulation effect, which could prevent or, 
indeed, restore microbiota alterations observed in disease [9,10] 
 
 
 
Figure 1. Overview of the possible implications of phenolic compounds at the gut level. 
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The aim of this manuscript was to consult the information available from in vitro and in vivo studies to 
review the transformations that the non-digested phenolic compounds undergo when they reach the colon 
and the possible influence they have on the transformation of other intestinal metabolites, such as short 
chain fatty acids (SCFAs), sterols, and microbial products of non-absorbed proteins. In addition, their 
possible implications in metabolic and microbial changes as well as in antioxidant and anti-inflammatory 
effects at the gut level were also considered. 
2. Microbial Phenolic Metabolites 
Phenolic compounds are commonly classified into two main groups, flavonoids and non-flavonoids. In the 
next section we will describe the catabolism pathways and the phenolic metabolites formed related with 
the chemical structures of flavonoids and non-flavonoids. 
2.1. Flavonoids 
Flavonoids possess an aglycone skeleton of two flavonoid rings (A- and B-rings) connected by a 
heterocyclic C-ring. In foods, except for flavan-3-ols, flavonoids are normally presented as glycosides or 
organic acid conjugates. 
The sub-class of flavan-3-ols includes the diastereomers catechin and epicatechin, and their 
corresponding gallate esters, epigallocatechin and epigallocatechin gallate. In foods, flavan-3-ols are 
present as monomers (catechin and epicatechin) or proanthocyanidins (variable attached monomers). To 
study the microbial modifications of flavan-3-ols, pure standards as well as grapes, tea, cocoa, berries, red 
wine, and their extracts have been used. The colonic catabolism of proanthocyanins undergoes a first 
degradation step resulting in the release of monomer structures with the subsequent hydrolysis of gallic 
acid from the galloylated forms [11–14]. Based on the literature, we propose the colonic pathways of 
monomeric flavan-3-ols and their corresponding gallate esters (Figure 2). The early appearance of simple 
phenolics (like catechol) suggests further degradation of gallic acid generated by hydrolysis of 
epigallocatechin gallate in the first steps of the colonic catabolism [11,12,14,15]. Similarly, the initial C-ring 
fission of flavan-3-ols (Figure 2A) produces the corresponding diphenylpropan-2-ol. Then, this is further 
converted into 5-(3′,4′,5′)-tri- and 5-(3′,4′)-dihydroxyphenyl-γ-valerolactone in the cases of gallate esters 
and monomers, respectively [11,14,16]. The subsequent catabolism of the tri- and dihydroxyphenyl-γ-
valerolactones originates different hydroxylated forms of phenylvaleric acid [11–15,17]. Neither 
trihydroxyphenylvaleric acid nor trihydroxyphenylpropionic acid have been described as microbial 
metabolites of gallate esters in in vitro fermentations. However, trihydroxyphenylvaleric acid was identified 
in human plasma [16]. Phenyl-γ-valerolactones and phenylvaleric acids have been described as exclusive 
microbial metabolites of flavan-3-ols. Their progressive microbial transformation releases different 
hydroxylated forms of phenyl (Figure 2B) and benzoic acids (Figure 2C), whose profile and abundance 
seem to depend on the particular metabolic activity of each individual microbiota and the composition of 
flavan-3-ols in the substrate [11–15,17]. Furthermore, other minor catabolites, such as hippuric acid, p-
coumaric acid, and vanillic acid, homovanillic acid, homovanillyl alcohol, and 3-O-methylgallic acid have 
been associated with the in vivo colon metabolism of flavan-3-ols [11,13,16,18]. 
Flavonols are the most common phenolic compounds in foods such as red wine, apples, onions, beer, 
spices, herbs, berries, and cocoa, with quercetin, kaempferol, and myricetin being the most studied. During 
the first steps of the colonic catabolism of the aglycone forms of quercetin and kaempferol, the initial 
metabolites formed are dihydroquercetin (taxifolin) and dihydrokaempferol, respectively, which are further 
metabolized to di- and hydroxyphenylpropionic acid, respectively (Figure 3A) [19–23]. These metabolites 
then enter the catabolic route of phenyl acids (Figure 2B) and benzoic acids (Figure 2C) to generate 
minor related compounds [19,22,23]. Following the intake of radiolabeled quercetin-4′-O-glucoside in rats, 
high concentrations of hippuric acid were found in the jejunum/ileum, urine, and plasma [22]. Furthermore, 
3′,4′,5′-trihydroxyphenylacetic acid and 3′,5′-dihydroxyphenylacetic acid were the main microbial 
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metabolites detected in rat feces after the administration of myricetin [24], probably derived from the 
intermediate dyhydromyricetin. However, the generation of quercetin from myricetin should not be 
discarded [25]. 
The flavanones hesperetin and naringenin are found in larger concentration in oranges, whereas 
eriodictyol is a flavanone commonly presented in aromatic herbs and nuts. Hydroxyphenylpropionic and 
phenylpropionic acids have been described as major fermentation products of eriodictyol and naringenin 
[23,26,27]. In addition, phloroglucynol was also detected in the fermentation vessels of naringenin [23] and 
eriodyctiol [28] which could be formed from the A-ring. In the case of hesperidin, 3-(3-hydroxy-4-
methoxyphenyl)propionic acid (dihydroisoferulic acid) and different hydroxylated forms of phenylpropionic 
acid have been reported as products of it colonic catabolism [27] (Figure 3B). 
 
 
 
Figure 2. Proposed colonic pathways of monomeric flavan-3-ols and their corresponding gallate esters 
 
Flavones, like apigenin and luteolin and their glycosides, are normally found in beer, olive oil, aromatic 
herbs, and nuts. In the same way as with the other flavonoid sub-classes, deglycosylation is the first 
microbial action. Apigenin aglycone is transformed into naringenin, whose microbial catabolism produces 
phenylpropionic acids [21,29] (Figure 3C). Luteolin undergoes an initial isomerization to form eriodictyol as 
an intermediate metabolite which is transformed to 3-(3′,4′-dihydroxypheyl)propionic acid [21,30] (Figure 
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3C). In coincidence with in vitro data, 3-(4′-hydroxyphenyl)propionic acid was the main metabolite detected 
in urine after the administration of apigenin-7-O-glucoside to human microbiota-associated rats [29].  
Genistein and daidzein are the most representative isoflavones and are normally present in their glycoside 
forms in soy products. The results of in vitro incubations of genistein, together with experiments where 
gnotobiotic rats were inoculated with isolated human equol-forming bacteria, have shown that, during the 
first steps of colonic catabolism, genistein, aglycone generated dihydrogenistein (Figure 4) which is partly 
converted into 5-hydroxy-equol [31,32]. After in vitro fermentation of genistein, Coldham et al. [33] 
observed that dihydrogenistein was metabolized into 6′-hydroxy-O-demethylangolensin which, in turn, was 
transformed into 2-(4-hydroxyphenyl)propionic acid and phloroglucinol. On the other hand, daidzein 
aglycone can be reduced to dihydrodaidzein and then converted into equol or O-desmethylangolensin 
[31,32,34] (Figure 4). Although more than one bacteria has been described as an isoflavone-converter 
[31,32], not all humans have the capacity to convert genistein and daidzein into their respective microbial 
metabolites [35], which could indicate that isoflavone transformer bacteria are not common among human 
intestinal flora 
 
 
 
Figure 3. Proposed colonic pathways of flavonols, flavanones, flavones, and hydrocinnamic acids 
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Figure 4. Proposed colonic pathways of isoflavones 
 
Anthocyanins are widely dispersed throughout the plant kingdom, being responsible for red, blue, and 
purple colors. Red wine, grapes, berries, and pomegranate are examples of anthocyanin-rich products. 
After microbial deglycosylation, ring fission of the aglycone releases two parts, one from the A-ring and the 
second one from the B-ring, which then undergo simultaneous catabolism [36,37]. Regarding the fission of 
the B-ring, both phenyl acids and benzoic acids have been reported as the microbial metabolites of 
anthocyanins (Figure 5). Gonzalez-Barrio et al. [37] proposed a complete colonic pathway for cyanidin 
including different alternative conversion pathways for the B-ring, and protocatechuic acid (benzoic acid) 
and 3-(3′,4′)-dihydroxyphenylpropionic acid (phenyl acid) were proposed as initial metabolites. The 
subsequent microbial metabolism of these initial products generates simpler compounds. Regarding 
benzoic acids, hydroxybenzoic acid has been reported to be a microbial metabolite of pelargonidin 
glucoside, protocatechuic acid of cyanidin glucoside, vanillic acid of peonidin glucoside, syringic acid of 
malvidin glucoside, methyl gallic acid of petunidin glucoside, and gallic acid of delphinidin glucoside [36–
40]. Considering the results obtained from previous studies, the generation of benzoic acids prevails over 
that of phenyl acids (Figures 2B,C and 5) 
Apart from B-ring fission, other microbial metabolites could also be generated from A-ring fission. The 
fission of ring A of anthocyanins could generate trihydroxybenzaldehyde [39,40], which could further be 
converted to phloroglucinol [37]. Due to the lack of complete information regarding the description of the 
colonic fate of some anthocyanins, we tentatively propose alternative pathways in Figure 5. Obviously, the 
acceptance or rejection of these must be confirmed by future studies. Along with some of the metabolites 
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described in in vitro studies, hippuric acid was also detected in human urine after the ingestion of 
raspberries [37]. 
 
 
Figure 5. Proposed colonic pathways of anthocyanins. 
 
 
2.2. No Flavonoids 
Phenolic acids, such as hydroxycinnamic and hydroxybenzoic acids, are present in numerous plant 
products. In plant tissues, phenolic acids form ether linkages with lignin through their hydroxyl groups in 
the aromatic ring and ester linkages with structural carbohydrates and proteins through their carboxylic 
group [1]. These bound phenolics survive stomach and intestinal digestion and reach the colon since, 
being the substrate to colon microbiota, cell wall fibrous materials are difficult to digest. 
Hydroxycinnamic acids are widely distributed in nature, with coffee, whole cereals, dried drupes, wine, 
berries, spices, and aromatic herbs being the richest sources. Caffeic, ferulic, and p-coumaric acids, as 
well as their tartaric and quinate esters, such as chlorogenic acid (quinate ester of caffeic acid), are 
included in this group, and their microbial degradation steps are proposed in Figure 3D. Chlorogenic acid 
underwent dihydroxylation, dehydrogenation, or ester hydrolysis as a first microbial transformation in 
simulated conditions [41]. In vitro fermentation of freeze-dried coffee confirmed the initial hydrolysis of 
chlorogenic acid into caffeic acid which later suffers degradation, with di- and mono-hydroxylated 
phenylpropionic acids the main metabolites detected [23,42]. Other metabolites, such as m-coumaric and 
hippuric acids, were detected in the urine of rats after the administration of chlorogenic acid [43]. As an 
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intermediate product of chlorogenic acid, caffeic acid degradation was expected to produce a similar 
metabolic profile [43] (Figure 3D). Dihydroferulic acid (3-(3-methoxy-4-hydroxyphenyl)propionic acid) 
[27,39] and 4-vinylguaiacol [44] together with minor degradation compounds have been described after in 
vitro fermentation of ferulic acid. 
On the other hand, hydroxybenzoic acids are made up of gallic acid and ellagic acid. Gallic acid is also 
part of the hydrolysable tannins’ and flavan-3-ols’ molecular structure. Its microbial transformation is 
proposed in Figure 2B, whereas the colonic fate of ellagic acid is explained in the following section. 
Ellagitannins are the main group of hydrolysable tannins. Particularly high concentrations of ellagitannins 
are found in muscardine grapes, pomegranates, and some berries and nuts. Intestinal breakdown of 
ellagitannins into ellagic acid was observed in vitro [2,37,45] and in vivo [46]. Ellagic acid is further 
metabolized by local bacteria, giving pentahydroxy-urolithins as the first metabolite which is successively 
dehydroxylated to tetra-, tri-, di-, and mono-hydroxy-urolithins, [2,37,45–47], as proposed in Figure 6A. An 
important person-to-person variability in the profile and amounts of urolithins has been observed with 
major urolithin A (dihydroxy-urolithin) or urolithin B (hydroxy-urolithin) producers, and others are incapable 
of producing any class of urolithins [2,3,37,45,47]. Gordonibacter urolithinfaciens and Gordonibacter 
pamelaeae were described as responsible for the transformation of ellagic acid into penta-, tetra-, and 
trihydroxyurolithin [48] and its absence could be associated with the inability of some individuals to 
produce urolithins 
Resveratrol (3,5,4′-trihydroxy-trans-stilbene) is the most common stilbene, present in grapes and wine, and 
it has been extensively studied. Regarding the in vitro experiments, dihydroresveratrol, 3,4′-dihydoxy-
trans-stilbene, and lunularin (3,4′-dihydroxy-bibenzyl) were described as microbial derivatives [49,50] 
(Figure 6B). Bode et al. [49] concluded that three colonic pathways of resveratrol can be distinguished in 
terms of the quantity of end products as a lunularin producer, dihydroresveratrol/lunularin producer, or 
dihydroresveratrol producer. Whereas dihydroresveratrol and lunularin were considered the main end 
products, the low amounts of 3,4′-dihydroxy-trans-stilbene detected seem to indicate that this product is 
intermediate or marginally produced by gut microbiota. The urine metabolic profile after an acute dose of 
trans-resveratrol confirmed the results found under in vitro fermentation [49,50]. 
Syringaresinol, pinoresinol, lariciresinol, secoisolariciresinol, and matairesinol are the most common 
lignans found in plant products. Besides being present in foods, secoisolariciresinol is a microbial 
degradation product of syringaresinol and also of lariciresinol, which, in turn, is derived from the microbial 
fermentation of pinoresinol [51,52] (Figure 6C). The final microbial products of secoisolariciresinol, with 
several intermediates, are enterodiol and its oxidized product enterolactone [53,54]. Secoisolariciresinol 
can also be converted to matairesinol, from which only enterolactone is obtained from microbial catabolism 
[52]. 
The phenolic alcohols, tyrosol, hydroxytyrosol and its precursors, oleuropein, and hydroxytyrosol acetate 
are the most representative compounds typically found in olives and virgin olive oil. Few studies have 
focused on the colonic pathway of these phenolic compounds. Oleuropein was transformed in vitro into its 
aglycone, elenolic acid, hydroxytyrosol, and hydroxytyrosol acetate [55,56] (Figure 7). Individual 
fermentation of tyrosol and hydroxytyrosol confirmed the low microbial metabolism of these compounds 
and their relative stability under in vitro colonic conditions [55]. An in vivo experiment following the 
administration of oleuropein to rats detected other related metabolites such as homovanillic acid [57]. 
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Figure 6. Proposed colonic pathways of hydrolysable tannins, resveratrol, and lignans. 
 
 
Considering the complex colonic pathways, it is possible to conclude that the first microbial transformation 
of phenolic compounds leads to the accumulation of initial metabolites that share characteristics from the 
original compound (particularly conserving their functional groups) and are considered markers of an early 
fermentation stage. The continuous exposure of the initial metabolites to microbiota leads to the 
accumulation of final catabolites, which can be common to different phenolic sub-groups. An elevated 
accumulation of some microbial metabolites would be indicative of the main microbial pathways probably 
common to several individuals. On the contrary, thos etabolites present in minor concentrations or in a 
smaller proportion of individuals could be related to a specific microbiota composition capable of activating 
secondary metabolic pathways 
Different profiles of metabolites observed after in vivo interventions suggest hepatic and renal metabolism 
prior to excretion via urine. Hippuric acid was the common phenolic metabolite detected in the largest 
amounts in plasma and urine after the intake of varied phenolic sources. The origin of hippuric acid can be 
through the microbial transformation of the quinic acid moiety or the hepatic metabolism of benzoic acids 
[58,59]. Nevertheless, the concentration of hippuric acid in urine decreased considerably after the antibiotic 
treatment of rats [60] and in the urine of ileostomy [11], suggesting an important contribution by the gut 
microbiota. 
In vitro and in vivo studies have contributed enough so far to confirm the capacity of gut microbiota to 
metabolize phenolic compounds (Box 1). The degradation pathway routes involve several reactions in 
which the side chain groups and the heterocyclic C-ring of flavonoids are more likely to be used by 
microorganisms, while the benzoic ring remains intact. Depletion of phenolic compounds along with the 
increase in bacteria growth observed in in vitro fermentations could be considered good evidence to 
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believe that these phytochemicals are used as carbon and energy sources. However, there are other 
reasons that can explain the utilization of phenolic compounds by gut microbiota. As xenobiotics, they may 
be degraded to reduce the toxicity that these compounds may have on resident bacteria 
 
 
Figure 7. Proposed colonic pathways of oleuropein. 
 
 
3. Impact of Diet Phenolic Compounds on Gut Microbial Fermentation Metabolites 
3.1. Short Chain Fatty Acids (SCFAs) 
SCFAs are saturated aliphatic organic acids consisting of one to six carbons, of which acetic (C2), 
propionic (C3), and butyric (C4) acids are the most abundant. SCFAs production mainly occurs in the 
proximal part of the colon, where the availability of substrates is most abundant. The majority of SCFAs 
(up to 95%) are rapidly absorbed by the colonocytes, leading to decreasing concentrations from the 
proximal to distal colon. Only a minor fraction of the SCFAs (about 5%) is excreted in the feces [63]. 
Isobutyric, isovaleric, and valeric acids, also called branched chain fatty acids (BCFAs), constitute the 
remaining 5% and are derived from the microbial fermentation of branched chain amino acids [64,65]. A 
disruption in the concentration of SCFAs, especially due to an increase in the proportion of BCFAs, could 
be a possible signal of loss of intestinal homeostasis [66,67]. 
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Acetic acid, propionic acid, and particularly butyric acid have been extensively studied due to their 
involvement in the maintenance of correct body functions [68,69]. Butyric acid is considered essential for 
maintaining the colon cellular function since it is the main energy source for colonocytes [70]. 
Chemopreventive properties have also been described for butyric acid due to its capacity to prevent the 
formation of malignant cells and to induce apoptosis in colonic cancer cells [71]. In fact, lower amounts of 
SCFAs [72] and butyric acid-producing bacteria [73] were found in the feces of colorectal patients than in 
those of healthy subjects. Contrarily, elevated amounts of BCFAs are presumed to be prejudicial to colonic 
health [74,75] and high concentrations have been observed in inflammatory bowel diseases (IBDs) [66] 
and obesity [67]. 
In vitro fermentation of pure phenolic compounds enables the extent to which phenolic compounds and gut 
microbiota are exclusively involved in SCFAs production to be seen. An improvement in the total 
production of SCFAs was observed after the in vitro incubation of chlorogenic acid, rutin, caffeic acid, 
quercetin [76], and olive oil polyphenols [77]. To the contrary, isolated proanthocyanidins [78] and 
punicalagins [45] suppressed the in vitro generation of SCFAs. The increments observed leave 
interpretations open to the thought that phenolic compounds could be transformed into SCFAs. However, 
this alternative is practically discarded since the ring cleavage of the aromatic ring of phenolic compounds 
was not observed under anaerobic conditions [79]. Rather than direct production, the increase in SCFAs 
observed after in vitro fermentation of pure phenolic standards is probably related to a higher fermentation 
rate of the released glycoside moieties and/or of the remaining carbohydrates in the culture media or the 
fece 
Phenolic-rich extracts have increased in interest since they can provide added value as food ingredients 
and can also be used in nutraceutical applications. Their involvement in SCFAs generation has shown 
mixed results. In two experiments, black tea extract, red wine-grape juice extract [17], and soy germ 
Box 1. Models Concerning the Study of Phenolic Microbial Metabolites 
 
In vitro and in vivo studies have been essential for building the colonic pathways of phenolic compounds. 
Basically, in vitro studies consist of anaerobic incubations where phenolic compounds represent the microbial 
substrate and bacteria cultures, human or animal feces, the microbial inoculum. The phenolic substrate used in 
these studies may include pure standards [11,19,20,26,30,38,49,55], isolated compounds [36,38,45], phenolic 
extracts [12,15,38,39,45], and food or pre-digested food [2,37,42,57]. In vitro fermentation models have some 
questionable points, mainly their limited representativeness of in vivo conditions. For example, in vitro 
incubations do not include enterohepatic recirculation, colonocyte absorption, mucosa-associated microbiota, 
and changes in physiological conditions during the transit time. The latter point has been partly overcome with 
the development of modern controlled batch cultures called “Simulator of Human Intestinal Microbial 
Ecosystem” (SHIME). The sample circulates through different reactors that represent the ascending, 
transversal, and descending colon in which pH and temperature are continuously controlled and the growth of 
microbiota is in line with the environmental conditions and substrate availability [12,17,61]. Despite the 
mentioned limitations, in vitro studies provide valuable information regarding the phenolic metabolites 
generated by gut microbiota. Fermentations are usually performed for 24–48 h during which sub-samples are 
collected at different time-points. Time-course metabolite generation allows colon metabolic pathways that 
probably take place under in vivo conditions to be defined. As microbial metabolites can be absorbed by 
colonocytes, their in vitro identification provides a useful tool for identifying these phenolic metabolites in 
plasma and/or urine in the human bioavailability or dietary intervention studies. 
In vivo studies are ideal complements to the in vitro ones. Nevertheless, complex ethical issues, concerning 
the study of the phenomena occurring during human digestion, limit in situ observations and sample collection. 
In general, phenolic compounds are usually analyzed in fractionated blood (plasma, serum…) and urine to 
determine which compounds are absorbed and their absorption and excretion kinetics. In general, phenolic 
compounds are quickly absorbed, reaching the Cmax in plasma between 0.5 and four hours after the intake, 
corresponding to the stomach and/or small intestine absorption [16,18,37,62], whereas the colonic metabolites 
appear in plasma later, indicating their gradual colonic biotransformation and, in some cases, showing a 
second increase in the plasma concentration after 4 h [16,18] 
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powder [61] were studied in a SHIME in vitro system. The tea extract and soy germ powder increased the 
concentration of acetic and propionic acids, whereas the soy germ and the mix extract only increased the 
concentration of propionic acid. In parallel, a slight decrease in the amount of butyric acid was observed 
after continuous feeding of black tea and red wine-grape juice extracts. A rise in the production of the three 
main SCFAs was observed after incubation of pomegranate extract [45]. Higher recoveries of urolithins in 
the batch cultures of pomegranate extract compared with that of punicalagins suggest major microbial 
activity and a possible involvement of phenolic microbial metabolites. Nevertheless, rats fed with raspberry 
seed extract produced more SCFAs and minor urolithins than rats that received strawberry seed extract 
[80]. Thus, the results of different studies are contradictory and phenolic compounds with similar chemical 
characteristics showed different behavior. 
Because the later data was obtained under in vitro conditions, it risky to extrapolate the same effects to in 
vivo conditions when extracts or phenolic compounds are ingested through the diet. Heterogeneous data 
have also been obtained from animal and human studies after exposure to a phenolic-rich diet. The 
concentration of acetic acid increased in the feces of pigs after two weeks of receiving a diet enriched with 
0.2% of green tea phenolic compounds [81]. In healthy humans, the inclusion of a red wine-grape juice 
extract, but not grape juice extract, over four weeks, reduced the concentration of isobutyric acid [82]. 
Furthermore, a decrease in the production of SCFAs in rats was noticed after the administration of an 
aqueous passion fruit leaf extract [83]. No changes in the production of SCFAs were observed after the 
inclusion of trans-resveratrol or quercetin (alone or in combination) in rats fed with a high-fat sucrose diet 
for six weeks [84] or in healthy humans after the intake of pomegranate juice for four weeks [85]. 
The role of non-digestible carbohydrates (dietary fiber) in the production of SCFAs is unquestionable. 
Based on its chemical and physical properties, dietary fiber is normally classified into soluble and 
insoluble. Pectin, oligosaccharides (fructooligosaccharides, FOS), and inulin are considered soluble fiber. 
The fermentability of soluble fiber is high due to its capacity for water solubilization, which allows the action 
of microbial enzymes. Insoluble fiber corresponds basically to cellulose, some hemicelluloses, lignin, and 
arabinoxylans, which are also fermented, but at a much lower rate than soluble fiber [86]. Many authors 
have postulated that the production of SCFAs may be enhanced when dietary fiber is administered in 
combination with phenolic compounds. However, this claim remains inconclusive. 
Replacement of part of the cellulose (maize starch) by strawberry and raspberry defatted seed extracts 
rich in ellagitannins enhanced the total SCFAs production and the proportion of butyric acid in rats after 
four weeks [80]. However, the results of the latter study were not only attributed to the phenolic 
compounds since their effectiveness was more marked in the raspberry extracts, coinciding with a major 
content of soluble fiber. In a similar experimental design, equivalent concentrations of dietary fiber were 
included in the diets of rats through soluble and insoluble fractions of bilberries, blackcurrants, and 
raspberries [87]. Rats fed with the soluble fraction of bilberries showed the highest caecal formation of 
SCFAs and fiber fermentability in coincidence with higher anthocyanin intake. 
Moreover, the addition of apple-pomace extract, in combination with FOS and cellulose, for four weeks 
[88], or lyophilized apple together with apple pectin [89], increased the proportion of butyric acid in rats 
compared with when fiber was consumed alone, suggesting an additional benefit that could be attributed to 
the presence of phenolic compounds in the extract. 
In some cases, the combination of fiber with phenolic compounds seems not to alter the gut metabolism of 
SCFAs. For example, apple fiber rich in phenolic compounds did not produce any change in the generation 
of SCFAs, either in combination with apple pectin under in vitro conditions [71] or together with 
boysenberry juice after four weeks of human consumption [90]. In line with the previous studies, rats fed 
with apple-pomace extract rich in proanthocyanins showed no difference in the production of SCFAs 
compared with rats fed with apple-pomace extract deprived of phenolic compounds [91], and similar 
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results were observed after combination of grape extract and inulin in the diet of rats [92]. Inhibitory effects 
in the production of SCFAs were observed when isolated apple polysaccharides were fermented in vitro 
together with purified apple phenolic extract rich in proanthocyanins [79]. Similarly, the suppression of 
SCFAs was also noticed in rats after four weeks of a combination of wheat and oat fiber with blackcurrant 
and chokeberry extracts (both rich in proanthocyanidins) [93] and low or high ellagitannin-rich strawberry 
extract in combination with FOS [94]. The conversion of SCFAs from starch was also suppressed by the 
addition of grape-seed extract to pig fecal incubations [95]. 
Since many factors such as the abundance and activity of specialized carbohydrate-fermented bacteria 
and enzyme expression and activity, as well as substrate availability, are involved in SCFAs synthesis, 
phenolic compounds could interact with one or more of these factors. Depending on the type and amount 
of the phenolic compounds ingested, they reach the colon in different proportions and degrees of 
polymerization [4,62]. In accordance with this, they could promote or inhibit the growth of carbohydrate-
fermented bacteria [76,96]. Bacterial enzymatic expression and activity is crucial for the release of 
monomeric compounds from polysaccharides to form SCFAs. In addition, different works suggest that 
polyphenols might modulate the activity of glyosidic enzymes differently [80,92,93]. 
In plant foods, phenolic compounds are naturally associated with dietary fiber. Thus, the physiological 
effects of fiber may depend not only on its chemical and physical properties, but also on its particular 
linkage and the composition of its phenolic compounds [44,97]. The effects observed to be hampered, 
particularly by proanthocyanins, may be associated with tight bonds among fiber and phenolic compounds 
which result in a delay in degradation and, thus, less fermentation. Nevertheless, Snelders et al. [44] 
observed that fiber fermentability was more related to the amounts of phenolic compounds present in the 
fiber matrix than to their form (free or bonded to fiber). Thus, performing studies to define the intrinsic 
composition of dietary phenolics and food fiber could be of great interest for understanding the role of both 
food components when these are alone or together. 
However, it is still questionable whether it is really desirable to stimulate the production of SCFAs. As 
SCFAs also represent energy extraction of non-absorbed macronutrients, they can provide approximately 
10% of the total energy intake [98]. This aspect is considered positive in populations with a diet rich in 
plant-derived polysaccharide food. Nevertheless, this may be detrimental in Western populations, because 
a greater capacity to harvest energy from the diet could contribute to the positive calorie intake balance 
typical of obesity [99]. In fact, the gut microbiota of obese individuals are especially rich in bacteria 
specialized in carbohydrate fermentation [99,100]. Hindering of SCFA production observed for some 
classes of phenolic compounds may be effective in reducing the energy harvest in overweight and obesity, 
which might partially explain the weight loss observed after the intake of food rich in phenolic compounds 
[101]. In synthesis, the versatility of phenolic compounds and their association with fiber, free or bound, 
could stimulate the design of different food products or recommendations depending on the effects 
expected to be attained. 
 
3.2. Bile Acids and Sterols 
Bile acids (BAs) are classified into primary and secondary. In humans, the primary BAs cholic and 
chenodeoxycholic acids are synthesized from cholesterol by hepatic enzymes and stored in the gallbladder 
(conjugated with the amino acids glycine and taurine) until being excreted into the duodenum to facilitate 
the digestion and absorption of lipophilic compounds. Most of the conjugated primary BAs are reabsorbed 
in the ileum and the remaining fraction reaches the colon, where cholic and chenodeoxycholic acids are 
metabolized into deoxycholic and lithocholic acids, respectively, by gut microbiota [102]. The main 
microbial catabolism steps include the deconjugation of amino acids and dihydroxylation by microbial 7-α-
dehydroxylase [102,103]. 
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Fecal cholesterol represents the non-absorbed dietary cholesterol in addition to that provided by intestinal 
desquamated cells. The microbial reduction of cholesterol releases coprostanol as the main metabolite, 
generating cholestanone and coprostanone as intermediates [104]. High excretion of sterols and their 
microbial metabolites through feces has been associated with hipocholesterolemic effects [105], but is also 
a common feature of high fat diets [106]. A continuous exposure to elevated luminal levels of secondary 
BAs and cholesterol microbial metabolites has been suggested to increase the susceptibility to intestinal 
inflammation and colorectal cancer [74,107–109]. In addition to the toxic effects of secondary sterols per 
se, the concentration of putrefactive compounds (see Section 3.3 below) could also increase the lumen 
toxicity due to the release of amino acids (glycine and taurine), these being products of the microbial 
hydrolysis of BAs. 
There is scarce data regarding the impact of phenolic compounds on the gut microbial transformation of 
BAs and cholesterol. Different studies have demonstrated that phenolic compounds have suppressing 
effects on the microbial conversion of sterols. For example, the amount of secondary BAs was reduced in 
rats fed with a diet containing tea polyphenols and gallotannins [110] or apple, grape, and red beet juices 
[111]. In another study with rats, the supplementation of a high fat diet with curcumin and caffeic acid 
reduced the concentration of deoxycholic acid in feces, whereas the administration of caffeic acid, 
catechin, rutin, and ellagic acid reduced the amount of lithocholic acid [112]. However, there was no 
evidence of lower conversion of primary to secondary BAs when red wine tannins were added to rat diets 
[113], or when healthy humans received pomegranate juice over a period of four weeks [85]. Regarding 
sterols, it seems that dietary phenolic compounds could also influence the conversion of cholesterol into 
their respective microbial derivatives, especially coprostanol. Compared with a control diet, rats that 
received tea polyphenols and gallotannins increased their excretion of fecal cholesterol in detriment to the 
excretion of coprostanol [110]. Similarly, pomegranate juice intake reduces the conversion rate of 
cholesterol to coprostanol in healthy adults [85]. On the other hand, a large proportion of coprostanol was 
observed in rats after the intake of apple, grape, and red beet juices [111]. These results suggest that the 
conversion of primary BAs to secondary BAs and cholesterol to coprostanol is hampered by phenolic-rich 
diets, but more data regarding the role of phenolic compounds on colonic sterol gut conversion in humans 
is needed. 
The negative implications of the secondary metabolites of sterols in the colon may be mitigated by 
phenolic luminal compounds. The inclusion of chlorogenic acid in the diet of mice reduced the deoxycholic 
acid's tumor-promoting effects [109]. In this line, protection against the cytotoxicity effects of deoxycholic 
acid in Caco-2 cells was observed when cells were incubated with proanthocyanidins [114]. In another in 
vitro study in which deoxycholic acid was incubated with HCT-116 cells, antigenotoxic and aticytotoxic 
activity was observed for quercetin, resveratrol, and rottlerin [115]. In the same study, genistein, curcumin, 
and epicallocatechin gallate showed no effect. 
High fat diets have also been associated with the increase of the activity of β-glucuronidase [106]. Many 
toxic metabolites are neutralized by glucuronide conjugation and it is the form that promotes their excretion 
from the body. Thus, deglucuronidation not only promotes the retention of toxic metabolites in the body but 
also increases gut environment toxicity. It has been also proposed that phenolic compounds could interfere 
with the activity of β-glucuronidase, but the results are inconsistent. A decrease in the activity of β-
glucuronidase has been observed in rats after diet supplementation with grape extract [92] and 
ellagitannins in combination with cellulose [94]. On the contrary, higher activity of β-glucuronidase was 
noticed in rats after the addition of blackcurrant polyphenols to the diet [93]. 
To date, the effects of phenolic compounds on the microbial transformation of colonic sterols have not 
been explored in depth and there is no information about the role of phenolic microbial metabolites. 
Regarding the changes in fecal sterol composition through the effect of phenolic-rich products, the data 
available in the literature is too scarce to enable solid conclusions to be drawn. Sterols are a non-invasive 
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and easy parameter to be analyzed in fecal samples with a relatively high sensitivity to change when the 
characteristics of the diet also change [106]. This converts them into good candidates for reflecting 
alterations in the gut lumen after dietary interventions, particularly those containing high fat. 
 
3.3. Products of Non-Absorbed Protein Metabolism 
Every day, variable amounts of nitrogenous compounds of dietary and endogenous origins reach the 
colon. Protein-rich diets, particularly those containing red meat, increase gut toxicity as a consequence of 
an excessive production of microbial products derived from protein fermentation [64,65,116,117]. These 
substances, also called putrefactive compounds, include ammonia, fecal phenolic (phenol and p-cresol) 
and indolic compounds (indol and skatole), sulphur compounds (hydrogen sulphide, methyl mercaptan, 
and dimethyl sulphide), branched chain fatty acids, and polyamides (putrescine, agmatine, cadaverine, 
tyramine, and histamine). Intestinal ammonia is generated through the microbial deamination of urea and 
amino acids [65,118]. Phenolic and indolic compounds are mainly derived from the microbial catabolism of 
aromatic amino acids (phenylalanine, tyrosine, and tryptophan) [65]. Sulphate-reducing bacteria produce 
sulphur metabolites as a product of anaerobic respiration during the catabolism of cysteine and methionine 
[119]. Polyamides, besides being present in food, are also released in the gut by the bacterial metabolism 
[120]. 
Elevated undigested luminal proteins could alter the intestinal ecology, stimulating the activity of nitrogen-
degrading bacteria, which are considered to have detrimental effects in gut homeostasis [121,122]. In 
parallel, microbial enzymatic expression and activity increase proportionally with the amount of substrate 
[122], thus promoting the accumulation of putrefactive compounds which are associated with gut integrity 
and function loss due to their potential cytotoxicity, genotoxicity, and carcinogenic activity, increasing the 
risk of inflammatory bowel disease (IBD) and the development of colorectal cancer [66,74,116,123]. 
The modification of dietary patterns, such as including dietary carbohydrates [89,116,117], and restricting 
energy intake [124], has shown an inverse relationship with the concentration of these putrefactive fecal 
compounds. However, there is insufficient information regarding the effects of phenolic compounds in this 
aspect. Among the limited number of studies focused on researching the relation between protein 
fermentation and phenolic compounds, the most numerous are those on polymeric and monomeric flavan-
3-ols. In the case of animal studies, a tea phenol-enriched diet reduced the pH and concentration of 
ammonia, phenol, p-cresol, and skatole in pig feces after two weeks of treatment [81]. Satisfactory results 
were also observed in humans after supplementation with grape seed extract [125] and flavan-3-ols [126]. 
Both products reduced fecal pH and hampered the production of sulphur compounds. A trend toward a 
decrease in phenol, p-cresol, 4-ethylphenol, indole, and skatole in feces was observed after consumption 
of grape seed extract, but these compounds were not studied after flavan-3-ol supplementation. In the 
case of ammonia, its fecal amounts were significantly reduced in the flavan-3-ol group and tended to 
decrease after grape seed extract intake. More consistent results, observed after the intervention with 
flavan-3-ols, may be related to the duration of the study, this being two and six weeks for grape seed 
extract and flavan-3-ols treatments, respectively. On the contrary, no changes in the production of 
ammonia and sulphides were noticed after continuous feeding of soygerm powder in a SHIME system [61]. 
A reduction of the pH of the feces observed after phenolic intervention could partly explain the decrease in 
the concentration of putrefactive substances, since microbial proteases are more active at neutral or 
slightly alkaline pH [127]. However, this is not a common effect. In some cases, phenolic compounds 
increase [92] or have no effects [80,83] on lumen pH. In addition, a reduction in fecal putrefactive 
compounds does not always respond to a reduction in the pH [80,92]. The differences may depend on the 
predominant class of bacteria and the availability preference of the substrate type. For example, 
Escherichia coli and Proteus mirabilis produced ammonia from amino acids even at low pH [118]. 
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Phenolic compounds and their microbial metabolites possibly collaborate with additional factors to reduce 
the accumulation of protein fermentation products. A reduction of protein conversion, beyond the decrease 
in pH in the gut lumen, may also be associated with the capacity of phenolic compounds to inhibit 
proteolytic bacteria and interfere with their enzymatic activity. Gram-negative Proteobacteria (especially E. 
coli), Bacillus spp., and Gram-positive Clostridia [118,128] have been implicated in gut proteolysis and 
their abundance in IBDs is probably associated with the typical morphological and physiological alterations 
[129,130]. Beside the capacity of phenolic compounds to inhibit the growth of several members of the 
proteolytic bacteria, it has been observed that phenols also possess the capacity to attenuate the 
expression of genes involved in the secretion of proteases, inhibiting their synthesis and their activity 
[125,131–133]. The degree to which the enzymatic activity is blocked depends on the phenolic 
concentration, its molecular structure, and its functional groups [133]. 
Abnormal concentrations of proteinases and putrefactive compounds in the lumen alter the permeability of 
the gut epithelium, promoting the movement of toxic substances across the intestinal barrier, which leads 
to a tendency to activate inflammatory mediators [129,134]. One of the reported mechanisms by which 
phenolic compounds improve barrier integrity is by increasing the expression of tight junction proteins 
[84,134–137]. This may mean that although some phenolic compounds are unable to reduce protein 
fermentation, they offer an alternative way of protecting colon integrity, enhancing the host tolerance to 
susceptible molecules present in the internal environment. 
Large intestine digestion is a dynamic system in which entrapped compounds in the digesta pass through 
the ascending, transversal, and descending colon before being excreted by feces. Local microbiota is 
active throughout the lumen, metabolizing non-absorbed products in the function of substrate preference 
and availability, and is also conditioned by the physiological conditions of the gut (pH, redox potential, 
transit time) [138]. The pattern of the native phenolic compounds present in food change between the 
colonic segments due to the microbial fermentation, resulting in the accumulation of different metabolites 
with different activity than their precursors. As major proteolytic activity is found in the terminal colon 
[64,123], it would be interesting to study the interaction of microbial proteolysis-phenolic metabolites in this 
part of the gut. In addition, we have found only one paper related to the study of the modification of fecal 
nitrogen compounds after the addition of phenolic-rich products in a high red meat diet in humans [139]. 
However, to have a better understanding of the role of dietary phenolic compounds in protein fermentation 
at gut level, more human and animal studies are needed. 
4. Impact of Phenolic Compounds on Intestinal Function 
4.1. Intestinal Redox Homeostasis 
Oxidative stress is defined as the damage promoted by an imbalance between pro-oxidant agents (free 
radicals) and endogenous (superoxide dismutases, SOD, catalase glutathione peroxidase, GPx, and 
glutathione, GSH) and exogenous mechanisms to neutralize their effects. Free radicals are highly reactive 
molecules capable of reacting with the biological components of cellular structures, such as the structural 
lipids of cell membranes, proteins, and nucleic acids (DNA damage), compromising good cell function and 
integrity. Moreover, the alteration of cellular components caused by oxidative stress in many cases 
precedes the over-expression of pro-inflammatory agents that are responsible for the activation of 
mechanisms that trigger cell damage [140]. Repeated bouts of inflammation can lead to the occurrence of 
IBDs, such as ulcerative colitis and Crohn’s disease, which are, in turn, risk factors of colon cancer [141]. 
Pro-oxidant substances are products of normal aerobic metabolism, but their levels increase as a 
consequence of toxic exposure (smoke, excessive alcohol intake, irradiation, some drugs, food 
components, toxins) and other particular situations (age, infection, stress). The gastrointestinal tract 
produces, receives, and retains these types of substances, which implies an elevated risk of alterations in 
cells and tissue in situations of over-production of free radicals and/or depletion of antioxidant reparative 
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mechanisms [142]. Dietary phenolic compounds could act as an antioxidant system in the gastrointestinal 
lumen and epithelium, reducing the oxidative damage in different ways: safeguarding the activity of 
endogenous antioxidants, decreasing free radical production, or neutralizing the latter by radical 
scavenging [6,7,9,140,143–147]. 
In vitro studies using cell-based methods are considered a good tool for deciphering the mechanisms by 
which phenolic compounds attenuate oxidative responses. Treatment of intestinal Caco-2 cells with 
different fractions of cranberry and apple peel phenolic extracts [140,143], as well as red wine extracts 
[144], effectively mitigated the membrane structure disruption caused by the pro-oxidants Fe/ascorbate 
and tertra-butyl hydroperoxide, respectively. Direct scavenging activity is the proposal mechanism by 
which urolithins suppress the generation of free radicals from activated neutrophils [145]. On some 
occasions, foods also collaborate with the pro-oxidant potential of the gut environment. For example, an 
overproduction of free radicals and a reduction of GSH activity were evident in Caco-2 cells when they 
were incubated with acrylamide, but the latter effects were reduced by cocoa phenolic extract, procyanidin 
dimer B2, and epicatechin [146]. In a similar way, protection against oxidative damage induced by the 
micotoxin deoxynivaleol in HT-29 cells was also observed when the culture media was enriched with 
epigallocatechin gallate [147]. 
The main entrance route for phenolic compounds is the gastrointestinal tract, where they reach a greater 
lumen concentration and remain longer compared with those observed in blood circulation [22,62]. Also, 
the extensive phase II metabolism (glucuronidation, sulphatation, and methylation) that phenolic 
compounds undergo during absorption and body distribution created doubts concerning their effectiveness 
as antioxidant agents at the systemic level [13,145]. In the case of colon lumen, the non-absorbed phenolic 
compounds and their microbial metabolites prevail in native-unconjugated forms [148]. During digestion, 
the antioxidant capacity of the luminal content can indeed increase compared with the original food, 
probably due to the release of phenolic compounds from the food matrix promoted by the physiological 
conditions and action of digestive enzymes [149]. In the large intestine, microorganisms have the ability to 
release those phenolic compounds intimately entrapped in the food matrix (particularly dietary fiber), which 
also contribute to the total antioxidant capacity at the gut lumen level [150,151]. Moreover, the phenolic 
compounds released from the digestive bolus can be distributed into intestinal fluids and favor direct 
contact with the colonic epithelium, mitigating the detrimental effects of free radicals at the cell level. 
The antioxidant status in in vivo studies (animals or humans) could be estimated by analyzing the 
antioxidant capacity of the intestinal content or fecal water by different methods, such as the oxygen 
radical absorbing capacity (ORAC), the ferric reducing antioxidant power (FRAP), the diphenyl-1-
picrylhydrazyl (DPPH), the free radical scavenger (TBARS), and the 2,2′-azinobis-(3-ethylbenzothiazoline-
6-sulphonate) radical cation (ABTS) [6,13,14,19,20,149–151]. The total antioxidant capacity of the 
intestinal content increased after the ingestion of grape seed extract in rats [151] and limited the production 
of free radicals in human fecal water after polyphenol-rich chocolate intake [152]. In contrast, some studies 
have noted no changes in the antioxidant capacity in colon tissue after the intake of phenolic-rich products 
[10]. The difference in the bioactivity between microbial phenolic metabolites and their parent compounds 
together with the progressive decrease of the lumen phenolic concentration due to the active colonic 
absorption could be an explanation for the unobserved antioxidant effects. However, it should be stressed 
that lack of effect in the total antioxidant capacity does not necessarily encompass the loss of other 
biological properties [10] (see next Section 4.2.). 
 
4.2. Intestinal Inflammation 
Inflammation is a biological phenomenon associated with the innate body immune response in the first line 
of defense to combat threats which could compromise human health. Episodes of controlled inflammation 
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are indispensable for suppressing chemical, biological, and physical injuries. However, in some cases, due 
to diverse genetic and environmental causes, uncontrolled inflammation responses predispose individuals 
to the development of chronic diseases. In the case of the gastrointestinal tract, IBDs are characterized by 
an unknown etymology of recurrent episodes of inflammation causing a progressive loss of cellular 
function and tissue degeneration that could develop into colon cancer [141,153]. 
The chronification of inflammation involves complex and interconnected mechanisms of molecular 
mediators, whose continued feedback promotes the perpetuation of inflammation. The over-production of 
free radicals (reactive oxygen and nitrogen species) and cytokines (TNF-α, IL-6, IL-8, PGE2, among the 
most studied), the up-regulation of nuclear factor kappa-B (Nf-κB) and monophosphate-activated protein 
kinase (MAPK), and the recruitment, activation, and adhesion of leukocytes have been identified as 
occurring in IBDs [7,8]. Phenolic compounds seem to inhibit or attenuate the intensity of the inflammatory 
response by modulating the cellular inflammatory mediators and/or neutralizing free radicals (see Section 
4.1 above). 
In vitro cultures of intestinal cells are particularly valuable models for identifying the target molecules 
involved in chronic inflammation which may be susceptible to regulation by phenolic compounds. The 
results obtained from these studies could be interesting for the design of new anti-inflammatory drugs 
capable of avoiding the adverse side effects observed for some drugs used to treat IBDs [154]. The 
possible mechanisms by which phenolic compounds could mitigate or suppress inflammatory responses in 
vivo can be predicted by cells activated by different types of inflammation promoters. The down-regulation 
of NF-κB is considered a therapeutic target in IBDs, since it prevents the activation of pro-inflammatory 
mediators, such as COX-2 and iNOS, which, in turn, are responsible for the production of cytokines and 
free radicals. Individual compounds, such as epigallocatechin gallate [147] and anthocyanins [155], and 
also phenolic mixtures obtained from apple peels [143], cocoa [8], cranberries [140], and red wine [156], 
have shown an in vitro ability to inhibit the activation of NF-κB pathways. In the latter studies, the inhibition 
of NF-κB activity was also associated with the down-expression of COX-2 [8,143,147,156] and iNOS 
[8,140,156]. Resveratrol [157] and cocoa phenolic compounds [146] were also effective as regulators of 
other signaling pathways such as JAK-STAT and MAPK, respectively. On the contrary, chlorogenic-rich 
fractions obtained from lyophilized blueberries did not show clear evidence as inhibitor agent of NF-κB 
[155]. 
Although less common compared with the data available regarding the anti-inflammatory potential of 
phenolic compounds, it seems that their microbial metabolites also possess similar properties. The down-
regulation of COX-2 in human adenoma cells was observed after the incubation of (3′,4′-
dihydroxyphenyl)acetic and 3-(3′,4′-dihydroxyphenyl)propionic acids [158], common phenolic catabolites 
detected in feces. Reclusion and adhesion of leukocytes play an important role in the development of 
inflammation since they also secrete pro-inflammatory cytokines. The secretion of cytokines TNF-α and IL-
6 was effectively inhibited by urolithins after activation of THP-1 human monocyte cells [159]. Urolithins 
were also effective as anti-inflammatory mediators in activated neutrophils, inhibiting cytokines and the 
secretion of the proteinases necessary for adhesion [145]. Fibroblasts are a type of cell that synthesizes 
the extracellular matrix and collagen, responsible for tissue cicatrization. Their activation, mediated by 
cytokines, monocytes, and free radicals, also involves the secretion of pro-inflammatory agents. In 
addition, the exacerbated extracellular production of collagen could lead to intestinal stenosis (bowel 
obstruction) [160]. Urolithins, especially urolithin A, were also effective at inhibiting the activation, 
migration, and adhesion of colon fibroblasts with a concomitant reduction of several secretory pro-
inflammatory mediators. These effects were even more evident than those shown by their precursor, 
ellagic acid [161]. 
Chemically induced IBD in animals is a revolutionary approach to studying the effect of phenolic 
compounds on inflammation under in vivo conditions [153]. The improvement in physical indicators (less 
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body weight loss) and hematological and histological probes, together with a reduction in the expression of 
pro-inflammatory mediators in combination with phenolic treatment, constitute evidence of the protection 
given by phenolic compounds against intestinal epithelium damage and the attenuation of the inflammatory 
response. Individual phenolic compounds [7,10,134,136,162], and phenolic extracts [7,8,163,164] have 
shown positive effects in the control of IBDs in animals, even to the same extent as sulphosalizine, a 
common medicine used in IBDs, but with fewer collateral effects [7]. Contrary to the later results, the 
administration of resveratrol to rats for six weeks induces the expression of inflammatory parameters [84]. 
Data from animal studies support the anti-inflammatory effect of phenolic compounds observed in in vitro 
experiments, but the role of phenolic metabolites in this aspect is still unclear, due to the lack of 
information about the phenolic disposition in tissues and feces in most of the later studies. 
Dietary intervention in human studies including IBD patients is basically conducted to observe the 
remission of clinical symptoms or the diminution in the number or intensity of relapses [165–167]. Despite 
phenolic compounds have been extensively studied in animal models of IBDs, data regarding human trials 
is currently limited to one study in which the administration of epigallocatechin gallate to patients with 
ulcerative colitis over 56 days showed a satisfactory degree of remission of symptoms with minimal side 
effects [166]. Due to the ethical issues mentioned above, human studies to investigate the in situ effects 
promoted by phenolic compounds are not always possible. Nevertheless, there are promising fecal 
inflammatory markers that could potentially be used in human studies with minimal invasiveness. 
Calprotectin and lactoferrin are binding proteins found in the cytoplasm of neutrophils, monocytes, and 
macrophages. Fecal calprotectin could be a good tool for the molecular screening of active intestinal 
inflammation, because its levels are substantially elevated in IBDs and colorectal cancer [167–169]. 
Furthermore, the amounts of calprotectin in feces have been shown to correlate well with the histological 
lesions caused by continuous inflammation in IBDs [167,168,170] and the tumor stage in colorectal cancer 
[169], indeed with better results than other common plasma biomarkers, such as the case of C-reactive 
protein [167,170]. A reduction in the fecal excretion of calprotectin was observed after surgical intervention 
[169] and oral probiotic administration [171]. Rats fed with a high fat diet in combination with grape seed 
extract showed lower levels of fecal calprotectin than the control animals [172]. 
Although collecting feces is easy and non-invasive, human studies concerning fecal inflammation 
biomarkers are scarce. To our knowledge, there is only one study involving IBDs patients and phenolic 
treatment. In this work, anthocyanin-rich bilberries were administrated to ulcerative colitis patients for nine 
weeks and the results at the end of the study showed a decrease in the fecal levels of calprotectin, which 
increased again when the bilberry treatment was stopped [173]. These results not only show the palliative 
effects of some phenolic compounds in IBDs, but also the inclusion of calprotectin as an index of 
inflammation response after dietary treatment. Exploring the association between phenolic compounds and 
intestinal inflammation through dietary treatment is a promising future approach to be considered. 
 
5. Phenolic Compounds and Gut Microbiota Modulation 
The gastrointestinal tract, especially the large intestine, houses the most abundant and complex microbiota 
in humans. The gut population, composed of approximately 1010–1012 cells per gram of intestinal content, 
participates in several metabolic functions that the host cannot fulfill by itself [174–176]. These metabolic 
functions and their derivative end products depend on the quantitative and qualitative features of the gut 
inhabitants. A harmonious balance in the composition of the gut microbiota has been associated with 
maintaining health and a higher life expectancy accompanied by a satisfactory quality of life. An imbalance 
in the microbial population is known as dysbiosis. Dysbiosis has been associated with intestinal and non-
intestinal metabolic disorders, which confirms the association between the microbiota and non-digestive 
functions [176]. 
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Although full characterization of the microbiota in homeostasis and disease still remains to be completed, 
some trends in its profile could be helpful for discriminating between the two states. A lower diversity of 
bacteria, change in bacteria functionality, and a decrease in the beneficial inhabitants together with a major 
abundance of detrimental opportunistic bacteria seem to be involved in metabolic alterations such as 
obesity and type-2 diabetes, and diseases of the gut such as IBDs and colorectal cancer 
[9,10,73,100,177,178]. An alteration of the microbial equilibrium undermines bowel functionality, alters host 
immunity, and increases susceptibility to pathogen colonization. 
The mechanisms by which the phenolic compounds modulate the gut microbiota still remain to be 
deciphered, but may involve direct and indirect interactions. Phenolic compounds could directly stimulate 
or inhibit bacterial growth. Inhibition is closely related to previously reported antimicrobial properties of 
phenolic compounds and stimulation presumably associated with the capacity of the bacteria to metabolize 
them [131,179]. The antimicrobial activity of phytochemicals has been extensively studied because is 
thought that it is the main cause by which phenolic compounds can modify the characteristics of the gut 
structure population. On the basis of several works [131], it could be said that phenolic compounds 
possess a selectively bacteriostatic or bactericide effect, inhibiting the growth of a wide range of potential 
pathogenic bacteria slightly affecting or even promoting the beneficial microbial population. However, it is 
important to consider the concentration and characteristics of the molecule (type of phenolic compound 
and if it is presented in conjugated or free form) because these factors seem to govern the modulation of 
the desired effects. Indirect implications include complex issues where numerous microbial-host and 
microbial-microbial interrelationships take place. Phenolic metabolites could affect the growth of other 
bacterial groups and, in turn, the over-growth of some bacterial groups could condition the development of 
others [76,179,180]. 
The prevalence of determinate microbiota members is preferred to others due to the efficacy they have 
shown in ameliorating the gut ecosystem with positive effects at the local and systemic levels. For this 
reason, most studies have focused on the effects of polyphenols on Bifidobacterium and Lactobacillus, but 
there is increasing interest in other emergent bacteria that could be relevant for the health of the host 
[9,101]. Under in vitro conditions, anthocyanins [38], phenolic compounds bound to the insoluble cocoa 
fraction [150], pomegranate extract [45], and soygerm powder [61] have stimulated the growth of 
Lactobacillus and Bifidobacterium. Pomegranate extract and apple pomace juice were also capable of 
increasing Bifidobacterium levels in rodents [111,163]. The Lactobacillus count was increased after the 
administration of apple and red beet pomace juice instead of water in rats [110]. Grape seed extract rich in 
proanthocyanins was able to increase the population of Bifidobacterium in healthy adults [125]. Although 
the phenolic compounds contained in a cocoa powder did not prevent the age-induced reduction of 
Lactobacillus and Bifidobacterium in rats after six weeks, they reduced the growth of Bacteroidetes, 
Staphylococcus, and Clostridium [181]. The latter prebiotic effects could also have been related to the 
possible presence of fiber in the phenolic sources. Dietary fiber is known to influence the microbiota profile, 
especially through the increase in probiotic microorganisms [182]. However, other sources deprived of 
dietary fiber, as in the case of incubation of individual compounds [76], green tea phenolic compounds in 
pigs [81], fiber-free juice [101], resveratrol administrated to rats [10], isoflavone supplementation in women 
[183], and cocoa-isolated phenolic compounds in healthy adults [184], have also shown positive effects to 
favor the increase in the number of Bifidobacterium [10,76,183,184], Lactobacillus [10,101,184], and 
butyrate-producing bacteria in parallel with the modulation of growth of bacteria associated with gut 
dysbiosis [10,76,184]. 
Diet is probably the most easily manipulable factor to modulate the composition of the gut microbiota, and 
the latter results show that phenolic compounds per se are presumably able to interact with gut inhabitants 
and produce changes, most of them toward a healthier profile. However, in a recent study by our group 
[85], no changes were observed in the microbiota composition of healthy adults after four weeks of 
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sustained intake of pomegranate juice with a high phenolic content. Therefore, the production of the 
microbial phenolic metabolites catechol and phenylpropionic acid was correlated with the presence of a 
higher percentage of some bacterial groups, supporting the existence of phenolic compound-bacteria 
interrelationships. Despite this fact, the moderate consumption of red wine by healthy volunteers over a 
period of 20 days increased the number of Firmicutes, Bacteroidetes, Bifidubacterium, and Prevotella 
[185]. The Bifidobacterium population also increased in the feces of healthy humans after six weeks of 
sustained intake of blueberry drink [186], basically promoted by the higher amounts of some species [187]. 
Recent studies have proposed the use of phenolic-rich sources as a therapeutic strategy to prevent and, in 
some cases, reverse the dysbiosis associated with different pathologies. Obese rodents or animals fed 
with obesogenic diets are common tools for studying the role of the microbiota in the metabolic syndrome. 
The metabolic syndrome includes a series of alterations, such as obesity, dyslipidaemia, glycosemia, and 
loss of insulin sensitivity. Thus, the attenuation of one of the latter factors could be considered as a 
protective factor of type 2 diabetes and cardiovascular diseases 
A high Firmicutes/Bacteroidetes ratio has been considered an index of obesity and its depletion a marker 
of successful treatment. However, the results in this context are ambiguous. The reduction in the incidence 
of obesity reflected by lesser weight gain and fat accumulation was observed after treatment with quercetin 
plus resveratrol [84], coffee [188], fiber-free plum [101] and cranberry extract [9], but no significant 
differences were observed after pomegranate peel extract intake by obese mice [163]. The majority of the 
latter phenolic treatments showed a modification of the microbial population with respect to their control 
counterparts, but it was not always encompassed by a decrease in the Firmicutes/Bacteroidetes ratio, 
suggesting the involvement of other bacteria or non-microbiota mediated effects. Nevertheless, a positive 
correlation between body mass index and the Firmicutes/Bacteroidetes ratio is still questionable because 
this parameter has not always been described in obesity [99,101,189]. The prevention of obesity is a target 
factor to reduce the incidence of type 2 diabetes, which could be reinforced by the additional effects 
provided by dietary phenolic compounds. For example, the administration of cranberry extract to mice for 
nine weeks increased the relative abundance of Akkermansia ssp., which has been linked with the 
enhancement of diabetic protective effects such as an increase in insulin sensitivity and better 
inflammatory parameters [9]. 
IBDs have also been associated with a microbial status in which Enterobacteriacea, especially E. coli, are 
more abundant than in the control subjects. The characterization of E. coli has revealed that the virulent 
types were more abundant in biopsy specimens in IBDs patients compared with healthy individuals, 
basically due to the expression of adhesines which facilitate the adherence of the bacteria to the 
epithelium surface [190]. The administration of resveratrol to IBD-induced rats for 25 days prevented the 
over-growth of Enterobacteriaceae, particularly E. coli [10]. Some studies confer the phenolic compounds 
with the in vitro properties of inhibiting the cellular adhesion of harmful bacteria with a minimal 
repercussion on the beneficial members of the gut microbiota [191]. 
All seem to indicate that the gut community responds positively to dietary phenolic compounds where the 
abundance of determinate bacteria could contribute to host health maintenance. After phenolic 
intervention, microbiota changes may by expressed on different taxonomic levels. Lack of difference at the 
phylum level does not necessarily indicate a lack of probiotic effects; sometimes the changes are evident 
at class, family, genus, or species levels [84]. 
Microbiota profile and, thus, microbiota modulation after diet intervention can be studied by different 
techniques, such as fluorescent in situ hybridization (FISH), quantitative PCR-based methods (qPCR) 
[76,101], and high-throughput sequencing; these are among the most widely used. The analyses by FISH 
and qPCR are based on identifying and quantifying specific bacterial groups, defined as oligonucleotide 
probes. For this, in most of the assays, the selected probes depend on the specific bacteria of interest in 
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the study and probably some important microbial changes may be omitted if the probe is not considered in 
the study. Other, more sophisticated techniques are based on the amplification and pyrosequencing of 
bacterial 16S ribosomal RNA and allow overall population bacterial genoma identification (metagenome) 
[101,177]. A more in-depth and detailed characterization of the whole microbiome provides information 
regarding changes not only in the phylum, class, family, and genus but also specific alterations observed 
at the species level. In summary, the phenolic compounds that may hamper the microbial imbalance in 
situations of risk of disease or those that may prevent dysbiosis by reinforcing beneficial bacteria could be 
included in therapeutic strategies to restore or maintain a healthy profile of the gut microbiota. It remains to 
be elucidated whether dysbiosis is a cause or consequence of several human pathologies associated with 
the microbiota. 
 
6. Conclusions and Future Perspectives 
The large intestine is a sophisticated and complex ecosystem where interrelationships among the host, 
microbiota, and its metabolic products (dietary and endogenous products) play a key role in local and 
systemic health. The inter-dependence between the latter factors is so tight that the alteration of one of 
them can govern the behavior of the others, altering the gut homeostasis and, thus, making the 
appearance of disease more likely. 
Dietary phenolic compounds reach the colon in variable amounts, enriching the gut lumen of the related 
metabolites derived from the local microbiota metabolism. Lumen phenolics (parent compounds and their 
metabolites) can actively take part in the innumerable interactions that occur in the large intestine. 
Depending on their nature, diet phenolic compounds apparently enhance the generation of beneficial 
metabolic products and/or hamper the production and effects of detrimental luminal compounds, protecting 
and prolonging gut homeostasis. The mechanisms by which phenolic compounds can interact with the gut 
metabolism may involve interference with enzymatic expression and activity, changes in the characteristics 
of the gut environment, changes in the modulation of the signaling pathways responsible for pro-oxidant, 
inflammatory, and carcinogenic effects, enhancement in the protection of the intestinal epithelium from the 
negative effects of toxic substances, and/or the modulation of the microbial population. 
There are still several aspects that require emphasizing. Phenolic compounds undergo active colonic 
microbial transformations, generating intermediate and final related metabolites that could be present in 
the digesta in higher concentrations than their precursors, without necessarily sharing the same bioactivity. 
In this context, studies focused on analyzing the parent compounds in food probably fail to estimate the 
phenomena occurring in the colon correctly. It would be important to identify whether the health benefits 
are associated with the parent compounds or their respective microbial derivatives in order to design the 
correct dietetic or technological strategies to obtain major and better results from phenolic dietary 
therapies. 
Phenolic compounds represent a wide group including several sub-groups that, although they have similar 
characteristics, are not completely equal. Differences in chemical structure, number of functional groups, 
and the combination of different moieties probably lead to these molecules having different functions. 
Despite the information obtained and published over recent years, the effects and mechanisms by which 
phenolic compounds promote changes in the human gut ecosystem are not yet completely elucidated. A 
solution could be partly promoted by the combination of metabolomic (characterization of metabolite 
changes in the gut environment after dietary intervention with phenolic compounds or phenol-rich foods), 
microbiome (gut bacteria collective genome), and metagenomic (for the identification of down- or over-
expressed proteins involved in microbial activities, whose classification thus depends on the function) 
disciplines to describe a more complete scenario promoted by phenolic compounds. 
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Given all of the above, the design and performance of more research, especially focused on human trials, 
is encouraged to confirm the efficacy of phenolic compounds at the gut level. The results provided by 
previous and future studies could be useful to the design of dietary recommendations not only to suppress 
or reduce symptoms in disease but also to provide the healthy population with simple tools to promote the 
maintenance of health. 
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